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Abstract 
The nuclear matrix (NM) is proposed to be a permanent network of core filaments 
underlying thicker fibres, present regardless of transcriptional activity. It is found to be 
both RNA and protein rich; indeed, numerous important nuclear proteins are 
components of the structure. In addition to mediating the organisation of entire 
chromosomes, the NM has also been demonstrated to tether telomeres via their 
TTAGGG repeats.  
 
In order to examine telomeric interactions with the NM, a technique known as the 
DNA halo preparation has been employed. Regions of DNA that are tightly attached to 
the structure are found within a so-called residual nucleus, while those sequences 
forming lesser associations produce a halo of DNA. Coupled with various FISH 
methodologies, this technique allowed the anchorage of genomic regions by the NM, 
to be analysed. In normal fibroblasts, the majority of chromosomes and telomeres 
were extensively anchored to the NM. Such interactions did not vary significantly in 
proliferating and senescent nuclei. However, a decrease in NM-associated telomeres 
was detected in quiescence.  
 
Since lamin A is an integral component of the NM, it seemed pertinent to examine 
chromosome and telomere NM-anchorage in Hutchinson-Gilford Progeria Syndrome 
(HGPS) fibroblasts, which contain mutant forms of lamin A. Indeed, genome tethering 
by the NM was perturbed in HGPS. In immortalised HGPS fibroblasts, this disrupted 
anchorage appeared to be rescued; the implications of this finding will be discussed. 
This study also suggested that telomere-NM interactions are aberrant in X-linked 
Emery-Dreifuss Muscular Dystrophy (X-EDMD), which is caused by mutant forms of 
emerin, another NM-associated protein. 
 
The positioning of selected genes in control and X-EDMD cell lines was examined in un-
extracted nuclei using 2D and 3D FISH. Subtle shifts in the organisation of these genes 
were detected in diseased cells; however, their expression levels remained unaltered.  
Furthermore, in order to examine the architectural integrity of the nuclear lamina in 
lamin A and emerin mutant cell lines, scanning electron microscopy (SEM) was 
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employed. This work revealed that such structures were indeed compromised in 
disease.      
 
The findings presented in this thesis highlight the importance of lamin A and emerin in 
mediating the organisation of the genome and taken together, promote the hypothesis 
that dysfunctional NM dynamics may well contribute to disease pathology. 
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1.1 INTRODUCTION 
 
Since the discovery that inner nuclear membrane proteins could cause disease, 
interest in nuclear structures and their functions has increased tremendously. As a 
result, evidence has accumulated which demonstrate that these structures participate 
in a multitude of cellular processes and indeed, are required for them to proceed 
accurately and efficiently. However, although considerable progress has been made in 
this field in the last decade, there are still substantial gaps in our knowledge. This fact 
is highlighted by our understanding of the nuclear lamina; many of its functions have 
been documented and detailed, yet, comprehension of how a defective lamina can 
lead to the array of lamina-associated diseases observed is poor. In light of this, this 
review intends to provide an overview of nuclear structure, highlighting specific 
diseases caused by lamin mutations; subsequently, potential disease mechanisms will 
be discussed, considering those therapeutic options available. 
 
1.2 NUCLEAR STRUCTURE 
1.2.1 Nuclear Envelope 
 
In the eukaryotic cell, nuclear and cytoplasmic activities are separated by the nuclear 
envelope (NE); between the two membranes of this structure sits the perinuclear 
space. The outer nuclear membrane (ONM) is continuous with the endoplasmic 
reticulum (ER) while the inner nuclear membrane (INM) is lined by the nuclear lamina 
(NL), which is instrumental in organising nuclear pore complex (NPC) localisation (Aebi 
et al., 1986; Gerace and Burke, 1988; Goldberg and Allen, 1996; Ris, 1997). A model of 
lamina organisation was originally proposed by Aebi and colleagues (1986), who using 
Xenopus oocytes, suggested that 2 sets of parallel 10 nm lamin filaments, with a repeat 
distance of 50 nm, are orthogonally arranged along the inner face of the NE. While this 
has been the accepted model for many years, Goldberg et al. (2008a) have recently put 
forward a modified version. They propose that the NL comprises of a single set of 
parallel filaments, 8–10 nm in diameter which are linked by 5 nm uncharacterised 
cross connections. Unlike the Aebi model, the filaments are predicted to be more 
tightly packed, with a repeat distance of 15 nm instead of 50 nm (Goldberg et al., 
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2008a). It is primarily composed of the intermediate filament type V proteins known as 
nuclear lamins (McKeon et al., 1986). Following the discovery that these were nuclear-
based (Aaronson and Blobel, 1975), immunolabeling identified them as INM proteins 
(Gerace et al., 1978).  
 
1.2.2 Nuclear Lamins  
1.2.2.1 Introduction 
 
Both A-type and B-type lamins exist; while A-type lamins are expressed mainly in 
differentiated somatic cells, B-type lamins are generally ubiquitous (Lehner et al., 
1987). Historically, it has been suggested that A-type lamin expression correlates with 
the onset of differentiation pathways (Lehner et al., 1987; Rober et al., 1989; Goldman 
et al., 2002; Hutchison and Worman, 2004). However, it is becoming clear that these 
proteins are present early in embryogenesis; this has been shown in murine (Schatten 
et al., 1985), sea urchin (Schatten et al., 1985) and porcine embryos (Foster et al., 
2007). In contrast, the necessity for B-type lamins is not disputed; they have been 
identified as essential. Their loss induces apoptosis and prevents cell growth; however, 
lmna-/- mice develop normally (Sullivan et al., 1999; Harbourth et al., 2001). Nuclear 
lamins are evolutionarily conserved and as a result, are seen in an array of phylogenies 
(for review, see Hutchison, 2002). 
 
1.2.2.2 Lamin encoding genes 
 
The major A-type lamins are lamin A and C; in humans, these are encoded at equal 
frequency by the LMNA gene through alternate splicing. It is the activation of an 
alternate splice site in intron 10 which leads to lamin C’s production (Fisher et al., 
1986). While the two isoforms share the primary 566 residues, their C-termini differ 
(Lin and Worman, 1993). It is not yet understood why, in evolutionary terms, these 
two isoforms are produced since mice producing exclusively lamin C are apparently 
healthy and fertile. This finding indicates that lamin A is perhaps dispensable (Fong et 
al., 2006).  
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Two other proteins, lamin C2 and lamin AΔ10, can also be encoded by this gene locus. 
However, their expression is somewhat restricted to certain cell types; meiosis-specific 
lamin C2 is found only in spermatocytes whereas, AΔ10 is confined to a few carcinoma 
cell lines (Alsheimer and Benavente, 1996). Interestingly, the latter product results 
from the deletion of exon 10, through alternate splicing (Hutchison, 2002) and is found 
to localise at the NE (Broers et al., 1999). In contrast, the human B-type lamins are 
generated by two separate genes. LMNB1 produces lamin B1 (Lin and Worman, 1995), 
while lamin B2 and B3 are the products of LMNB2 (Biamonti et al., 1992).  
 
For years, it was assumed that lamin proteins were restricted to the nuclear periphery 
of the interphase nucleus (e.g. Gerace et al., 1978) however, this appears not to be the 
case. Immunofluorescence has revealed the presence of an internal, diffuse lamin 
network; these speckles are absent from nucleolar regions and most prominent during 
nuclear growth (Goldman et al., 1992; Bridger et al., 1993; Hozak et al., 1995; Broers et 
al., 1999; Barboro et al., 2002).  
 
1.2.2.3 Post-translation modifications of lamin proteins 
 
Lamin proteins consist of 3 domains; an amino terminal head domain, a central helical 
rod domain and lastly, a carboxy-terminal globular domain. The central rod domain is 
divided into 4 sub-domains, denoted 1A, 1B, 2A and 2B; these are separated by the 
linkers, L1, L12 and L2 (Parry and Steinert, 1999). L1 and L2 are highly conserved, 
indicating their potential significance in lamin function and structure (Conway and 
Parry, 1988). These polypeptides go on to form parallel, coiled-coil dimers; the two 
molecules interact through their alpha-helical rod domains. Subsequently, these 
dimers assemble into polar, head-to-tail polymers (Strelkov et al., 2004; for review, see 
Herrmann et al., 2007).  
 
Present at the C-terminus is a highly conserved CAAX motif (c, cysteine; aa, 2 aliphatic 
residues; x, any amino acid) which is absent in both lamin C and C2 (see figure 1.1). 
This sequence acts as a signal to indicate that farnesylation can proceed. Indeed, 
during post-translational modifications, a farnesyl group is added to the cysteine 
residue by a farnesyltransferase (Beck et al., 1990). This farnesyl group is required for 
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pre-lamin A’s integration into the inner nuclear membrane (Lutz et al., 1992; Hennekes 
and Nigg, 1994). Following this, cleavage of the terminal AAX residues occurs; which is 
catalysed by the zinc metalloproteinase, ZMPSTE24, also denoted as FACE1 in humans 
(Sinensky et al., 1994). This event exposes the farnesylated cysteine which 
subsequently undergoes carboxymethylation; a step catalysed by isoprenylcysteine 
carboxyl methyl transferase (ICMT). To produce mature lamin A, this aforementioned 
cysteine plus the other terminal 14 amino acids must be removed by a second 
cleavage event; this again requires ZMPSTE24 (see figure 1.1). If the farnesyl group is 
not cleaved, the protein remains associated with the NE and is not released and 
inserted into the NL (Holtz et al., 1989; Hennekes and Nigg, 1994). Since lamin C lacks 
this specific CAAX motif, it does not undergo these post-translational modifications 
(Fisher et al. 1986). 
Figure 1.1: Lamin A processing in normal cells 
FTase = farnesyltransferase; ICMT = isoprenylcysteine carboxyl methyl transferase. 
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1.2.2.4 Functions of nuclear lamins 
1.2.2.4.1 Genome organisation 
 
In addition to the structural properties of the NL, lamins are implicated in numerous 
other important nuclear functions. Perhaps most significantly is their role in mediating 
chromatin organisation; A- and B- type lamins have been demonstrated to bind DNA in 
vitro (Shoeman and Traub, 1990; Luderus et al., 1992; Stierle et al., 2003) and core 
histones (Taniura et al., 1995). Indeed, around 500 genes have been shown to interact 
with the NL in Drosophila (Pickersgill et al., 2006). Research using human fibroblasts 
reveals that over 1,300 distinct genomic sites associate with this peripheral structure; 
such regions have thus been termed lamina-associated domains (LADs; Guelen et al., 
2008). These LADs are generally characterised by low expression levels (Guelen et al., 
2008) which concurs with the observation that NL-associated genes in Drosophila are 
found to be transcriptionally silent (Pickersgill et al., 2006). Taken together, the 
findings suggest that the NL is an area of transcriptional repression. 
 
1.2.2.4.2 Signalling pathways: transcription, proliferation and differentiation factors 
 
Both A- and B-type lamins also sequester transcription factors to the nuclear 
periphery, thus regulating their transcriptional activity. One such protein is c-fos; this 
protein is a member of the AP-1 transcription factor complex, a dimeric complex which 
regulates gene transcription. Significantly, c-fos is recruited to the NE through lamin 
A/C binding; importantly, this tethering is found to suppress the onset of c-fos 
mediated transcription (Ivorra et al., 2006; Gonzalez et al., 2008). Phosphorylation of c-
fos by the mitogen activated protein kinase (MAPK), ERK1/2, is demonstrated to 
release c-fos from its inhibitory interaction with lamin A/C which, in turn induces the 
transcription of AP-1 target genes (Gonzalez et al., 2008). A similar role for B-type 
lamins has also been demonstrated; lamin B1 is found to sequester Oct-1, a 
transcription factor which regulates the expression of genes involved in oxidative 
stress response pathways (Malhas et al., 2009). Further strengthening their role in 
signalling pathways, reports have revealed that nuclear lamins also interact with the 
kinase, JIL-1 (Bao et al., 2005), the transcription factor, MOK2 (Dreuillet et al., 2002; 
Dreuillet et al., 2008), the tumour suppressor, ING1 (Han et al., 2008) and also the 
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enzyme, 12-lipoxygenase (12-LOX; Tang et al., 2000).  In addition, lamin A associates 
with lamina-associated polypeptide 2 alpha (LAP2α; described later) and the 
retinoblastoma protein (pRb) to form a complex, which prevents the degradation of 
the latter (Ozaki et al., 1994; Johnson et al., 2004).  This is significant since pRb is a key 
tumour suppressor protein which acts to regulate cell cycle progression.  
 
Lamin A is also demonstrated to interact with factors involved in cellular 
differentiation. Indeed, the sterol response element binding protein 1 (SREBP1) is 
found to bind to both mature and immature lamin A (Lloyd et al., 2002; Capanni et al., 
2005). This is of interest since SREBP1 regulates the expression of genes involved in 
adipocyte differentiation, such as the peroxisome proliferator-activated receptor 
gamma (PPARγ; Fajas et al., 1998). Furthermore, lamin A participates in muscle 
differentiation pathways; the ectopic expression of lamin A leads to a transient 
increase in the transcription of muscle-specific genes (Lourim and Lin, 1989). 
Additionally, the protein is present in the speckles of proliferating skeletal-muscle cells, 
while absent in those actively differentiating (Muralikrishna et al., 2001). Moreover, A-
type lamins interact with both cyclin D3, a cyclin involved in muscle differentiation 
(Mariappan et al., 2007). 
  
1.2.2.4.3 Transcription and DNA replication 
  
The activity of RNA polymerase II, an enzyme which catalyzes transcription, is inhibited 
by the presence of a dominant negative lamin mutant.  This highlights the need for 
intact lamin organisation during mRNA synthesis (Spann et al., 2002). Since this finding 
was demonstrated using Xenopus cell free extracts, it has been suggested that the 
inhibitory effect observed results from lamin B loss as this amphibian only expresses B-
type lamins (Stick et al., 1985). Lamin A has also been implicated in supporting RNA 
splicing (Jagatheesan et al., 1999).  
 
Various studies demonstrate a link between lamin proteins and DNA replication; 
indeed, their highly conserved tail motifs directly bind to proliferating cell nuclear 
antigen (PCNA; Shumaker et al., 2008), which acts to mediate the interaction between 
DNA polymerase and DNA (Lee and Hurwitz, 1990). Furthermore, B-type lamins are 
 Chapter 1: Introduction 
 
8 
 
necessary for efficient DNA replication; this has been mainly proven by the 
manipulation of Xenopus egg extracts (Newport et al., 1990; Meier et al., 1991; 
Goldberg et al., 1995; Ellis et al., 1997). When lamin B3 is depleted from egg extracts, 
the initiation of DNA replication is inhibited until its re-introduction (Goldberg et al., 
1995). Furthermore, lamin B is seen to co-localise with replication sites (Moir et al., 
1994; Philimonenko et al., 2006).  Ellis et al. (1997) report that lamin proteins are 
required for the production of replication foci; they propose elongation can proceed in 
their absence. Despite this finding, other studies demonstrate that this is not the case 
(Moir et al., 1994; Moir et al., 2000). 
 
1.2.3 Other INM Proteins 
1.2.3.1 LEM domain proteins 
 
Numerous other INM proteins have been identified, many of which interact with 
lamins and/or chromatin (figure 1.2). Several of these belong to the LAP2-emerin-
MAN1 (LEM) domain family; a group of proteins which share a conserved motif, ~40 
amino acids in length (Lin et al., 2000; Cai et al., 2001; Laguri et al., 2001; Wolff et al., 
2001). In mammalian cells, 4 such LEM proteins have been characterised: LAP2, 
emerin, MAN1 and NET25/LEM2 (Schirmer et al., 2003; Wilson and Foisner, 2010). The 
LEM domain binds the 10 kDa barrier-to-autointegration factor (BAF), a DNA cross-
linking protein and thus mediates chromatin interactions (Lee and Craigie, 1998; 
Segura-Totten and Wilson, 2004; Margalit et al., 2005). Importantly, lamin A also 
interacts with BAF, although the avidity of such binding is less than that seen for BAF-
LEM complexes (Holaska et al., 2003; Margalit et al., 2007). 
 
1.2.3.2 Emerin 
 
Emerin is an integral INM protein (Nagano et al., 1996) whose expression is almost 
ubiquitous; it is detected in all human cells apart from those non-myocytes found in 
the heart (Manilal et al., 1996). Its correct nuclear localisation requires A-type lamins 
since they are found to anchor emerin at the NE; indeed, in cells lacking functional A-
type lamins, the protein is mislocalised to the ER (Sullivan et al., 1999; Burke and 
Stewart, 2002; Holaska et al., 2002; Muchir et al., 2003). In agreement with these 
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findings, emerin colocalises with lamin proteins in vitro and in vivo (Manilal et al., 
1998; Clements et al., 2000; Vaughan et al., 2001; Lee et al., 2001; Goldman et al., 
2005).   
 
 
 
Figure 1.2: An overview of the nuclear envelope 
 
Evidence is building to suggest that emerin has a role in regulating gene expression, 
however, studies showing this are still few and far between (Holaska and Wilson, 
2006). Emerin binds Bcl-2-associated transcription factor (Btf; Haraguchi et al., 2004) 
and germ cell-less (GCL; Holaska et al., 2003), both of which are repressors of 
transcription. Interestingly, Btf is a pro-apoptotic factor, which associates with the NE 
following the initiation of apoptosis (Haraguchi et al., 2004). GCL, on the other-hand, is 
involved in E2F signalling (Holaska et al., 2003). Additionally, emerin is thought to be 
involved in mRNA processing; this stems from the observation that the protein 
interacts with the splicing factor, YT521-B, in vivo (Wilkinson et al., 2003). 
 
1.2.3.3 Lamina-associated polypeptide 2 (LAP2) family 
 
The alternate splicing of the LAP2 produces six LAP2 isoforms, each of which exhibit 
varying functions and localisation; while LAP2α is found dispersed throughout the 
nucleus, LAP2-β, -δ, -γ, -ε are bound to the INM (Harris et al., 1994; Berger et al., 1996; 
Dechat et al., 1998; Vlcek et al., 1999). Of the isoforms, LAP2α and β are documented 
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to participate in regulating gene expression. Indeed, LAP2α-lamin A complexes anchor 
pRb to the nuclear edge, which thus affects the transcription of S-phase genes and 
influences cell cycle progression (Markiewicz et al., 2002). LAP2β can repress 
transcription either through GCL binding or via its recruitment of the histone 
deacetylase (Nili et al., 2001; Somech et al., 2005). LAP2β also binds to HA95, a 
chromatin-associated factor (Martins et al., 2003).     
 
1.2.3.4 Lamin B Receptor 
 
Another protein of note is the lamin B receptor (LBR). This 58 kDa protein, also known 
as p58, harbours two significant, functional domains; the N-terminus confers the 
ability to bind both lamin B and chromatin, while, the C-terminus exhibits sterol Δ14- 
reductase activity (Silve et al., 1998). LBR also interacts with the heterochromatin 
protein 1 alpha (HP1α; Ye and Worman, 1996); a factor which is thought to participate 
in gene silencing (Nielsen et al., 1999). Importantly, mutations in LBR have been found 
to result in two phenotypically distinct diseases; these disorders will be discussed later 
in the review. 
 
1.2.4 Nuclear Matrix 
1.2.4.1 Overview 
 
Significantly, the NL forms part of a larger nuclear structure, the nuclear matrix (NM; 
figure 1.2). The NM is composed of two main constituents; the peripheral NL and the 
internal NM (Nickerson, 2001). The term NM was first coined by Berezney and Coffey 
in 1974 and was at the time, used to describe a newly isolated nuclear fraction. The 
authors had achieved this by treating nuclei with both high salt molarities and DNase I, 
which functioned to extract the soluble proteins present and remove the DNA 
(Berezney and Coffey, 1974). Since then, criticism over the technique has been rife; 
some suggest that the structure is an artefact resulting from harsh, non-physiological 
extraction methods (Hancock, 2000). As a consequence of this, numerous 
modifications to this biochemical technique have been made resulting with nuclei 
being subjected to more physiologically accurate conditions; as a result, the term 
nucleoskeleton has been adopted (Jackson and Cook, 1988; Philimonenko et al., 2001). 
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There is a general consensus in the field that the NM or nucleoskeleton is a 
proteinaceous, RNA-rich network of thick polymorphic fibres, underlying which are 
thinner core filaments (Jackson and Cook, 1988; He et al., 1990; Philimonenko et al., 
2001). It is also found to be present regardless of transcriptional activity (Philimonenko 
et al., 2001).  
 
1.2.4.2 Functional relevance of the NM 
1.2.4.2.1 Genome organisation 
 
Within the interphase nucleus, chromosomes are non-randomly organised (Foster and 
Bridger, 2005). Although it is uncertain which nuclear elements mediate such 
arrangement, the most likely candidate for doing so is the NM (de Lange, 1992; Gerdes 
et al., 1994; Luderus et al., 1996; Ma et al., 1999; Croft et al., 1999; Elcock and Bridger, 
2008; Elcock and Bridger, 2010). Indeed, the genome is reported to interact with the 
NM at specific DNA sequences, known as matrix-attachment regions (MARs); although 
thousands of these regions exist, they are, in general, poorly characterised (Bode et al., 
2000). Telomeres which serve as caps at the extreme ends of chromosomes 
(Blackburn, 1994; Zakian, 1995) are anchored to the NM via their TTAGGG repeats, 
throughout the nuclear volume and not just at the periphery (de Lange, 1992; Luderus 
et al., 1996). Indeed, these repetitive elements are found to contain one MAR every 1 
kb (Luderus et al. 1996). Telomeres are of great interest since they shorten with each 
cell cycle; once they have reached a critical length, the cell enters a state termed 
replicative senescence (Allsopp et al., 1992; Bodnar et al., 1998). Telomeres can be 
replaced by the activity of telomerase; however this enzyme is switched off in somatic 
cells (Greider and Blackburn, 1989; Bodnar et al., 1998).  
 
Although it is not fully understood which NM proteins mediate genome interactions 
with the NM, it is becoming apparent that A-type lamins are involved in such 
associations. This is in light of their DNA binding properties (Shoeman and Traub, 1990; 
Taniura et al., 1995; Stierle et al., 2003) and recognition as MAR-binding proteins 
(Luderus et al., 1992; Bode et al., 2003). Furthermore, A-type lamins are shown to 
associate with telomeres (Raz et al., 2008); indeed, the loss of such proteins 
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significantly disrupts telomere localisation and maintenance (Gonzalez-Suarez et al., 
2009).         
 
1.2.4.2.2 DNA replication 
 
There is an abundance of research which demonstrates that the NM is required for 
efficient DNA replication. Indeed, newly synthesised DNA is found to associate with the 
structure (Berezney and Coffey, 1975; Hassan and Cook, 1993). Several enzymes which 
participate in DNA replication are also attached to the NM: DNA polymerase alpha 
(DNA pol α), DNA primase, 3’–5’ exonuclease, RNase H and DNA methylase (Smith and 
Berezney, 1980, 1982, 1983; Foster and Collins, 1985; Tubo and Berezney, 1987a, b, c; 
Martelli et al., 1998). Furthermore, primer recognition proteins, such as annexin II and 
the glycolytic enzyme, 3-phosphoglycerate kinase (PGK), exhibit NM attachment 
(Vishwanatha et al., 1992). In line with these observations, other studies reveal that 
replication factories, the discrete sites at which replication is demonstrated to occur, 
are anchored to the NM (Hassan and Cook, 1993; Hozak et al., 1993; Hozak et al., 
1994; Djeliova et al., 2001a, 2001b; Radichev et al., 2005). Replication forks are also 
associated with the structure (Vaughn et al., 1990). The attachment of replication 
factories to the NM is important for the initiation of replication (Djeliova et al., 2001a; 
Radichev et al., 2005). However, origins of replication are not associated with the NM 
throughout the cell cycle; they associate with the structure in late G1 and are released 
following initiation in S-phase (Djeliova et al., 2001a; Djeliova et al., 2001b).  
 
1.2.4.2.3 Transcription and splicing 
 
Importantly, the NM provides the foundation upon which transcription factories 
operate. The sites of RNA polymerase I and II mediated-transcription are attached to 
this nuclear substructure (Dickinson et al., 1990; Jackson et al., 1993; Iborra et al., 
1996). Actively transcribing DNA is fed through fixed RNA polymerase molecules 
(Iborra et al., 1996); in line with this, transcriptionally active genomic regions are found 
associated with the NM, while inactive regions are not (Ciejek, 1983; Jackson and 
Cook, 1993; Gerdes et al., 1994). Transcription factors such as the estrogen receptor 
(Alexander et al., 1987; Metzger and Korach, 1990), steroid hormone receptor 
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(Barrack, 1987), corticosteroid receptor (Van steensel et al., 1991) and vitamin D 
receptor (Bidwell et al., 1994) are NM-associated. Furthermore, elements required for 
ribosomal assembly, pre-mRNA processing and splicing, including nucleophosmin/B23, 
hnRNPs and spliceosomes, are also attached to the NM (Zeitlin et al., 1987, 1989; 
Mattern et al., 1996).  
 
A fully functional NM is required to support transcription; if lamin proteins are missing 
or mutant, this process is perturbed. Spann et al. (2002) reported that the presence of 
mutant lamin A inhibits the activity of RNA polymerase. Furthermore, depleting lamin 
B1 levels by interference technology significantly disrupts RNA synthesis (Tang et al., 
2008). 
 
1.2.4.2.4 DNA repair 
 
In addition to its role in chromatin modelling, replication and transcription, the NM is 
thought to serve as a platform for the regulation of cell cycle progression and DNA 
repair. Indeed, DNA repair occurs at the NM (McCready and Cook, 1984; Harless and 
Hewitt, 1987) and NM-associated DNA is preferentially repaired following genotoxic 
stress (Mullenders et al., 1988). However, such repair is not exclusively a NM-
associated event (Mullenders et al., 1988).  Furthermore, DNA is recruited to the NM 
following genotoxic stress (Koehler and Hanawalt, 1996). The CSA (Cockayne syndrome 
group A) protein, which is important for transcription-coupled repair (TCR), is 
translocated to the NM following ultraviolet (UV) irradiation, in a CSB-dependent 
manner (Kamiuchi et al., 2002). A significant relationship exists between the NM and 
p53; this major tumour suppressor protein initiates an array of key cellular responses. 
Concomitant with an increase in p53 levels, p53 binding to the NM augments in 
response to DNA damage (Jiang et al., 2001). It has thus been suggested that this 
interaction is vital for the correct and efficient activation of p53-related pathways, 
following genotoxic stress (Jiang et al., 2001). By creating structural mutants, it was 
demonstrated that residues 67–98, located in the protein’s N-terminus, mediate this 
binding (Jiang et al., 2001). Further adding to the view that the NM has a role in co-
ordinating DNA damage signalling, Rad51, a key homologous recombination protein, is 
reported to be a NM protein (Mladenov et al., 2006, 2007, 2009). Such binding is 
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mediated by a putative NM targeting signal in Rad51; in response to DNA damage, this 
interaction facilitates the formation of NM-associated nuclear foci. Indeed, when 
Rad51 is mutated to eliminate NM binding, these foci no longer assemble (Mladenov 
et al., 2009).  Other DNA damage response proteins, such as Brca1, Brca2, ATM, also 
associate with the NM (Gately et al., 1998; Huber and Chodosh, 2005).  
 
1.3 GENOME ORGANISATION 
1.3.1 Introduction 
 
Over the past decade, much progress has been made in order to elucidate the nuclear 
organisation of the genome. The positioning of chromosomes in the interphase 
nucleus is shown to be non-random; each occupies a specific domain, known as a 
‘chromosome territory’ (Cremer et al., 1982; Strasburger, 1905, cited in Rothmann et 
al., 1997, p1105; Boveri, 1909, cited in Bridger and Foster, 2005, p213). These 
territories can be visualised by using fluorescence in situ hybridisation (FISH) on fixed 
cells, however, it is also possible to view these structures in living cells via the 
incorporation of labelled nucleotides (Zink et al., 1998; Visser and Aten, 1999). 
Historically, the interchromatin domain (ICD) model has been accepted, whereby little, 
if any, intermingling between neighbouring chromosome sites exists (Cremer et al., 
1993; Zirbel et al., 1993; Visser et al., 2000; Cremer et al., 2000; Kosak and Groudine, 
2002). However, recent evidence suggests that this is not the case. Branco and Pombo 
(2006) used high-resolution in situ hybridisation to demonstrate significant 
intermingling between territories; indeed, the degree of interaction correlated with 
translocation frequency.     
 
Interestingly, this spatial arrangement of chromosomes appears to alter both upon 
differentiation (Solovei et al., 2004; Foster et al., 2005) and exit from the cell cycle 
(Bridger et al., 2000; Mehta et al., 2010). Studies have shown that individual 
chromosomes have preferential neighbours in nuclei (Nagele et al., 1999); an 
organisation which appears to be cell type specific (Marella et al., 2009). Several 
studies have demonstrated that, within interphase nuclei, chromosome territories are 
radially organised (Croft et al., 1999; Bridger et al., 2000; Boyle et al., 2001); however, 
the basis of such positioning has caused much debate. Boyle et al. (2001) suggest that 
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it is driven by gene density while others (Sun et al., 2000; Bolzer et al., 2005) propose 
that chromosome organisation is size-dependent. Unfortunately, the study of chicken 
cells has done little to clarify the situation since the organisation of their macro- and 
micro-chromosomes fits both hypotheses (Habermann et al., 2001; Parada and 
Mistelli, 2002).  
 
Certain groups report that transcriptionally active sequences tend to be positioned 
either towards the territory edge or outside the territory altogether (Scheuermann et 
al., 2004; Morey et al., 2009). Indeed, gene-rich chromatin loops radiating away from 
chromosome territories have been reported (Volpi et al., 2000; Mahy et al., 2002; 
Ragoczy et al., 2003). However, in some cases, these gene-rich regions are found at the 
chromosome territory edge regardless of transcription status (Mahy et al., 2002). It is 
thus possible that such gene-rich sequences are poised in these peripheral positions to 
enhance transcription factory accessibility. Recent research suggests that both GC 
content and replication timing could also be important for positioning chromatin 
domains within nuclear space (Hepperger et al., 2008; Grasser et al., 2008).  
 
1.3.2 Nuclear periphery: an area of repression? 
 
Historically, the nuclear edge has been regarded as an area of transcriptional inactivity. 
Indeed, constitutive heterochromatin is consistently found to associate with both the 
nuclear periphery and nucleoli, while the early-replicating, transcriptionally active, 
euchromatin occupies a more internal position (for review, see Deniaud and Bickmore, 
2009). This observation concurs with the apparent gene-density dependent radial 
positioning of chromosomes revealed by FISH studies (Boyle et al., 2001). 
Unfortunately, however, the picture is not as straightforward as perhaps once 
imagined; work is continually being published which makes the transcriptional 
distinction between the nuclear edge and interior increasingly less certain. 
 
Research shows that the nuclear interior is unquestionably, a hot-bed of 
transcriptional activity. Regions of increased gene expression (RIDGEs) are found 
located within the nuclear interior, while anti-RIDGEs, transcriptionally inactive 
genomic regions, are often observed at the periphery (Caron et al., 2001; Versteeg et 
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al., 2003; Goetze et al., 2007; Gierman et al., 2007). Indeed, Kosak et al. (2007) report 
that the majority of transcribed genes are positioned within the nuclear interior. In line 
with this, Takizawa et al. (2008) demonstrated that the transcriptionally active allele 
tends to cluster within the nuclear interior, unlike its inactive counterpart.  
 
As mentioned previously, the genome interacts with the NL at multiple sites, known as 
LADs (Guelen et al., 2008). Importantly, such domains are found to be regions of low 
levels of gene expression (Guelen et al., 2008).  Is the nuclear periphery, however, 
incompatible with transcription? By tracking nascent RNA production, it is evident that 
transcription occurs throughout the nucleus, both within the nuclear interior and at 
the nuclear edge (Wansink et al., 1993).  Work performed using mice demonstrates 
that the IFNγ locus is located at the nuclear periphery regardless of whether the gene 
is active or inactive (Hewitt et al., 2004). A study involving the human 
immunodeficiency virus (HIV) further strengthens the opinion that the nuclear edge is 
not unsuited to gene expression (Dieudonne et al., 2009). Recently, three groups have 
focussed on the transcriptional consequences of artificially tethering regions of the 
genome to the nuclear edge. Reddy et al. (2008) reported that while cxcl5 and cxcl1 
were significantly down-regulated as a result of such anchorage to the nuclear 
periphery, no noteworthy changes were observed in any of the other genes examined. 
Conclusions from the studies of Bickmore and Spector appear to confirm this, in that 
targeting to the nuclear edge represses some, but not all genes (Finlan et al., 2008; 
Kumaran and Spector, 2008). To further complicate matters, it is emerging that NPCs 
are in fact areas of high transcriptional activity; this view is, in part, formed by 
observing events occurring in both yeast and Drosophila (Akhtar and Gasser, 2007). 
Indeed, this chimes with Blobel’s early gene-gating hypothesis where he suggested 
that high levels of gene transcription at NPCs would logically facilitate mRNA export 
(Blobel, 1985).   
 
1.3.3 What is the functional relevance of gene repositioning? 
 
Specific genes are found to be repositioned from the nuclear periphery to the interior 
during their activation (Chuang et al., 2006; Dundr et al., 2007; Lanctot et al., 2007). 
Other studies demonstrate that when expression is increased, loci move towards the 
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nuclear interior, while when repressed they preferentially associate with the nuclear 
edge (Brown et al., 2001; Kimura et al., 2002; Zink et al., 2004; Szczerbal et al., 2009). 
However, it is becoming apparent that rather than nuclear repositioning dictating 
transcriptional activity, it is expression that drives repositioning. Indeed, purely 
relocating the Mash1 locus from the periphery to a more interior position was not 
sufficient to activate transcription (Williams et al., 2006). Furthermore, the looping out 
of a gene from its chromosome territory, into a more interior position, was insufficient 
to up-regulate gene expression (Morey et al., 2009). Taken together, these conclusions 
infer that an internal nuclear position is more important for attaining high 
transcriptional activity, than for the actual activation event per se (Ragoczy et al., 
2006).  
 
1.3.4 Gene positioning and transcription factories 
 
It is generally accepted that transcription occurs in discrete foci known as transcription 
factories, which are found to be distributed throughout the nucleus, attached to an 
underlying nucleoskeleton (figure 1.3; Iborra et al., 1996). Contrary to popular belief, 
mRNA is generated from active genes during infrequent bursts rather than continual 
periods of transcription (Raj et al., 2006). The majority of active genes reside within 
transcription factories, while inactive loci are found outside these structures (Osborne 
et al., 2007). There is some evidence to indicate that certain genes preferentially co-
transcribe. Using RNA FISH, Osborne et al. (2007) demonstrated that in mouse B-
lymphocytes, the proto-oncogene, Myc, preferentially shares the same transcription 
factory as the highly transcribed, Igh; a significant finding since the two gene loci are 
frequently involved in lymphoma-related translocation events. Importantly, it appears 
that functionally-related genes come together in order to be transcribed (figure 1.4). 
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The mouse β-globin gene co-localises, at high frequency, to the same transcription 
factory as other erythroid-specific genes; an observation which has been proven by 
both RNA FISH and 4C (chromosome conformation capture-on-chip) studies (Osborne 
et al., 2004; Simonis et al., 2006). In yeast, tRNA genes, which are generally scattered 
throughout the genome, are reported to cluster into nucleolar-based factories when 
transcribed (Thompson et al., 2003). Furthermore, the transcription of specific snRNA 
genes is found to occur at coiled bodies (Frey et al., 1999). Recent work by Peter 
Cook’s group suggests that such factories appear to specialize in the production of 
certain transcript species. Plasmids were introduced into cells, which subsequently 
assembled into minichromosomes; the transcription of these elements was tracked 
using FISH. Interestingly, only ~ 20 transcription factories were employed to transcribe 
the 8000 minichromosomes present per cell; this indicates (1) that factory specificity 
exists and (2) that one factory can process multiple transcripts simultaneously. The 
study reported that this selectivity was driven by intronic status and promoter type (Xu 
and Cook, 2008). This implies that specific sequences are transcribed by selected 
factories; thus, surely if this is the case, the distribution of different transcription 
factory types would influence the position of genes within the nucleus. Perhaps some 
genes are positioned within the vicinity of necessary factories, which contain the 
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required transcription factors, while other genes need to migrate some distance in 
order to be expressed or repressed. This begs the question: which particular elements 
target gene sequences to specific transcription factories? Elucidating such factors will 
also aid in understanding the basis of genome organisation. 
1.3.5 What can evolution tell us? 
 
Perhaps one of the most thought-provoking articles on genome organisation in recent 
years has been that published by Solovei et al. (2009). The group investigated and 
compared the nuclear architecture of rod photoreceptor cells in both nocturnal and 
diurnal mammals. Significantly, the results questioned the widely accepted theory; 
that the heterochromatic rich regions of the periphery are a staple in nuclear 
organisation. The study discovered that, in rod photoreceptor cells of the mouse, this 
typical arrangement is in fact reversed; gene-dense regions decorate the nuclear edge, 
while gene-poor regions localise in the interior. In line with this, the majority of 
transcription machinery is also found peripherally. Interestingly, all genes, regardless 
of transcriptional activity, were located towards the nuclear edge. The authors 
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reported that this ‘inverse’ pattern of organisation in the retina was indeed associated 
with nocturnal vision; diurnal mammals have conventionally arranged rod 
photoreceptor nuclei.   This finding has led to many questions; one of which centres 
around evolution. The demonstration that an ‘inverse’ version of the ‘conventional’ 
genome organisation exists, suggests that each must confer an evolutionary advantage 
to the corresponding organisms. Solovei et al. (2009) suggest that this inverse 
arrangement facilitates, in some way, the transmission of photons. Whether or not this 
is the sole reason, the study reveals the flexibility of the organisation and indicates 
that it remains unchanged through evolution for a purpose. Evidently, this ‘purpose’ 
will be inextricably linked to transcriptional regulation; however, for the time being, 
the answer remains elusive.  It will be extremely fruitful to identify those elements 
which encode the global organisation of the genome.  
 
1.3.6 Closing remarks 
 
Over the past decade, major advances have been made in terms of elucidating the 
organisation of the genome. It is now becoming increasingly apparent that the 
functional relevance of this organisation is somewhat complex; indeed, the 
transcriptional distinction between the nuclear periphery and nuclear interior is not as 
straightforward as once imagined. The repositioning of certain genes correlates with 
changes in expression; however, with other loci, it does not. It is likely that gene 
repositioning is used in order to regulate the expression of specific genes; it is probably 
not representative of a blanket genomic response. Furthermore, the significance and 
role of transcription factories in mediating this organisation should not be overlooked. 
As our understanding of these factories increases, so too will our comprehension of 
genome organisation and the nuclear structures which dictate it. 
 
1.4 LAMINOPATHIES  
1.4.1 Introduction  
 
The laminopathies are a collection of human diseases that result primarily from 
mutations in lamin-encoding genes, namely LMNA; this genomic region is found to 
harbour over 180 different disease-causing mutations (Hutchison and Worman, 2004; 
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Gruenbaum et al., 2005; Jacob and Garg, 2005; Capell and Collins, 2006). Interestingly, 
mutations in LMNA can produce clinically distinct disorders, which exhibit tissue 
specificity; unfortunately, this presents a huge problem when attempting to 
understand the disease mechanisms involved.  In addition, other lamin-binding 
proteins such as emerin and LAP2α, when defective, are seen to produce so called 
‘secondary laminopathies’ (Jacob and Garg, 2006). In this respect, several disorders 
have both primary and secondary causes. A fact which highlights how inextricably 
interconnected these proteins have become throughout evolution. Taking this into 
account, the section will aim to provide an overview of the laminopathy diseases, 
discuss the proposed disease mechanisms involved and briefly touch on potential 
future therapies. 
 
1.4.2 Premature Ageing Syndromes 
1.4.2.1 Hutchinson-Gilford Progeria Syndrome (HGPS) 
 
Hutchinson-Gilford Progeria Syndrome (HGPS) is an extremely rare premature ageing 
disease, which affects 1 in 4–8 million live births (Capell and Collins, 2006). It was first 
reported in 1886 by Hutchinson and then, later by Gilford in 1904. Patients with the 
disease invariably exhibit micrognathia, alopecia, short stature, insulin resistance, 
delayed dentition and absent sexual maturation; these features become noticeable 
after the first twelve months of life (DeBusk, 1972). The mean age of HGPS patients at 
death is 13.4 years (DeBusk, 1972) when cardiovascular disease i.e. atherosclerosis, is 
usually the cause (Baker et al., 1981). 
 
In 2003, Eriksson et al. produced a seminal paper which showed that of the 20 classical 
HGPS patients studied, 18 of these exhibited a G608G mutation in exon 11 of the 
LMNA gene. Although, this mutation was a silent C>T transition at position 1824, it was 
demonstrated that the single nucleotide substitution activated a cryptic splice site.  As 
a result of this activation, there was found to be a 150 bp deletion at the mRNA level 
from the carboxy terminus of lamin A. This event produced a mutant protein lacking its 
pre-terminal 50 amino acids (Eriksson et al., 2003). Simultaneously, De Sandre-
Giovannoli et al. (2003) also demonstrated the occurrence of lamin A truncation in 
HGPS patients.  It was found that this deletion interferes significantly with the protein’s 
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post-translational modifications; it removes a cleavage site required by ZMPSTE24, the 
zinc metalloproteinase. As a result, it abnormally remains associated with the NE. This 
farnesylated, truncated version of lamin A has been termed progerin or LAΔ50 (figure 
1.5; Goldman et al., 2004). Interestingly, in another study, which involved 3 HGPS 
patients, it was observed that the de novo LMNA mutations were paternally-derived 
(D’Apice et al., 2004). 
 
The mode of inheritance can also be autosomal recessive; Plasilova et al. (2004) 
reported homozygotes harbouring a missense mutation in LMNA at residue 1626 
(K542N). This resulted in the replacement of a charged lysine molecule with an 
uncharged asparagine, an event which did not activate a cryptic splice site, as 
previously described (e.g. Eriksson et al., 2003). The authors thus suggested that this 
mutation interferes with docking sites for emerin, LAP2α and DNA interaction 
(Plasilova et al., 2004). Furthermore, compound heterozygosity has been observed in a 
patient with both R471C and R527C LMNA mutations (Cao and Hegele, 2003). A 
somatic and gonadal mosaic form has also been noted in an unaffected parent, whose 
child suffers from HGPS (Wuyts et al., 2005). 
 
1.4.2.2 Werner’s Syndrome (WS) 
 
Another disorder which displays progeroid features is Werner’s syndrome (WS); this is 
a rare, autosomal recessive disease caused by mutations in the WRN gene, which 
encodes a RecQ-type DNA/RNA helicase (Yu et al., 1996). Interestingly, it is found that 
in 70% of cases, the patient is the result of a consanguineous marriage (Goto et al., 
1981). The symptoms observed in WS overlap somewhat with those seen in HGPS: 
short stature, alopecia, bilateral cataracts, atrophic skin, hypogonadism and low body 
weight (Goto et al., 1997). Malignancy and atherosclerosis are the two main causes of 
death with 50% of patients dying before the age of 40 (Goto et al., 1997). Significantly, 
of the 1100 WS patients reported worldwide, 810 of these originate in Japan (Goto et 
al., 1997). 
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Figure 1.5: Lamin A processing in normal and classical HGPS cells 
In normal cells, which harbour wildtype LMNA, mature and functional lamin A is generated. 
However, in classical HGPS, the 50 amino acid deletion removes the site required for the final 
cleavage step. Consequently, prelamin A remains farnesylated. FTase = farnesyltransferase; 
ICMT = isoprenylcysteine carboxyl methyl transferase. This has been influenced by a figure 
presented by Young et al. (2006).  
 
Of the 129 samples sent for molecular diagnosis from patients presenting with WS 
symptoms, 26 lacked a WRN mutation. Subsequently, LMNA was sequenced; it was 
found that of these 26, 15% carried novel heterozygous, missense mutations in this 
gene. Accordingly, this phenotype has been termed atypical WS; adding it to the 
increasing list of laminopathies (Chen et al., 2003).    
 
1.4.3 Myopathies and Neuropathies 
1.4.3.1 Emery-Dreifuss Muscular Dystrophy (EDMD) 
 
Emery-Dreifuss Muscular Dystrophy (EDMD) was first described as an X-linked disorder 
by Emery and Dreifuss, in 1966; it was found to be a recessive trait, occurring only in 
males. Sufferers of X-EDMD share symptoms such as muscle weakness, early 
contractures of the elbows, cardiac disorders and shortening of the Achilles tendons 
(Emery and Dreifuss, 1966). Years later, the disease’s molecular cause was mapped to 
Xq 28, the home of the STA or EMD gene. It emerged that the encoded 34kDa protein, 
emerin, was defective in the five X-EDMD patients studied (Bione et al., 1994). This 
was a significant finding since previous to this discovery, defects in inner nuclear 
membrane proteins had not been seriously considered as a viable source of human 
disease. In the majority of cases, there is loss of emerin expression rather than the 
generation of a defective product (Yates et al., 1999). 
  
Subsequently, a paper documented LMNA mutations as the cause of autosomal 
dominant EDMD (Bonne et al., 1999). Numerous studies have confirmed these 
observations (Raffaele di Barletta et al., 2000; Brown et al., 2001) and in addition, it 
has been shown that an autosomal recessive form of EDMD exists (Raffaele di Barletta 
et al., 2000). These studies were the first to show that mutations in this gene could 
cause a disease phenotype in humans.  As is the case in many laminopathies, the 
symptoms displayed in autosomal EDMD can vary dramatically from patient to patient 
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(Raffaele di Barletta et al., 2000); however, the sex-linked form is usually less severe 
(Bonne et al., 2000).   
 
Linking the disease phenotype to the mutation site is not as straightforward as 
expected; the analysis of numerous AD-EDMD patients showed no significant 
correlation between the two (Bonne et al., 2000). As a result, the involvement of a 
modifier gene has been postulated (Bonne et al., 2000). Nonetheless, a study 
conducted by Brown et al. (2001) did observe that the majority of LMNA exons 
affected in EDMD shared a common feature; the mutations disrupt residues in the 
protein’s central rod domain. Perhaps unsurprisingly, it was revealed that the disease-
causing mutations altered those evolutionarily conserved residues. Consequently, the 
authors suggested a functional or structural importance of these sites (Brown et al., 
2001). Significantly, dominant mutations in SYNE1 and SYNE2, which encode the 
proteins nesprin-1 and nesprin-2, respectively, are also a cause of EDMD (Zhang et al., 
2007; Puckelwartz et al., 2009). 
  
1.4.3.2 Dilated Cardiomyopathy (DCM) 
 
Dilated cardiomyopathy (DCM) is characterised by the presence of systolic dysfunction 
and cardiac dilation; it is a leading cause of congestive heart failure worldwide (Kasper 
et al., 1994). Although DCM can result from a plethora of disorders (Kasper et al., 
1994), evidence has shown that in certain patients, a LMNA mutation is the source 
(Fatkin et al., 1999; Song et al., 2007). Significantly, Taylor et al., (2005) provided the 
first evidence to show that a mutant form of LAP2α is sufficient to produce disease in 
humans; they revealed an Arg690Cys LAP2 mutation in a DCM patient. Mutations in 
EMD also cause X-linked familial atrial fibrillation (Karst et al., 2008). 
 
1.4.3.3 Limb-Girdle Muscular Dystrophy (LGMD) 
 
Mutations in LMNA are also found to be responsible for Limb-Girdle Muscular 
Dystrophy 1B; this is a slow, progressive disease characterised by cardiac involvement 
(Van der Kooi et al., 1996). Evidence for this was first provided by Muchir et al. (2000); 
they identified missense, codon deletion and splice donor site mutations in patients 
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with the disease. In addition to these, LGMD1B can result from synonymous codon 
changes in LMNA which act to perturb mRNA splicing. In one published case, although 
the substitution (AAG>AAA) did not change the encoded amino acid (lysine), it 
activated a cryptic splice site. This resulted in the insertion of a string of 15 amino acids 
into the protein (Muchir et al., 2000).  More recently, it has been demonstrated that 
mutations in EMD also cause LGMD (Ura et al., 2007). 
 
1.4.3.4 Charcot-Marie Tooth (CMT) Type 2 B1 
 
In addition, homozygous LMNA mutations are the cause of the periphery axonopathy, 
Charcot-Marie Tooth (CMT) type 2 B1 (De Sandre-Giovannoli et al., 2002). In a study 
involving several Algerian families, a novel mutation (892C>T) was identified in exon 5 
of the LMNA gene, resulting in a R298C amino acid substitution. Research performed 
using Lmna-/- mice show that they exhibit axonal enlargement, a reduction in axonal 
density and nerve demyelination; concurrently, similar manifestations are observed in 
human CMT2 patients (De Sandre-Giovannoli et al., 2002). 
 
1.4.4 Lipodystrophies 
1.4.4.1 Dunnigan-Type Familial Partial Lipodystrophy (FLPD) 
 
LMNA mutations are also found to cause the autosomal dominant disorder, Dunnigan-
Type Familial Partial Lipodystrophy (FLPD; Cao et al., 2000; Shackleton et al., 2000; 
Speckman et al., 2000). Sufferers of the disease display symmetrical lipodystrophy of 
the trunk and extremities as well as insulin-resistant diabetes and type V 
hyperlipidemia (Dunnigan et al., 1974). Although the majority of FLPD patients harbour 
missense mutations, the incorrect splicing of the gene is demonstrated to cause 
disease too (Morel et al., 2006). It was found that a novel G>C mutation led to intron 
8’s inclusion in the mRNA; this resulted in a truncated lamin A isoform, 516 residues in 
length (Morel et al., 2006).  
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1.4.4.2 Mandibuloacral Dysplasia (MAD) 
 
Two categories of Mandibuloacral Dysplasia (MAD) exist, type A and type B; these 
diseases are caused by mutations in LMNA or ZMPSTE24, respectively (Novelli et al., 
2002; Agarwal et al., 2003). MAD-A results from a homozygous LMNA missense 
mutation (R527H; Novelli et al., 2002) while heterozygous, usually compound, 
ZMPSTE24 defects lead to type B disease (MAD-B; Agarwal et al., 2003). Patients with 
MAD display characteristic features: mandibular hypoplasia, cutaneous atrophy, insulin 
resistance, diabetes mellitus and lipodystrophy (Young et al., 1971; Freidenberg et al., 
1992; Simha and Garg, 2002).  
 
1.4.5 Additional Laminopathies 
1.4.5.1 Restrictive Dermopathy (RD) 
 
First reported by Witt et al. (1986), restrictive dermopathy (RD) is characterised by 
tight, translucent, dysplasic skin; this is documented to severely compromise physical 
movement and to impact on other bodily functions. As a result, the disorder is fatal 
(Verloes, 1992). The disease is caused by mutations in either LMNA or ZMPSTE24, 
although most cases result from the latter (Navarro et al., 2004; Navarro et al., 2005). 
In LMNA, a heterozygous splicing mutation leads to the partial or complete loss of 
exon 11, an event which causes RD. In contrast, the activation of a premature stop 
codon, caused by the insertion of a single nucleotide is what mutates the ZMPSTE24 
gene in the disease (Navarro et al., 2004). As a consequence of both events, 
farnesylated pre-lamin A accumulates in the nucleus and thus, exerts its dominant-
negative effects (Navarro et al., 2004; Navarro et al., 2005). Significantly, in one 
reported case, the disease phenotype of a homozygous ZMPSTE24 mutation was 
rescued by the presence of a heterozygous mutation in LMNA, in the same patient 
(Denecke et al., 2006). This finding acts to emphasize the deleterious effects of pre-
lamin A on the nucleus and how it leads to cellular pathology. 
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1.4.5.2 Lamin B Mutants 
 
Only recently, has it been demonstrated that mutations in B-type lamin proteins cause 
viable disease in humans; interestingly, the disorders produced are phenotypically 
distinct (Worman and Bonne, 2007). Padiath et al. (2006) produced the first evidence 
of this; LMNB1 duplications were discovered in patients with autosomal dominant 
leukodystrophy. This disorder, first noted in 1984 (Eldridge et al., 1984), is 
characterised by slow, progressive neurological wasting which has striking similarities 
with chronic progressive multiple sclerosis (Eldridge et al., 1984). There is prominent 
symmetrical loss of myelin from nerve cells in the central nervous system (Schiffmann 
and van der Knaap, 2004). Indeed, Lamin B1 is required for correct oligodendrocyte 
maturation and the formation of myelin (Lin and Fu, 2009). In addition, by sequencing 
the LMNB2 gene in patients with Acquired Partial Lipodystrophy (APL), known also as 
Barraquer-Simons Syndrome, a novel heterozygous mutation was discovered (Hegele 
et al., 2006). 
 
As a review by Worman and Bonne (2007) highlighted, our grasp on how mutations in 
B-type lamins cause pathology is limited; this is understandable since research into 
lamins and disease has been predominantly focussed on lamin A/C. 
 
1.4.5.3 Lamin B Receptor (LBR) Mutants 
 
Mutations in the lamin B receptor (LBR) are found to produce three distinct clinical 
phenotypes known as Greenberg Dysplasia (Waterham et al., 2003), Pelger-Huet 
Anomaly (PHA; Hoffman et al., 2002) and Reynolds Syndrome (Gaudy-Marqueste et al., 
2010). Greenberg Dysplasia, also referred to Hydrops-ectopic calcification-moth-eaten 
skeletal dysplasia, is an autosomal recessive, fatal disorder (Waterham et al., 2003). 
Patients display a number of severe symptoms: short limbs, post axial polydactyly 
(both hands), abnormal chondro-osseous calcification, chondrodystrophy and fetal 
hydrops (Chitayat et al., 1993; Waterham et al., 2003). The cause of the disease is a 
substitution mutation in exon 13 of the LBR gene (Waterham et al., 2003). LBR encodes 
the enzyme, 3β-hydroxysterol Δ14-reductase; when active, it catalyses the reduction of 
the C14-C15 double bond of cholesterol-8-14-dien-3β-ol, producing cholesterol-8-en-3β-
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ol.  An LBR mutant allele thus generates a truncated, non-functional version of this 
enzyme (Waterham et al., 2003).  
 
In contrast, PHA has an autosomal dominant mode of inheritance, characterised by the 
hypolobulation of granulocyte nuclei (Hoffman et al., 2002). It usually results from 
heterozygous LBR mutations and is a far more benign disorder. However, a 
homozygote PHA sufferer has been identified; this child exhibited mild congenital 
abnormalities (Oosterwijk et al., 2003). It cannot go unnoticed that the very same 
genetic abnormality i.e. a homozygous LBR mutation, produces two significantly 
different phenotypes, PHA and Greenberg Dysplasia. Consequently, it has been 
postulated that the two disorders be seen as part of a continuous phenotypic 
spectrum rather than as two discrete entities, since the inconsistency could be as a 
result of allelic heterogeneity (Oosterwijk et al., 2003).  
 
1.5 DISEASE MECHANISMS 
1.5.1 Introduction 
 
The fact that different LMNA mutations can lead to an array of diseases, each with 
tissue-specific phenotypes, highlights the importance of the gene in normal nuclear 
functioning. Unfortunately, there is no clear correlation between mutation position 
and the resulting phenotypes. Thus, it is proposed that the various laminopathy 
pathologies should be placed along a continuous phenotypic spectrum rather than 
being categorised as distinct, individual diseases (Capell and Collins, 2006). This next 
section proposes that it is not the activity of just one disease mechanism that causes 
pathology in this collection of disorders, but the amalgamation of several. 
 
1.5.2 The Mechanical Role of the INM proteins 
 
It has been found that the accumulation of mutant lamin A induces changes in nuclear 
morphology; these modifications are observed to worsen with age (Bridger and Kill, 
2004; Goldman et al., 2004). They include the thickening of the NL, nuclear stiffness, 
the mislocalisation of NPCs, nuclear blebbing and aberrant nuclear shape (Fidzianska 
and Hausmanowa-Petrusewicz, 2003; Goldman et al., 2004; Columbaro et al., 2005; 
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Scaffidi and Misteli, 2005; Filesi et al., 2005; Capell et al., 2005; Yang et al., 2005; Wang 
et al., 2006; Meaburn et al., 2007; Verstraeten et al., 2008; Park et al., 2009). In 
agreement, the lack of functional A-type lamins in EDMD was found to severely 
compromise the integrity of the nuclear envelope (Sullivan et al., 1999). 
 
Perhaps an obvious result of perturbed lamin A is a compromised NL; indeed, 
numerous studies have produced evidence to support this hypothesis. Dahl et al. 
(2004) used Xenopus oocyte nuclei to prove the NL’s role as a ‘molecular shock 
absorber’. In this study, the lamina was observed to be elastic and compressible; 
however, both these features exhibited thresholds. In addition to disrupting the 
nuclear architecture, the authors suggested that defective LMNA products could in fact 
weaken responses to mechanical stimuli, thus perturbing nuclear integrity (Dahl et al., 
2004).  
 
In agreement, mice lacking A-type lamins are found to have defective nuclear 
mechanics (Lammerding et al., 2004; Broers et al., 2004); when such Lmna-/- mouse 
embryonic fibroblasts (MEFs) are subjected to mechanical strain, their ability to cope is 
significantly compromised (Lammerding et al., 2004; Broers et al., 2004). Indeed, nuclei 
are extremely prone to bursting (Broers et al., 2004) and more susceptible to apoptosis 
(Lammerding et al., 2004). Importantly, the activation of transcription in response to 
mechanical stress is perturbed in lamin A/C-deficient cells; it is thus proposed that this 
is the cause of the increase in apoptosis observed (Lammerding et al., 2004). Indeed, 
more recent work by Lammerding’s group demonstrates that HGPS patient fibroblasts 
also exhibit nuclear stiffness (which increases with passage number) and marked 
reductions in cell viability and wound healing responses, when compared to normal 
cells (Verstraeten et al., 2008). In line with mouse models, HGPS cells are also more 
susceptible to apoptosis when subjected to repetitive mechanical strain (Verstraeten 
et al., 2008).   
 
Research has highlighted the problem with viewing cytoplasmic and nuclear activities 
separately; loss of dialogue between the two is proposed to greatly affect nuclear 
behaviour (Broers et al., 2004). Indeed, protein structures known as LINC (linker of 
nucleoskeleton and cytoskeleton) complexes are found to connect the nucleus with 
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the cytoplasm (Crisp et al., 2006). These complexes are composed of a protein family 
known as nesprins, which are tethered to the outer nuclear membrane by SUN 
proteins (Padmakumar et al., 2005; Haque et al., 2006). Importantly, SUN1 and SUN2 
interact with A-type lamins (Padmakumar et al., 2005; Haque et al., 2006). It is thus 
possible to envisage how mutations in lamin A may impact on the dialogue between 
the nucleus and cytoskeleton. Using mouse embryonic fibroblasts (MEFs), the 
resilience of Lmna-/- and Lmna+/+ cells were compared. In Lmna-/- cells, interactions 
between cytoskeletal actin, tubilin and vimentin structures were perturbed, in addition 
to reductions in mechanical stiffness (Broers et al., 2004). Indeed, a study by Nikolova 
et al. (2004) reported that cytoskeletal desmin became detached from nuclear surfaces 
in lamin A/C deficient mice; again evidence of disrupted associations between the two 
cellular compartments. In contrast, Piercy et al. (2007) reported no disruption of 
desmin networks in AD-EDMD. 
 
While A-type lamins are expressed in many human tissue-types, EDMD appears to 
affect primarily muscle. Why this selectivity? It has been proposed that since these 
tissues are most likely to be subjected to mechanical strain via muscle contractions, 
they are in all probability, highly susceptible to the nuclear fragility caused by a 
disrupted lamina (Hutchison et al., 2002; Capell and Collins, 2006). In addition, 
concomitant with the fact that HGPS patients suffer fatal cardiovascular traumas, 
evidence shows that vascular cells are severely compromised by the presence of 
progerin. As a result, these cells have a reduced proliferative capacity and prematurely 
senesce (McClintock et al., 2006).  
 
1.5.3 Chromatin organisation 
 
Numerous groups have reported changes in genome organisation that occur as a 
consequence of mutant lamin A or accumulated pre-lamin A (Sewry et al., 2001; 
Fidzianska and Hausmanowa, 2003; Goldman et al., 2004; Filesi et al., 2005; Maraldi et 
al., 2006; Meaburn et al., 2007; Lattanzi et al., 2007; Hakelien et al., 2008; Park et al., 
2009). Indeed, the peripheral loss or abnormal distribution of heterochromatin has 
been repeatedly documented in such cells (Sabatelli et al., 2001; Goldman et al., 2004; 
Filesi et al., 2005; Columbaro et al., 2005; Meaburn et al., 2007; Lattanzi et al., 2007). 
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In line with this, modifications to heterochromatin markers such as HP1α and 
trimethyl-K9-histone 3 have been frequently observed in these mutant cells (Filesi et 
al., 2005; Scaffidi and Misteli, 2005; Shumaker et al., 2006; Lattanzi et al., 2007; 
Hakelien et al., 2008). The reduction or loss of lamin species in Drosophila (Gurudatta 
et al., 2010), C. elegans (Liu et al., 2000) and mice (Sullivan et al., 1999; Nikolova et al., 
2004; Arimura et al., 2005; Yang et al., 2006) reveal similar perturbations in chromatin 
organisation. Research also demonstrates that other INM proteins have a role in 
mediating chromatin organisation; however, such evidence is far less extensive. 
Chromosome 18 is found to be mis-localised in Lmnb1−/− knockout murine cells (Malhas 
et al., 2007) and neutrophils from LBR mutants exhibit chromatin disorganisation 
(Hoffmann et al., 2002). Furthermore, mutations in EMD are shown to perturb correct 
chromatin localisation in patient muscle and skin cells (Fidzianska et al., 1998; 
Ognibene et al., 1999) and chromosome positioning in dermal fibroblasts (Meaburn et 
al., 2007). Since the NL is shown to interact with and tether chromatin to the nuclear 
edge (Pickersgill et al., 2006; Guelen et al., 2008), it is unsurprising that mutations 
affecting its protein components, lead to the loss of peripheral heterochromatin. The 
disruption of complexes involving the DNA-bridging protein, BAF, is also most probably 
responsible, in part, for the perturbation of chromatin organisation reported in LMNA 
and EMD mutants (Margalit et al., 2007). Similarly, such disorganisation in PHA cells is 
likely to result from interrupted interactions between HP1α and LBR.    
 
1.5.4 Gene Expression 
 
Since chromatin disorganisation has been repeatedly observed in laminopathy-based 
disease, it is logical to question whether this leads or contributes to aberrant gene 
expression. Indeed, studies have investigated gene activity in X-EDMD (Tsukahara et 
al., 2002), MAD-A (Amati et al., 2004) and HGPS (Ly et al., 2000; Csoka et al., 2004; 
Marji et al., 2010) patients; the consensus was significant alteration in gene 
expression. Tsukahara et al. (2002) demonstrated that the introduction of emerin into 
X-EDMD cells, rescued the expression of almost half of the genes affected. Thus, the 
authors hypothesized that as a way of compensating for emerin loss, cells modify the 
activity of various genes (Tsukahara et al., 2002).  In one study examining gene activity 
in HGPS, alterations were seen most frequently in genes involved in cell division and 
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RNA/DNA synthesis (Ly et al., 2000). In another, by Csoka et al. (2004), 1.1% of the 
genes tested exhibited at least a 2-fold change. Of those genes affected, the most 
significant groups included those that encoded transcription factors and extracellular 
matrix proteins (Csoka et al., 2004). It was found that the MEOX2/GAX gene displayed 
a major shift in expression; this is noteworthy since its product is a homebox 
transcription factor which negatively regulates mesodermal cell proliferation. The fact 
that the prominent cell types displaying pathology in HGPS are of mesodermal and 
mesenchymal origin, is surely of some importance (Csoka et al., 2004; Hutchison and 
Worman, 2004). Furthermore, the introduction of GFP-progerin into normal 
immortalised fibroblasts results in the misregulation of 194 and 1013 genes, 
respectively, after 5 and 10 days of expression. The extent to this misregulation ranged 
from −14-fold to +17.3-fold. Significantly, the over-expression of wild-type lamin A also 
led to aberrant gene expression, however, the severity of such mis-regulation was 
considerably less severe than that seen for progerin’s presence (Scaffidi and Misteli, 
2008).   While the majority of evidence linking lamins and gene expression focuses on 
A-type lamins, the NE sequestration of the transcription factor, Oct-1 is perturbed in 
lamin B mutant cells, which leads to the deregulated expression of down-stream genes 
(Malhas et al., 2009). 
 
The analysis of hearts from Lmna knock-in and Emd knock-out mice also reveal 
changes in gene expression (Muchir et al., 2007a; Muchir et al., 2007b). Significantly, 
these mouse models provided evidence of the inappropriate activation of the ERK1/2 
branch of the MAPK pathway; a pathway which is postulated to contribute to the 
pathogenesis of cardiomyopathy. Thus, it is hypothesised that the hyperactivation of 
ERK1/2 signalling is involved in the cardiac disease observed in both autosomal and X-
linked EDMD (Muchir et al., 2007a; Muchir et al., 2007b). Indeed, the expression of 
several MAPK pathway components is considerably altered prior to the development 
of heart disease (Muchir et al., 2007a; Muchir et al., 2007b). Furthermore, there 
appears to be a dosage effect of MAPK activation; the onset of cardiomyopathy in 
these mice appears earlier in homozygotes (Muchir et al., 2007a; Muchir et al., 2007b). 
In line with this, a recent paper by Emerson et al. (2009) reports the deregulation of 
ERK1/2 signalling in lamin A mutant patient fibroblasts. The observation that 
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mutations in LMNA and EMD can affect convergent pathways goes someway to 
explaining how they induce similar disease phenotypes in humans.  
 
Also implicated in the pathogenesis of EMD-related disease is the Wnt-signalling 
pathway. Emerin is found to interact with the transcriptional coactivator, β-catenin, 
and regulate its activity; this binding is mediated by an APC-like domain harboured by 
emerin (Markiewicz et al., 2006). In fibroblasts lacking emerin, β-catenin accumulates 
in the nucleus; an event which results in the deregulated transcriptional activation of 
β-catenin downstream target genes (Markiewicz et al., 2006). This is a significant 
finding since Wnt signalling is involved in cardiac muscle formation (Eisenberg and 
Eisenberg, 2006) and as a result, it was suggested that the disruption of this pathway 
could possibly play a role in the cardiomyopathy seen in emerin null patients 
(Markiewicz et al., 2006). Indeed, a recent study confirms that emerin-β-catenin 
complexes also exist in cardiomyocytes; significantly, these are important for the 
structure of intercalated discs in such cells (Wheeler et al., 2010).  However, Wheeler 
et al. (2010) suggest that the role of β-catenin in cardiomyocytes appears to be Wnt-
independent. Taken together, these studies have begun to unravel the multi-faceted 
nature of emerin’s function within the cell and also contribute to our understanding of 
how mutations in EMD can contribute to the pathogenesis, particularly of cardiac 
tissue, seen in EDMD and other EMD-related diseases.  
 
1.5.5 Role in DNA Repair 
 
Liu et al. (2005) produce evidence to suggest that both unprocessed prelamin A and 
truncated lamin A act in a dominant-negative manner to perturb DNA damage and 
repair pathways. The authors show that the accumulation of both truncated lamin A 
(seen in HGPS) and unprocessed prelamin A (seen in Zmpste24 deficient mice) leads to 
delayed checkpoint response, partly through the inefficient recruitment of p53 binding 
protein 1 (53BP1) and Rad51. This could contribute to the high levels of aneuploidy 
and micronuclei reported in the Zmpste24 null mice. Indeed, various chromosomal 
aberrations have been previously reported in several HGPS cell lines (Mukherjee and 
Costello., 1998; Corso et al., 2005). In addition, increased γ-H2AX concentrations were 
observed in these cells, indicating that DNA damage was rife. The Zmpste24 deficient 
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mice were also overly sensitive when exposed to DNA damaging agents. Moreover, 
this revealed elevated susceptibility to double strand breaks (DSBs). Another finding 
worthy of note was that the frequency of non-homologous end joining (NHEJ) in these 
mice was raised; NHEJ is a DNA repair process which functions to rescue DSBs. Further 
experiments uncovered that this possibly occurred to compensate for the impairment 
of another DSB repair response, homologous recombination (HR; Liu et al., 2005).  
Taken together, this study proposes that in some way, mutant lamin A perturbs those 
pathways involved in sensing and responding to DNA damage. Indeed, Liu et al. (2005) 
suggests that this reduced capacity to recruit DNA repair proteins is related to the fact 
that the truncated form of lamin A localises more intensely at the NE and ER, than 
mature lamin A (Pendas et al., 2002).  
 
In agreement with these findings, Varela et al. (2005) demonstrated that p53 signalling 
is involved in the accelerated ageing phenotype displayed by Zmpste24-/- mice. Using 
microarray analysis, the group revealed that in these mice, there was an up-regulation 
in various down-stream targets of p53, the tumour suppressor protein. These included 
p21 and Gadd45a. Significantly, they reported similar results for Lmna deficient mice. 
Varela et al. (2005) hypothesize that mutant lamin A perturbs nuclear integrity and as a 
result, a so-called structural checkpoint is activated. Consequently, the initiation of 
DNA damage responses occurs, such as an increase in p53 transcription. In theory, this 
could lead to a ‘senescence-like programme’ which induces the premature ageing 
phenotype exhibited by laminopathy patients (Varela et al., 2005, p.566). Indeed, 
symptoms reminiscent of accelerated ageing are observed in mice who have p53 
hyperactivity (Tyner et al., 2002).   
 
1.5.6 Role in Proliferation and Differentiation 
 
It is becoming increasingly obvious that the nuclear roles emerin and lamin A/C play 
are both multi-faceted and complex; in addition to those previously aforementioned, 
these proteins are found to regulate cell proliferation and/or differentiation. Very 
significantly, A-type lamins, along with LAP2α, are seen to form a complex with pRb; in 
fact, they prevent its targeted degradation by the proteosome (Johnson et al., 2004). 
This stabilisation of pRb by lamin A is necessary for p16-mediated cell cycle arrest at G1 
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(Nitta et al., 2006). In support of this, Pekovic et al. (2007) later demonstrated that 
both lamin A and LAP2α play a part in regulating the phosphorylation and localisation 
of pRb. They also found that a mutant variant of either protein could perturb this 
control, leading to a disruption in proliferative checkpoints (Pekovic et al., 2007).   In 
agreement, Bridger and Kill (2004) reported an increased capacity for proliferation in 
HGPS fibroblasts. Taken together, this evidence shows a direct, undisputable link 
between A-type lamins and a key factor involved in cell proliferation and 
differentiation. Importantly, pRb’s hypo-phosphorylated form, which functions to 
prohibit cell cycle progression in non-proliferating cells, binds to the NM (Mittnacht 
and Weinberg, 1991; Mancini et al., 1994). 
 
Interestingly, when mutant lamin A is ectopically expressed in C2C12 murine 
myoblasts, muscle differentiation is perturbed (Favreau et al., 2004; Markiewicz et al., 
2005). Markiewicz et al. (2005) hypothesised that it is the disruption of these 
aforementioned complexes that impairs pRb function and thus affects muscle 
differentiation. Subsequently, Frock et al. (2006) pondered the influence of A-type 
lamins and emerin on skeletal muscle satellite cell differentiation. Using Lmna-/- 
myoblasts, the authors demonstrated that these cells in fact have a reduced 
differentiation potential and also exhibit decreased levels of pRb, MyoD and desmin; 
significantly, these proteins are required for successful muscle differentiation. To 
confirm this, the artificial expression of MyoD or desmin in Lmna-/- cells returned their 
differentiation potentials to normal (Frock et al., 2006).  
 
These findings indicate that reductions in a myoblast’s ability to differentiate could 
lead to the disease phenotype experienced in EDMD (Frock et al., 2006). Furthermore, 
disruptions to pRb1/E2F and MyoD pathways plus impaired differentiation kinetics 
have been documented in emerin null mice. This is consistent with the perturbed 
muscle regeneration noted in these animals (Melcon et al., 2006). Additionally, cyclin 
D3, a factor proposed to be required for muscle differentiation, has been identified as 
a novel partner of lamin A/C (Mariappan et al., 2007). Furthermore, the interaction 
which exists between A-type lamins and the adipocyte differentiation factor, SREBP1 is 
reduced in FPLD patients (Lloyd et al., 2002). 
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It is found that the two main types of stem cells exhibit different profiles of lamin 
expression; the majority of mesenchymal stem cells (MSC) express lamin A, while in 
many haematopoetic stem cell (HSC) lineages the protein is absent (Rober et al., 1990; 
Weissman et al., 2001). Since the primary tissues affected in laminopathy-based 
diseases are derived from MSCs, it is logical to suggest that lamin mutations could 
disrupt aspects of their development such as their differentiation, repair and 
maintenance (Wilson, 2000). Concurrently, lymphoblastoid cells which are of HSC 
origin do not appear to require A-type lamins for survival (Hornbeck et al., 1988). 
Indeed, the exogenous expression of progerin, in both normal immortalised fibroblasts 
and hMSCs, is found to aberrantly activate components of the Notch signalling 
pathway; a pathway which is important for the regulation of stem cell differentiation 
(Scaffidi and Misteli, 2008). Similarly, the analysis of HGPS patient cell lines 
demonstrated a perturbation of Notch signalling. Thus, Scaffidi and Misteli (2008) 
propose that progerin disrupts hMSC differentiation and cell fate which may 
contribute to the tissue-specific deterioration seen in HGPS patients. Furthermore, in 
light of the observation that low levels of the protein are generated in normal 
individuals (Scaffidi and Misteli, 2006; McClintock et al., 2007), progerin accumulation 
may also be implicated in the tissue degeneration exhibited during physiological ageing 
(Scaffidi and Misteli, 2008).   
 
In line with this, pre-lamin A accumulation has recently been reported in the vascular 
smooth muscle cells (VSMCs) of aged individuals and in those with athersclerosis; 
significantly, such accumulation was absent in samples from the young and healthy 
(Ragnauth et al., 2010). This phenomenon was also observed in VSMCs that were aged 
in vitro (Ragnauth et al., 2010). Taken together, the findings of these studies (Scaffidi 
and Misteli, 2006; McClintock et al., 2007; Scaffidi and Misteli, 2008; Ragnauth et al., 
2010) suggest that HGPS could be a model for normal ageing.   
 
1.5.7 Summarising the similarities and differences between laminopathy-based 
disease in mice and humans 
    
Mice engineered to lack emerin display a mild clinical phenotype and while such mice 
demonstrate reduced motor co-ordination, they do not exhibit muscle weakness, joint 
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contractures or significant cardiac problems. Furthermore, the life-spans of these mice 
are not significantly different to wild-type (Ozawa et al., 2005). These findings suggest 
that emerin loss in mice does not induce a comparable phenotype to that seen in 
human X-EDMD patients. Thus, it has been suggested that these discrepancies are due 
to interspecies differences and possibly due to the fact that emerin’s absence may be 
compensated by other INM proteins such as MAN1 (Ozawa et al., 2005). 
 
In contrast to the Emd-/- mouse model, Lmna mutant mice display severer phenotypes 
and generally mimic human disease more accurately. Lamin A/C null mice exhibit 
skeletal and cardiac disorders which are characteristic of human EDMD; their growth 
rate is retarded and they die at 8 weeks (Sullivan et al., 1999). LmnaL530P/L530P mice 
display a phenotype similar to HGPS in humans; indeed, they die prematurely at 4 
weeks (Mounkes et al., 2003). This is very interesting since, in humans, this mutation is 
known to cause AD-EDMD (Mounkes et al., 2003). The mouse model which 
investigated the effect of LmnaN195K/N195K mutations revealed that such mice develop 
similar cardiac dysfunction to the DCM caused by the heterozygous form of this 
mutation in humans (Mounkes et al., 2005). Similarly, homozygous LmnaH222P mice 
exhibit a phenotype comparable to their human counterparts (Arimura et al., 2005). 
Taken together, Lmna mouse models serve as a good platform to study LMNA-
mediated human disease; however, the study by Mounkes et al. (2003) demonstrates 
that genotype-phenotype correlations are not always translated from human to mice. 
Furthermore, the disease phenotypes exhibited in these mice result from homozygous 
Lmna mutations as opposed to the heterozygous disease-causing mutations in Homo 
sapiens. Indeed, Lmna-/+ mice are generally indistinguishable from wild-type 
counterparts (Sullivan et al., 1999; Arimura et al., 2005; Mounkes et al., 2005).   
 
1.5.8 Potential Therapies 
1.5.8.1 Farnesyltransferase inhibitors (FTIs) 
 
The majority of HGPS cases result from a point mutation that activates a cryptic splice 
site in exon 11 of LMNA; this creates a truncated protein, termed progerin, which lacks 
the terminal 50 amino acids. The loss of these residues removes the cleavage site 
required by the endoprotease, ZMPSTE24 (Eriksson et al., 2003). As a result, the 
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necessary cleavage cannot occur and thus, the protein remains both 
carboxymethylated and farnesylated. The presence of this farnesyl group causes the 
protein to remain anchored to the NE and thus, is prevented from being incorporated 
into the NL (Hennekes and Nigg, 1994). The loss of ZMPSTE24 activity in humans, 
which causes the disease, RD, also prevents lamin A maturation and thus, retention of 
the farnesyl group (Navarro et al., 2005). Progerin is shorter than and thus, distinct 
from, the resulting pre-lamin A molecule in RD.      
 
Experiments using farnesyltransferase inhibitors (FTI) have been instrumental in 
understanding the detrimental effects associated with the retention of this farnesyl 
group (figure 1.6). Since this farnesyl group is involved in the targeting of pre-lamin 
A/progerin to the INM, by preventing the addition of this group by FTI treatment, the 
immature protein cannot associate with the NE and thus, remains in the nucleoplasm 
(Toth et al., 2005). In this way, pre-lamin A/progerin’s disruption of nuclear shape can 
be largely reduced. Indeed, FTI treatment of typical HGPS and RD cells has been shown 
to reverse and reduce abnormal nuclear morphology (Toth et al., 2005; Mallampalli et 
al., 2005; Glynn and Glover, 2005; Capell et al., 2005; Yang et al., 2005). Significantly, 
FTIs also ameliorate misshapen nuclei in atypical HGPS cells, which harbour missense 
mutations that do not result in pre-lamin A/progerin accumulation (Toth et al., 2005; 
Verstraeten et al., 2006).  This alleviation of nuclear abnormalities is likely to be a 
consequence of a reduction in the incorporation of mutant lamin A generated by such 
LMNA mutations, into the INM (Toth et al., 2005). The demonstration that the 
introduction of GFP-progerin into normal fibroblasts induced a significant rise in 
nuclear aberrations confirms progerin’s dominant negative-effect as a protein (Glynn 
and Glover, 2005).  
 
The treatment of LmnaHG/- mice with FTIs is shown to improve survival and ameliorate 
other disease symptoms such as body weight and spontaneous bone fractures (Yang et 
al., 2008). It can also prevent the onset as well as progression of cardiovascular disease 
(Capell et al., 2008).   Interestingly, treatment with FTI-277 has been shown to reverse 
the incorrect localisation of nucleolar proteins seen in HGPS fibroblasts (Mehta et al., 
2010). The treatment of human fibroblasts with this same drug resulted in the 
redistribution of heterochromatin (Mattioli et al., 2008). FTI therapy has also been 
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demonstrated to rescue the perturbed gene expression observed in HGPS cultured 
cells (Marji et al., 2010). Furthermore, the morphological defects induced by the 
accumulation of pre-lamin A in aged VSMCs, are reversed by FTIs (Ragnauth et al., 
2010).  
 
The use of FTIs does not constitute a cure; indeed, HGPS mice still die prematurely 
(Yang et al., 2008). While treating ageing C. elegans with these drugs is documented to 
restore perturbed nuclear shape and improve motility, it cannot extend the life-span of 
the worms (Bar et al., 2009). In addition, incubation of HGPS fibroblasts in FTIs is 
shown to reverse nuclear stiffness and improve responses in wound healing assays; 
however, the sensitivity of such cells to mechanical strain is not ameliorated 
(Verstraeten et al., 2008).  Evidently, not all elements of the disease phenotype are 
improved or rescued after treatment with FTIs. While Liu et al. (2006) demonstrated 
that abnormal nuclear shape could be reversed in HGPS and RD cells by using FTIs, the 
aberrant levels of DNA damage and constant activation of DNA damage pathways 
could not be alleviated. Thus, it has been suggested that abnormal nuclear morphology 
and the elevation in DNA damage possibly represent two distinct and unrelated 
phenotypes which result from the accumulation of pre-lamin A. Consequently, its use 
as a single therapy has been questioned (Liu et al., 2006).   
 
Significantly, it has been demonstrated that in the presence of FTIs, prelamin A and 
progerin prenylation can occur via an alternative pathway involving 
geranylgeranyltransferase (GGT; Varela et al., 2008). The activity of this additional 
enzyme (GGT) is suggested to partially counteract the FTI treatment of prelamin A and 
progerin accumulation (figure 1.6). Thus, it is thought to account for the incomplete 
success of FTI therapy in mouse models (Varela et al., 2008).  
 
1.5.8.2 Combination therapy: statins and aminobisphosphonates 
 
In addition to FTIs, there are two other classes of drugs, statins and 
aminobisphosphonates, which affect lamin biosynthesis. Statins work by preventing 
the activity of HMG-CoA reductase (Sinensky et al., 1990), while 
aminobisphosphonates target farnesyl-pyrophosphate synthase (Amin et al., 1992; 
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Keller and Fliesler, 1999).  Historically, statins and aminobisphosphonates have been 
used to treat high cholesterol levels and bone disease, respectively. However, since 
these drugs interfere with the pathway involved in the production of 
farnesyltransferase, they can also be employed to prevent prelamin A’s farnesylation 
and thus, maturation (Pereira et al., 2008; see figure 1.6).  Indeed, Varela et al. (2008) 
demonstrated that the combination therapy of statins and aminobisphosphonates 
ameliorated progerin/pre-lamin A specific defects in HGPS and Zmpste24-/- cells. 
Furthermore, improvements to body weight, reductions in subcutaneous fat levels and 
extended lifespans were observed in Zmpste24-/- mice undergoing statin-
aminobisphosphonate treatment (Varela et al., 2008). 
 
1.5.8.3 Morpholino oligonucleotides 
 
Scaffidi and Misteli (2005) took a different approach to reversing the cellular 
phenotype in HGPS. Instead, the experiment involved the use of a modified 
oligonucleotide; this small anti-sense molecule was targeted to the cryptic splice site 
commonly activated in HGPS. Since the molecule has a sequence that is 
complementary to this site, it is able to sterically inhibit the splicing activity. The group 
successfully prevented the production of 90% of progerin from the mutant allele and 
furthermore, the treated HGPS cells showed vast improvements in their nuclear 
morphology. Nuclear behaviour, such as histone modifications and the expression of 
select genes were also rescued. Another interesting point to note was that the 
improvements in nuclear shape occurred without entering mitosis.  Importantly, they 
demonstrated that merely introducing wild type lamin A into HGPS cells did not 
reverse the cellular phenotype; this was true even at high concentrations for 
prolonged periods (Scaffidi and Misteli, 2005).   
 
However, there is evidence to suggest that the activation of the cryptic splice site is 
not 100% efficient (Reddel and Weiss, 2004). The authors examined the transcript 
levels of lamin A produced from both alleles (mutant and normal) in HGPS 
heterzygotes. They discovered that the splicing event is in fact incomplete and that the 
mutant allele can still produce fully functional lamin A; this is possible since the silent 
mutation does not alter the amino acid encoded (Reddel and Weiss, 2004).  
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1.5.9 Consolidating the roles of INM proteins: a model for laminopathy-based 
disease 
 
This review has highlighted the need for an intact NL in cellular integrity; indeed, the 
wide array of disease phenotypes described adds credence to this observation. 
However, this overview has also drawn attention to the fact that the scientific 
community have a long way to go in terms of determining those mechanisms involved 
in the manifestation of disease. In the future, it is likely that additional NE proteins will 
be discovered, bringing along with them new laminopathy disorders. Indeed, the 
recent discovery of lamin B mutations in human disease supports this prediction. All in 
all, this will contribute to the rapidly progressing, exciting field of research that is NE 
proteins.  
 
1.6 CONCLUSION 
 
This review of the literature has highlighted the importance of NE and NM proteins, 
especially lamin A, in maintaining the correct functioning of the nucleus. Indeed, the 
plethora of diseases which arise from mutant or absent forms of these proteins, 
further strengthen this view. Since the organisation of the genome is perturbed in a 
number of these disorders, it is necessary to ponder how and why this occurs and 
whether it has an effect on nuclear processes such as transcription and DNA repair. As 
the NM is demonstrated to mediate genome organisation, it seems pertinent to 
examine these interactions in cells which harbour mutant NM proteins. This should 
hopefully reveal the importance of such proteins in NM function.     
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2.1 INTRODUCTION 
2.1.1 What is the NM? 
 
The NM is a proteinaceous and RNA-rich network which spans the nucleus; it is 
proposed to consist of thick polymorphic fibres, underlying which are 10 nm filaments 
that connect this internal NM to the peripheral NL (Jackson and Cook, 1998; He et al., 
1990; Nickerson et al., 2001). Originally, the term NM was used to describe the 
residual nuclear structure which remained following DNA digestion and extraction 
using high salt molarities (Berezney and Coffey, 1974). On the other hand, the phrase 
nucleoskeleton refers to the nuclear structure which is isolated using a gentler, more 
physiological method (Jackson and Cook, 1988). In addition to the terms NM and 
nucleoskeleton, nuclear scaffold has also been assigned by some to describe the 
nuclear structure isolated using the detergent, lithium di-iodosalicylic acid (LIS; 
Mirkovitch et al., 1984). However, to avoid confusion, much of the field use such terms 
interchangeably (Nickerson, 2001). Although research shows that at least 300 NM-
associated proteins exist (Mika and Rost, 2005), the structural composition of the NM 
has not yet been fully determined (Nickerson, 2001). The NM provides a platform for 
replication and transcription; indeed, factories for both processes are associated with 
the structure (Jackson and Cook, 1985; Hozak et al., 1993; Cook, 1999; Anachkova et 
al., 2005).   
 
2.1.2 The isolation and visualisation of the inner NM 
 
Different methodologies have been employed to isolate and visualise the inner NM. In 
general, a detergent, usually Triton X-100 is used to extract plasma and nuclear 
membranes. Such treatment removes the majority of phospholipids and a proportion 
of both cellular and nuclear proteins (Aaronson and Blobel, 1974). In order to remove 
the chromatin which obscures the view of the underlying inner NM, the residual 
structures are subjected to nucleases/DNase I, which partially digest the DNA. The 
primary dissimilarities between different NM preparations revolve around the elution 
of this DNA; some methodologies employ 2M NaCl (Berezney and Coffey, 1974), while 
others use lower salt concentrations (Capco et al., 1982; Fey et al., 1986; He et al., 
1990; Nickerson et al., 1992). Conversely, the procedure used to isolate the 
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nucleoskeleton involves agarose beads, physiological buffers and electro-elution 
(Jackson and Cook, 1988).  
 
A protocol which employs 0.25 M ammonium sulphate followed by 2M NaCl has been 
used to visualise NM structure (He et al., 1990; see figure 2.1.1). The elution of 
digested chromatin is achieved by using 0.25M ammonium sulphate; along with the 
DNA, the bulk of histones and other soluble proteins are also removed. Such treatment 
uncovers the outer NM, which is composed of non-uniformly-arranged, polymorphic 
fibres which run throughout the nuclear interior. Between these fibres, there are large 
gaps of differing sizes. Further extraction by 2M NaCl removes the outer NM proteins 
and in the process of doing so, reveals thinner, regular filaments which are 9–13 nm in 
diameter (He et al., 1990; Nickerson et al., 1992). It is proposed that these filaments, 
termed the core filaments of the NM, are both protein and RNA rich and the 
framework on which the aforementioned polymorphic fibres are built (He et al., 1990). 
Indeed, approximately 70% of total nuclear RNA remains after this high-salt extraction 
(He et al., 1990). The treatment of this framework with RNase A, results in the almost 
complete removal of core filaments, leaving the nucleus as an empty shell; 
significantly, the NL remains intact and is largely unaffected. This provides evidence 
that intact RNA is an essential component of the inner NM (He et al., 1990).   
 
In order to improve the preservation of NM ultrastructure, this methodology used by 
He et al. (1990) has been subject to modifications. Nickerson et al. (1997) employed 
the cross-linking agent, formaldehyde, to stabilise the structure of the NM before the 
removal of attached chromatin. Importantly, following this use of formaldehyde, 
digested chromatin could be removed without the use of non-physiological salt 
concentrations. Later, Wan et al. (1999) demonstrated that by chemically modifying 
nucleosomal amine groups, which are thought to complicate the removal of digested 
material, chromatin could be removed easily without the need for non-physiological 
salt concentrations. In this same study, three methodologies were tested and 
compared: (1) original (He et al., 1990), (2) formaldehyde-cross linking (Nickerson et 
al., 1997) and (3) amine modification (Wan et al., 1999). Significantly, the visualisation 
of the nuclear interior using these different protocols revealed that the internal NM is 
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indeed built upon a highly-branched network of filaments approximately 10 nm in 
diameter (Wan et al., 1999).   
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2.1.3 The role of the NM in organising the genome 
2.1.3.1 Overview  
 
Within the interphase nucleus, chromosomes are non-randomly organised (Foster and 
Bridger, 2005). It is uncertain whether the positioning of these chromosomes is driven 
by gene density (Croft et al., 1999; Bridger et al., 2000; Boyle et al., 2001; Meaburn et 
al., 2005, 2007) or size (Sun et al., 2000; Bolzer et al., 2005; Mora et al., 2006); indeed, 
some groups provide evidence to suggest that it is a combination of the two 
(Habermann et al., 2001; Tanabe et al., 2002; Mayer et al., 2005; Mora et al., 2006; 
Neusser et al., 2007). Since this radial positioning of chromosomes appears to change 
according to cellular state (Bridger et al; 2000; Meaburn et al., 2007; Mehta et al., 
2010) and differentiation (Galiova et al., 2004; Kim et al., 2004), much debate 
surrounds its functional relevance.   
 
Importantly, the NM appears to mediate the organisation of the genome; the structure 
is involved in tethering chromatic regions within the interphase nucleus (de Lange, 
1992; Gerdes et al., 1994; Ma et al., 1999; Weipoltshammer et al., 1999). Indeed, the 
genome interacts with the NL at multiple sites named LADs; these are typically 
characterised by low levels of gene expression (Guelen et al., 2008). It is hypothesised 
that the NM organises chromatin into repeating loops, approximately 50–200 kb in 
length; the DNA sequences at the base of these loops, which interact with the NM are 
termed MARs (matrix attachment regions; Cockerill and Gerrard, 1986) or SARs 
(scaffold attachment regions; Gasser and Laemmli, 1986), depending on the nuclear 
extraction procedure used for their examination (Bode et al., 1992; Heng et al., 2004). 
From this point onwards, the term MAR will refer to both MARs and SARs. MARs 
function as cis-acting elements which are involved in transcriptional regulation 
(Laemmili et al., 1992; Boulikas, 1995; Schubeler et al., 1996; Bode et al., 2000; Martins 
et al., 2004). They are shown to function as both transcriptional enhancers (Blasquez 
et al., 1989; Bode et al., 1992; Allen et al., 1996) and insulators (Kalos and Fournier, 
1995; Namciu et al., 1998; Antes et al., 2001; Farrell et al., 2002; Yusafzai and 
Felsenfeld, 2004; Goetze et al., 2005).  Importantly, MARs demarcate transcriptionally 
active chromatin domains (Bode and Maass, 1988); however, they are also found 
within intronic DNA (Kas and Chasin, 1987). MARs bind to an number of proteins 
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including: scaffold attachment factor-A (SAF-A; Romig et al., 1992; Fackelmayer et al., 
1994; Fackelmayer and Richter, 1994; Gohring and Fackelmayer, 1997; Kipp et al., 
2000), scaffold attachment factor-B (SAF-B; Renz and Fackelmayer, 1996), DNA 
topoisomerase II (Adachi et al., 1989), lamin B1 (Luderus et al., 1992), A-type lamins 
(Luderus et al., 1994), NuMa (Luderus et al., 1994), nucleolin (Dickinson and Kohwi-
Shigematsu, 1995) and CTCF (Dunn et al., 2003). 
 
Although approximately 100,000 MARs are estimated to exist within the genome 
(Bode et al., 1996), the characterisation of these sequences to date has not been 
extensive (Bode et al., 2000; Nickerson, 2001). A consensus element is yet to be 
reported and in line with this, it has been suggested that the interactions are more 
dependent on the structural conformation of MARs than the DNA sequences alone 
(Bode et al., 1998). However, MARs are typically AT rich; the weak bonds between AT 
bases are predicted to facilitate the binding of MAR-associated proteins (Platts et al., 
2006). Indeed, MAR-like regions of AT-rich sequences, known as ‘AT islands’ are found 
to be thermodynamically unstable, highly flexible and susceptible to base unpairing 
(Woynarowski et al., 2001). It is proposed that MARs and DNA topoisomerases may 
work together to regulate the topology of chromatin regions, thus facilitating 
transcriptional processes (Bode et al., 1992).  
 
2.1.3.2 DNA halo preparations 
 
NM preparations involving the use of DNase I are extremely useful for visualising and 
characterising the structural morphology and composition of the inner NM, however, 
they are not appropriate for examining NM-DNA interactions.    In order to examine 
such genomic associations, a methodology known as the DNA halo preparation was 
developed; while many variations of this technique exist, the majority of 
methodologies employ detergents and salt or LIS to extract histones, other non-soluble 
proteins and non-NM associated DNA (Wiegant et al., 1992; Tocharoentanaphol et al., 
1994; Luderus et al., 1996; Ma et al., 1999; Ratsch et al., 2002; Iarovaia et al., 2004). 
Once interphase nuclei have been subjected to such preparation, residual structures 
known as nuclear or DNA halos are found to remain. These structures are composed of 
a residual nucleus, surrounded by a halo of DNA; the residual nucleus is composed of 
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the NM and NM-associated DNA, while the halo contains extracted DNA. The coupling 
of DNA halo preparations with FISH, thus termed HALO-FISH (Volpi and Bridger, 2008), 
has been used for genomic mapping and the study of genomic interactions with the 
NM (Elcock and Bridger, 2010b). Indeed, the spatial resolution achieved with these 
DNA halos is significantly higher than that attained using FISH on metaphase 
chromosomes or interphase chromatin (Wiegant et al., 1992; Heng et al., 1992).  The 
organisation of the human dystrophin gene into loop domains has been studied 
extensively at such high resolution using HALO-FISH (Tocharoentanaphol et al., 1994; 
Iarovaia et al., 2004); importantly, the results correspond to those generated using 
biochemical approaches (Iarovaia et al., 2004). Indeed, using this technique, it has 
been demonstrated that one of the gene’s loop attachment regions is a major deletion 
hotspot (Iarovaia et al., 2004). Similarly, Repping et al. (2003) employed a variation of 
HALO-FISH (named sperm HALO-FISH) to accurately determine the copy number of 
DAZ (Deleted in AZoospermia), a gene associated with spermatogenic failure. 
 
2.1.3.3 Examining genomic interactions with the NM 
2.1.3.3.1 Chromosome territories (CT) 
 
In addition to its use as a tool for high resolution mapping, HALO-FISH has been 
frequently employed to examine genome interactions with the NM. Ma et al. (1999) 
demonstrated that CTs remain intact after extraction using 2M NaCl. Thus, despite the 
loss of histones and other soluble proteins, CT organisation is still maintained. The 
combination of RNase A and 2M NaCl is found to disrupt such CT organisation; this 
implicates the involvement of the NM’s core filaments in mediating such genome 
arrangements. This disruption of CTs was accompanied by the extraction of a subset of 
nuclear proteins, which could be implicated in the mediation of CT organisation. 
However, significantly, despite this perturbation of CT structure, the majority of 
chromosome mass remained within the periphery of the residual nucleus. An 
additional study by Croft et al. (1999) revealed that the anchorage of chromosomes 18 
and 19 differed according to gene density; gene-rich HSA-19 was found to be tightly 
associated with the NM, while gene-poor HSA-18 was extracted into the surrounding 
DNA halo.  
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2.1.3.3.2 Telomeric DNA  
 
Using telomere specific probes for HALO-FISH, Luderus et al. (1996) examined 
telomere anchorage by the NM; DNA halos were produced using either LIS or NaCl 
extraction methodologies. Significantly, both protocols revealed that the majority of 
telomeres are attached to the NM; thus, concurring with previous biochemical data 
produced previously (de Lange, 1992). More recent work also concurs with this notion 
(Ratsch et al., 2002). Furthermore, it was demonstrated that the internal NM rather 
than the peripheral NL, was responsible for this telomere anchorage (Luderus et al., 
1996). Telomeres are found throughout the nuclear volume and exhibited no 
significant clustering; the exception to this was in late telophase/early G1, when a ring 
of telomeres around the nuclear periphery, was reported (Luderus et al., 1996). 
 
2.1.3.3.3 Genes and other specific genomic regions 
 
Gerdes et al. (1994) used HALO-FISH to study the interactions of specific genes with 
the residual nucleus. Strikingly, transcriptionally active genes were observed to tightly 
associate with the NM, whereas transcriptionally inactive genes were extracted into 
the DNA halo and thus, assumed to be non-NM associated (Gerdes et al., 1994).  
Furthermore, HALO-FISH has been used to determine whether MYC and IGK exhibit 
different interactions with the NM when involved in a Burkitt’s lymphoma (BL) 
translocation event (Ratsch et al., 2002). In normal monocytes, MYC and IGK were 
associated with the residual nucleus, in 40% and 8% of cases, respectively. In the BL-
derived cells, there were differences between those genes found on translocated 
chromosomes and those on non-translocated chromosomes. Significantly, the majority 
of the activated MYC (78%) and IGK (88%) alleles were associated with the NM. In 
contrast, the non-translocated MYC and IGK alleles were attached to the residual 
nucleus in 50% and 62% of cases, respectively (Ratsch et al., 2002). In line with Gerdes 
et al. (1994), these findings also demonstrate a correlation between transcriptional 
activity and NM-association. Providing further evidence that NM interactions are 
functional, Iarovaia and colleagues (Iarovaia et al., 2005) studied the interaction of a 
~170 kb region of HSA-19 with the NM, in both proliferating and differentiated cells. 
Significantly, in these two states, the anchorage of this region differed; in proliferating 
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nuclei, it was extracted into the DNA halo while upon differentiation, it was found to 
be attached to the NM (Iarovaia et al., 2005).  
 
2.1.4 Using DNA halo preparations as a platform to analyse genomic interactions 
with the nuclear matrix 
2.1.4.1 Chromosomes 
 
Since it has been demonstrated that the NM is involved in mediating the organisation 
of CTs (Ma et al., 1999), it seemed pertinent to question whether different 
chromosomes have varying levels of interactions with the structure in human 
fibroblasts. In order to do this, HALO-FISH was performed using whole chromosome 
probes for HSA-1, -13, -15, -17 and -18. In light of the observation that the organisation 
of CTs in interphase nuclei changes according to proliferative state (Bridger et al; 2000; 
Meaburn et al., 2007; Mehta et al., 2010), the interaction of these chromosomes with 
the NM was examined in both proliferating and senescent (in 10% serum) nuclei. The 
marker of proliferation, pKi67, was used to differentiate between these populations 
(Kill, 1996).   
 
2.1.4.2 Telomeres 
 
Telomere interactions with the NM were also investigated in three distinct cellular 
states: proliferation, quiescence (G0) and senescence. In order to do this, the DNA halo 
preparation has been coupled with telomere PNA FISH (Peptide Nucleic Acid 
Fluorescence in situ Hybridisation); this allowed us to differentiate between those 
telomeres that are tightly attached to the NM and those which are not. Proliferating 
and senescent populations (in 10% serum) were distinguished by the use of either 
bromodeoxyuridine (BrdU) incorporation and detection or anti-pKi67 staining. Control 
HDFs were induced into quiescence using serum-starvation and their proliferative 
status verified using anti-pKi67. Importantly, the results demonstrate that in all 3 
cellular states, the majority of telomeres remain associated with the NM in human 
dermal fibroblasts. Interestingly, no significant differences in telomere anchorage by 
the NM were observed when comparing proliferating and senescent populations; 
however, significantly fewer were associated with the structure in quiescence.  
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2.1.4.3 Genes 
 
In order to investigate whether the anchorage of specific genes by the NM changes on 
entry into senescence, CCND1, C-MYC and CTNNA1 were examined in proliferating 
(pKi67+) and senescent (in 10% serum; pKi67−) HDFs using the DNA halo assay. 
Significantly, the binding of each gene to the NM did not differ statistically between 
pKi67+ and pKi67− extracted nuclei. However, importantly, the extent to which specific 
genes were anchored by the NM did vary. These results demonstrate that different 
genes are bound with varying avidities to the NM and importantly, such binding does 
not change detectably on entry into senescence.  
 
Taken together, the findings presented in this chapter reveal that genome interactions 
do not differ significantly in proliferating and senescent cells using the DNA halo assay.  
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2.2 MATERIALS AND METHODS 
2.2.1 Cell Culture 
 
Primary human dermal fibroblasts were grown in Dulbecco’s Modified Eagle Medium 
(DMEM; Gibco, Invitrogen) containing 10% (v/v) newborn calf serum (NCS), 2% (v/v) 
penicillin/streptomycin (Invitrogen) and L-glutamine (v/v) (Invitrogen); the cells were 
kept at 37°C, in an atmosphere containing 5% C02. Cells were passaged twice weekly. 
At pre-confluence, the medium was removed and the cells were rinsed with versene 
(phosphate buffered saline (PBS; 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM 
KH2PO4; pH7.4) with 0.2% (w/v) ethylenediaminetetra-acetic acid; EDTA). Following 
this, the culture was treated with 0.25% trypsin (2.5% stock solution ((Gibco)) 1:10 
dilution in versene (v/v)); the cells were continually checked using an Olympus CK2 
light microscope until complete cell detachment from the substratum. The cell 
suspension was then added to a 15 cm2 centrifuge tube and the flask rinsed using 5 ml 
medium. The completion of the trypsin reaction was initiated by the addition of the 
medium containing the remaining cells. This cell suspension was centrifuged for 5 
minutes at 200 g; following this, the supernatant was removed, leaving only the pellet, 
which was then re-suspended in fresh medium. Using a haemocytometer, the number 
of cells was counted (viewed with a light microscope; 20x lens) and the cell density was 
calculated using the following equation: 
 
Number of cells/Number of squares on haemocytometer grid x Volume in tube x 104 
 
The cells were then seeded at a density of 5 x 105 per 75 cm2 flask or 2 x 105 per 10 cm2 
dish, along with an appropriate volume of medium and grown as aforementioned. For 
DNA halo preparations, the cells were grown for 2 days on SuperFrost® (Fisher 
Scientific) slides, in QuadriPERMTM chambers (Greiner Bio One), at a starting density of 
1 x 105. In order to arrest cells in G0, cells were twice washed with serum-free medium 
after 24 hours of growth and then fed with 0.5% NCS medium; cells were then left for 
7 days. 
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2.2.2 BrdU Labelling 
 
Cells were seeded on SuperFrost® slides (Fisher Scientific) in QuadriPERMTM chambers 
at a density of 1 x 105 and were left to grow for 24 hours. The medium was then 
removed and replaced with medium containing BrdU and FrdU (3 µg/µl) (Sigma 
Aldrich). After 24 hours, the media was removed, cells were washed once with 
medium (10% NCS) and then re-fed with medium (10% NCS). Following an additional 
24 hours, the slides were taken through the DNA halo preparation.  
 
2.2.3 DNA Halo Preparation 
 
The methodology used to create DNA halos is the same as that published by Bridger 
and Lichter (1999). After two days of growth, the medium was removed and the slides 
were placed in Coplin jars, on ice, containing CSK buffer (10 mM Pipes pH 7.8, 100 mM 
NaCl, 0.3 M sucrose, 3 mM MgCl2, 0.5% (v/v) Triton-X 100) for 15 minutes. The slides 
were then washed three times in 1 x DNA halo buffer (DHB; 140 mM NaCl, 27 mM KCl, 
110 M NaPO4, 15 mM KH2 PO4). Following this, they were placed in extraction buffer (2 
M NaCl, 10 mM Pipes pH 6.8, 10 mM EDTA, 0.1% (w/v) digitonin (Sigma Aldrich), 0.05 
mM (v/v) spermine (Sigma Aldrich), 0.125 mM (v/v) spermidine (Sigma Aldrich)) for 4 
minutes. The slides were rinsed consecutively in 10 x DHB (1.4 M NaCl, 270 mM KCl, 
1.1 M NaPO4, 150 mM KH2PO4) , 5 x DHB, 2 x DHB and 1 x DHB, for 1 minute each. They 
were then taken through an ethanol series of 10%, 30%, 70% and 95% (v/v), 
respectively. The slides were then air dried and stored at −80°C until FISH was 
performed. 
 
2.2.4 Directly labelled total human chromosome probes  
Chromosome probes were made in-house via the amplification of flow sorted 
chromosomes (a kind gift from Professor M. Bittner) by DOP-PCR (degenerate 
oligonucleotide primed polymerase chain reaction; Telenius et al., 1992; Cheung and 
Nelson, 1996). Subsequently, these were labelled using Biotin-16-2'-deoxy-uridine-5'-
triphosphate (Biotin-16-dUTP). FISH probes were prepared by making the following 
solution: 8 µl PCR product, 7 µl COt-1 DNA (Roche), 3 µl herring sperm, with 1/20
th 
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volume of 3M sodium acetate (pH 5.4) and 2 volumes of 100% ethanol, per slide. This 
probe solution was then incubated at −80°C for at least 30 minutes. Following this, it 
was centrifuged at 13,700 g at 4°C for 15 minutes and then washed with 70% ethanol. 
The centrifugation and washing procedure was repeated once more, finishing with a 
final centrifugation. The DNA pellet was subsequently dried; to which 12 µl of 
hybridisation buffer (50% formamide, 10% dextran sulphate (Helena Biosciences), 10% 
20 x saline sodium citrate (SSC; 3M NaCl, 0.3M tri-sodium citrate; pH 7.0), 1% (v/v) 
Polyoxyethylene sorbitan monolaurate (Tween-20 (Sigma-Aldrich)) per slide, was 
added. This solution was mixed and left at 37°C for at least 2 hours, overnight in some 
cases.   
2.2.5 Directly labelled human single gene probes 
2.2.5.1 DNA Isolation from BAC clones 
 
Bacterial Artificial Chromosomes (BACs) were obtained from Invitrogen. A small 
portion of glycerol stock from the respective BAC clone was streaked onto a Luria-
Bertani (LB) agar plate (1% (w/v) NaCl; 1% (w/v) tryptone, 0.5% (w/v) yeast extract, 
1.5% (w/v) Agar Technical (Oxoid, Fisher Scientific); 12.5 µg/ml (w/v) chloramphenicol 
(Sigma)). The plate was then incubated at 37°C overnight. Next, a single colony from 
the plate was used to inoculate 10 ml of LB broth (1% (w/v) NaCl; 1% (w/v) 
bactotryptone, 0.5% (w/v) yeast extract (Oxoid, Fisher Scientific); 12.5 µg/ml (w/v) 
chloramphenicol (Sigma)); this solution was left in a shaking incubator at 37°C 
overnight.  
 
In order to make glycerol stocks of the BAC clone, 0.5 ml of the bacterial culture was 
placed in an eppendorf with 0.5 ml glycerol, mixed and then stored at −80°C. The 
remainder of the culture was centrifuged at 1,700 g for 10 minutes at room 
temperature. The supernatant was discarded and 300 µl of P1 solution (15 mM Tris 
(pH 8), 10 mM EDTA, 100 µg/ml RNase A) was added to the pellet. After vigorous 
vortexing, the cells were transferred into a 2 ml eppendorf. Next, 300 µl of P2 solution 
(0.2 M NaOH, 1% (w/v) sodium dodecyl sulphate (SDS) was added to the cells in a 
dropwise manner; following this, the tube was inverted 5 times and left at room 
temperature for a maximum of 5 minutes. 300 µl of P3 (3 M CH3COOK) was then 
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added slowly and after gentle mixing, the eppendorf was placed on ice for 10 minutes. 
Next, the tube was centrifuged at 8,100 g for 10 minutes at 4°C; the supernatant was 
then transferred into a tube containing 800 µl of ice-cold isopropanol and inverted 
several times before being placed at −20°C overnight. 
 
Following the overnight incubation, the tube was centrifuged at 8,100 g for 15 minutes 
at 4°C. The supernatant was removed and 500 µl of ice-cold 70% ethanol was added. 
The tube was inverted several times and then centrifuged for 5 minutes at 4°C (8,100 
g). The supernatant was then removed and the pellet was left to dry at room 
temperature. When dry, the pellet was re-suspended in 40 µl of diethyl 
pyrocarbonate-treated water (DEPC-treated) and left at 4°C overnight. Once fully re-
suspended, 5 µl of the solution was loaded onto a 1% agarose gel, in order to check for 
the presence of DNA. 
 
2.2.5.2 Single probe preparation 
The respective DNA was then labelled using a Nick Translation kit (Invitrogen). Each 
mix contained: 5 µl dNTP mix (minus dTTP), 1 µl Biotin-16-dUTP (Roche), 5 µl Pol 
I/DNase I Mix, DEPC-treated water (Fisher Scientific) and DNA. Once mixed and 
centrifuged briefly, the solution was incubated at 15°C overnight. To verify the 
fragment sizes, 5 µl of the solution was loaded onto a 2% agarose gel. 
In order to remove the unincorporated nucleotides, Illustra MicroSpin G-50 Columns 
(GE Healthcare) were used. Initially, the column was placed into the collection tube 
and centrifuged at 3,200 g for 1 minute. The collection tube was discarded and the 
column placed into a sterile eppendorf. After adding the DNA solution, the column was 
again centrifuged at 3,200 g for 1 minute. The column was then discarded; to the DNA 
solution in the tube, 5 µl herring sperm DNA (10 mg/ml), 10 µl 3M NaAC and 2.25 V of 
100% ice cold ethanol was added. After gentle mixing, the solution was incubated at 
−80°C for 1 hour. Following this, the tube was centrifuged at 13,700 g for 30 minutes at 
4°C. The supernatant was discarded and the pellet washed with 200 µl of ice cold 70% 
ethanol. Again, the tube was centrifuged at 13,700 g for 15 minutes at 4°C. The 
supernatant was discarded and the pellet was dried for approximately 15 minutes 
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using the Speed Vac® Plus SC110A (Savant). The pellet was re-suspended in 20 µl of 
DEPC-treated water (at room temperature for several hours or overnight at 4°C) and 
then stored at -20°C. 
For each slide, 5 µl probe DNA was mixed with 5 µl COt-1 DNA and then dried for 15 
minutes using the Speed Vac® Plus SC110A. Once the pellet had dried, it was re-
suspended in 12 µl of hybridisation mix (detailed previously).  
2.2.6 2-Dimensional Fluorescence in situ Hybridisation 
The DNA probes were denatured at 75°C for 10 minutes. Following this, the probes 
were kept at 37°C for 30 minutes to 2 hours; after this incubation, 12 µl of probe was 
added to the appropriate slide, covered by a coverslip secured using rubber glue 
(Halfords). Next, the slides were left at 37°C in a humid hybridisation chamber for at 
least 18 hours. 
 
After removing the slides from the hybridisation chamber, the rubber was carefully 
taken off. The slides were then washed in buffer A (50% formamide, 2 x SSC (pH 7.0)), 
pre-warmed to 45°C, for 15 minutes, with 3 changes of buffer. Subsequently, the same 
procedure was performed with buffer B (0.1 x SSC (pH 7.0)) but instead incubated at 
60°C. The slides were then plunged into 4 x SSC at room temperature. Following the 
post-hybridisation wash procedures, 100 µl of blocking solution, 4% bovine serum 
albumin (BSA) (Sigma Aldrich) was added to the slides, which were covered by 
parafilm; these were then incubated at room temperature for 10 minutes. In order to 
detect the labelled probe, each slide was incubated in 100 µl of a 1:200 dilution (made 
up in 1% BSA) of streptavidin-Cy3 antibody (Amersham Life Sciences Ltd) for 1 hour at 
room temperature. After which, the slides were washed with 4 x SSC (0.5% Tween-20) 
3 times, for 5 minutes per wash. At this point, the slides were mounted in 
counterstain, Vectashield (Vector Laboratories) containing 4', 6-diamidino-2-
phenylindole (DAPI). 
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2.2.7 Telomere PNA FISH 
 
Telomeres were detected using a Telomere PNA FISH Kit/FITC (Dako); the protocol was 
carried out according to manufacturer’s instructions. The procedure was performed at 
room temperature, unless stated otherwise. Slides were immersed in tris-buffered 
saline (TBS, pH 7.5) for 2 minutes and then placed in 3.7% formaldehyde (in TBS; v/v) 
for exactly 2 minutes. Following this, slides were washed in TBS twice for 5 minutes at 
a time. They were immersed in pre-treatment solution for 10 minutes and then 
washed twice with TBS for 5 minutes per wash. Next, the slides were taken through an 
ice cold ethanol series comprising of 70%, 85% and 95% (v/v) ethanol for 2 minutes per 
concentration. After this, the slides were air dried and then 10 µl of Telomere PNA 
Probe/FITC (or Cy3) was added to each slide and covered with a coverslip. The slides 
were placed in a pre-heated oven set at 80°C for 5 minutes and then put in the dark for 
approximately 1 hour. In order to remove the coverslips, the slides were immersed in 
the ‘Rinse Solution’ for 1 minute and then placed in the ‘Wash Solution’ for 5 minutes 
at 65°C. Following this, the slides were taken through the ice-cold ethanol series (70%, 
85% and 95% (v/v)) for 2 minutes per concentration and then air dried. At this point, 
slides were mounted with Vectashield (Vector Laboratories) containing DAPI. 
  
2.2.8 Indirect Immunofluorescence 
 
Slides were washed 3 times in PBS and incubated at room temperature for 1 hour in 
the necessary primary antibody (rabbit anti-human pKi67 (Novocastra) diluted 1:1500; 
BrdU mouse anti-human diluted 1:100 (BD Pharmingen); all dilutions made using 1% 
(v/v) NCS). Cells were then washed 3 times in PBS and incubated at room temperature 
for 1 hour in a fluorochrome-conjugated secondary antibody (pKi67: swine anti-rabbit 
TRITC diluted 1:30 (Dako);  BrdU: donkey anti-mouse Cy3 diluted 1:100 (Jackson 
Laboratory)). Following 3 more washes with PBS, slides were mounted with 
Vectashield (Vector Laboratories) containing DAPI. 
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2.2.9 Image Capture  
 
DNA halo prepared nuclei were visualised using one of 3 different microscope systems 
and respective lenses; grey-scale images of randomly selected nuclei were captured 
using various cameras. Images were pseudocoloured and merged using various 
versions of Digital Scientific software (table 2.2.1).   
 
Table 2.2.1: An overview of the microscopes, lenses, cameras and software used to visualise, 
capture and process DNA halo prepared nuclei. 
 
2.2.10 Image Analysis 
2.2.10.1 Chromosome territories 
 
The images were converted into TIFFs and then the colour balance modified using IP 
Lab Spectrum Software. Using Adobe Photoshop, the images were cropped and split 
into individual colour channels i.e. red, blue and green; each channel was saved 
separately. Next, the residual nucleus was identified and selected using NIH Image/ 
Scion Image; following this, the colour of the residual nucleus was modified and 
density threshold and binary functions were performed (figure 2.2.1).  
Microscope 
system 
Lens Camera Imaging Software 
Leica 
fluorescence 
microscope 
Leica  Plan 
Fluoropar 100x 
oil immersion 
lens 
Cooled charge-coupled 
device (CCD) camera 
(Sensys, Photometrics) 
Smart Capture VP 
V1.4 (Digital 
Scientific) 
Olympus BX41 
fluorescence 
microscope 
Olympus 
UPlanFL N 100x 
oil immersion 
lens 
Model viewpoint GS 
digital camera (Digital 
Scientific) 
Smart Capture V3.0 
(Digital Scientific) 
Zeiss Axioplan 
2 fluorescence 
microscope 
Zeiss Ph3 Plan-
NEOFLUAR 100x 
oil immersion 
lens 
Cooled charge-coupled 
device (CCD) camera 
(Sensys, Photometrics) 
Smart Capture V2.0 
(Digital Scientific) 
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This allowed the centre of the nucleus to be determined. The distance from the 
nuclear centre to each furthest chromosome territory edge (CTE) was determined.  
These distances were divided by the distance from the nuclear centre to each 
respective nuclear edge (NE). Results were presented as a CTE/NE ratio. This process 
was performed for at least 50 nuclei, from which an average CTE/NE ratio was 
established, for each chromosome and cell line. For an overview of the analysis 
process, see figure 2.2.2. Using this data, bar charts were plotted and error bars were 
added which corresponded to the ± standard error mean (SEM) (SEM: standard 
deviation/ square root of n, where n is the sample size). 
 
 
 
Figure 2.2.1:  An overview of the analysis method used to examine chromosome anchorage 
by the NM  
The blue channel captures the DAPI-stained nucleus and surrounding DNA, while the red 
channel detects the probe signal. The residual nucleus is selected and removed using NIH 
image/ Scion Image (see resultant ‘Blue’ channel). The image denoted ‘Result’ is the outcome 
of superimposing the red channel on the blue channel image; this allows the aforementioned 
distances to be calculated. 
 
2.2.10.2 Telomeres 
 
30 nuclei were analysed per dataset. The images were opened in Photoshop 5.0.2 and 
analysed manually; the number of telomeres within (1) the residual nucleus and (2) 
within the DNA halo, were counted. BrdU or pKi67 staining was used to differentiate 
between proliferating (BrdU/pKi67+) and senescent (BrdU/pKi67−) nuclei. Using this 
data, bar charts were plotted and error bars were added which corresponded to the ± 
SEM. 
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Figure 2.2.2: An overview of the analysis procedure employed to measure CT extraction 
following HALO-FISH. NC = nuclear centre; CTE = chromosome territory edge; NE = nuclear 
edge.  
 
2.2.11 Statistical Analysis  
 
The Student’s t-test (unpaired) was used to statistically compare the results; p < 0.05 
was considered significant. 
 
 
 
 
 
Split images into 
colour channels 
Outline the periphery 
of the residual 
nucleus and cut-out 
Calculate NC using XY 
co-ordinates 
Measure distance 
from NC to furthest 
CTE 
Measure distance 
from NC to 
corresponding NE 
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2.3 RESULTS 
2.3.1 Using DNA halo preparations to examine chromosome interactions with the 
nuclear matrix 
2.3.1.1 An assay to examine chromosome anchorage by the nuclear matrix 
 
In order to examine chromosome interactions with the NM, control HDFs were 
subjected to the DNA halo preparation. As a consequence of the permeabilisation and 
extraction stages, the residual nucleus should only theoretically consist of the 
inextractable NM and any NM-associated DNA and protein (Gerdes et al., 1994). 
Conversely, the DNA halo is composed of extracted DNA (figure 2.3.1a). It is thus 
possible to differentiate between those sequences which were attached to the NM at 
the point of fixation and those which were not (or were very loosely associated with 
the structure). 2D FISH was then employed to visualise specific chromosomes and to 
investigate whether different chromosomes interact with the NM to varying extents. 5 
chromosomes were studied: HSA-1, -13, -15, -17 and -18 (figure 2.3.1). HSA-1 was 
chosen since it is the largest chromosome; HSA-13 was selected due to the fact that it 
is acrocentric and thus, associates with nucleoli (Henderson et al., 1972; Sullivan et al., 
2001) and has a similar gene density to HSA-18. HSA-15 was selected since it is 
significantly more gene dense than HSA-13 but is of a comparable size and is also 
acrocentric (Deloukas et al., 1998). HSA-17 and HSA-18 were chosen since although 
they are similar in size, HSA-17 is gene-rich, while HSA-18 is gene-poor (Deloukas et al., 
1998). Furthermore, they are not acrocentric chromosomes.  
 
In order to compare chromosome anchorage by the NM, the distance from the nuclear 
centre to each furthest chromosome territory edge (CTE) was determined.  These 
distances were divided by the distance from the nuclear centre to each respective 
nuclear edge (NE). At least 50 nuclei were analysed per dataset and the collation of 
these results was presented as an average CTE/NE ratio.  
Chapter 2: Using the DNA halo assay to examine the role of the nuclear matrix in mediating 
genome organisation 
 
64 
 
Fi
gu
re
 2
.3
.1
: A
n
al
ys
in
g 
N
M
-c
h
ro
m
o
so
m
e
 in
te
ra
ct
io
n
s 
u
si
n
g 
H
A
LO
-F
IS
H
 
(a
) 
A
 c
o
n
tr
o
l 
H
D
F 
w
h
ic
h
 h
as
 b
ee
n
 e
xt
ra
ct
e
d
 u
si
n
g 
th
e 
D
N
A
 h
al
o
 p
re
p
ar
at
io
n
; 
N
M
-a
ss
o
ci
at
ed
 D
N
A
 i
s 
an
ch
o
re
d
 t
o
 t
h
e 
re
si
d
u
al
 n
u
cl
eu
s,
 w
h
ile
 e
xt
ra
ct
e
d
, 
n
o
n
-N
M
 a
ss
o
ci
at
ed
 D
N
A
 f
o
rm
s 
th
e 
fa
in
t 
h
al
o
 s
u
rr
o
u
n
d
in
g 
th
e 
st
ru
ct
u
re
. D
N
A
 h
as
 b
ee
n
 s
ta
in
ed
 u
si
n
g 
D
A
P
I a
n
d
 c
an
 b
e 
se
e
n
 in
 b
lu
e.
 (
b
) 
C
o
n
tr
o
l H
D
Fs
 w
er
e 
su
b
je
ct
e
d
 t
o
 t
h
e 
D
N
A
 h
al
o
 p
re
p
ar
at
io
n
 a
n
d
 2
D
-F
IS
H
. 
Sp
ec
if
ic
 p
ro
b
es
 w
e
re
 u
se
d
 f
o
r 
ch
ro
m
o
so
m
es
 1
, 1
3
, 1
5
, 1
7
 a
n
d
 1
8
. 
C
h
ro
m
o
so
m
e 
p
ai
n
ts
 a
re
 d
ep
ic
te
d
 
in
 r
ed
 (
C
y3
).
 I
n
 o
rd
er
 t
o
 d
if
fe
re
n
ti
at
e 
b
et
w
ee
n
 p
ro
lif
er
at
in
g 
(p
K
i6
7
+)
 a
n
d
 s
en
es
ce
n
t 
n
u
cl
ei
 (
p
K
i6
7
–)
, 
H
A
LO
-F
IS
H
 n
u
cl
ei
 w
e
re
 a
ls
o
 s
ta
in
ed
 w
it
h
 a
n
ti
-p
K
i6
7
, 
w
h
ic
h
 c
an
 b
e 
se
en
 in
 g
re
en
 (
FI
TC
).
  
 
Chapter 2: Using the DNA halo assay to examine the role of the nuclear matrix in mediating 
genome organisation 
 
65 
 
2.3.1.2 The majority of chromosome mass is attached to the NM regardless of 
cellular state 
 
In order to test whether chromosomes form different interactions with the NM in 
proliferative and non-proliferative states, HALO-FISH was coupled with anti-pKi67 
staining (figure 2.3.1b). pKi67 is a nucleolar antigen which exists only in proliferating 
cells (Gerdes et al., 1984; 1986; Kill, 1996). Therefore, it can be used to differentiate 
between proliferating and senescent cells. Nuclei positive for pKi67 were scored as 
proliferative, while those negative were deemed senescent. Significantly, all 
chromosomes except for HSA-18 were largely attached to the residual nucleus. This 
suggests that, typically, many MARs exist within chromosomes 1, 13, 15 and 17 which 
anchor the chromosomes to the residual nucleus, thus preventing their extraction. On 
the other hand, since HSA-18 was frequently extracted into the DNA halo as a whole 
chromosome, this indicates that far fewer MARs are located within chromosome 18. 
However, this data for HSA-18 is tentative since the number of nuclei examined per 
population was less than half (n = 24) than that analysed for the other 4 chromosomes 
(n = 50). This was due to technical difficulties with the HSA-18 probe DNA.  
Nevertheless, it is likely that the extraction trend for HSA-18 is correct since it concurs 
with previous data by Croft et al. (2001).  The anchorage of all chromosomes analysed 
did not change according to cellular state; indeed, statistical; analysis demonstrated 
that NM-chromosome interactions were similar in both proliferating and senescent 
nuclei (figure 2.3.2; 2.3.3). The CTE/NE ratios for each chromosome indicate that, on 
average, the chromosome territory edge barely exceeded that of the corresponding 
nuclear periphery. However, there were statistical differences between chromosomes 
(figure 2.3.2b), suggesting that although there is a mass anchorage of these 5 
chromosomes, there are variations in the levels of NM attachment.     
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Figure 2.3.2: Examining chromosome anchorage by the NM in proliferating and 
senescent control HDFs using the DNA halo assay 
(a) The ratio of furthest chromosome territory edge (CTE) to respective nuclear edge 
(NE) for specific chromosomes in pKi67+ and pKi67– nuclei. Error bars represent ± SEM. 
(b) Statistical analysis of NM-chromosome interactions using the Student’s t-Test. + = 
pKi67+; – = pKi67–. Green shading indicates no significant difference between the 
populations, yellow shading depicts a p-value < 0.05 and red shading represents p-value 
< 0.01.  
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Figure 2.3.3:  Chromosome 
anchorage in proliferating and 
senescent control HDFs using the 
DNA halo assay 
Modified box plots of the ratio of 
furthest chromosome territory 
edge (CTE) to respective nuclear 
edge (NE) for specific 
chromosomes in pKi67+ andpKi67– 
nuclei. Q1 = lower quartile; Min = 
lowest value recorded; Med = 
median; Max = maximum value 
recorded; Q3 = upper quartile. 
 
Figure 2.3.3:  Chromosome 
anchorage in proliferating and 
senescent control HDFs using the 
DNA halo assay 
Modified box plots of the ratio of 
furthest chromosome territory 
edge (CTE) to respective nuclear 
edge (NE) for specific 
chromosomes in pKi67+ and pKi67– 
nuclei. Q1 = lower quartile; Min = 
lowest value recorded; Med = 
median; Max = maximum value 
recorded; Q3 = upper quartile. 
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2.3.2 Using DNA halo preparations to examine telomere interactions with the NM 
2.3.2.1 An assay to examine telomere anchorage by the NM 
 
I have coupled the DNA halo preparation with telomere PNA FISH, in order to examine 
telomere interactions with the NM in control HDFs. Resulting images were analysed by 
scoring the number of telomere signals within the residual nucleus and the number of 
telomeres in the DNA halo (figure 2.3.4). From these values, the percentage of 
telomeres extracted into the DNA halo was calculated.  
 
 
 
To check the consistency of the results (within a slide), 3 sets of 30 nuclei were 
analysed. In each of the three data sets, on average approximately 15% of telomeres 
were extracted into the DNA halo (figure 2.3.5).  When comparing the three data sets 
(nuclei = 30), no statistical differences were observed, suggesting that the results 
produced by the assay are consistent and reproducible. Furthermore, these data 
indicate that the analysis of a population of 30 nuclei provides an accurate 
representation of telomere anchorage in this control population. 
Figure 2.3.4: Telomere anchorage in a control 
HDF using the DNA halo preparation. 
The residual nucleus and surrounding DNA halo 
have been counterstained using DAPI (blue) while 
telomere signals can be seen in green (FITC). 
Magnification = x100; scale bar = 10 µm.  
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2.3.2.2 Examining telomere anchorage by the NM in proliferating and senescent 
(senescent) HDFs using the DNA halo assay 
 
To determine whether telomere associations with the NM vary between different 
cellular states, we determined the percentage of telomeres in the DNA halo for 
proliferating and senescent cell populations. Control HDFs were grown on glass slides 
in QuadriPERMTM chambers and then incubated in a mixture of 
BrdU/fluorodeoxyuridine (FrdU) for 24 hours. Following another 24 hours growth, the 
cells were subjected to the DNA halo preparation. In order to differentiate between 
those cells which had incorporated the thymidine analogue (BrdU) and those which 
had not, residual nuclei were stained with anti-BrdU. Proliferating nuclei stained 
positive for the presence of BrdU (BrdU+), while senescent nuclei were BrdU negative 
(BrdU−; figure 2.3.6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3.6: Examining telomere anchorage by the NM in proliferating and senescent HDFs 
using the DNA halo assay.  
Control HDFs were subjected to the DNA halo preparation and telomere PNA-FISH. The 
residual nucleus and surrounding DNA halo have been counterstained using DAPI (blue) while 
telomere signals are green (FITC). Proliferating nuclei have been detected using anti-BrdU or 
anti-pKi67 staining (red; TRITC). Magnification = x100; scale bar = 10 µm.  
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For proliferating (BrdU+) nuclei, an average of 14.1% (± 7.8 (± standard deviation); 
nuclei = 90) of telomeres were extracted into the DNA halo, while for senescent 
(BrdU−) nuclei, this value was 16.5% (± 7.7; nuclei = 90; see figure 2.3.7). Importantly, 
when comparing these results to the pooled HDF population presented in the previous 
section (2.3.2.1), which exhibited 15.1% (± 8.1; nuclei = 90) of telomeres in the DNA 
halo, there were no statistical differences. This is significant since it demonstrates that 
DNA halo preparations performed separately produce statistically similar levels of 
telomere anchorage by the NM. When statistically comparing BrdU+ and BrdU− nuclei, 
a significant difference was detected using p < 0.05; however, there was no difference 
with p < 0.01. Thus, this suggests that there may be a small difference between 
telomere interactions with the NM in proliferating and senescent nuclei using the DNA 
halo assay.  
 
Since the use of BrdU in living cells is documented to induce a senescent-like 
phenotype, in terms of gene expression and the number of MARs that exist (Michishita 
et al., 1999; Suzuki et al., 2001; Suzuki et al., 2002), it seemed necessary to examine 
telomere anchorage in proliferating and senescent nuclei using another method to 
differentiate between the two populations. Therefore, anti-pKi67 was employed; cells 
grown in the absence of BrdU preceding the DNA halo preparation were stained with 
anti-pKi67 (figure 2.3.6). Importantly, there was no significant statistical difference 
between the pKi67 populations; in pKi67+ residual nuclei, an average of 10.9% (± 4.9; 
nuclei = 30) of telomeres were extracted into the DNA halo, while in pKi67− nuclei, a 
mean of 9.3% (± 5.1; nuclei = 30) were scored in the DNA halo (nuclei = 30; figure 
2.3.8).  
 
Thus, while nuclei grown in the presence of BrdU demonstrated that senescent nuclei 
exhibited an increase in telomeres in the DNA halo; pKi67-differentiated nuclei 
displayed the reverse trend. When statistically comparing BrdU+ and pKi67+ nuclei, no 
significant difference was detected. However, BrdU− and pKi67− were statistically 
different. This could suggest that telomere anchorage does not differ between 
proliferating and senescent nuclei and therefore, the discrepancy between the results 
represents a variation which is either inherent with the assay. Therefore, taken 
together, these findings suggest that on average, 9–17% of telomeres are not 
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anchored by the NM in control HDFs. This concurs with the results of a biochemical 
study performed by de Lange (1992), which reported that at least 80% of telomeric 
DNA is attached to the NM.  
 
 
 
 
 
 
2.3.2.3 The number of detectable telomeres is reduced in senescence 
 
Theoretically, it should be possible to detect almost all telomeres within in a normal 
diploid human nucleus using PNA FISH (Thisted et al., 1999). Although the visualisation 
of all telomeres is possible in metaphase (using telomere PNA FISH), this is not true of 
interphase nuclei; a maximum of 92 telomeres has been reported in cultured human 
haematopoietic cells (Lansdorp et al., 1996). In our study, the average number of 
telomeres scored per nucleus using the DNA halo assay was statistically lower in 
senescent populations; indeed, this was demonstrated when either anti-BrdU or anti-
pKi67 was used to differentiate between proliferating and senescent states (figure 
2.3.7 and 2.3.8). Thus, there was an 11% difference when comparing BrdU+ and BrdU− 
populations and almost a 20% difference between pKi67+ and pKi67− nuclei. 
Figure 2.3.7: Examining telomere anchorage by the NM in proliferating (BrdU+) and 
senescent (BrdU−) nuclei using the DNA halo assay  
The random population refers to the initial dataset analysed without differentiating between 
proliferating and senescent nuclei. Proliferating and senescent populations were 
distinguished by the presence or absence, respectively, of BrdU incorporation. For each 
population, n = 90. Significant differences between BrdU+ vs. BrdU− and random 
populations are denoted by stars (1 = p < 0.05; 2 = p < 0.01). Error bars represent ± SEM.  
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2.3.2.4 Examining telomere anchorage by the NM in quiescent HDFs using the DNA 
halo assay 
 
In order to examine telomere anchorage in quiescent HDFs using the DNA halo assay, 
cells were induced to enter quiescence by serum-starvation (0.5% NCS for 7 days), 
subjected to the DNA halo preparation and telomere PNA FISH. To confirm that the 
majority of the culture was quiescent, nuclei were stained with anti-Ki67 (figure 2.3.9). 
This methodology was performed on two separate occasions in order to confirm any 
detectable trends. The difficulty with analysing quiescent populations of cells is that 
there is no way to differentiate between the already senescent cells and newly 
quiescent populations. However, since approximately 60–70% of cells were 
proliferating in the control cultures at the point of serum-starvation induced 
quiescence, an equal proportion should be susceptible to quiescence induction. Thus, 
if quiescent cells exhibit a different pattern of telomere anchorage by this NM, this 
should be detected in a shift in the percentage of telomeres in the DNA halo. 
Significantly, the mean percentage of telomeres extracted into the DNA halo was 
16.6% (± 5.8; nuclei = 30) in experiment 1 and 18.4% (± 6.0; nuclei = 30) in experiment 
Figure 2.3.8: Examining telomere anchorage by the NM in proliferating (pKi67+) 
and senescent (pKi67−) nuclei using the DNA halo assay 
Proliferating and senescent populations were distinguished by the presence or 
absence, respectively, of anti-pKi67 staining. For each population, 30 nuclei were 
analysed. Significant differences between pKi67+ and pKi67− populations are 
denoted by stars (p < 0.01). Error bars represent ± SEM. 
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2, which were not statistically different (figure 2.3.10a). Importantly, both quiescent 
datasets were significantly different to proliferating (pKi67+) and senescent (pKi67−; 
senescent) populations (figure 2.3.9b). These results suggest that telomere anchorage 
is reduced in quiescence.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3.9: Examining telomere anchorage by the NM in quiescent HDFs using the DNA 
halo assay.  
Control HDFs were grown in low-serum for 7 days in order to induce entry into quiescence. 
This was performed on two separate occasions. The cells were then subjected to the DNA halo 
preparation and telomere PNA-FISH. Slides were also stained with anti-pKi67 to ensure that 
the nuclei were non-proliferating. The residual nucleus and surrounding DNA halo have been 
counterstained using DAPI (blue), while telomere signals can be seen in green (FITC). 
Magnification = x100; scale bar = 10 µm.  
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Figure 2.3.10: Examining telomere anchorage by the NM in quiescent HDFs using the DNA 
halo assay  
Control HDFs were grown in low-serum for 7 days in order to induce entry into quiescence. This 
was performed on two separate occasions. Significant differences between the populations are 
denoted by stars (p < 0.01); the colour of the stars refers to the specific dataset. (a) Mean 
percentage of telomeres in the DNA halo in two quiescent datasets; (b)  Comparing the mean 
percentage of telomeres extracted into the DNA halo in proliferating, senescent and quiescent 
populations. Error bars represent ± SEM.  
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2.3.3 Examining the interaction of specific genes with the NM  
 
In order to determine whether genes interact differently with the NM in different 
cellular states, the NM anchorage of 3 genes, CCND1, C-MYC and CTNNA1 was 
examined in proliferating (pKi67+) and senescent (pKi67−) control HDFs using the DNA 
halo assay (figure 2.3.11). Interestingly, in both pKi67+ and pKi67− populations, CCND1 
alleles were observed within the residual nucleus in over 95% of cases (nuclei = 30; 
figure 2.3.11; 2.3.12). Thus, regardless of cellular state, CCND1 appears to be tightly 
bound to the NM. In proliferating nuclei, approximately 75% of C-MYC alleles were 
found within the residual nucleus, while the remaining 25% were extracted into the 
DNA halo (nuclei = 30; figure 2.3.12). These extracted alleles were observed as loops 
emanating from the residual nucleus rather than discrete spots in the DNA halo. In 
senescent nuclei, the anchorage of C-MYC by the NM increased slightly, although this 
was not statistically significantly. Similarly, 80% of CTNNA1 alleles were associated with 
the NM in pKi67+ nuclei; this increased to 88% in pKi67− nuclei (nuclei = 30; figure 
2.3.12). Importantly, CCND1 signals were more condensed than those for C-MYC and 
CTNNA1. In conclusion, these findings demonstrate that the anchorage of selected 
genes by the NM did not change on entry into senescence using our DNA halo assay. 
However, differences in the level of gene packaging were observed.  
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Figure 2.3.11: Examining NM-gene interactions in control HDFs using the DNA halo 
assay 
The residual nucleus and surrounding DNA halo have been counterstained using DAPI 
(blue). Gene specific probes (CCND1, C-MYC and CTNNA1) have been used to 
investigate the anchorage of certain genes by the NM. Gene signals are depicted in red 
(Cy3), while anti-pKi67 can be seen in green (FITC). Magnification = x100; scale bar = 10 
µm.  
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 Figure 2.3.12: Examining NM-gene anchorage in proliferating and senescent 
control HDFs using the DNA halo assay. Error bars represent ± SEM.  
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2.4 DISCUSSION 
2.4.1 Using DNA halo preparations as a platform to analyse genomic interactions 
with the nuclear matrix 
The NM consists of an internal NM and a peripheral NL (Nickerson et al., 2001). This 
internal NM is composed of thick polymorphic fibres built around core filaments 
approximately 10 nm in diameter (He et al., 1990). Significantly, the NM complex is 
proposed to organise eukaryotic DNA into loops of 50–200 kb in length (Heng et al., 
1992; 2001). The DNA sequences which anchor the base of these loops to the NM, in 
interphase and metaphase cells have been termed MARs or SARs, respectively 
(Mirkovitch et al., 1984; Cockerill and Gerrard, 1986; and Laemmli, 1986; Bode et al., 
1992). These loops can be visualised following the extraction of histones and other 
soluble proteins in DNA halo preparations (Vogelstein et al., 1980; Gerdes et al., 1994). 
The use of such extraction procedures to study genome interactions with the NM have 
revealed that chromosomes (Ma et al., 1999; Croft et al., 1999), telomeres (Luderus et 
al., 1996; Ratsch et al., 2002), genes (Gerdes et al., 1994; Ratsch et al., 2002) and other 
genomic regions (Iarovaia et al., 2005) are indeed anchored by this nuclear structure. 
 
2.4.2 Chromosome anchorage by the NM in normal fibroblasts in the DNA halo assay 
 
Previous work performed demonstrates that following such preparations involving 2M 
NaCl, the majority of CTs remain within the residual nucleus and are not extracted into 
the DNA halo; this is true of HSA-1, -2, -4, -7, -9, -11, -14, -19 and -22 (Ma et al., 1999; 
Croft et al., 1999). However, HSA-18 is the one documented exception to this rule; this 
chromosome is consistently extracted into the DNA halo, which suggests that not all 
CTs are anchored to the NM to the same extent (Croft et al., 1999). Thus, it seemed 
pertinent to examine the associations of selected chromosomes with the NM in human 
HDFs. The anchorage of HSA-1 and HSA-18 by the NM have been studied by Ma et al. 
(1999) and Croft et al. (2001), respectively; however, to the best of my knowledge, NM 
associations with HSA-13, -15 and -17, have not been investigated elsewhere. In line 
with Ma et al. (1999), HSA-1 resisted extraction and remained tightly anchored to the 
residual nucleus, which suggests that it interacts with the NM at numerous sites. In line 
with this hypothesis, HSA-1 was observed to be the most structured of the 
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chromosomes examined in this study. The other 3 chromosomes (HSA-13, -15 and -17) 
were also demonstrated to be avidly associated with the NM. Previous work by Croft 
et al. (1999) suggested that there may be a correlation between gene-density and NM-
attachment; indeed, gene-poor HSA-18 was loosely anchored by the NM, while gene-
rich HSA-19 exhibited tight associations with the structure. The preliminary HSA-18 
data presented in this study appears to confirm this trend. However, HSA-13, which is 
also of similar gene density to HSA-18 (Deloukas et al., 1998), remained tightly 
attached to the NM. It is likely that HSA-13’s anchorage by the nucleolus was partly 
responsible for its ability to resist extraction. In line with the fact that both HSA-13 and 
-15 are acrocentric and are tethered by the nucleolus (Henderson et al., 1972; Sullivan 
et al., 2001), both chromosomes were seen to decorate the edges of remnant nucleoli. 
Therefore, these findings do not negate the possibility of a relationship between gene-
density and NM anchorage; instead, they suggest that although gene-poorer 
chromosomes such as HSA-13 and HSA-18 are likely to interact at far fewer sites than 
gene-richer chromosomes, HSA-13 remains within the residual nucleus due to its 
association with the nucleolus, while HSA-18, which lacks such anchorage, is extracted 
into the DNA halo. The findings also indicate that chromosome size is probably not a 
determinant of NM-association since HSA-17 and HSA-18 are of a similar size (Deloukas 
et al., 1998) but are anchored to differing extents by the NM (this study; Croft et al., 
1999). However, the different cell types used in these separate studies must be taken 
into account; HDFs were used in this current investigation while Croft et al. (1999) 
employed lymphoblasts and Ma et al. (1999) used both dermal and lung fibroblasts. It 
is possible that chromosome anchorage by the NM differs according to cell type; 
indeed, while the positioning of chromosomes is largely similar in both human 
fibroblasts and lymphoblasts, some differences have been reported (Boyle et al., 
2001).   
 
There is evidence to suggest that there is a correlation between transcriptional activity 
and NM-binding (Gerdes et al., 1994; Ratsch et al., 2002; Iarovaia et al., 2005). Indeed, 
active genes are found in smaller loops whereas inactive regions form part of much 
larger DNA loops (Bode et al., 2000). In line with this, Croft et al. (2001) demonstrated 
that the gene-rich chromosome, HSA-19 is tightly associated with the NM while gene-
poor HSA-18 is loosely anchored by the structure. This study also indicates that HSA-18 
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has a loose association with the NM. Since chromosome positioning appears to alter 
on exit from the cell cycle (Bridger et al., 2000; Meaburn et al., 2007; Mehta et al., 
2010), it seemed pertinent to examine and compare chromosome anchorage by the 
structure in normal proliferating and non-proliferating (senescent) nuclei. Our results 
demonstrate that global chromosome interactions with the NM do not appear to differ 
in the two proliferative states. These findings are certainly not incompatible with 
observations that the genome is rearranged on cell cycle exit (Bridger et al., 2000; 
Meaburn et al., 2007; Mehta et al., 2010); however, they do suggest that NM-MARs 
attachments are released and reformed in order to allow shifts in chromosome 
positioning. These data confirm earlier accounts that the CTs are anchored by the NM 
(Ma et al., 1999; Croft et al., 1999). The results also demonstrate that there are no 
obvious differences in chromosome attachment to the NM in proliferating and non-
proliferating nuclei. However, performing HALO-FISH with chromosome-specific 
probes cannot reveal any changes in NM interactions occurring at a more local scale. 
Indeed, it is likely that the nature of specific NM-MARs interactions differ between the 
two proliferative states as a result of their differing transcriptional profiles (Gerdes et 
al., 1994). 
 
2.4.3 Telomere anchorage by the NM in normal fibroblasts in the DNA halo assay 
2.4.3.1 Proliferating vs. senescent nuclei 
 
In order to examine telomere interactions with the NM, we have coupled the DNA halo 
preparation (as per Bridger and Lichter, 1999) with telomere PNA FISH. When 
examining such interactions in HDFs using this assay, the results consistently reveal 
that approximately 85–90% of telomeres are anchored by the NM. Significantly, this 
concurs with previous biochemical data which demonstrates that at least 80% of 
telomeric DNA is attached to this nuclear structure (de Lange, 1992). The results also 
confirm earlier HALO-FISH experiments using telomere-specific probes (Luderus et al., 
1996; Ratsch et al., 2002). Although the study of NM-telomere interactions using 
HALO-FISH is not novel, the consistent results of this study demonstrate that we have 
produced a reliable and reproducible assay which generates quantitative data. 
Therefore, this assay can now be used to compare telomere anchorage in different cell 
and disease states.  
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Human fibroblasts have a limited lifespan in vitro; their maximum replicative capacity 
is known as the Hayflick limit (Hayflick and Moorhead, 1961). Indeed, telomere length 
is found to be an indicator of such proliferative capacity (Allsopp et al., 1992). 
Telomeres are shortened with each cell division due to the end replication problem; 
once telomere length reaches a critical length, the cells enter replicative senescence 
(Bodnar et al., 1998; Stewart and Weinberg, 2006). This can be achieved in culture by 
passaging cells repeatedly until this state is achieved. It has been demonstrated that 
such eroded telomeres trigger DNA damage checkpoint responses which in turn leads 
to this irreversible G1/S cell cycle arrest (d’Adda di Fagagna et al., 2003). In light of 
these facts, we thought it pertinent to investigate and compare telomeric interactions 
with the NM in senescence with those in a proliferating population of HDFs.  
 
Interestingly, our results demonstrate that the majority of telomeres associate with 
the NM, regardless of cellular state. There was a significant difference (p < 0.05) 
between telomere anchorage when BrdU was used to differentiate between 
proliferating and senescent nuclei. However, the fact that BrdU is documented to 
induce changes in gene expression and MAR anchorage (Michistuta et al., 1999; Suzuki 
et al., 2001; Suzuki et al., 2002), this difference should be interpreted with caution. 
When anti-pKi67 staining was used to distinguish proliferating and senescent nuclei, no 
difference was detected. Thus, taken together, these data suggest that telomere 
anchorage does not change on entry into senescence. Telomeres are found to contain 
a MAR every 1 kb of telomeric DNA, which is far more frequent than the genome as a 
whole (Luderus et al. 1996). Since telomeres in cultured human fibroblasts are 
observed to shorten approximately 50–150 bp per division (Harley et al., 1990; Levy et 
al., 1992; Wright et al., 1997; Londono-Vallejo et al., 2001), this suggests a 2.5–7.5 kb 
loss of telomeric DNA after 50 divisions. Thus, this translates into the elimination of 2–
7 MARs in human fibroblasts over a lifetime of 50 divisions. Considering that the mean 
telomere length of chromosomes in such cells is 6–9 kb (Allsopp et al., 1992; Decker et 
al., 2009), this indicates the possible loss of a large proportion of telomeric MARs. The 
results suggest that even with the probable reduction in MARs anchoring a telomere to 
the NM, the telomere remains attached to the residual nucleus in our assay. However, 
obviously, since telomeres are predicted to be shorter in senescence cells, this does 
mean that there is less telomeric DNA to anchor. Therefore, the findings suggest that 
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telomere length does not influence the avidity of telomere binding to the NM, which is 
in fact in agreement with previous work performed by Luderus et al., (1996). 
 
2.4.3.2 The number of detectable telomeres decreases in senescence  
 
The mean number of telomeres detected in the senescent cells was significantly less 
than the average number observed in the proliferating population. This is unsurprising 
since telomere length is reduced with every cell division and thus, it would be 
expected that the senescent telomeres would be shorter than telomeres in 
proliferating cells (Allsopp et al., 1992). Since PNA signal intensity is directly correlated 
with telomere length (Lansdorp et al., 1996), those telomeres that were critically short 
could have possibly avoided detection. However, in a study which employed Q-FISH to 
detect telomere length in metaphases, signal-free telomeric ends were not reported 
for control human fibroblasts, although they were present in those derived from HGPS 
patients (Decker et al., 2009). This probably reflects the differences between the ease 
of signal detection in interphase and metaphase cells. Is it possible that this reduction 
in detectable telomeres in senescence distorted the results regarding NM-telomere 
binding in proliferating versus senescent cells? This would only be the case if the 
majority of short telomeres were not associated with the NM and thus, were extracted 
into the DNA halo. However, since there appears to be no relationship between 
telomere length and the avidity of NM binding (this study; Luderus et al., 1996), this is 
not likely to be of concern.  
 
2.4.3.3 Quiescence 
 
Although both quiescence and senescence are non-dividing states, they represent two 
very distinct phases; the former is reversible under physiological conditions while the 
latter is not. Furthermore, quiescent cells are considerably less metabolically active 
than senescent populations (Blomen and Boonstra, 2007). Within the laboratory, 
quiescence can be induced in three ways; by serum starvation, contact inhibition and 
by loss of adhesion (Coller et al., 2006). 
 
Chapter 2: Using the DNA halo assay to examine the role of the nuclear matrix in mediating 
genome organisation 
 
84 
 
Furthermore, as quiescence is distinctly different to both proliferation and senescence, 
it seemed logical to examine telomere anchorage by the NM in quiescent cells. These 
investigations are of particular relevance since radial chromosome positioning in 
interphase nuclei changes according to cellular state (Bridger et al; 2000; Meaburn et 
al., 2007; Mehta et al., 2010) and differentiation (Galiova et al., 2004; Kim et al., 2004). 
Significantly, the proportion of telomeres associated with the NM decreased 
significantly in both quiescent populations. This could suggest that the binding of 
certain telomeres to the structure is weaker in quiescence. However, since the initial 
study (which did not differentiate between proliferative state) demonstrated that 
approximately 15% of telomeres are extracted into the DNA halo, it is possible that 
there is no general difference between NM-telomere interactions in proliferating, 
senescent and quiescent cells. Therefore, this suggests that in control HDFs, regardless 
of proliferative state, 9–19% of telomeres are not associated with the residual nucleus 
when using the DNA halo assay. Indeed, this chimes with biochemical work by de 
Lange (1992), which reported that at least 80% of telomeres are anchored by the NM. 
Thus, this range is likely to represent biological differences between individual cells.    
 
2.4.4 Gene anchorage by the NM 
 
Research demonstrates that transcriptionally active genes tend to remain attached to 
the residual nucleus, while transcriptionally inactive genes are generally extracted into 
the DNA halo (Gerdes et al., 1994; Ratsch et al., 2002). Indeed, alpha-satellite 
sequences, which are non-transcribed, form part of DNA loops rather than associate 
with the NM (Yaron et al., 1998). Other genomic regions also have a cell-state specific 
relationship with the structure (Iarovaia et al., 2005). Thus, the anchorage of genes by 
the NM appears to have a functional importance (Gerdes et al., 1994; Ratsch et al., 
2002; Iarovaia et al., 2005).  In order to determine whether the anchorage of specific 
genes changes on entry into senescence, NM associations with CCND1, CTNNA1 and C-
MYC were examined in control HDFs using the DNA halo assay. These genes (CCND1, 
CTNNA1 and C-MYC) are found on chromosomes 11 (Motokura et al., 1991), 5 
(Furukawa et al., 1994) and 8 (Leder, 1982; Taub et al., 1982; Dalla-Favera et al., 1982; 
Takahashi et al., 1991), respectively. Apart from HSA-11 (Ma et al., 1999), the NM 
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anchorage of these parent chromosomes has not been examined in this or any 
previous study. 
 
Significantly, CCND1 was typically attached to the NM in both proliferating and non-
proliferating nuclei. This is important since CCND1 is a key regulator of the G1/S phase 
transition; it associates with the cyclin-dependent kinase, CDK4, to form a holoenzyme, 
which in turn functions to phosphorylate pRb (Dowdy et al., 1993; Ewen et al., 1993). 
This hyperphosphorylation of pRb causes the release of E2F; an event which leads to 
the transcriptional activation of S-phase genes and thus, cell cycle progression (Bartek 
et al., 1996).  In G1 and G2 phase fibroblasts, cyclin D1 levels are high while in S-phase, 
CCND1 expression is reduced (Yang et al., 2006). Thus, CCND1 expression occurs 
throughout the cell cycle to varying extents (Stacey, 2003), thus concurring with the 
demonstration by our assay that CCND1 is consistently associated with the NM.  
 
Interestingly, in senescent cells, CCND1 alleles were also typically anchored by the NM.  
In line with this, CCND1 is highly expressed in senescent human fibroblasts (Fukami et 
al., 1995; Fukami-Kobayashi and Mitsui, 1998) and in fact, expression levels are higher 
than those seen in young fibroblasts (Fukami et al., 1995).  Taken together, the findings 
of our study indicate that CCND1 remains associated with the NM in both cell cycle 
states. Furthermore, the results appear to fit with the previously proposed correlation 
between transcriptional activation and NM association (Gerdes et al., 1994).  
 
C-MYC is a transcription factor which influences the expression of numerous genes; C-
MYC target genes are involved in many cellular processes including cell cycle regulation 
and differentiation (for review, see Riggelen et al., 2010). The association of C-MYC 
with the NM has been previously examined in human monoctyes; indeed, in that 
particular study, 40% of signals were associated with the residual nucleus while 60% 
were extracted into the DNA halo (Ratsch et al., 2002). This is interesting since C-MYC 
is expressed at low levels in resting human monocytes (Lee et al., 1987). Importantly, 
these findings support the correlation between transcriptional activity and NM-
association (Gerdes et al., 1994). In contrast to the results reported by Ratsch et al. 
(2002), my study demonstrated that the large majority of C-MYC signals were 
associated with the residual nucleus. However, this is likely to be due to differences in 
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cell type (dermal fibroblast vs. monocyte) and proliferation status 
(proliferating/senescent vs. quiescent). While C-MYC is low in resting monocytes (Lee 
et al., 1987), the gene is expressed at high levels in a proliferating HDF culture (see 
chapter 4.3). Although C-MYC expression in a senescent HDF culture was not examined 
in this thesis, there is evidence to suggest that C-MYC expression is reduced in 
senescent human fibroblasts (Dean et al., 1986). Since C-MYC was associated with the 
residual nucleus in both proliferating and senescent HDFs to similar extents, this does 
not necessarily correlate with the gene activity/NM-association hypothesis. However, 
to investigate this fully, total RNA would ideally be extracted from a senescent culture 
of HDFs on the same day as the DNA halo preparation. This would allow a fairer 
analysis of C-MYC expression and NM-binding. 
 
2.4.5 How does the NM organise the genome within interphase nuclei? 
 
The findings presented here in this chapter do indeed indicate that the organisation of 
the genome is mediated by the NM. In line with previous data, CTs remained attached 
to the residual nucleus following extraction with 2M NaCl (Ma et al., 1999). The results 
presented in this chapter demonstrate that the NM is involved in anchoring CTs within 
interphase nuclei. Since the components of the outer NM are proposed to be removed 
by 2M NaCl treatment (He et al., 1990; Nickerson et al., 1992), this suggests that it is 
the core filaments of the inner NM and the peripheral component of the NM, the NL, 
which mediate such organisation. The removal of RNA species by RNase A is shown to 
destroy the integrity of core filaments (He et al., 1990); importantly, after such 
treatment, although CT structure is disrupted, the majority of CT mass remains within 
the residual nucleus (Ma et al., 1999). This is very significant since it suggests that even 
when core filaments are lost, chromosomes are still tethered inside the nucleus. 
Although these filaments are not resistant to RNase A, the NL is found to remain intact 
(Ma et al., 1999). Thus, it is likely that the NL is responsible for the overall anchorage of 
CT within the nucleus, while the core filaments of the inner NM are important for 
mediating specific, more local interactions.  Indeed, the NL is found to interact with the 
genome at over a 1000 sites known as LADs (Guelen et al., 2008). 
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While the peripheral component of the NM (NL) is implicated in organising interphase 
chromosomes, it appears that the internal NM is responsible for the overall tethering 
of telomeres. The evidence for this comes from Luderus et al. (1996) who 
demonstrated that telomeres do not generally associate with the NL; indeed, 
telomeres were found throughout the nuclear volume. Since telomeres are found to 
remain attached to the residual nucleus after 2M NaCl extraction (this study; Luderus 
et al., 1996), it is likely that the core filaments of the inner NM (rather than outer NM 
proteins) mediate telomere anchorage. Taken together, the results of this suggest that 
different elements of the NM have a role to play in organising different genomic 
regions. The obvious question is: how are these MARs tethered by the core filaments 
of the NM? Furthermore, what are the proteinaceous elements of these core 
filaments?  
 
2.4.6 How are MARs tethered by the NM? 
 
Unfortunately, the structural composition of the internal NM has not been fully 
characterised. The proteins of the internal NM can be categorised according to their 
release during NM preparations; indeed, 0.25 M ammonium sulphate extraction 
appears to reveal thick polymorphic fibres of the NM, while 2M NaCl removes the 
outer layer of NM proteins and exposes the core filaments of the NM (He et al., 1990). 
Since the methodology used in this chapter employs 2M NaCl to extract histones, 
other soluble proteins and non-NM associated DNA, this suggests that both the core 
filaments and peripheral NL are responsible for organising the genome. This also 
indicates that while this outer layer of NM proteins may contribute to mediating NM-
MAR associations, it is not instrumental; indeed, this study and others (Ma et al., 1999) 
demonstrate that in spite of their removal, DNA is still held in place. As a result, this 
leaves few characterised candidates for this role. While A-type lamins and the nuclear 
mitotic apparatus protein (NuMA) have been identified as minor components of these 
core filaments (Zeng et al., 1994; He et al., 1995; Hozak et al., 1995), much of their 
composition remains uncharacterised (for review, see Nickerson, 2001).   
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2.4.7 Conclusion  
 
Although the NM has been repeatedly visualised and isolated using various 
methodologies, the exact protein composition of the structure is still not fully 
understood (Nickerson, 2001). This is despite the fact that hundreds of NM associated 
proteins have been identified (Mika and Rost, 2005). It is uncertain which elements of 
the NM mediate telomere tethering, however, some NM proteins, such as the lamin 
protein family, are reported to bind telomeric DNA. In light of this study, it will be 
interesting to investigate whether mutations in certain NM associated proteins affect 
telomere anchorage by the NM.  
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3.1 INTRODUCTION 
3.1.1 The composition of the NM 
 
Although research demonstrates that at least 300 NM-associated proteins exist (Mika 
and Rost, 2005), the structural composition of the NM has not yet been fully 
characterised (Nickerson, 2001). While the peripheral component of the structure is 
well understood, the protein constituents of the internal portion require further 
elucidation.   The most abundant proteins of this inner NM are found to be hnRNP 
proteins and numatrin/nucleophospmin (Mattern et al., 1996). Other important inner 
NM proteins include NuMA (Zeng et al., 1994; He et al., 1995) and A-type lamins 
(Hozak et al., 1995; Barboro et al., 2002).  
However, it appears that there are two categories of internal NM proteins: those that 
are released by 2M NaCl treatment and those that resist such extraction (He et al., 
1990). The elution of digested chromatin by 0.25 M ammonium sulphate reveals a 
network of polymorphic fibres (He et al., 1990).  The subsequent addition of 2M NaCl 
to this structure further extracts these fibres to expose thinner, less heterogeneous 
filaments which have been termed the core filaments of the internal NM (He et al., 
1990). Therefore, 2M NaCl extracts a layer of ‘outer’ NM proteins; this is important 
since it implicates core filaments, rather than the complete NM, in being the primary 
mediator of DNA anchorage. Proteome analysis demonstrates that lamin A/C forms 
part of the insoluble nuclear fraction which remains after 2M NaCl extraction (Takata 
et al., 2009). Since the peripheral NL is also present within this pellet, this alone cannot 
provide evidence of the protein within the 2M NaCl-resistant internal nuclear matrix. 
Research confirming lamin’s internal nuclear localisation after 2M NaCl is not 
abundant. 
The use of electro-elution to remove partially digested chromatin (Jackson and Cook, 
1988) is also shown to reveal core filaments of similar morphology and size to those 
reported by He et al. (1990). In places, these filaments appear to underlie polymorphic 
fibres (Hozak et al., 1995), which again is an observation consistent with He et al. 
(1990). Using this method, Hozak et al (1995) demonstrated that anti-lamin A 
antibodies react, albeit weakly, with these core filaments; although, the intensity of 
staining was stronger at the ‘knobs’ and ‘clumps’ polymorphic fibres. Thus, this 
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suggests that although lamin A proteins are components of the core filaments, they 
are not the major constituents (Hozak et al., 1995). Therefore, although the method 
used to localise lamin A to the core filaments is different (i.e. salt- vs electro-elution), it 
does suggest that the protein is also likely to remain as part of the internal network 
following 2M NaCl extraction. 
Significantly, the lamin-associated INM, emerin, is also found to be part of the high-salt 
resistant insoluble nuclear fraction (Squarzoni et al., 1998; Ellis et al., 1998; Takata et 
al., 2009). However, so far, it has only been visualised at the nuclear periphery; a 
localisation mainly mediated by its interaction with the A-type lamins of the NL 
(Squarzoni et al., 1998).   
 
3.1.2 Which proteins mediate the NM’s role at organising the genome? 
 
As demonstrated and discussed in chapter 2, the organisation of the genome is 
mediated by the NM (de Lange, 1992; Gerdes et al., 1994; Luderus et al., 1996; Ma et 
al., 1999; Croft et al., 1999; Elcock and Bridger, 2008). The NM is composed of a 
peripheral NL and an internal network of fibres and filaments (inner NM; Jackson and 
Cook, 1988; He et al., 1990; Nickerson et al., 1997; Wan et al., 1999). The NL’s role in 
organising the genome is well characterised (Pickersgill et al., 2006; Guelen et al., 
2008) and this is partly aided by the knowledge of its constituents.  Since the NM is 
proposed to arrange the genome into repeating loops of 50–200 kb, the peripheral 
component of the NM alone cannot be responsible for mediating such organisation. 
While the MARs which mediate the formation of these loops exist in their thousands, 
their characterisation is poor (Bode et al., 2000).  
 
A number of MAR-binding proteins have been identified and examined (Adachi et al., 
1989; Luderus et al., 1992; Romig et al., 1992; Luderus et al., 1994; Fackelmayer et al., 
1994; Fackelmayer and Richter, 1994; Dickinson and Kohwi-Shigematsu, 1995; Renz 
and Fackelmayer, 1996; Gohring and Fackelmayer, 1997; Kipp et al., 2000; Dunn et al., 
2003) and significantly, a few, including A-type lamins and NuMa (Luderus et al., 1994), 
are also recognised as constituents of the inner NM (Zeng et al., 1994; He et al., 1995; 
Hozak et al., 1995). Logically, this implicates the involvement of such proteins in 
tethering DNA to the inner NM. Indeed, A-type lamins have DNA binding properties 
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(Shoeman and Traub, 1990; Taniura et al., 1995; Stierle et al., 2003) and are 
demonstrated to associate with telomeres (Raz et al., 2008); in line with this, the loss 
of such proteins significantly disrupts telomere localisation and maintenance 
(Gonzalez-Suarez et al., 2009).         
 
3.1.3 How can studying human disease aid our understanding of the NMPs? 
 
The composition of the NM is reported to be modified in various human diseases; this 
is especially true of certain cancer types (Sjakste et al., 2004). As a result, NM-
associated proteins are useful as diagnostic biomarkers for cancers such as those 
affecting the prostate, colon and bladder (Leman and Getzenberg, 2008). Significantly, 
the lamin composition of the NM is also disrupted in human prostate cancer 
(Coradeghini et al., 2006). It is likely that in disease cells, a number of MAR-binding 
proteins are also displaced and as a result, their ability to organise the genome 
correctly, is perturbed.  Indeed, chromatin disorganisation has been reported in cancer 
(Bartova et al., 2000; Cremer et al., 2003; Bartova et al., 2005; Wiech et al., 2005; 
Harnicarova et al., 2006; Murata et al., 2007; Meaburn and Misteli, 2008; Weich et al., 
2009; Meaburn et al., 2009). 
 
Therefore, since both lamin A and emerin are shown to form part of the inner NM, it is 
logical to question whether mutant forms of these proteins affect the NM’s ability to 
tether genomic regions effectively. This is especially relevant to A-type lamins which 
have been extensively implicated in mediating genome organisation (Shoeman and 
Traub, 1990; Luderus et al., 1992; Taniura et al., 1995; Stierle et al., 2003; Bode et al., 
2003). Emerin’s role in tethering chromatin within the interphase nucleus is less well 
characterised and is indirect. There is no evidence that emerin binds DNA directly; 
however, the protein probably exerts its effect via its binding to the highly conserved 
chromatin factor, BAF (Lin et al., 2000; Lee et al., 2001; Segura-Totten and Wilson, 
2004). While research using non-extracted cells demonstrates that chromatin 
disorganisation can result from mutations in LMNA (Sewry et al., 2001; Fidzianska and 
Hausmanowa, 2003; Goldman et al., 2004; Filesi et al., 2005; Maraldi et al., 2006; 
Meaburn et al., 2007; Lattanzi et al., 2007; Hakelien et al., 2008; Park et al., 2009) and 
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EMD (Fidzianska et al., 1998; Ognibene et al., 1999; Meaburn et al., 2007), the nature 
of NM-genomic interactions in such mutants has not been examined.  
 
As discussed in 1.4, HGPS is caused by LMNA mutations; the classical and most 
common form of the disease, results from a de novo mutation affecting codon 608 
(GGC>GGT; G608G). A number of other mutations in LMNA also result in HGPS; this is 
known as atypical HGPS.  This term is also applied to patients who exhibit an HGPS 
phenotype, in spite of the fact that LMNA is wildtype (see chapter 5.1; Bridger and Kill, 
2004). These latter atypical patients (referred to as atypical type 2) are of great 
interest since eventually their cells will reveal another genetic cause of HGPS. 
Mutations in LMNA can also result in autosomal EDMD (Bonne et al., 1999; Raffaele Di 
Bartletta et al., 2000). An X-linked version of EDMD exists; this disease results from 
mutations in EMD, the gene encoding emerin (Bione et al., 1994). Unlike autosomal 
EDMD, most cases of X-EDMD involve the absence of emerin rather than the presence 
of a mutant protein (Yates et al., 1999). Interestingly, a phenotype combining both 
HGPS and myopathy has been reported in a patient harbouring a point mutation at 
S143F in lamin A/C (Kirschner et al., 2005). 
 
3.1.4 Using DNA halo preparations to examine NM-genome interactions in 
laminopathy fibroblasts 
 
In light of the observation that both lamin A and emerin are components of the NM 
and that in cells expressing mutant forms of these proteins, the genome displays 
evidence of disorganisation (Ognibene et al., 1999; Sullivan et al., 1999; Sabatelli et al., 
2001; Sewry et al., 2001; Capanni et al., 2003; Fidzianska & Hausmanowa-Petrusewicz, 
2003; Goldman et al., 2004; Nikolova et al., 2004; Columbaro et al., 2005; Filesi et al 
2005; Scaffidi and Misteli, 2005; Arimura et al., 2005; Meaburn et al., 2007), it seemed 
pertinent to test whether genome interactions with the NM are perturbed in disease. 
In order to do this, a multi-faceted approach was adopted.  
 
Firstly, chromosome interactions with the NM were examined in cells derived from 
classical and atypical HGPS cell lines and compared with controls. Interestingly, the 
interactions of certain chromosomes were perturbed in HGPS cell lines. Secondly, in 
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order to determine whether telomere anchorage by the NM is disrupted in disease, 
three diseases were studied: HGPS, X-EDMD and cutaneous malignant melanoma. The 
effect of telomerase activation on telomere interactions with the NM was also 
examined by comparing mortal and immortalised HGPS fibroblasts. Significantly, it was 
observed that telomere anchorage by the NM was disrupted, to varying extents, by the 
presence of mutant lamin A as well as in the absence of emerin. Attempts were made 
to rescue perturbed telomere interactions in X-EDMD; however, these were not 
successful. Interestingly, the activation of telomerase in classical HGPS cells appeared 
to completely rescue perturbed telomere interactions.  
 
Taken together, the results of this chapter confirm that lamin A and emerin are 
important for mediating genome organisation. Importantly, they further strengthen 
the link between A-type lamin proteins and telomere biology.  
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3.2 MATERIALS AND METHODS 
3.2.1 Cell Culture 
 
Primary HDFs were maintained in conditions aforementioned in 2.2.1. ED5364 (X-
EDMD carrier), G12660 (HGPS + Myopathy) and AP (X-EDMD patient) (provided by 
Professor Glenn Morris, Professor Manfred Wehnert and Professor Chris Hutchison, 
respectively) were grown in 10% (v/v) fetal bovine serum (FBS), while AG06297 and 
AG08466 were grown in 15% (v/v) FBS.  
 
3.2.2 DNA Halo Preparation 
 
As per chapter section 2.2.3. 
 
3.2.3 Directly labelled total human chromosome probes and 2D FISH 
 
As per chapter sections 2.2.4 and 2.2.6. 
 
3.2.4 Telomere PNA FISH 
 
As per chapter 2.2.7. 
 
3.2.5 Transient transfection  
 
Emerin cDNA was cloned into the HindIII and BamHI sites of the vector pEGFP-C2 
(Clontech; figure 3.2.1; Fairley et al., 1999). The resulting construct, emerin-pEGFP-C2 
(referred to as EMD-GFP from this point onwards) which encodes emerin-green 
fluorescent protein (GFP), was generated previously to this study and was a kind gift 
from J. Ellis (Kings College, London). Cells were transfected with EMD-GFP using 
GeneJuice® Transfection Reagent (Novagen®). Cells were seeded in QuadriPERM
TM 
chambers at a density of 1 x 105 per slide and then left to grow for 24 hours. After this 
time, cells were transfected according to the manufacturer’s protocol; following a 
series of optimisation experiments (which are detailed in section 3.3), 5 µg of EMD-
GFP and 15 µl of GeneJuice® Transfection Reagent were selected as the optimal 
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transfection conditions. Following another 24 hours, slides were either taken through 
the DNA halo preparation or fixed with methanol: acetone for 10 minutes on ice.    
 
 3.2.6 Indirect immunofluorescence 
 
In order to detect the presence of lamin A/C, emerin and pKi67 following the DNA halo 
preparation, slides were washed 3 times in PBS and incubated at room temperature 
for 1 hour (or overnight at 4°C) in primary antibody (rabbit anti-human pKi67 
(Novocastra) diluted 1:1500; mouse monoclonal anti-human lamin A/C (Novocastra) 
diluted 1:10; mouse monoclonal anti-human emerin (Novocastra) diluted 1:20; all 
dilutions made using 1% (v/v) NCS). Cells were then washed 3 times in PBS and 
incubated at room temperature for 1 hour in a fluorochrome-conjugated secondary 
antibody (Lamin A/C and emerin: rabbit anti-mouse FITC/TRITC diluted 1:30 (Dako); 
pKi67: swine anti-rabbit TRITC diluted 1:30 (Dako)). Following 3 more washes with PBS, 
slides were mounted with Vectashield (Vector Laboratories) containing DAPI. 
 
In order to detect the presence of GFP in DNA halo prepared nuclei following 
transfection, slides were washed 3 times in PBS and incubated at room temperature 
for 1 hour in primary antibody (polyclonal rabbit anti-human GFP diluted 1:1000 
(eBiosciences)). Slides were again washed 3 times in PBS and then incubated for 1 hour 
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in a secondary antibody (swine anti-rabbit diluted 1:30 (Dako)). Following this 
incubation, slides were washed 3 times in 2 x SSC and fixed with 4% paraformaldehyde 
(in PBS; v/v) for 10 minutes at room temperature. The slides were then taken through 
telomere PNA FISH. 
 
3.2.7 Image capture and analysis  
As per chapter 2.2.9 and 2.2.10. 
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3.3 RESULTS  
3.3.1 Lamin A/C is revealed to be an inner NM protein using the DNA halo 
preparation 
 
Research has demonstrated that lamin A is an inner NM protein (Hozak et al., 1995; 
Barbaro et al., 2002), which is retained within the inextractable nuclear structure 
following 2M NaCl (Ma et al., 1999). Thus, it seemed pertinent to investigate whether 
lamin A/C remains within the residual nucleus after the DNA halo preparation, which 
also employs high-salt. In methanol:acetone fixed control (2DD) HDFs, anti-lamin A/C 
staining was seen as a rim decorating the nuclear periphery; in addition, the antibody 
reacted with some foci within the nucleoplasm (figure 3.3.1). Indeed, such anti-lamin A 
foci have been detected previously; however, their appearance is reported to be cell-
cycle dependent (Goldman et al., 1992; Bridger et al., 1993).   
 
Significantly, after the DNA halo preparation, the pattern of anti-lamin A/C staining 
was considerably different; the strong rim staining was lost and instead, anti-lamin A/C 
reacted at sites throughout the nucleoplasm, in addition to the prominent foci 
observed in non-extracted nuclei (figure 3.3.1). This is an important finding since it 
confirms earlier work which proves that lamin A resists extraction using 2M NaCl (Ma 
et al., 1999). These staining patterns also suggest that lamin A/C forms a network that 
runs throughout the nucleoplasm, which is not normally observable in non-extracted 
nuclei. In methanol:acetone fixed nuclei, the antibodies to lamin A/C probably cannot 
access the epitopes buried deep within nucleoplasm, likely due to obscuring 
chromatin. However, in DNA halo preparations, such accessibility is greatly improved 
as a result of the less dense nucleoplasmic environment formed by extracting non NM-
associated protein and DNA.        
    
3.3.2 Mutant lamin A is mis-localised in the NM using the DNA halo assay   
Since antibody staining demonstrates that lamin A/C is highly associated with the salt-
resistant structure which remains following the DNA halo preparation, it seemed 
logical to investigate such staining in HDFs derived from HGPS patients. 3 HGPS patient 
HDF lines were selected; AG06297, AG08466 and G12660. AG06297 is termed a 
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classical HGPS cell line since it harbours the G608G (GGC>GGT) splice-site mutation in 
LMNA, while the patient from which AG08466 was derived exhibited atypical (type 2) 
HGPS. As aforementioned, such atypical patients display an HGPS phenotype, 
however, they do not harbour a mutation in LMNA (Dr. N. Levy; personal 
communication) and the affected gene is yet to be determined (see chapter 5). Finally, 
G12660 originates from a patient presenting with HGPS symptoms as well as myopathy 
(Kirschner et al., 2005); these cells contain a missense mutation in LMNA (c428>t, 
p.S143F) which is predicted to result in a protein that exerts a dominant negative 
effect (Kandert et al., 2007).    
Figure 3.3.1: Lamin A/C staining in control and HGPS HDFs before and after the DNA halo 
preparation. DNA has been counterstained in blue (DAPI), while anti-lamin A/C can be seen in 
green (FITC). Scale bar = 10 µm.  
In non-extracted nuclei, the pattern of anti-lamin A/C staining at the nuclear rim in 
AG08466 and G12660 HDFs was very similar to that found in control HDFs. However, in 
the classical HGPS cell line, anti-lamin A/C invaginations were observed in addition to 
the peripheral staining (figure 3.3.1). When comparing anti-lamin A/C localisation in 
cells subjected to the DNA halo preparation, there were differences between control 
and HGPS cell lines. For both AG08466 (atypical HGPS) and G12660 (HGPS plus 
myopathy), the anti-lamin staining displayed in these cells appeared different to 
controls, in terms of intensity and pattern. While this is perhaps unsurprising for 
G12660, since it produces a mutant lamin A protein, it was unexpected for AG08466, 
which produce wild-type lamin A (Dr. N. Levy; personal communication). One possible 
explanation for this is that the disease-causing mutant protein in AG08466, in some 
way, affects lamin A localisation. Most strikingly, large aggregates of anti-lamin A/C 
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were detected in residual nuclei of classical HGPS HDFs (AG06297; figure 3.3.1); 
indeed, these nucleoplasmic structures were seen in the majority of AG06297 cells. 
Conversely, these aggregates were not observed in AG08466 nor G12660 (figure 3.3.1). 
This is a significant finding since classical HGPS cells generate a truncated version of 
lamin A, known as progerin (Eriksson et al., 2003; De Sandre-Giovannoli et al., 2003) 
and thus, it appears that such aggregates were unique to cells producing progerin.  
 
3.3.3 Examining chromosome associations with the NM in HGPS HDFs using the DNA 
halo assay 
 
In order to determine whether NM-chromosome interactions are perturbed in 
laminopathy-based disease, the anchorage of selected chromosomes by the NM was 
examined in both classical (AG06297) and atypical (type 2; AG08466) HGPS HDFs. The 
results presented in chapter 2 demonstrate that DNA halo preparations generate 
reproducible inextractable nuclear structures, which can be coupled with various FISH 
procedures to study NM-genome associations. Therefore, it seemed logical to examine 
chromosome anchorage in HGPS using the DNA halo assay. Since the interactions of 
HSA-1, -13, -15 and -17 with the NM in control HDFs were examined in chapter 2, 
these chromosomes were selected for investigation in this study (figure 3.3.2). 
Furthermore, as the data in chapter 2 revealed no differences between such 
chromosome anchorage in proliferating and senescent control HDFs, proliferation 
status was not considered in this analysis of HGPS cells.   Results (see figure 3.3.3 and 
3.3.4) were then compared to those reported in chapter 2.3 for control HDFs. 
Significantly, for all chromosomes and cell lines, the majority of chromosome mass was 
observed within the periphery of the residual nucleus. The full extraction of 
chromosome territories into the DNA halo was not observed. In both classical 
(AG06297) and atypical (type 2; AG08466) HGPS nuclei, the anchorage of 
chromosomes 1 and 13 by the NM was disrupted; however, no differences were 
observed for chromosomes 15 and 17 (see figure 3.3.3). When comparing NM-
chromosome interactions in the 2 HGPS cell lines, only one statistical difference was 
detected; this was with chromosome 13. Taken together, the findings of this section 
reveal that the anchorage of selected chromosomes by the NM is perturbed in HGPS.   
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Figure 3.3.2: Investigating chromosome anchorage by the NM in HGPS using the DNA halo 
assay.  
Control and HGPS HDFs were subjected to the DNA halo preparation and 2D-FISH. Specific 
probes were used for chromosomes 1, 13, 15 and 17. DNA has been stained using DAPI and 
can be seen in blue, while chromosome paints are depicted in green (FITC). Magnification = 
x100; scale bar = 10 µm. 
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Figure 3.3.3: Examining NM-chromosome interactions in HGPS using the DNA halo assay 
(a) Mean chromosome territory edge (CTE)/nuclear edge (NE) ratio for 4 chromosomes; a ratio 
below 1 denotes that the furthest CTE lies within the corresponding NE, while a ratio above 1 
signifies that the furthest CTE lies outside the corresponding NE. Error bars represent ±  SEM. 
(b) Statistical analysis of NM-chromosome interactions in control and X-EDMD using the 
Student’s t-Test. Green shading indicates no significant difference between the populations, 
yellow shading  depicts a p < 0.05 and red shading represents p < 0.01. P = pKi67+, 
proliferating; S = pKi67−, senescent; R = random. 
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Figure 3.3.4: Chromosome anchorage by the NM is perturbed in HGPS 
Chromosome anchorage by the NM was examined in 2 HGPS cell lines: Classical (AG06297) and 
Atypical (AG08466) and compared to proliferating (P) and senescent (S) control (2DD) 
populations. Modified box plots for control and HGPS populations for each chromosome (Q1 = 
lower quartile; Min = lowest value recorded; Med = median; Max = maximum value recorded; 
Q3 = upper quartile). 
 
3.3.4 Examining telomere associations with the NM in HGPS HDFs using the DNA halo 
assay 
3.3.4.1 Telomere anchorage by the NM in HGPS 
3.3.4.1.1 Telomere anchorage by the NM is disrupted in HGPS 
 
Lamin A is demonstrated to be a component of the internal NM (Hozak et al., 1995) 
and is found to associate with telomeric DNA (Shoeman and Traub, 1990; Raz et al., 
2008). Therefore, it seemed pertinent to examine whether mutant lamin A affects the 
capacity of the NM to anchor telomeric DNA. To do this, NM-telomere associations 
Chapter 3: Mutations in lamin A and emerin disrupt nuclear matrix-genome interactions 
 
104 
 
were analysed in 3 HGPS cell lines (AG08466, AG06297 and G12660) using the DNA 
halo assay (see figure 3.3.5).  
 
Figure 3.3.5: Investigating telomere anchorage in HGPS HDFs using the DNA halo assay 
The residual nucleus and surrounding DNA halo have been counterstained using DAPI (blue) 
while telomere signals can be seen in green (FITC). Magnification = 100x; scale bar = 10 µm. 
 
Interestingly, the mean percentage of telomeres extracted into the DNA halo was 
significantly higher in all HGPS cell lines when compared to the control; however, the 
severity of the differences varied between the HGPS cell lines (figure 3.3.6). In the 
atypical (type 2) HGPS cell line, AG08466, approximately 20% (± 11.9 (± standard 
deviation); nuclei = 90) of telomeres were, on average, extracted into the DNA halo. 
This was statistically different to the 15% (± 8.1; nuclei = 90) observed in control HDFs, 
using p > 0.05 not p > 0.01. Taking into account the slight variation inherent within an 
assay such as this (as shown in chapter 2), it is thus likely that telomere anchorage by 
the NM in AG08466 is only slightly perturbed, if not normal. Indeed, this cell line 
generates wild-type lamin A. In the cell lines (AG06297 and G12660) harbouring LMNA 
mutations, NM-telomere interactions were significantly perturbed (p > 0.0001). In the 
classical HGPS cell line (AG06297), 30% (± 9.1; nuclei = 90) of telomeres were, on 
average, extracted into the DNA halo, which was twice the fraction reported for 
control cells in chapter 2.  Surprisingly, the highest mean percentage, 37% (± 10.9; 
nuclei = 90) was seen in G12660, the cell line derived from a patient suffering from a 
combination of HGPS and myopathy.  This is interesting since unlike AG06297, which 
produces a truncated version of lamin A (progerin), G12660 expresses full-length lamin 
A containing a point mutation.  Regarding the spread of results within each dataset, all 
3 HGPS cell lines exhibited a greater variance than control; furthermore, the maximum 
value recorded for all HGPS cell lines was approximately 60%, while in control cells, the 
Chapter 3: Mutations in lamin A and emerin disrupt nuclear matrix-genome interactions 
 
105 
 
highest noted was below 40% (figure 3.3.6b). Taken together, these findings suggest 
that telomere anchorage is disrupted considerably in LMNA mutants.  
 
 
Figure 3.3.6: Telomere anchorage by the NM is perturbed in HGPS using the DNA halo assay 
Telomere-NM interactions were examined in 3 HGPS cell lines: atypical HGPS (AG08466), 
classical HGPS (AG06297) and HGPS + Myopathy (G12660). (a) Mean percentage of telomeres 
extracted into DNA halo in control versus 3 different HGPS cell lines (samples were random 
with regards to proliferation status). Statistical differences between control and HGPS cell lines 
have been determined by the Student’s t-test and are denoted by stars (1 = p < 0.05; 2 = p < 
0.01). Error bars represent ± SEM.  (b) Modified box plots for control and HGPS populations 
(Q1 = lower quartile; Min = lowest value recorded; Med = median; Max = maximum value 
recorded; Q3 = upper quartile). 
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3.3.4.1.2 Proliferating vs. senescent HGPS 
 
pKi67 is a nucleolar antigen which exists only in proliferating cells (Kill, 1996). 
Therefore, it can be used to differentiate between proliferating (Ki67+) and senescent 
(pKi67−) cells. Importantly, no difference between the two populations was observed 
when comparing NM-telomere associations in control HDFs using the DNA halo assay 
(chapter 2). In order to examine whether this is also the case in LMNA mutant HGPS 
HDFs (AG11513 and G12660), telomere PNA FISH was coupled with pKi67 staining. 
Since AG06297 was no longer available to use, another classical HGPS cell line, 
AG11513, was employed (figure 3.3.7). Significantly, in both pKi67+ and pKi67− 
AG11513 HDFs, a mean 30% (nuclei = 30) of telomeres were extracted into the DNA 
halo. This is an important finding for 2 reasons; firstly, it suggests that telomere 
anchorage by the NM does not change on entry into senescence using the DNA halo 
assay, in classical HGPS. Secondly, it demonstrates that 2 individual cell lines 
harbouring the same mutation (AG06297 and AG11513) exhibit very similar NM-
telomere interactions. This is significant since it reinforces the notion presented in 
chapter 2, that the DNA halo assay produces reproducible results.  
 
Figure 3.3.7: Telomere anchorage by the NM in proliferating, senescent and hTERT 
immortalised HGPS HDFs using the DNA halo assay. 
The residual nucleus and surrounding DNA halo have been counterstained using DAPI (blue). 
Anti-telomere signals can be seen in green (FITC), while anti-pKi67 is pseudo-coloured red 
(TRITC). Magnification = x100; scale bar = 10 µm. 
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While there was no significant difference in the mean percentage of telomeres in the 
DNA halo, when comparing pKi67+ and pKi67− populations in classical HGPS, this was 
not the case for G12660. In senescent G12660 nuclei, nearly 40% (± 16.7; nuclei = 30) 
of telomeres were extracted into the DNA halo, whereas, this value was 30% (± 11.6; 
nuclei = 30) in the pKi67+ population (figure 3.3.8a). The higher variance observed 
inpKi67− HDFs suggests that a proportion of nuclei are more susceptible to extraction 
than others (figure 3.3.b). Indeed, for one G12660 pKi67− nucleus, approximately 80% 
of telomeres were detected in the DNA halo. In contrast, the maximum value in the 
AG11513 pKi67− population was below 60% and in control HDFs, this was less than 
40%.  
 
Significantly, these data suggest the absence of a clear-cut correlation between 
telomere-NM associations and proliferative state using the DNA halo assay in HGPS. 
However, there was an obvious reduction in the mean total number of telomeres 
scored in senescent nuclei for both HGPS cell lines. Importantly, this decrease was 
concomitant with that observed for control HDFs (figure 3.3.8a).   
 
3.3.4.1.3 Telomere anchorage in hTERT immortalised HGPS cells 
 
To examine the impact of telomerase activation on telomere anchorage by the NM, 
hTERT-immortalised classical HGPS fibroblasts (TAG06297; Wallis et al., 2004) were 
studied using the DNA halo assay (figure 3.3.7). TAG06297 was generated by 
expressing a retroviral vector encoding the catalytic subunit of telomerase (hTERT) in 
the HGPS HDF cell line, AG06297 (Wallis et al., 2004). On average, 13.8% (± 11%; nuclei 
= 30) telomeres were extracted into the DNA halo in the hTERT-immortalised HGPS cell 
line, TAG06297 (figure 3.3.9). This was statistically different (p < 0.001) to the 
percentage of 30% (± 9.1; nuclei = 90) recorded for AG11513; however, it was very 
similar to the value recorded for proliferating control HDFs (figure 3.3.9). Furthermore, 
there was a statistical difference between the average total number of telomeres 
scored for immortal and mortal HGPS populations; far fewer (69.4 ± 20.3; nuclei = 30) 
telomeres were observed in the immortalised HGPS cells (figure 3.3.9).    
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Figure 3.3.8: Telomere associations with the NM in proliferating vs. senescent HGPS using 
the DNA halo assay  
(a) Mean percentage of telomeres extracted into DNA halo and mean total number of 
telomeres scored for proliferating (P; pKi67+) and senescent (S; pKi67−) HGPS HDFs.  Statistical 
differences between proliferating and senescent populations for each cell line have been 
determined by the Student’s t-test and are denoted by stars (1 = p < 0.05; 2 = p < 0.01). Error 
bars represent ± SEM.  (b) Modified box plots for mean percentage of telomeres extracted into 
DNA halo and mean total number of telomeres scored (Q1 = lower quartile; Min = lowest value 
recorded; Med = median; Max = maximum value recorded; Q3 = upper quartile). 
 
Figure 3.3.9: Telomere anchorage in immortalised classical HGPS HDFs  
(a) Mean percentage of telomeres extracted into DNA halo and mean total number of 
telomeres scored for proliferating mortal and immortalised classical HGPS populations 
compared with control.  Statistical differences between mortal and immortalised HGPS 
populations have been determined by the Student’s t-test and are denoted by stars (p < 0.01). 
Error bars represent ± SEM. (b) Modified box plots for mean percentage of telomeres 
extracted into DNA halo and mean total number of telomeres scored (Q1 = lower quartile; Min 
= lowest value recorded; Med = median; Max = maximum value recorded; Q3 = upper 
quartile). 
 
 
3.3.5 Emerin is revealed to be a NM-protein using the DNA halo assay 
 
Previous research demonstrates that emerin is a NM protein (Squarzoni et al., 1998; 
Ellis et al., 1998; Takata et al., 2009); however, its association with the NM appears 
limited to periphery of salt-extracted nuclei (Squarzoni et al., 1998). To test whether 
emerin remains following the extraction procedure used in this current study, control 
HDFs were subjected to the DNA halo preparation and stained with anti-emerin (figure 
3.3.10). In methanol:acetone fixed nuclei, anti-emerin decorates the nuclear edge 
(figure 3.3.10). However, in DNA halo prepared HDFs, the intensity of rim staining 
decreased; instead, emerin is found throughout the nucleoplasm. Indeed, this 
difference between anti-emerin staining patterns in non-extracted and extracted 
nuclei is very similar to that seen for anti-lamin A/C (section 3.3.1).  
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Figure 3.3.10: Emerin is revealed to be a NM protein using the DNA halo assay 
Anti-emerin staining was employed to detect the protein’s localisation and presence in 
methanol:acetone (2D) fixed and DNA halo prepared control and X-EDMD nuclei. Since the 
carrier X-EDMD cell line (ED5364) has a mixed population of emerin positive and negative 
nuclei, both categories are depicted in this figure. DNA is counterstained using DAPI (blue), 
while anti-emerin can be visualised in red (TRITC). Telomere PNA FISH (FITC; green) was used 
to paint telomeres in DNA halo prepared cells (bottom panel). Scale bar = 50 µm (x20); 10 µm 
(x100). 
 
3.3.6 Telomere anchorage by the NM in X-EDMD HDFs  
3.3.6.1 Mutations in EMD disrupt telomere associations with the NM using the DNA 
halo assay 
 
Since emerin resisted extraction during the DNA halo preparation, this confirmed that 
it is indeed associated with the NM (Squarzoni et al., 1998; Ellis et al., 1998; Takata et 
al., 2009). In light of the observation that EMD mutant cells exhibit perturbed genome 
organisation (Fidzianska et al., 1998; Ognibene et al., 1999; Meaburn et al., 2007), it 
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seemed logical to investigate the effect of emerin loss on NM function. To do this, NM-
telomere associations were examined in cells derived from both an X-EDMD carrier 
(ED5364) and patient (AP). The carrier cell line, ED5364, originated from the mother of 
a child with X-EDMD; DNA sequencing of EMD in this cell line revealed the presence of 
a heterozygous point mutation (c.315T>G/ p.Tyr105X) in exon 4 (chapter 5), which 
results in the formation of a premature stop codon. This mutation, which has 
previously been reported in another case, produces an unstable mutant protein, 
leading to an absence of emerin in all affected nuclei (Muntoni et al., 1998). Within the 
carrier, it is expected that one population of cells express functional emerin while the 
remaining cells are emerin null; this is expected to be random due to the nature of X 
chromosome inactivation (Lyon, 1961). However, deviations from this expected 50:50 
ratio of normal to mutant protein, have been observed in X-EDMD carriers (Manilal et 
al., 1997; 1998). Once in culture, the majority of ED5364 cells were emerin-negative 
(~90%; figure 3.3.10); this is unsurprising since emerin null cells appear to be 
hyperproliferative (Markiewicz et al., 2006). In contrast, all AP cells were negative for 
emerin, as a result of an EMD mutation (figure 3.3.10; previously reported by 
Markiewicz et al., 2002). 
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Figure 3.3.11: Examining telomere anchorage in X-EDMD carrier HDFs using the 
DNA halo assay. Error bars represent ±SEM.  
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In order to confirm that the ED5364 sample analysed contained mostly emerin null 
cells, residual nuclei were stained using anti-emerin; only those negative for emerin 
were included (figure 3.3.10). There was no significant difference between the ED5364 
emerin negative population and the ED5364 sample analysed at random (figure 
3.3.11). Interestingly, there was a statistically significant increase (p < 0.01) in the 
mean percentage of telomeres extracted into the DNA halo, in both ED5364 (emerin−) 
and AP cell lines (figure 3.3.12). On average, 25.7% (± 13.6; nuclei = 90) telomeres 
were not associated with the residual nucleus in emerin -ED5364 HDFs. This figure was 
only slightly higher in AP (28% ± 7.4; nuclei = 30). The variation present within the 
ED5364 sample was considerably higher than for control and AP cells (figure 3.3.12); 
this is further highlighted by the huge difference between the minimum and maximum 
values recorded for ED5364. The variation within the AP sample was similar to the 
control. Perhaps unexpectedly, the highest percentage was detected in a nucleus 
derived from the ED5364 cell line (figure 3.3.12).  In spite of these differences in 
variation, it can still be concluded that telomere anchorage is disrupted in both carrier 
and patient X-EDMD cell lines.       
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Figure 3.3.12: Telomere anchorage by the NM is perturbed in X-EDMD.  
Telomere-NM interactions were examined in 2 X-EDMD cell lines: an X-EDMD carrier (c; 
ED5364) and patient (p; AP). (a) Mean percentage of telomeres extracted into DNA halo in 
control versus X-EDMD carrier (ED5364) and X-EDMD patient (AP; samples were random with 
regards to proliferation status). Statistical differences between control and X-EDMD cell lines 
have been determined by the Student’s t-test and are denoted by stars (p < 0.01). Error bars 
represent ± SEM.  (b) Modified box plots for control and X-EDMD populations (Q1 = lower 
quartile; Min = lowest value recorded; Med = median; Max = maximum value recorded; Q3 = 
upper quartile).  
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3.3.6.2 Attempting to rescue perturbed telomere-NM associations in X-EDMD 
fibroblasts 
3.3.6.2.1 Overview  
 
Since the absence of emerin appears to perturb telomere anchorage by the NM, 
attempts were made to rescue this function of the NM by introducing EMD-GFP into 
ED5364 cells. In order to do this, cells were transiently transfected with emerin-GFP 
using GeneJuice (Novagen) (figure 3.3.13).  
 
3.3.6.2.2 Optimisation 
 
In order to determine the most optimal conditions for transfection, several 
optimisation experiments were performed (table 3.3.1). Control HDFs were seeded in 
QuadriPERM dishes at a density of ~0.9 x 105; after 24 hrs of growth, the transfection 
was performed using GeneJuice. The optimisation process was started by using the 
GeneJuice to DNA ratio of 3:1, which is recommended by the manufacturers 
(Novogen). However, since the guidelines did not cover cells grown in QuadriPERM 
chambers, the manufacturer’s protocol was slightly modified and a higher starting 
concentration of 2 µg EMD-GFP DNA was used per slide. Following the execution of the 
transfection procedure, cells were left for 48 hrs and then fixed using 
methanol:acetone or taken through the DNA halo preparation. However, visualisation 
of the slides using UV microscopy revealed the absence of signal and thus indicated 
that the transfection was unsuccessful. Indeed, DAPI staining detected a high amount 
of DNA on the slide, confirming that the majority of DNA did not enter the cell.   
 
Following this unsuccessful attempt to transfect the HDFs with EMD-GFP, the 
experiment was repeated using control and ED5364 fibroblasts. Both the volume of 
serum-free medium and amount of DNA used per slide was increased to 300 µl and 2.7 
µg respectively. Since the volume of GeneJuice remained the same as before, the ratio 
of GeneJuice to plasmid DNA was reduced to 2.2:1. After 48 hrs, the slides were 
prepared accordingly and checked; the transfection was successful and emerin-GFP 
was visualised at the NE in both 2D-fixed and DNA halo nuclei. This demonstrated that 
the emerin-GFP survived the DNA halo preparation and also confirmed that emerin is 
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Table 3.3.1: An overview of the transient transfection experiments performed in order to 
determine optimal conditions. M:A = methanol:acetone; C = control. 
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No 
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2 
1(C) 2DD 6 0 0 0 N/A M:A 
N/A 
2 (C) 2DD 6 0 0 0 N/A 
DNA 
halo 
3 2DD 6 300 6 2.7 (2.2:1) 48 M:A 
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4 2DD 6 300 6 2.7 (2.2:1) 48 
DNA 
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halo 
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DNA 
halo 
3 
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hrs) 
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N/A 
2 (C, 24 
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Yes 
4 2DD 5 300 15 5 (3:1) 24 M:A 
5 (C, 48 
hrs) 
2DD 5 0 0 0 N/A M:A N/A 
6 (C, 48 
hrs) 
2DD 5 0 0 0 N/A M:A N/A 
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Yes 4 ED5364 5 300 25 5 (5:1) 24 M:A 
5 ED5364 5 300 30 10 (3:1) 24 M:A 
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indeed associated with the inextractable NM. However, the transfection efficiency was 
low (~5%) and thus, I proceeded with the optimisation. 
 
The aim of the next step of the process was to increase the transfection efficiency and 
also to determine whether the length of exposure to the transfection reagent 
augmented such efficiency.  In order to do this, the transfections were performed 
using 2 different DNA concentrations: 2.5 and 5 µg and 2 different exposure times (24 
and 48 hrs); the GeneJuice:DNA ratio was constant at 3:1. All slides were fixed using 
methanol:acetone after 24  or 48 hrs; since this was an optimisation procedure, it was 
illogical to take the slides through the DNA halo preparation due the procedure’s 
expense. The results of this experiment demonstrated that by doubling the DNA 
concentration, the transfection efficiency was increased to 10–15%. The findings also 
revealed that such efficiency was similar in cells transfected for 24 and 48 hrs; thus, 
suggesting that an incubation of 24 hrs is sufficient for such a transfection.  
 
Although transfection efficiency was increased when the DNA concentration used 
doubled, the percentage of transfected cells was still low. In light of this, a different 
optimisation approach was employed; instead, 3 different GeneJuice:DNA ratios were 
used: 3:1, 4:1 and 5:1. In addition, a higher concentration of DNA (10 µg) was tested at 
a ratio of 3:1. The visualisation of the slides using UV microscopy revealed that the use 
of a GeneJuice to DNA ratio of 3:1 using 5 µg were the most efficient transfection 
conditions (figure 3.3.13).  
 
3.3.6.2.3 Transfection experiments 
 
Although, at best, the transfection efficiency was low (10–15% emerin-GFP positive), 
this still allowed for a sufficient number of nuclei to be analysed. Thus, the use of this 
transfection method was continued with the aim to correct the perturbed telomere 
anchorage observed in the ED5364 HDFs. Alongside the cells exposed to the 
transfection reagent and DNA, non-exposed ED5364 cells were used as a control. The 
transfection was repeated three times on three different days to test the accuracy and 
reproducibility of the results. Following the first transfection experiment, telomere 
PNA FISH was performed using one of the slides. Importantly, the FISH procedure 
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appeared to destroy the fluorescence of the GFP, which was present beforehand. 
Therefore, in order to differentiate between the transfected and non-transfected cells, 
anti-GFP staining was used; GFP-positive cells were deemed transfected while GFP-
negative were categorised as non-transfected. 
 
 
 
Figure 3.3.13: Using transient transfections to introduce EMD-GFP into X-EDMD carrier HDF  
Representative images of (a)  Methanol:acetone fixed HDFs (x20);  emerin-GFP is green, (b) 
Methanol:acetone fixed HDFs (x100);  emerin-GFP is green, (c) DNA halo prepared nucleus 
(x100); emerin-GFP is green, (d) DNA halo prepared nucleus (x100);  anti-GFP is green (FITC), 
(e) DNA halo prepared nucleus (x100);  anti-telomere signals are red (Cy3). Scale bar = 50 µm 
(x20); 10 µm (x100). 
 
For each experiment, the mean percentage of telomeres recorded in the DNA halo was 
between 20–25% for control (non-exposed) ED5364 nuclei, while this value rose to 29–
34% for cells transfected with emerin-GFP. Thus, transfecting the cells with emerin-
GFP led to a decrease, not the expected increase, in the number of NM-telomere 
interactions; in short, correct telomere anchorage was not restored (figure 3.3.14). 
One limitation of a transient transfection is that the transcription of the exogenous 
DNA cannot be regulated; therefore, it is likely that varying amounts of emerin-GFP 
were generated during the transfections.   
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Figure 3.3.14: Attempting to rescue perturbed telomere-NM associations in X-EDMD 
 (a) Mean percentage of telomeres extracted into DNA halo and mean total number of 
telomeres scored; samples were random with regards to proliferation status. Statistical 
differences between normal and transfected X-EDMD cell lines have been determined by the 
Student’s t-test and are denoted by stars  (1 = p < 0.05; 2 = p < 0.01). Error bars represent ± 
SEM. (b) Modified box plots for mean percentage of telomeres extracted into DNA halo and 
mean total number of telomeres scored for normal and transfected X-EDMD cell lines (Q1 = 
lower quartile; Min = lowest value recorded; Med = median; Max = maximum value recorded; 
Q3 = upper quartile). 
 
3.3.7 Examining telomere anchorage by the NM in Melanoma cells using the DNA 
halo assay 
3.3.7.1 Telomere anchorage in tumourigenic and non-tumourigenic melanoma 
 
To investigate whether telomere-NM associations are disrupted in cutaneous 
malignant melanoma, 2 cell lines were employed (figure 3.3.15). The first, UACC 903 
Parental, is a highly tumourigenic human metastatic cell line. The second was a non-
tumourigenic version of UACC 903 which had been rescued by the addition of 
chromosome 10 by microcell fusion (named UACC 903 Clone 3); both cell lines were 
created previously by Parris et al. (1999). These cells presented an opportunity to test 
firstly, whether telomere interactions with the NM are disrupted in cancer and 
secondly, to examine whether the tumourigenic potential of a cell line alters telomere 
anchorage.  
 
 
Figure 3.3.15: Telomere anchorage in tumourigenic and non-tumourigenic melanoma cell 
lines using the DNA halo assay. 
The residual nucleus and surrounding DNA halo have been counterstained using DAPI (blue) 
while telomere signals can be seen in green (FITC). Magnification = x100; scale bar = 10 µm.  
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There was no significant difference in the mean number of telomeres attached to the 
residual nucleus halo when comparing the highly tumourigenic and rescued melanoma 
cells (figure 3.3.16a). In both cell lines, approximately 9% of telomeres were extracted 
into the DNA halo (figure 3.3.16b). Variance was greater in the non-tumourigenic cell 
line, which could suggest that the addition of the chromosome 10 had rescued 
telomere anchorage for some but not all cells. Since telomere anchorage in control 
melanocytes has not been examined in this or any other study, it was not possible to 
determine whether the average value of 9% was different to that of normal, un-
transformed melanocytes. When comparing the telomere anchorage in these cell lines 
with that observed in control HDFs, the difference between the two was not as vast as 
that for control vs. HGPS. However, one factor which makes comparisons difficult is 
that both the tumourigenic and rescued melanoma cell lines were immortalised at the 
time of analysis.  It is possible that the activation of telomerase alone influenced 
telomere anchorage by the NM irrespective of disease-state. Interestingly, there was a 
significant increase in the total number of telomeres recorded for the rescued, UACC 
903 Clone 3 cell line. Since these cells contain an additional copy of chromosome 10, a 
slight rise (i.e. of 4) would be expected. However, the increase recorded was 34%. 
 
Figure 3.3.16: Telomere anchorage in tumourigenic and non-tumourigenic melanoma cell 
lines using the DNA halo assay.  
(a) Mean percentage of telomeres extracted into DNA halo and mean total number of 
telomeres scored for proliferating (P; pKi67+) and senescent (S; pKi67−) HGPS HDFs.  Statistical 
differences between proliferating and senescent populations for each cell line have been 
determined by the Student’s t-test and are denoted by stars (1 = p < 0.05; 2 = p < 0.01). Error 
bars represent ± SEM. (b) Modified box plots for mean percentage of telomeres extracted into 
DNA halo and mean total number of telomeres scored (Q1 = lower quartile; Min = lowest value 
recorded; Med = median; Max = maximum value recorded; Q3 = upper quartile). 
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3.4 DISCUSSION 
3.4.1 Chromosome anchorage in HGPS 
 
While it is uncertain which specific NM-proteins are involved in anchoring the genome 
to the NM, A-type lamins are likely participants since they are shown to bind DNA 
(Shoeman and Traub, 1990; Taniura et al., 1995; Stierle et al., 2003). In order to 
investigate the effect of mutant lamin A (progerin) on such interactions, chromosome 
anchorage in classical HGPS fibroblasts was examined. Furthermore, to test whether 
perturbed NM associations are a common occurrence in HGPS, nuclei derived from an 
atypical HGPS patient producing normal lamin A, were also analysed.   
 
The results demonstrate that the interaction of some chromosomes with the NM is 
perturbed in HGPS. Importantly, however, not all chromosome interactions were 
disrupted in the cell lines studied. The majority of the chromosome mass was found 
within the residual nucleus; this was generally true for all chromosomes studied. This 
indicates that despite progerin’s presence in classical HGPS cells, the anchorage of 
whole chromosomes is still able to occur. Since the LMNA mutation in AG06297 is 
heterozygous, on one allele LMNA is wild-type while on the other, LMNA is mutated. 
However, due to the fact that the mutation is dominant-negative, the transcriptional 
processing of the normal LMNA is thought to be affected (De Sandre-Giovannoli et al., 
2003). Thus, it could be assumed that in AG06297, the majority of protein generated 
by LMNA is aberrant. How does the presence of progerin and the lack of normal lamin 
A affect telomere anchorage by the NM? It is unlikely that the G608G LMNA mutation 
directly disrupts lamin A’s ability to interact with DNA since the protein’s DNA binding 
site is situated between amino acids 411–553 (Stierle et al., 2003). It is more plausible 
that progerin disrupts telomere anchorage due to its inability to integrate into the NM 
correctly.  If lamin A was largely responsible for anchoring all MARs to the NM in 
control nuclei, it would be expected that in HGPS, the majority of chromosome mass 
would be extracted into the surrounding DNA halo. However, this evidently did not 
occur. The results from the study suggest that lamin A is involved in the anchorage of a 
sub-set of MARs as opposed to entire chromosomes. The observation that interactions 
with the NM are disrupted for specific chromosomes indicates that A-type lamins are 
not alone in mediating these associations; there are likely to be numerous other NM-
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proteins which participate in maintaining MAR-NM complexes.  Since this section of 
the study concentrated on global chromosome organisation, events occurring on a 
more local scale have not been determined. While the global anchorage of only certain 
chromosomes is perturbed, it is possible that the interactions of specific MARs with 
the NM are more significantly disrupted.     
 
Our findings concur with previous research which indicates that chromatin 
organisation is disrupted in LMNA mutant cells (Sullivan et al., 1999; Sabatelli et al., 
2001; Sewry et al., 2001; Capanni et al., 2003; Fidzianska & Hausmanowa-Petrusewicz, 
2003; Goldman et al., 2004; Nikolova et al., 2004; Arimura et al., 2005; Columbaro et 
al., 2005; Filesiet al 2005; Scaffidi & Misteli, 2005).  However, the observation that only 
certain chromosomes are affected agrees with earlier data produced by our laboratory 
(Meaburn et al., 2007). Therefore, it would be pertinent to investigate the anchorage 
of specific MARs in disease.  
 
3.4.2 Telomere anchorage by the NM is disrupted in HGPS 
 
Significantly, we have demonstrated that telomere anchorage by the NM is disrupted, 
to varying extents, in all three HGPS cell lines. A spectrum of severity existed; telomere 
anchorage was least perturbed in the atypical HGPS cell line (AG08466; whose 
mutation status is unknown), while the highest disruption was observed in the cell line 
derived from a patient exhibiting both HGPS and myopathy symptoms (G12660). In 
line with this trend, although AG08466 and AG06297 have similar growth potentials, 
the fraction of nuclei exhibiting abnormal nuclear morphology in AG06297 is 
considerably higher than in AG08466 (Bridger and Kill, 2004). Furthermore, the 
percentage of such nuclei for AG08466 is much more similar to control than to 
AG06297 (Bridger and Kill, 2004). Interestingly, there was no clear correlation between 
proliferative state and telomere anchorage in HGPS; this is a relevant observation since 
the radial positioning of certain chromosomes appears to change according to cellular 
state (Bridger et al; 2000; Meaburn et al., 2007; Mehta et al., 2010).   
 
Combined with the mutation status of each HGPS cell line, the results indicate several 
interesting points. The atypical HGPS cell line (AG08466), which harbours no mutation 
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in LMNA and hence produces functional lamin A, is least affected in terms of telomere 
anchorage by the NM. In contrast, telomere-NM interactions in AG06297, which 
produces a mutant form of lamin A (progerin), are more severely affected. Taken 
together, these observations suggest that the protein affected in AG08466 is not as 
important for maintaining correct anchorage by the NM as lamin A.  
 
More significantly, telomere anchorage was most perturbed in cells derived from the 
patient exhibiting both HGPS and myopathy symptoms. G12660 harbours a missense 
mutation in the LMNA gene (c428>t, p.S143F) which is predicted to generate a 
dominant negative protein (Kandert et al., 2007). This specific mutation leads to the 
substitution of a serine residue with phenylalanine; importantly, serine 143 is highly 
conserved and situated within the coiled region 1B of lamin A/C’s rod domain 
(Kirschner et al., 2005). Kandert et al. (2007) suggest that the S143F mutation would 
likely disrupt lamin assembly and dynamics. How could this mutation impinge on 
telomere-NM associations? Again, as is the case with the classical HGPS cell line, 
AG06297, it is likely that the mutation affects the integration of lamin A into the NM, 
rather than DNA binding per se. Furthermore, it is feasible that S143 is an important 
phosphorylation site which is involved in lamin assembly or is required for some 
unknown process. Indeed, lamin phosphorylation is reported be necessary for the 
breakdown of the NL during mitosis (Lee et al., 2001). The phosphorylation of lamins is 
performed by protein kinase C in interphase and by cyclin-dependent kinases during 
mitosis (CDKs; Buendia et al., 2001). 
 
In line with our study which has demonstrated that telomere binding to the NM is 
reduced in HGPS, De Vos et al. (2010) reported that the absence of lamin A resulted in 
increased telomere and nuclear mobility. Indeed, the authors suggest that lamin A is 
integral for maintaining ‘internal inertia’ (De Vos et al., 2010). They also propose that 
intranuclear lamin molecules are important for correct telomere localisation within the 
nucleus (De Vos et al., 2010). In fact, this concurs with the observation of another 
recent study which demonstrated that the loss of functional lamin A is concomitant 
with a migration of telomeres towards the nuclear periphery (Gonzalez-Suarez et al., 
2009). These results indicate that when wild-type lamin A is absent, telomeres are no 
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longer correctly anchored by the NM via lamin A-containing complexes and thus, 
telomere mobility is increased. 
 
However, the presence of progerin in HGPS nuclei has been reported to reduce 
telomere mobility rather than increase it (De Vos et al., 2010). Raz et al. (2008) also 
demonstrate that lamin-telomere binding is augmented in lamin mutants. Significantly, 
treatment of HGPS cells with FTIs is able to rescue perturbed telomere motility (De Vos 
et al., 2010). These studies both report a stiffening of the NL in HGPS nuclei and as a 
result, a reduction in nuclear mobility (Raz et al., 2008; De Vos et al., 2010).  
 
What could account for the discrepancies in findings between our study and these two 
studies?  Firstly, in Raz et al. (2009), the LMNA mutations disrupted different residues 
(R133L and R220Q) to those used in our current study (S143F, G608G). The HGPS cell 
line used by De Vos and colleagues harboured a G608C mutation, which should in 
theory produce the same progerin molecule as G608G. We have shown in our study 
that different lamin mutants vary in their capacity to disrupt telomere-NM 
interactions. Thus it is possible that these particular mutations increase rather than 
reduce telomere binding. Furthermore, the use of such distinct methodologies makes 
it difficult to directly compare the respective results. Raz and colleagues (2008) 
employed chromatin immunoprecipitation (ChiP) and quantitative PCR, while De Vos 
et al. (2010) used transfection biology to track telomere mobility. In contrast, our 
investigation involved a NM extraction followed by telomere PNA FISH. The nature of 
the non-physiological NM extraction dictates that the results must be considered 
within the context of the investigation and thus do not assume to be representative of 
processes occurring in vivo. However, nonetheless, the data generated from all three 
studies do highlight the significance of lamin A in telomere biology.   
 
3.4.3 The hTERT-immortalisation of HGPS cells appears to rescue disrupted NM-
telomere interactions 
 
On average, telomeres in HGPS fibroblasts are significantly shorter than those found in 
controls (Allsopp et al., 1992; Decker et al., 2009) and as a result, it has been suggested 
that lamin A has a direct influence over telomere length (Decker et al., 2009). Indeed, 
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telomeres in fibroblasts which express mutant lamin A or over-express the wild-type 
form are shown to have an accelerated rate of shortening (Huang et al., 2008). In light 
of this, it seemed pertinent to assess telomere-NM interactions in hTERT-immortalised 
HGPS cells. Indeed, telomere anchorage by the NM was significantly increased in 
hTERT-immortalised HGPS fibroblasts and was comparable to that found in controls. 
This suggests that the activation of telomerase in HGPS cells enables the restoration of 
correct telomere-NM associations. However, it must be noted that while the 
proportion of telomeres detected in the DNA halo was reduced in the hTERT-
immortalised HGPS nuclei, so too was the overall number of telomeres scored per 
nucleus. In fact, one would expect there to be increase in the number of detectable 
telomeres since the telomeres were theoretically longer (and signal intensity 
correlates with telomere length). It is possible that telomeres cluster together in 
response to telomerase activation; this would account for the observed reduction in 
individual telomeres. However, there is no scientific basis for this hypothesis. 
 
Nonetheless, this increase in telomere anchorage by the NM in hTERT immortalised 
HGPS is revealing since it implies that the interactions can be rescued in spite of 
progerin’s presence. In fact, this chimes with the earlier demonstration that the 
expression of hTERT can rescue the proliferation defects associated with the 
expression of progerin (Kudlow et al., 2008). This poses the question: does telomerase 
activation ameliorate progerin-induced deficiencies via telomere elongation? Kudlow 
and colleagues (2008) suggest that this is not the case since in their study, 
improvements were observed almost immediately following hTERT expression. It is 
also unlikely that the increased NM-telomere interactions in hTERT-immortalised HGPS 
reported in this chapter are as a direct result of increased telomere length. Indeed, 
Luderus et al. (1996) demonstrate that the avidity of telomere binding to the NM is not 
correlated to telomere length. The role of telomere biology in HGPS pathology is 
becoming more apparent; telomeres in cells over-expressing wild-type lamin A enter 
senescence at a similar length to controls, while those in cells expressing mutant lamin 
A senesce at lengths much shorter (Huang et al., 2008). As a result, Huang and 
colleagues (2008) suggest that mutant lamin may suppress signals from shortened 
telomeres, thus allowing telomeres to continue to shorten in these diseased cells. 
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The telomere repeat binding factor 1 (TRF1) is demonstrated to bind to telomeric 
repeats (Chong et al., 1995). Importantly, the availability of TRF1 is critical for de novo 
telomere formation; it is thus suggested that TRF1 availability as well as the status of 
telomerase activation, are together determinants of proliferative capacity in HDFs 
(Okabe et al., 2000; 2004). Indeed, TRF1 is upregulated in immortalised human 
fibroblasts and the amount of TRF1 correlates with proliferative lifespan (Okabe et al., 
2000, 2004). Significantly, TRF1 is found to tether telomeres to the NM (Luderus et al., 
1996). In line with this, far higher numbers of TRF1-NM complexes are observed in 
immortalised cells than in mortal cells (Okabe et al., 2004). This concurs with the 
increase in NM-telomere associations observed in our immortalised HGPS nuclei. It is 
logical to hypothesize that TRF1’s function is perturbed in mortal HGPS cells in some 
way by the presence of progerin. When these cells are immortalised and TRF1 is 
upregulated, it is possible that this restores some aspects of previously disrupted 
telomere biology.   
 
Interestingly, the proliferative capacity of normal HDFs can be extended and thus, 
cellular senescence delayed, by expressing exogenous TRF1. However, TRF1’s influence 
over proliferative lifespan is limited; it is not able to support prolonged proliferation or 
de novo telomere formation (Okabe et al., 2004). Okabe and colleagues (2004) also 
discovered that TRF1 in immortal cells forms greater associations with the NM than 
the protein present in mortal cells. This indicates that mortal cells may lack the specific 
factors required for such NM-TRF1 binding and thus, may limit the ability of exogenous 
TRF1 to participate correctly in telomere dynamics (Okabe et al., 2004). If TRF1 is 
restricted from interacting with the NM in mortal HGPS, telomere maintenance could 
also be affected.   
 
3.4.4 The effect of mutations in EMD on telomere anchorage by the NM 
 
Several studies demonstrate that emerin forms part of the high-salt resistant insoluble 
nuclear fraction, otherwise referred to as the NM (Squarzoni et al., 1998; Ellis et al., 
1998; Takata et al., 2008). Furthermore, the protein has been observed at intranuclear 
sites in complexes with A- and B-type lamins (Manilal et al., 1998).  The fact that 
emerin has a hydrophobic C-terminus which anchors it to the inner nuclear membrane 
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(Manilal et al., 1996) poses certain questions: would emerin be able to anchor 
telomeres in the internal NM or does another isoform of the protein exist?  While 
emerin interacts with the chromatin factor, BAF (Lin et al., 2000; Lee et al., 2001; 
Segura-Totten and Wilson, 2004), there is also no evidence that the protein binds 
telomeric DNA; however, we have demonstrated that telomere anchorage is 
perturbed in both X-EDMD patient and carrier cell lines.  
 
With the aim of correcting the disrupted telomere anchorage demonstrated in X-
EDMD, emerin-GFP was transiently transfected into X-EDMD carrier HDFs. Although 
this was performed on 3 separate occasions, the trend was the same each time; in 
transfected nuclei, there was an increase in the percentage of telomeres unattached to 
the NM. Although the disrupted interactions were not rescued, the results suggest that 
emerin does indeed contribute to telomere anchorage by the NM. Furthermore, the 
data suggest that the amount of emerin required for this function lies within a 
restricted range; too little or too much of the protein is detrimental to the cell. Thus, it 
is possible that a proportion of the nuclei generated emerin within this range and as a 
result, perturbed telomere anchorage was rescued. However, in the remaining 
population, nuclei were under- or over-loaded with emerin-GFP and hence, NM-
telomere associations remained unchanged or were further disrupted.   
 
Ideally, it would have been more useful to perform a stable transfection with these 
cells, however, in culture, the cell line tends to stop growing after approximately 11 
passages. To confirm emerin’s involvement in tethering telomeres to NM, the next 
logical step would be to knock-down emerin in normal cells using siRNA technology. 
While the results presented here do suggest that emerin is important for tethering 
telomeres to the NM, a study by Markiewicz et al. (2002) indicates another possible 
explanation. The authors demonstrated that the solubility of both A and B type lamins 
was increased in X-EDMD cells; thus, it is possible that the perturbed telomere 
anchorage observed in X-EDMD is due to this increased solubility of lamins rather than 
the absence of emerin. 
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3.4.5 Telomere anchorage by the NM is unaffected in Melanoma 
 
Since the composition of the NM is repeatedly perturbed in cancer (Lemen and 
Getzenberg, 2008; Lever and Sheer, 2010) and lamin organisation is disrupted in 
certain cancer types (Kaufmann et al., 1991; Broers et al., 1993; Moss et al., 1999; 
Willis et al., 2008; Sun et al., 2010), it seemed pertinent to examine telomere 
anchorage in cancerous cells. Indeed, certain elements of the genome are reported to 
be disorganised in cancer (Cremer et al., 2003; Bartova et al., 2005 and 2005; 
Harnicarova et al., 2006; Murata et al., 2007; Meaburn and Mistelli, 2008; Wiech et al., 
2009). In this study, no significant differences were found when comparing telomere-
NM interactions in highly tumourigenic and non-tumourigenic melanoma cell lines. 
However, the rescued (non-tumourigenic) cell line retained its immortality. As 
previously discussed, the activation of telomerase in cells appears to influence 
telomere anchorage by the NM.  
 
Interestingly, although telomere anchorage by the NM was very high (>90%) in the two 
melanoma cell lines, the amount of DNA extracted into the DNA halo was also much 
higher than observed for any of the other cell lines studied. This could be interpreted 
as the existence of fewer stable MAR-NM interactions in melanoma. Furthermore, this 
significant increase in halo DNA could be accounted for by an increase in single-
stranded DNA breaks; indeed, genomic instability is constantly reported in cancer 
(Negrini et al., 2010). It also indicates that any increases in telomere extraction 
reported do not simply correlate with the efficiency of the extraction. 
 
3.4.6 What do these studies suggest about the involvement of the NM in disease 
pathology? 
 
We have demonstrated that genome organisation is disrupted in both HGPS and X-
EDMD; however, what possible implications could this have for the functioning of the 
disease cell? The observation that the telomere-NM interactions are perturbed by 
mutant lamin or absent emerin, suggests firstly, that the NM is dysfunctional. This 
indicates that other NM-related processes could also be disordered in these diseased 
cells. Indeed, the NM is involved in both transcription and DNA replication (Jackson 
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and Cook, 1985; Hozak et al., 1993; Cook, 1999; Djeliova et al., 2001a, 2001b; Radichev 
et al., 2005; Anachkova et al., 2005). The nuclear structure also provides a platform for 
DNA damage response pathways (Jiang et al., 2001). Furthermore, the key tumour 
suppressor protein, pRb, associates with the NM (Mittnacht and Weinberg, 1991; 
Mancini et al., 1994).  
 
Our results infer the disorganisation of telomeres within the nuclear volume; it is 
possible that this disorganisation could negatively affect the maintenance and correct 
functioning of telomeres. In human fibroblasts, telomere shortening is demonstrated 
to trigger senescence through a p53 dependent pathway (Herbig et al., 2004). It has 
been suggested that in cells expressing mutant lamin A, this pathway is inefficient and 
thus, telomeres continue to shorten in such cells, creating problems for the cell (Huang 
et al., 2008).  Taken together, our results suggest that the effect of mutant lamin A on 
telomere biology, within the context of NM function, is likely to be multi-faceted.  The 
presence of mutant lamin A appears to interfere with correct telomere anchorage by 
the NM. However, since lamin A’s interaction with DNA is mediated by residues 411–
553 of the protein (Stierle et al., 2003), it is unlikely that the lamin mutations 
presented in this study directly disrupt the protein’s ability to bind DNA. Instead, it is 
more probable that lamin assembly, structure and integration into the NM is disrupted 
when such mutations are present, thus, perturbing lamin-associated processes.  
Furthermore, in cells expressing mutant lamin A, the NM’s involvement in DNA 
damage response pathways could be compromised.  
 
It is possible that the activation of telomerase and all associated consequences, in 
some way compensates for the lack of functional A-type lamins. Indeed, as 
aforementioned A-type lamins are involved in regulating telomere structure, length 
and function (Gonzalez-Suarez et al., 2009). Lamin A also functions to stabilise the 
DNA-damage response protein, 53BP1 (Gonzalez-Suarez et al., 2009). Thus, perhaps 
only when telomeres are extended in a manner independent of lamin A, does the 
absence of functional lamin A become less of a problem for the cell. Obviously, to 
answer the question of how telomerase activation appears to rescue disrupted NM-
telomere associations in HGPS, an investigation of a far greater scale than this current 
one would have to be performed. 
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The findings from this study also indicate that lamin A and emerin are not necessarily 
important for maintaining the anchorage of all MARs by the NM. This is especially 
evident from the observation that not all telomeres are extracted into the DNA halo in 
HGPS and X-EDMD nuclei.  Indeed, this concurs with the aforementioned results 
produced by studying chromosome-NM interactions in HGPS. This, therefore, points to 
the involvement of other proteins, such as TRF1 (Chong et al., 1995; Luderus et al., 
1996), in the maintenance of these interactions. This poses several questions: are 
lamin A and emerin present at all NM-MAR complexes at varying loads or are the 
proteins restricted to the particular regions of certain chromosomes? What factors 
dictate which MARs associate with which proteins? Further investigation is required to 
increase our comprehension of these NM-associated proteins and their role in disease 
pathology. 
 
Although telomere anchorage did not appear to be perturbed in melanoma cells, even 
though lamin distribution was observed to be disrupted, the results concur with 
observations of immortalised HGPS fibroblasts.  Indeed, taken together, these findings 
indicate that telomerase activation alone has the ability to influence telomere 
interactions with the NM and thus analysing disease cells which are immortalised 
complicates the interpretation of results. 
 
3.4.7 Model 
 
The studies presented here in this chapter demonstrate that correct genome 
organisation is disrupted in human disease. Furthermore, the capacity for the NM to 
mediate such organisation appears to be perturbed in cells lacking functional lamin A 
and emerin. Therefore, I have thus proposed a model of disease pathology in HGPS 
and X-EDMD. Figure 3.4.1 summarises how such interactions can be examined using 
the DNA halo preparation while figure 3.4.2 predicts how mutations in lamin A and 
emerin affect genome organisation in disease.  
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(a) 
(b) 
Figure 3.4.1: Telomere anchorage is perturbed in cells lacking functional lamin A and emerin 
(a) Normal cells: Through their MARs, certain sequences are anchored by the NM; these would 
be resistant to extraction during the DNA halo preparation and thus, would be found in the 
residual nucleus. Those sequences less-tightly associated with the NM would be subject to 
extraction and as a result, become part of the surrounding DNA halo. 
(b) Lamin A deficient/mutant cells: When lamin A is missing or mutated, NM-MAR associations 
are disrupted; consequently, regions of DNA which normally form strong interactions with 
the NM are released into the DNA halo. 
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(a) 
(b) 
Figure 3.4.2: The role of lamin and emerin proteins in the maintenance of NM-MAR 
interactions  
(a) Normal cells: A and B-type lamin proteins form complexes with emerin at NM 
filament junctions; these complexes are then involved in anchoring MARs. 
(b) Lamin A deficient/mutant cells: When lamin A is mutant or missing, these MAR-NM 
associations are disrupted.  
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4.1 INTRODUCTION 
4.1.1 The role of emerin in the nucleus 
 
It is not fully understood why mutations in EMD specifically affect tendons, skeletal 
muscles and the cardiac conduction system. Originally, two main hypotheses were 
proposed in order to explain the tissue-type specificity observed in X-EDMD. Firstly, it 
was suggested that nuclei lacking functional emerin suffered from both increased 
fragility and impaired mechanics; thus, this could theoretically account for why 
mechanically strained tissues were primarily affected. In line with this hypothesis, 
nuclear architecture is disrupted in the myonuclei of X-EDMD patients (Fidzianska and 
Hausmanowa-Petrusewicz, 2003) and emerin-deficient murine fibroblasts display 
abnormal nuclear shape (Lammerding et al., 2005). Furthermore, emerin is found to 
associate with a number of important structural proteins including lamin A/C and 
certain nesprin isoforms (Clements et al., 2000; Lee et al., 2001; Mislow et al., 2002; 
Wheeler et al., 2007). It also caps the pointed ends of actin filaments (Holaska et al., 
2004). However, research performed in mice indicates that it is the cell’s inability to 
respond transcriptionally to mechanical strain rather than an abnormality in nuclear 
mechanics that significantly contributes to the pathogenesis of X-EDMD (Lammerding 
et al., 2005). In agreement, evidence is building to suggest that emerin has a role in 
regulating gene expression. Indeed, microarray analysis has indicated that at least 60 
genes are abnormally expressed in X-EDMD fibroblasts (Tsukahara et al., 2002). 
  
Significantly for this study, emerin is found to interact, via an APC-like domain, with β-
catenin, a key mediator of the Wnt signalling pathway (Markiewicz et al., 2006). 
Through this association, emerin is able to regulate the flux of β-catenin into the 
nucleus and thus, β-catenin activity. The β-catenin/TCF-4 transcription complex results 
in the up-regulation of numerous down-stream target genes (van de Wetering et al., 
2002). The loss of interaction between emerin and β-catenin leads to an accumulation 
of β-catenin within the nucleus and consequently, influences the expression of β-
catenin response genes (Markiewicz et al., 2006). Indeed, in X-EDMD cells which are 
emerin null, β-catenin activity is significantly elevated along with the expression of the 
β-catenin target gene, C-MYC (Markiewicz et al., 2006).  
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4.1.2 Examining the role of emerin in gene positioning and transcriptional regulation  
 
In light of this link between emerin and the regulation of gene expression, it seemed 
pertinent to investigate both the position and expression of 4 β-catenin down-stream 
target genes (CCND1, CDH1, CTNNA1 and C-MYC; as reported by van de Wetering et 
al., 2002) in X-EDMD and control fibroblasts.  In this way, several hypotheses could be 
tested. Firstly, whether the loss of an INM protein disrupts the organisation of the 
genome; secondly, how (and if) the absence of emerin impacts on the expression of β-
catenin target genes and lastly, whether there is a relationship between gene 
expression and interphase nuclear positioning. Indeed, numerous studies suggest a 
correlation between gene positioning and transcriptional regulation (for review, see 
Elcock and Bridger, 2010). It also allows for a comparison of gene positioning in 
proliferating versus non-proliferating nuclei; relevant since some chromosomes appear 
to change their nuclear positions on entry into quiescence and senescence (Bridger et 
al., 2000; Meaburn et al., 2007; Mehta et al., 2010). 
 
The results of this chapter reveal the selected genes are aberrantly positioned in X-
EDMD; importantly, such organisation was more disrupted in senescent X-EDMD 
nuclei. However, these differences in gene positioning were observed as subtle rather 
than major shifts in location.  Both CTNNA1 and CCND1 were located more interiorly in 
proliferating and senescent X-EDMD nuclei, respectively. There were also other 
statistically significant differences between emerin null and control cells. Interestingly, 
in control and X-EDMD nuclei, CCND1 was positioned differently in proliferating and 
senescent nuclei; in proliferating nuclei, the alleles occupied an interior/intermediate 
location, while in senescent nuclei, the alleles were positioned more peripherally. With 
the exception of this and C-MYC in AP nuclei, the other genes generally occupied 
statistically similar locations in both proliferating and senescent nuclei within each cell 
line. The observation that the shift in CCND1 position is still able to occur in X-EDMD 
fibroblasts suggests that gene positioning is not massively disrupted in the absence of 
emerin.  Furthermore, using RT-PCR to examine mRNA levels of these particular genes, 
no changes in expression were detected. Taken together, these findings demonstrate 
that while gene positioning is subtlety disrupted in X-EDMD, the transcriptional 
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regulation of such genes in these cells is not perturbed.  Furthermore, this study 
highlights the complexity of emerin’s structural and regulatory roles in the nucleus. 
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4.2 MATERIALS AND METHODS 
4.2.1 Cell Culture 
 
Control (2DD) and emerin null (AP, KK and TR) primary HDFs were grown as per 2.2.1. 
The emerin null cells were provided by Professor Chris Hutchison.   
 
4.2.2 2-Dimensional Fluorescence in situ Hybridisation (2D FISH) 
4.2.2.1 Cell Fixation 
 
Cells were harvested as per usual; the resulting cell suspension was centrifuged for 5 
minutes in order to produce a pellet. To this pellet, hypotonic buffer (0.075M KCl (0.7 g 
in 125 ml)) was added drop-wise with agitation. This cell suspension was then left for 
15 minutes at room temperature and centrifuged for 5 minutes. The buffer was 
discarded and the cells resuspended in a small volume of solution remaining. At this 
point, the fixative 3:1 (v/v) methanol:acetic acid was added drop-wise with agitation. 
The cells were next placed on ice for at least an hour, spun, with the fixation procedure 
being repeated at least 5 times more. However, the cells were only left on ice for 5–15 
minutes at a time. 
 
4.2.2.2 Slide Preparation 
 
The cells were resuspended in fresh fixative, producing a slightly opaque solution. 
These cells were then dropped from a height onto SuperFrost® slides, made humid by 
the steam of the water bath. The density and spread of the cells were next assessed 
using the light microscope (20x) and if satisfactory, the slides were aged for at least 
two days at room temperature or by baking the slides in an oven at 70°C for one hour. 
The slides were then dehydrated using an ethanol row (70%, 90% and 100% ethanol; 
five minutes per concentration). Following this, the slides were air dried. 
 
4.2.2.3 Probe Preparation 
 
As per chapter section 2.2.5. 
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4.2.2.4 Probe and Slide Denaturation and Hybridisation 
 
As per chapter section 2.2.6. 
 
4.2.2.5 Washing 
 
As per chapter section 2.2.6. 
 
4.2.3 3-Dimensional Fluorescence in situ Hybridisation (3D FISH) 
4.2.3.1 Cell Fixation and Preparation 
 
Cells were seeded at 1 x 105 on SuperFrost slides in QuadriPERM chambers and grown 
for 2 days. The slides were then washed 3 times in PBS and placed in 4% 
paraformaldehyde (v/w; in PBS) for 10 minutes. Following this, the slides were washed 
with PBS three times and then placed in 0.5% Triton X-100/Saponin (v/w; in PBS) for 20 
minutes. Again, the slides were washed three times using PBS; next, they were placed 
in 20% glycerol (v/v; in PBS) for at least 30 minutes. Slides were then dipped into liquid 
nitrogen and removed after several loud cracking sounds were heard. At this point, the 
slides were stored at -80°C until required. Once thawed, the slides were taken through 
4 –7 additional freeze-thaw (liquid nitrogen-thaw-glycerol) cycles.   
 
Following these freeze-thaw cycles, the slides were placed in PBS for 30 minutes, with 
2 changes of PBS. After this, the slides were left in 0.1N HCl (v/v) for 10 minutes; they 
were then washed twice with 2 x SSC (v/v) for 3 minutes per wash. Slides were then 
left in buffer B (50% formamide, 2 x SSC (v/v) (pH 7.0)) overnight. 
 
4.2.3.2 Probe Preparation 
 
As per chapter section 2.2.5. 
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4.2.3.3 Slide Denaturation 
 
The slides were incubated at 73°C in buffer A (70% formamide, 2 x SSC (pH 7.0) (v/v)) 
for 3 minutes and then buffer B (50% formamide, 2 x SSC (pH 7.0) (v/v)) for 1 minute. 
During the remaining minute, 12 µl of probe was pipetted onto a pre-warmed 
coverslip. After this minute, the slides were removed quickly from the denaturation 
buffer and gently placed on top of the coverslip. The slide and coverslip were sealed 
using rubber cement and then placed at 37°C for at least 48 hours. 
 
4.2.3.4 Washing 
 
As per chapter section 2.2.6. 
 
4.2.4 Indirect Immunofluorescence 
 
100 µl of primary anti-pKi67 antibody (1:1500) (Novocastra Laboratories Ltd) was 
added to a coverslip, onto which a slide was placed. The slides were then incubated at 
room temperature for 1 hour. After which, the slides were washed in 1 x PBS for 15 
minutes, with 3 changes of buffer. 100 µl of secondary antibody (Swine anti-rabbit 
antibody (1:30 dilution (TRITC) or 1:50 dilution (FITC)(Dako)) was applied to each slide 
in a manner identical to the primary; at this point, slides were incubated for 1 hour at 
room temperature. All antibodies used were diluted in 1% (v/v) newborn calf serum 
(NCS; previously diluted in 1 x PBS).  Next, they were washed in 1 x PBS for 15 minutes, 
again with 3 changes of buffer. Following this, the slides were mounted in DAPI. 
 
4.2.5 Image capture and analysis  
4.2.5.1 2D images 
 
Randomly selected nuclei were visualised using an Olympus UPlanFL N 100x oil 
immersion lens on an Olympus BX41 fluorescence microscope. Grey-scale images of 
the nuclei were captured using a Model viewpoint GS digital camera (Digital Scientific); 
these were pseudocoloured and merged using Smart Capture V3.0 software (Digital 
Scientific). Images were converted into PICTs and using IP Lab Spectrum Software, the 
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colour balance of these PICTs were optimised. The enhanced versions of the images 
then underwent a simple erosion analysis, whereby the nucleus was divided into 5 
shells, using a script originally written by P. Perry, as previously described (Croft et al., 
1999; Bridger et al., 2000). The script determines the pixel intensity of DAPI and 
chromosome probe. The background was eliminated from the FISH signal by 
subtracting mean pixel intensity within the segment nucleus. The normalisation of 
probe signal distribution was achieved by dividing probe % by DAPI signal % in each 
shell. This was calculated for 5 shells in all 50 nuclei and from these data, a graph was 
plotted using Microsoft Excel software. Standard error bars were added which 
correspond to the ± SEM. The Student’s t test was used to statistically compare 
datasets; a p-value of < 0.05 was considered significant. 
 
4.2.5.2 3D image capture and analysis 
 
3D z stacks were obtained using a Nikon Eclipse confocal microscope TE 2000 with a 
100x oil immersion lens and C1 (EZ-C1) software version 3.00. An optical step size of 
0.2 µm was used; the pixel dwell was 4.56 and 8 averages were taken for each image. 
Measurements were acquired and 3D reconstructions performed using Imaris 5.7.0 
software (Bitplane). The distance from the gene signal to the nearest nuclear edge was 
presented as a percentage of the approximate radius (0% = nuclear periphery, 100% = 
nuclear interior). 40 signals were analysed per dataset and the Student’s t test was 
used to compare datasets; a p-value of < 0.05 was considered significant. The 
explanation of this analysis process is expanded in section 4.3.1.3. 
 
4.2.6 Reverse transcription-polymerase chain reaction (RT-PCR) 
4.2.6.1 RNA extraction 
 
Total RNA was extracted from cells using the GenEluteTM Mammalian Total RNA 
Miniprep Kit (Sigma-Aldrich). Before starting, 10 µl of 2-mercaptoethanol (2-ME) was 
mixed with 990 µl of lysis solution. The cells were then harvested as per usual to 
produce a pellet; to this, 250 µl of the lysis Solution/2-ME was added. This cell solution 
was then vortexed to remove all clumps. The lysed cells were added to a GenElute 
Filtration column and centrifuged at a maximum speed (13,700 g) for 2 minutes. The 
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Filtration column was then discarded and 250 µl of 70% ethanol was added to the 
lysate. This lysate/ethanol solution was placed into a GenElute Binding column and 
centrifuged at maximum speed for 15 seconds. The flow-through liquid was discarded. 
To the collection tube, 500 µl of Wash Solution 1 was added and then the tube was 
centrifuged at maximum speed for 15 seconds. The Binding column was next 
transferred into a fresh 2 ml collection tube and to this, 500 µl of Wash Solution 2 was 
added. Following centrifugation for 15 seconds (maximum speed), the resulting flow-
through liquid was discarded and a second 500 µl of Wash Solution 2 was placed into 
the column. The column was centrifuged for 2 minutes, the flow-through discarded 
and then centrifuged for another 1 minute. The Binding column was transferred into a 
fresh 2 ml collection tube; 40 µl of Elution Solution then added. The RNA solution was 
collected following centrifugation of 1 minute at maximum speed. 
 
4.2.6.2 DNase I treatment 
 
The resulting RNA solution was next treated with DNase I (Amplification Grade; Sigma) 
in order to remove any contaminating DNA. To 40 µl of total RNA, 5 µl 10x Reaction 
Buffer and 5 µl of Amplification Grade DNase I (1 unit/µl) were added. This solution 
was then gently mixed and incubated at room temperature for 15 minutes. Following 
this period, 5 µl of Stop Solution was added to the RNA solution and heated at 70°C for 
10 minutes.  Using a Nanodrop (2000c, Thermo Scientific), the quality and 
concentration of the RNA samples were then tested. 
 
4.2.6.3 Reverse transcription  
 
Complementary DNA (cDNA) was generated from total RNA using SuperScriptTM III 
Reverse Transcriptase (Invitrogen). 3 µg of total RNA was mixed with 100 ng of random 
primers and 1 µl 10 mM dNTP mix; sterile, DEPC-treated water was added to 13 µl. The 
solution was heated to 65°C for 5 minutes and then incubated on ice for at least 1 
minute. After a brief centrifugation, 4 µl 5X First-Strand Buffer, 1 µl 0.1M DTT, 1 µl 
SuperScriptTM III RT (200 units/ µl) and 1 µl sterile, DEPC-treated water was added to 
the tube. The solution was mixed gently using a pipette and then incubated at 25°C for 
5 minutes. Following this period, the solution was incubated at 50°C for 30–60 
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minutes. To inactivate the reaction after this time, the solution was heated to 70°C for 
15 minutes. 
 
4.2.6.4 Polymerase chain reaction  
 
Using specific primers (table 4.2.1), 5 genes were amplified using the cDNA generated 
by RT. In order to do this, the KAPAHiFiTM kit (KAPA Biosystems) was used; the 
components of each reaction can be seen in table 4.2.2, while the cycling parameters 
are detailed in 4.2.3. 
 
Table 4.2.1: The primer pairs employed to amplify CCND1, CDH1, CTNNA1, C-MYC and 
GAPDH. 
TA  refers to the annealing temperature used. 
 
4.2.6.5 Agarose gel electrophoresis 
 
Amplification products from the PCR reactions were visualised using agarose gel 
electrophoresis. A 1% agarose gel solution containing 2% (v/v) ethidium bromide 
(Sigma) was poured into a sealed gel casting platform; to this, a gel comb was inserted. 
When the gel had set, it was placed inside a tank, which was pre-filled with 1 X Tris-
Borate EDTA (TBE; 89 mM Tris, 89 mM borate, 2 mM EDTA) buffer. Following this, the 
PCR samples were loaded into the wells. The resultant gel was visualised using a UV-
Gene Primer Sequences TA (°C) Product size (bp) 
CCND1 F1: 5'-TGT TTG CAA GCA GGA CTT TG-3' 
R1: 5'-CCT TCC GGT GTG AAA CAT CT-3' 
60 264 
CDH1 F1: 5'-GGC TCA AGC TAT CCT TGC AC-3' 
R1: 5'-CTT GAG CCC AGG AGT TTG AG-3' 
60 140 
F2: 5’-TGC CCC CAA TAC CCC AGC GT-3’ 
R2: 5’-ACG GTG GCT GTG GAG GTG GT-3’ 
65 213 
CTNNA1 F1: 5'-GGG ACT TGC GTA GAC AGC TC-3' 
R1: 5'-GCT TGC AGA CAT TCG AAC AA-3' 
60 239 
C-MYC F1: 5'-TTC GGG TAG TGG AAA ACC AG-3' 
R1: 5'-CAG CAG CTC GAA TTT CTT CC-3' 
60 203 
F2: 5’-TCC ACC TCC AGC TTG TAC CTG-3’ 
R2: 5’-CGC CTC TTG ACA TTC TCC TCG-3’ 
62 557 
GAPDH F1: 5'-ACA GTC AGC CGC ATC TTC TT-3' 
R1: 5'-GAC AAG CTT CCC GTT CTC AG-3' 
60 259 
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transilluminator. Band intensities were analysed and compared using AlphaEaseFC 
software. 
 
Component Volume 
PCR grade water Up to 25.0 µl 
5x KAPAHiFi Buffer 5.0 µl 
dNTP mix (10 mM each dNTP; final concentration 0.3 mM) 0.75 µl 
Forward primer (10 μM; final concentration 0.3 μM) 0.75 µl 
Reverse primer (10 μM; final concentration 0.3 μM) 0.75 µl 
Template cDNA 1.0 µl 
KAPAHiFi DNA Polymerase (1 U/μl) 0.5 µl 
Final Volume 25.0 µl 
 
Table 4.2.2: The PCR reaction components employed to amplify CCND1, CDH1, CTNNA1, C-
MYC and GAPDH. As per manufacterer’s instructions (KAPA Biosystems). 
 
Phase Temperature Duration Cycles 
Initial denaturation 95°C 3 m 1 
Denaturation 98°C 20 s 
35 Annealing As per 4.2.1 15 s 
Extension 72°C 30 s 
Final extension 72°C 3 m 1 
 
Table 4.2.3: The cycling parameters used to amplify CCND1, CDH1, CTNNA1, C-MYC and 
GAPDH. As per manufacterer’s instructions (KAPA Biosystems). s = seconds; m = minutes. 
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4.3 RESULTS 
4.3.1 Using 2D and 3D FISH to examine interphase gene positioning in control and 
emerin null nuclei 
4.3.1.1 Overview 
 
In order to determine whether interphase gene positioning is disrupted in X-EDMD, 
HDFs from 3 X-EDMD cell lines (AP, KK and TR) and 1 control (2DD) were prepared for 
2D or 3D FISH. To verify that the X-EDMD cell lines were emerin null as predicted, anti-
emerin staining was performed; indeed, control HDFs were positive for anti-emerin 
while such staining was absent in all 3 of the X-EDMD cell lines (figure 4.3.1).  Probes 
specific to 4 genes (CCND1 (cyclin D1), CDH1 (E-cadherin), CTNNA1 (alpha catenin) and 
C-MYC (C-MYC)) were generated and then used for 2D and 3D FISH. To differentiate 
between proliferating and senescent nuclei, anti-pKi67 staining was employed. 
 
4.3.1.2 2D FISH analysis 
 
Approximately 50 2D nuclei were captured per cell line, per gene and per proliferation 
status; representative images can be seen in figure 4.3.2. Subsequently, the positioning 
of genes within interphase 2D nuclei was assessed using erosion analysis software 
(Croft et al., 1999; Bridger et al., 2000; Boyle et al., 2001; Meaburn et al., 2005; 
Meaburn et al., 2007). This software divides the flattened DAPI-stained 2D nucleus into 
5 concentric shells of equal area and individually measures the intensity of DAPI and 
probe signal in each shell. To normalise the data for each shell, the percentage of 
probe signal was divided by the percentage of DAPI signal. From this data, histograms 
were generated, with the mean normalised signal for each shell presented along the Y-
axis while the X-axis depicts shell number; shell 1 is the most interior and shell 5 is the 
most peripheral. Such histograms for all 4 cell lines and genes in both proliferating 
(green bars) and senescent (purple bars) nuclei can be observed in figure 4.3.3.  
Statistical differences between datasets were determined using the Student’s t test; a 
p-value below 0.05 was deemed significant. The outcome of statistical tests using data 
from 2D FISH assays is summarised in figure 4.3.4.  
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Figure 4.3.1: Anti-emerin staining in control and X-EDMD HDFs 
In order to confirm that HDFs derived from X-EDMD cell lines were indeed emerin null, 
methanol:acetone fixed control and X-EDMD nuclei were subjected to anti-emerin staining. 
DAPI (blue) is used to counterstain the nucleus, while anti-emerin is pseudocoloured green 
(FITC).  As expected, in control HDFs, anti-emerin reacted with the periphery of the nucleus 
and also at foci within the nucleoplasm. Conversely, in all 3 X-EDMD cell lines, no anti-emerin 
staining was observed. Magnification = x20; scale bar = 50 µm. 
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Figure 4.3.2: Using 2D-FISH to analyse the position of CCND1, CHD1, CTNNA1 and C-MYC in 
control and X-EDMD HDFs 
DNA has been counterstained using DAPI (blue), while gene signals can be seen in green (FITC). 
Magnification = x100; scale bar = 10 µm. 
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Figure 4.3.3: Gene positioning in proliferating and senescent control and X-EDMD nuclei 
using 2D FISH analysis 
Mean proportion (%) of hybridization signals for each of the 4 genes in eroded shells of control 
and X-EDMD nuclei. Using an erosion script, nuclei were divided into five concentric shells of 
equal area; shell 1 being nearest to the nuclear periphery while shell 5 was the most interior 
(Croft et al., 1999; Bridger et al., 2000; Boyle et al., 2001; Meaburn et al., 2007). The % of signal 
in each shell was divided by the corresponding % of DAPI signal; the graphs represent the 
normalised signals. Green bars refer to proliferating (pKi67+) data, while purple bars denote 
signal distribution in senescent (pKi67−) nuclei. 50 nuclei were analysed per dataset with 3 
exceptions (2DD CTNNA1 (47); KK CTNNA1 (48); AP C-MYC (49)); error bars are representative 
of SEM. For AP CDH1, the graph presents data from a pKi67 random population. 
 
4.3.1.3 3D FISH analysis 
 
In order to verify the accuracy of the data produced by the 2D FISH assay, the position 
of these genes were analysed using 3D FISH. Since a consistent difference in CCND1 
location was observed between pKi67+ and pKi67− populations in control and X-EDMD 
HDFs using the 2D FISH assay, this gene was examined in all cell lines. For the other 3 
genes, only control and 1 X-EDMD (AP) cell line was examined with 3D FISH. 20 nuclei 
were captured per population and the gene position assessed manually using Imaris: 
an example of a reconstructed 3D nucleus can be seen in 4.3.5. The distance from each 
gene signal to the nearest nuclear periphery (X-, Y- or Z-axis) was measured and then 
normalised by dividing this distance by the radius of the nucleus. The radius was 
calculated by dividing the width (rather than the length) of the nucleus by 2. As a 
result, the normalised gene distance from the nuclear periphery is presented as a 
percentage of the nuclear radius in frequency distribution line charts.  
 
For each nucleus, the distance of the gene signals from the nearest nuclear edge has 
been analysed either as individual alleles or as an average of the two; the mean 
distance for each allele or the average can be seen in 4.3.6a and b, respectively. The 
allele closest to the nuclear periphery was categorised as allele 1, while the remaining 
allele was classified as allele 2.  Statistical differences between datasets were 
calculated as per the 2D analysis; see figure 4.3.7 for an overview. 
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Figure 4.3.4: Statistical tests for 2D analysis positioning data  
The tables contain the results of statistical tests (Student’s t-test; unpaired; two-tailed 
distribution) comparing interphase gene positioning in control and X-EDMD nuclei using the 2D 
FISH analysis. The results have been colour-coded; green represents no statistical difference 
(ND; p > 0.05); yellow denotes a statistical difference (*; p < 0.05, > 0.01); red represents a 
statistical difference of higher significance (**; p < 0.01). (a) Proliferating (pKi67+) versus 
senescent nuclei, (b) Control versus emerin null nuclei, (c) Emerin null versus emerin null 
nuclei. 
 
4.3.1.4 CCND1 
 
Using the 2D FISH assay, the nuclear position occupied by CCND1 in proliferating nuclei 
(pKi67+) was similar in all 4 cell lines (3 emerin null plus 1 control). CCND1 was 
positioned towards the interior in proliferating control and X-EDMD nuclei (figure 
4.3.3). While the mean location of CCND1 in TR pKi67+ nuclei did not differ significantly 
from the control, the gene alleles were statistically more interior (than the control) in 
AP (shell 5; p < 0.05) and KK (shell 1; p < 0.05) pKi67+ populations (figure 4.3.4b). 3D 
positioning confirmed that in AP proliferating nuclei, CCND1 alleles were located more 
interiorly than in control. In contrast, CCND1 in TR pKi67+ nuclei was reported to be 
positioned more interiorly than in control 3D preserved nuclei; this was not detected in 
2D nuclei. While no statistical differences were observed when comparing this gene’s 
position within X-EDMD cell lines (pKI67+) using the 2D FISH assay, disparities were 
observed in 3D (figures 4.3.6 and 4.3.7c).   
 
When comparing the datasets for senescent (pKi67−) populations, many more 
differences were observed. 2D analysis data demonstrated that in all 3 X-EDMD cell 
lines (pKi67−), CCND1 occupied a different location to control (figure 4.3.4b). CCND1 
occupied an intermediate position in control 2D nuclei, while in AP, KK and TR, the 
alleles were generally found in interior locations (figure 4.3.3). However, there were 
disparities within X-EDMD; CCND1 was positioned more interiorly in AP than KK or TR 
(figures 4.3.3) and indeed, this was demonstrated statistically (figure 4.3.4c). In 3D, 
CCND1 alleles were located more peripherally than control in KK, while in AP and TR, 
the gene alleles were positioned no differently to controls (figure 4.3.7b). As a result, 
the 3D location of CCND1 in KK is significantly different to the other 2 X-EDMD cell 
lines (figure 4.3.7c).  
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For control, KK and TR, CCND1 shifted from an interior position in proliferating nuclei 
to an intermediate location in senescent nuclei, using the 2D FISH assay (figures 4.3.3 
and 4.3.4a). This was confirmed using 3D positioning (figure 4.3.7a). The 2D analysis 
demonstrated no significant statistical difference between the position of these alleles 
in pKi67+ and pKi67− AP nuclei; CCND1 remained interior in pKi67− nuclei (figure 
4.3.4a). However, 3D positioning detected a change in position in AP senescent nuclei 
which was not evident using 2D FISH (figures 4.3.6 and 4.3.7a). 
 
 
 
Figure 4.3.5: An example of a reconstructed 3D nucleus. 
Control and X-EDMD HDFs were subjected to 3D FISH. This is an example of a control 3D 
reconstructed nucleus; the DNA is counterstained using DAPI (blue), while CTNNA1 gene 
signals can be seen in red (Cy3). 
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Figure 4.3.6a: Gene positioning in 3D-preserved nuclei (individual alleles) 
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Figure 4.3.6b: Gene positioning in 3D-preserved nuclei (average) 
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Figure 4.3.6: Gene positioning in 3D-preserved nuclei 
Frequency distribution plots of the position of 4 genes within proliferating (pKi67+) and 
senescent (pKi67−) control and X-EDMD nuclei. Measurement data have been normalised by 
dividing the distance from the nuclear edge by the approximate radius and are reported as 
percentages; 0% represents the nuclear edge while 100% denotes the nuclear interior. Results 
are presented for (a) individual alleles or (b) as an average of the two alleles.  For (a) allele 1 
refers to the allele closest to the nuclear periphery. 
 
Figure 4.3.7: Statistical tests for 3D positioning data  
The tables contain the results of statistical tests (Student’s t-test; unpaired; two-tailed 
distribution) comparing gene positioning in 3D-preserved control and X-EDMD nuclei. The 
results have been colour-coded; green represents no statistical difference (ND; p > 0.05); 
yellow denotes a statistical difference (*; p < 0.05, > 0.01); red represents a statistical 
difference (**; p < 0.01). (a) Proliferating (pKi67+) versus senescent (pKi67−) nuclei,  (b) 
Control versus emerin null nuclei, (c) Emerin null versus emerin null.  
 
4.3.1.5 CDH1 
 
When comparing the position of CDH1 in control and emerin null proliferating nuclei 
using the 2D FISH assay, there were no significant differences (figure 4.3.4b). In all cell 
lines (pKi67+), the gene alleles occupied an interior position (figure 4.3.3). In senescent 
nuclei, CDH1 occupied a similar interior location in control and TR nuclei, while in KK 
the gene alleles were statistically positioned more intermediately (figures 4.3.3 and 
4.3.4b). 3D FISH demonstrated that CDH1 was significantly closer to the nuclear edge 
in AP nuclei (proliferating and senescent) than in the control (figures 4.3.6 and 4.3.7); a 
difference which was not detected by the 2D analysis (figure 4.3.4b).  
 
CDH1 occupied statistically similar positions in pKi67+ and pKi67− control and TR 2D 
nuclei (figures 4.3.3 and 4.3.4a). For KK, there was one significant difference (shell 3; p 
< 0.05) when comparing pKi67+ and pKi67− nuclei. A comparison between CDH1 
positioning in pKi67 + and pKi67− AP 2D nuclei could not be performed since anti-pKi67 
staining was unsuccessful; however, in a proliferation-random population, CDH1 was 
interior (figure 4.3.3). In contrast, CDH1 was positioned towards the periphery in AP 
pKi67+ and pKi67− 3D nuclei (figure 4.3.6); a location which was significantly different 
to control (figure 4.3.b).  
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4.3.1.6 CTNNA1 
 
2D analysis revealed that there were statistically significant differences when 
comparing the position of CTNNA1 in proliferating control and X-EDMD HDFs (figure 
4.3.4b). CTNNA1 occupied an intermediate location in control nuclei while in emerin 
null nuclei, the gene alleles were intermediate and interior (figure 4.3.3). Within the 
proliferating X-EDMD cell lines, there was one significant difference for AP vs. KK (shell 
3; p < 0 .05, figure 4.3.4c). 
 
The nuclear positions of CTNNA1 in senescent nuclei were similar in control, KK and TR 
cell lines (figure 4.3.3); when comparing these 3 cell lines, only one difference was 
detected (KK vs. TR; shell 1; p < 0.05, figure 4.3.4). The location of the gene in pKi67− 
AP nuclei was different to that found in control (shells 2 (p < 0.01) and 4 (p < 0.05)) and 
TR (shell 1; p < 0.01) nuclei. 3D analysis demonstrated that CTNNA1 occupied a similar 
position in proliferating control and AP nuclei, however, the gene alleles were more 
interiorly positioned in senescent AP nuclei (figures 4.3.6 and 4.3.7b). Apart from shell 
3 (*) in KK, no significant differences were detected for CTNNA1 when comparing 
pKi67+ and pKi67− populations by 2D analysis (figure 4.3.4a); this concurred with the 
data produced for control and AP HDFs by 3D FISH (figure 4.3.7). 
 
4.3.1.7 C-MYC 
 
No statistical differences were observed when comparing the position of C-MYC in the 
proliferating nuclei of control and emerin null nuclei using the 2D FISH assay (figure 
4.3.4b); in all cell lines, C-MYC occupied a peripheral position (figure 4.3.3). In control 
and TR pKi67− nuclei, the gene alleles were peripheral, while for AP and KK, C-MYC had 
bimodal and intermediate distributions, respectively (figure 4.3.3). Indeed, the 
locations of C-MYC alleles in AP and KK pKi67− were statistically different to those 
found in control pKi67− nuclei (2DD vs. AP, shell 1, p < 0.05; 2DD vs. KK, shells 1 and 4, 
p < 0.05; figure 4.3.4b).    
 
For both control and TR populations, no statistically significant differences were found 
between proliferating and senescent populations (figure 4.3.4a), which is in agreement 
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with control 3D data (figures 4.3.6 and 4.3.7). However, there were changes in the 
signal intensity in shell 1 (p < 0.05) for KK and AP and in shell 5 (p < 0.01) for AP, when 
comparing pKi67+ and pKi67− 2D nuclei (figure 4.3.4a). This concurs with 3D data for 
AP nuclei, which demonstrated that C-MYC alleles were located more interiorly in 
senescent nuclei (figure 4.3.7a). 
 
4.3.1.8 Overview of positioning results 
4.3.1.8.1 Control vs. X-EDMD 
 
The 2D analysis results demonstrate that the interphase positioning of selected genes 
are perturbed in X-EDMD. Interestingly, the organisation of such genes was most 
affected in senescent X-EDMD nuclei. Significantly, CCND1 was located more interiorly 
in senescent X-EDMD than in control HDFs. CDH1 was positioned similarly to controls 
in all X-EDMD populations (pKi67+ and pKi67−) apart from senescent KK nuclei. 
Furthermore, CTNNA1 location was disrupted in the majority of proliferating and 
senescent X-EDMD datasets. Significantly, in two-thirds of the X-EDMD cell lines, C-
MYC was positioned incorrectly in senescent nuclei.  
 
4.3.1.8.2 Proliferating vs. senescent  
 
By combining the findings from both 2D and 3D FISH assays, it is evident that the 
position of CCND1 shifts from an interior position in proliferating (pKi67+) nuclei to a 
more intermediate location in senescent (pKi67−) nuclei. In the control cell line, none 
of the other genes demonstrated a change in location according to proliferative state; 
however, this was not true for the X-EDMD cell lines. A shift in the position of CDH1 
and CTNNA1 was observed in senescent KK nuclei. Furthermore, C-MYC appeared to 
move away from the periphery in senescent AP and KK nuclei; for AP this was shown 
using both 2D and 3D analysis.  An overview of these findings can be observed in table 
4.3.1. 
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4.3.1.8.3 2D vs. 3D analysis  
 
In general, 3D analysis detected similar shifts in gene positioning between proliferating 
and senescent nuclei as the 2D FISH assay. However, the differences observed when 
comparing control and X-EDMD populations were not so similar when using 2D and 3D 
analysis. Furthermore, 3D positioning demonstrated that genes were far closer to the 
nuclear periphery than the 2D assay suggested. This was particularly true of CDH1; 
while 2D analysis revealed that the gene alleles were interior in both proliferating and 
senescent populations, the 3D assay showed that the genes were significantly more 
peripheral. Interestingly, in the 3D analysis, all gene alleles (regardless of proliferation 
status) were observed to be in the bottom half of the nucleus; this suggests that genes 
are not only radially organised but also exhibit polarity within the nucleus. 
 
 
CCND1 CDH1 CTNNA1 C-MYC 
P S P S P S P S 
2DD (control)  I IM** I I IM IM P P 
AP I I I IM IM P B** 
KK I I** I I* IM IM* P IM* 
TR I I* I I IM I P P 
 
Table 4.3.1: Interphase gene positioning in control and X-EDMD HDFs using the 2D FISH assay 
 
I = interior, IM = intermediate, P = peripheral, B = bimodal. Significant differences between 
proliferating (P) and senescent (S) nuclei are denoted by stars (*, p < 0.05; **, p < 0.01).  
 
4.3.2 Using RT-PCR to examine gene expression 
 
The expression levels of the 4 genes (CCND1, CDH1, CTNNA1 and C-MYC) were 
investigated using RT-PCR; GAPDH was used as an internal control. Total RNA was 
extracted from control and 3 X-EDMD cell lines; this RNA was then used to produce 
cDNA, which was consequently employed for PCR (figure 4.3.8). To determine whether 
the proliferative state of the culture influenced expression, RNA was extracted from 
the control cell line at 2 different passages (Ki67+: P10 = 71.1%; P19 = 56.5%). The 
percentage of pKi67 positive cells within the emerin null cell lines varied at the time of 
extraction; 77.9% (TR), 62.6% (AP) 52.1% (KK) cells (figure 4.3.9). The primer pairs 
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employed can be seen in section 4.2. In order to verify C-MYC’s expression level, 2 
primer sets were employed; the first were designed independently while the second 
pair was employed as per Markiewicz et al. (2006). Difficulty was experienced with 
CDH1 since many unrelated PCR products were amplified along with the gene’s cDNA; 
thus, in order to verify expression levels, two different primer pairs were used (figure 
4.3.8). C-MYC expression levels were lowest in TR; this was shown using both sets of 
primers (figure 4.3.9). Since the GAPDH band intensity for this cell line was very similar 
to the other cell lines, it is likely that the reduced C-MYC levels are correctly reflective 
of expression in TR. Apart from C-MYC, no obvious differences were detected when 
comparing the band intensities (using AlphaEaseFC software) of the other 4 genes in 
the 5 cell lines (figure 4.3.9).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.8: Analysing the expression of CCND1, CDH1, CTNNA1, C-MYC and GAPDH using 
RT-PCR. 
Gene specific primers were employed to amplify regions of CCND1, CDH1, CTNNA1, C-MYC and 
the positive control, GAPDH. In order to confirm CDH1 and C-MYC expression levels, two 
different primer pairs were used. RT-PCR products were separated and visualised using 
agarose gel electrophoresis.  
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Figure 4.3.9: Analysing the expression and proliferative capacity of control and 
X-EDMD HDFs.  
(a) The proliferative capacities of 3 X-EDMD and 2 control cultures were 
determined using anti-Ki67 staining. At least 200 pKi67+ nuclei were scored per 
separate count for each cell line. (b) PCR was performed using primers specific to 
CCND1, CDH1, CTNNA1, C-MYC and GADPH; the RNA used to generate cDNA was 
derived from 3 X-EDMD and 2 control HDF cultures. The control RNA extractions 
were derived from the same cell line; however, the proliferative capacity of each 
culture differed (see (a)). The relative intensities of PCR bands following RT-PCR 
and gel electrophoresis (see figure 4.3.8) were measured and compared using 
AlphaEaseFC software. 
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4.4 DISCUSSION 
4.4.1 Overview 
 
In order to investigate the effect of emerin’s absence on genome organisation, the 
positions of 4 genes (CCND1, CDH1, CTNNA1 and C-MYC) were determined in control 
and emerin null nuclei. This was performed using primarily 2D FISH on interphase 
nuclei; 3D gene positioning was employed to validate 2D analysis data. The basis of the 
study was multi-faceted. It was performed to investigate whether the absence of a 
protein which forms part of the inner nuclear membrane and NM, would disrupt the 
organisation of specific genes. These 4 genes were chosen using data which 
demonstrate that their expression is indirectly affected by emerin, via β-catenin and 
the Wnt signalling pathway (van de Wetering et al., 2002; Markiewicz et al., 2006). If 
indeed changes in gene expression were detected, it would serve as a useful platform 
to investigate the relationship between gene positioning and transcriptional 
regulation.   
 
4.4.2 Emerin’s role in mediating genome organisation  
4.4.2.1 Overview 
 
While numerous previous studies have demonstrated that genome organisation is 
disrupted in disease (Bartova et al., 2000; Cremer et al., 2003; Bartova et al., 2005; 
Hanicarova et al., 2006;  Meaburn et al., 2007; Murata et al., 2007; Meaburn and 
Mistelli., 2008; Wiech et al., 2009; Meaburn et al., 2009), research examining genome 
organisation in X-EDMD is limited. Meaburn et al. (2007) examined the interphase 
nuclear position of 4 chromosomes (4, 13, 18 and X) in an X-EDMD carrier, as well as in 
a number of laminopathy cell lines. It was demonstrated that in the X-EDMD carrier, 
chromosomes 13 and 18, the smaller chromosomes, occupied a more interior nuclear 
location than control fibroblasts, whereas, the locations of the larger chromosomes, 4 
and X, remained normal. The positions occupied by chromosomes 13 and 18 were thus 
suggested to mimic those found in normal senescent cells (Meaburn et al., 2007). 
These results imply that the absence of emerin is not incompatible with the correct 
localisation of certain chromosomes. Indeed, when the positions of chromosomes 
were examined in several X-EDMD lymphoblastoid cell lines, no significant changes in 
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organisation were detected (Boyle et al., 2001; Meaburn et al., 2005).  Taken together, 
this selective mis-positioning poses several questions: firstly, why are certain 
chromosomes affected while others are not? Is this due to emerin’s involvement in 
tethering these specific, smaller chromosomes to the nuclear periphery in particular 
cell types? 
 
4.4.2.2 Selected genes are aberrantly positioned in X-EDMD  
 
Results from our study indicate that the absence of emerin does affect the positioning 
of selected genes in X-EDMD nuclei. Interestingly, the majority of differences between 
control and X-EDMD nuclei were seen in senescent rather than proliferating 
populations. Of the 4 genes, the positioning of CCND1 and CDH1 was particularly 
disrupted.  
 
Our laboratory has previously demonstrated that chromosomes can change nuclear 
position on entry into quiescence or senescence (Bridger et al., 2000; Meaburn et al., 
2007). It thus seemed pertinent to compare gene positioning in proliferating and 
senescent (senescent) cells. The genes positioned in this current chapter were located 
on 4 different human chromosomes: CCND1 = 11q13 (Motokura et al., 1991); CDH1 = 
16q22.1 (Mansouri et al., 1988; Natt et al., 1989; Chen et al., 1991); CTNNA1 = 5q31 
(Furukawa et al., 1994); C-MYC = 8q24.12–q24.13 (Leder, 1982; Taub et al., 1982; 
Dalla-Favera et al., 1982; Takahashi et al., 1991).  In our current study, 3 out of the four 
genes were observed to occupy similar positions in both proliferating and senescent 
control nuclei. The exception to this was CCND1; significantly, CCND1 was observed to 
statistically shift from an interior position in proliferating nuclei, to a more 
intermediate location in senescent populations. This was observed using both 2D and 
3D analyses. Chromosome positioning demonstrates that HSA-11, which harbours 
CCND1, occupies an intermediate location in both proliferating and senescent nuclei 
(Meaburn et al., 2008; Mehta et al., unpublished data). Since 2D analysis revealed that 
CCND1 is interiorly positioned in proliferating HDFs, this could suggest that in these 
cells, the gene loops away from its parent chromosome. It is possible that this change 
in position is either representative of a global re-organisation of chromosomes in 
senescence or due to a more specific re-positioning event; indeed, exploring the 
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relationship between positioning and transcriptional regulation is currently very topical 
(Elcock and Bridger, 2010).  
 
Although CDH1, CTNNA1 and C-MYC did not change position in senescent control 
nuclei, their nuclear locations differed from those documented for their respective 
parent chromosomes. While CDH1 and its parent chromosome, HSA-16, are interiorly 
positioned in proliferating nuclei, their locations do not match in senescence; despite 
the fact that HSA-16 is intermediately placed, CDH1 remains within the nuclear interior 
(this study; Boyle et al., 2001; Mehta et al., unpublished data). Furthermore, although 
CTNNA1 occupied an intermediate location in senescent nuclei, its parent 
chromosome, HSA-5, is found peripherally positioned (Meaburn et al., 2008; Mehta et 
al., unpublished data). Finally, C-MYC was reported to be a peripheral gene in both 
pKi67+ and pKi67− populations, while its parent chromosome, HSA-8, is intermediate 
(this study; Boyle et al., 2001; Mehta et al., unpublished data). Since gene- and 
chromosome-specific FISH was not coupled in this study, it is not possible to verify 
whether or not these differences in chromosome and gene positioning are reflective of 
actual differences in location or an inherent error between the investigations. 
Nevertheless, such observations are worthy of note and future studies may reveal the 
looping of these specific genes, away from their parent chromosomes.         
 
In X-EDMD HDFs, there were a number of statistical differences when comparing gene 
positioning in proliferating and senescent nuclei. KK exhibited differences in all four 
genes between the two proliferative states. Most significantly, like the control, CCND1 
was observed to change location in senescence in all 3 X-EDMD cell lines. In AP, C-MYC 
occupied different positions in proliferating and senescent nuclei; this was 
demonstrated using both 2D and 3D analyses.   
 
The significance of this change in CCND1 position in senescent nuclei requires further 
investigation; however, the observation that this re-positioning is still able to occur in 
X-EDMD cells, despite the absence of emerin, strengthens the view that local and 
global genome organisation is partly, but not entirely, disrupted in X-EDMD.  
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4.4.3 Emerin’s involvement in the regulation of gene expression 
 
The fact that no major changes in gene expression were detected in our study is 
intriguing in light of recent studies which demonstrate emerin’s involvement in the 
canonical Wnt signalling pathway. Markiewicz et al. (2006) demonstrated that emerin 
interacts with β-catenin through an APC-like domain and importantly, regulates the 
flux of the protein into the nucleus. Significantly, in cells which harbour emerin lacking 
this APC-like domain, β-catenin accumulates in the nucleus. In line with this, β-catenin 
activity was found to be five-fold higher in the X-EDMD (emerin null) cells. In order to 
test whether this increase in activity resulted in the up-regulation of down-stream 
target genes, the expression of C-MYC was tested using RT-PCR; indeed, C-MYC was 
considerably up-regulated in the X-EDMD cells (Markiewicz et al., 2006).  
 
The implication of the article (Markiewicz et al., 2006) is that the increased activity of 
β-catenin caused by the lack of regulation (due to emerin’s absence) would result in 
the mis-expression of its down-stream target genes. It has been shown that the 4 
genes investigated in our study are β-catenin target genes (van de Wetering et al., 
2002).  However, in our study, no change in gene expression was detected for any of 
the genes tested; there was no notable difference in expression levels when comparing 
control and X-EDMD. The fact that the levels of expression for all 4 genes were 
extremely similar for 3 emerin null cell lines and 2 control cell lines increases the 
likelihood that our data are both accurate and reproducible. In contrast, Markiewicz et 
al. (2006) displayed RT-PCR results for only one emerin null and a control cell line. The 
fibroblast cultures used by Markiewicz et al. (2006) had been, on average, through 
fewer passages (P6–12) than the cell lines used in our study (P9 and p19, control; P16–
P21, emerin null). However, the proliferative capacities (% pKi67+) of the cultures used 
in both studies were similar. Furthermore, at the time of RNA extraction for RT-PCR in 
our study, the 3 X-EDMD cell lines each had differing pKi67 populations. Since the band 
intensities for all genes were very similar in all X-EDMD cell lines, this implies that the 
expression levels of the genes were not considerably different in proliferating and 
senescent nuclei.  
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4.4.4 How integral is emerin for normal cellular function? 
 
The results from our study do raise some important points: how important is emerin as 
a structural protein and as a regulator of signalling pathways? Research does 
demonstrate that emerin is not essential for cell growth in mammalian cultured cells 
(Harborth et al., 2001) or for normal development in C. elegans (Gruenbaum et al., 
2002). This indicates that emerin’s role in cellular and nuclear activities are 
dispensable. Indeed, in our study, the absence of emerin does not appear to 
dramatically disrupt the expression or positioning of the genes tested, although there 
were moderate shifts in position. The fact that the changes in position were of 
significance perhaps suggests that emerin is involved in the ‘fine-tuning’ of global and 
local genome organisation, rather than the overall anchorage of genomic regions. 
Since chromosome positioning has only been examined in carrier, rather than patient, 
X-EDMD HDFs previously, the status of chromosome organisation has not been 
confirmed. The results presented in this chapter indicate that it is unlikely that global 
genome organisation is disrupted to a considerable extent in such nuclei. However, 
whether the differences in gene positioning were as a result of changes at the local 
level or indirectly due to disruptions in chromosome localisation is an area which 
requires further investigation. Despite these minor disruptions in gene positioning, this 
study did not reveal any changes in gene expression; this is an important finding. It 
reveals that the expression of the four genes analysed is not significantly perturbed in 
X-EDMD, which questions emerin’s importance in the Wnt-signalling pathway. 
Nevertheless, this current study does not negate the possibility of a relationship 
between gene expression and positioning.  
 
Emerin is evidently important enough for its loss to create a human disease phenotype 
in the form of X-EDMD. The key to understanding emerin’s role in X-EDMD most 
probably lies in examining events occurring in those tissue types, i.e. skeletal and 
cardiac muscle, which are specifically affected in the disorder. While emd null mice 
show no overt muscle phenotype, muscle regeneration is perturbed as a result of 
disrupted pRb and MyoD pathways (Melcon et al., 2006). Rb-MyoD pathway disruption 
in X-EDMD has also been demonstrated using mRNA expression profiling analysis 
(Bakay et al., 2006). Furthermore, it has been reported that emerin binds β-catenin in 
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cardiomyocytes; importantly, in murine cells lacking emerin, both β-catenin signalling 
and intercalated disc function, are disordered (Wheeler et al., 2010). Taken together, 
these studies provide evidence of emerin’s role in muscle regeneration and cardiac 
function, which aids understanding of why the pathogenesis of X-EDMD appears to be 
restricted to particular cell types. 
 
4.4.5 Conclusion  
 
In conclusion, the results of this study suggest that in the absence of emerin, some 
gene positioning is affected, while transcriptional regulation appears largely 
unchanged in fibroblasts. This study promotes the hypothesis that the impact of 
emerin’s loss in X-EDMD is more severe in those cell types primarily affected in the 
disease i.e. myocytes.  
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5.1 INTRODUCTION 
5.1.1 X-linked Emery-Dreifuss Muscular Dystrophy (X-EDMD) 
5.1.1.1 Overview  
 
While autosomal EDMD can result from mutations in EMD and LMNA, X-EDMD is 
caused by EMD mutations (Bione et al., 1994; Bione et al., 1995). In the majority of X-
EDMD cases, EMD mutations lead to an absence of the protein in patient cells; 
however, mutant forms of emerin can also cause X-EDMD (Yates et al., 1999). More 
recently, EMD mutations have also been demonstrated to cause limb-girdle muscular 
dystrophy (Ura et al., 2007) and familial atrial fibrillation (Karst et al., 2008). 
 
5.1.1.2 Emerin  
 
Emerin is a LEM domain-containing, type II integral nuclear membrane protein 
(Nagano et al., 1996) which is encoded by EMD (originally denoted STA). The gene, 
which comprises of 6 exons, is relatively small at 2 kb; the protein is a serine-rich 
molecule 34 kDa in size and 254 amino acids in length (Bione et al., 1994; Nagano et 
al., 1996; Manilal et al., 1996). The protein exists in four phosphorylated forms, three 
of which are associated with the cell cycle (Ellis et al., 1998). While the majority of the 
polypeptide resides in the nucleoplasm, its hydrophobic C-terminus anchors it to the 
nuclear membrane (Manilal et al., 1996). Although emerin expression is ubiquitous, 
levels are highest in cardiac and skeletal muscle (Bione et al., 1994). Importantly, 
correct emerin localisation is dependent on its interaction with A-type lamins 
(Vaughan et al., 2001). 
 
5.1.1.3 X-EDMD carrier, ED5364 
 
ED5364 is a HDF cell line derived from an X-EDMD carrier; previous work has been 
performed using this cell line (Meaburn et al., 2007). It is known that the disease-
causing mutation resides in EMD (unpublished data, G. Morris); however, the specifics 
are unknown. In order to determine the nature and location of the mutation present in 
ED5364, EMD was amplified and sequenced using ED5364 genomic DNA. A 
Chapter 5: Investigating the disease-causing mutations present in Atypical (type 2) HGPS 
patients 
 
 
171 
 
heterozygous point mutation was discovered in exon 4 of EMD (c.315T>G), which is 
predicted to lead to the substitution of tyrosine with a stop codon (p.Tyr105X).  
 
5.1.2 Atypical Hutchinson-Gilford Progeria Syndrome (HGPS) 
5.1.2.1 Overview 
 
Hutchinson-Gilford Progeria syndrome (HGPS) is a rare, premature ageing disease 
caused by mutations in LMNA (De Sandre-Giovannoli et al., 2003; Eriksson et al., 2003). 
Numerous HGPS cell lines have been studied and in most cases, a mutation in LMNA is 
the source of disease (e.g. AG01972, AG11498, AG06297; Eriksson et al., 2003). 
However, in at least four HGPS patients (AG08466, AG11572, AG03199 and AG10578), 
a mutation in this gene has not been identified. Significantly, neither AG08466 nor 
AG11572 harbour a LMNA mutation (Dr. N. Levy; personal communication) which 
indicates that the genetic cause of the disease resides in another gene or other genes.  
Interestingly, in culture, these two cell lines act differently to LMNA mutated HGPS 
strains; they both exhibit a greater growth potential and lower fractions of abnormal 
nuclei (Bridger and Kill, 2004). 
  
5.1.2.2 Candidate Genes 
 
The mutation of several candidate genes could potentially result in the clinical 
phenotype exhibited by HGPS patients. These include ZMPSTE2, LAP2 and EMD. As 
aforementioned in chapter 1, ZMPSTE24, encodes a zinc metalloproteinase involved in 
the processing of lamin A precursors (Pendas et al., 2002; Bergo et al., 2002; Navarro 
et al., 2005). Research has shown that mutated Zmpste24 in mice causes HGPS-like 
symptoms (Fong et al., 2004). Furthermore, it has been postulated that HGPS and AR-
MAD, a human disorder resulting from mutations in ZMPSTE24, could be variants of 
the same disease (Plasilova et al., 2004). Having said that, ZMPSTE24 mutations also 
cause restrictive dermopathy; a laminopathy presenting with clinical phentotypes very 
disimilar to those seen in HGPS (Navarro et al., 2005; Levy et al., 2005; Mouslon et al., 
2005). However, it has been demonstrated that there are two wild-type alleles for 
ZMPSTE24 in both AG08466 and AG11572 (personal communication, Dr. N. Levy). This 
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leaves the two remaining candidate genes, EMD and LAP2; since EMD has been 
discussed previously (see 5.1.1), LAP2 will now be discussed in more detail. 
 
5.1.2.3 Lamina-associated polypeptide 2 alpha (LAP2α) 
 
Through alternate splicing, the lamina-associated polypeptide 2 (LAP2) gene encodes 6 
isoforms; α, β, β’, γ, ε and δ (Foisner and Gerace, 1993; Harris et al., 1994; Berger et al., 
1996). Though all 6 isoforms have been characterised in the mouse (Berger et al., 
1996), this is only true of α, β and γ, in humans (Harris et al., 1994; Harris et al., 1995). 
The human LAP2 gene, located on 12q22, is composed of 8 exons, which span 35 kb in 
total; the splicing of exons 1–4 produce LAP2α, while exons 1–3 and 5–8 encode LAP2β 
(see table 5.1.1; Harris et al., 1995). As a result, α and β exhibit distinct C-termini, while 
sharing a common, 187 residue N-terminal domain (Harris et al., 1994). Consequently, 
the two isoforms exhibit different nuclear localisation; LAP2α lacks a trans-membrane 
domain and is thus nucleoplasmic, whereas LAP2β is membrane bound (Foisner and 
Gerace, 1993; Harris et al., 1994; Dechat et al., 1998). Furthermore, they display 
different chromosomal associations (Vlcek et al., 1999). 
 
Significantly, LAP2α is found to associate with lamin A; this interaction occurs between 
LAP2α’s C-terminal 78 residues and amino acids 319–566 of lamin A/C (see figure 
5.1.1; Dechat et al., 1998; Dechat et al., 2000a; Dechat et al., 2000b). Together, these 
proteins can be seen as intranuclear speckles, which are most prominent during G1 
(Dechat et al., 2000b). Furthermore, the presence of wildtype lamin A appears to be 
necessary for the correct localisation of LAP2α in the nucleus (Dechat et al., 2000b). 
Subsequently, Markiewicz et al. (2002) reported that these proteins are in fact 
involved in the nuclear tethering of the retinoblastoma protein (pRb). Indeed, the 
proteosomal degradation of pRb is regulated by these intranuclear protein complexes 
(Johnson et al., 2004).  
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Exon Exon composition of LAP2 isoforms 
   
1 1–92 1–92 1–92 
2 93–134 93–134 93–134 
3 135–187 135–187 135–187 
4 188–693 NP NP 
5 NP 188–220 188–220 
6 NP 221–329 NP 
7 NP 330–359 221–250 
8 NP 362–453 251–344 
 
Table 5.1.1: The exon composition of the LAP2 isoforms  
Bold type indicates that the exon is specific to that isoform whereas NP (not present) signifies 
that the exon is not a component of the isoform’s mRNA. The data displayed in this table has 
been derived from a research article by Harris et al. (1995). 
 
 
 
 
 
 
 
 
 
 
To put this into context, pRb’s function within the cell must be considered. When 
hypo-phosphorylated, pRb binds to the transcription factor, E2F and blocks its 
transctivation domain (Mittnacht, 1998). However, when phosphorylated by the cyclin-
dependent kinases, D and E, pRb releases E2F, allowing it to activate the transcription 
of S-phase specific genes; an event which eventually leads to cell proliferation (for 
review, see Yamasaki and Pagano, 2004; Frolov and Dyson, 2004). In agreement, a loss 
of lamin A from tumour strains is concomitant with their hyper-proliferation (Venables 
et al., 2001), while, the protein’s up-regulation occurs when a proliferative cell 
C-terminus N-terminus 
Figure 5.1.1: The structure of LAP2α 
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becomes quiescent (Pugh et al., 1997). In contrast, entry into quiescence is 
accompanied by the down-regulation of LAP2α expression (Pekovic et al., 2007).  
 
Aside from LAP2α’s participation in the regulation of cell cycle progression, it is also 
implicated in chromatin organisation. A stretch of ~350 amino acids in the protein’s C-
terminal mediates this interaction (Vlcek et al., 1999). Interestingly, its association with 
chromosomes is dependent on the protein’s phosphorylative state (Dechat et al., 
1998; Vlcek et al., 2002; Gajewski et al., 2004). During interphase, LAP2α is found 
dispersed throughout the nuclear interior, being absent from only nucleoli (Harris et 
al., 1994; Dechat et al., 1998) whereas in metaphase, it is cytoplasmic (Dechat et al., 
2004). Furthermore, the protein sits at telomeres in a complex with BAF. This event is 
postulated to be necessary for chromosome repositioning during nuclear assembly 
(Dechat et al., 2004). In addition, the re-organisation of chromatin in apoptosis 
appears to be, in part, reliant on the early cleavage of LAPα (Gotzmann et al., 2000).  
 
Unfortunately, LAP2α’s expression in human tissues has not yet been fully 
characterised. However, studies suggest that its expression is altered during 
development, with high levels being reported during cardiac development (Taylor et 
al., 2005) and its down-regulation occurring in myogenesis (Markiewicz et al., 2005).  
 
Adding further credence to the possibility that LAP2α is mutated in one of the two 
HGPS strains, Taylor et al. (2005) reported it as the molecular cause of DCM in two 
siblings. The heterozygous substitution led to the replacement of an arginine 
(hydrophilic and charged) with a cysteine (hydrophobic and uncharged) at codon 690 
(Taylor et al., 2005). Significantly, the affected amino acid resides in the portion of the 
protein mediating an interaction with lamin A/C and as a result this association is 
weakened in these cells (Dechat et al., 2000b). Thus, it could be postulated that this 
aforementioned mutation results in the destabilisation of the lamin A-LAP2α-pRb 
complex, leading to the loss of cell cycle control. 
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5.1.2.4 Hypothesis 
 
The difficulty with a mutation search such as this one is that the disease-causing 
mutations present could potentially reside in one of numerous genes. Therefore, a 
candidate gene approach has been selected. By assessing the literature, 2 such genes, 
EMD and LAP2, have been chosen on the basis of their respective protein’s functional 
relationship with lamin A. Indeed, emerin is shown to interact with lamin A (Manilal et 
al., 1998; Clements et al., 2000; Vaughan et al., 2001; Lee et al., 2001) and this 
association is required for emerin’s localisation at the NE (Sullivan et al., 1999; Burke 
and Stewart, 2002; Holaska et al., 2002; Muchir et al., 2003). Since LAP2α is observed 
to form a complex with A-type lamins, which acts to tether pRb in the nucleoplasm, it 
is thus plausible that a mutation in LAP2α could perturb lamin A function. Out of the 
two candidate genes chosen, the gene encoding LAP2α is most likely to be mutated in 
these two HGPS cell lines. Two main factors influenced this decision; firstly, the loss of 
functional LAP2α disrupts lamin A-LAP2α-pRb complexes, leading to deregulated cell 
cycle control (Markiewicz et al., 2002; Pekovic et al., 2007). Secondly, EMD mutations 
generally lead to muscle specific phenotypes; in AG11572 and AG08466, the patients 
show no signs of muscular dystrophy. 
 
In order to test this hypothesis, both EMD and LAP2 (exon 4) were amplified and 
sequenced in AG08466 and AG11572 using primers targeted to genomic DNA. 
Although, so far, this search has failed to reveal any mutations in either cell line for 
either gene, it has been an important study since it aids the elimination of EMD and 
LAP2 (exon 4) from the list of candidate genes implicated in causing atypical HGPS. 
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5.2 METHODS AND MATERIALS 
5.2.1 Cell Culture 
 
Primary HDFs from HGPS patients AG08466 and AG11572 (both, Coriell cell repository) 
were grown in DMEM containing 15% (v/v) fetal bovine serum, 2% (v/v) 
penicillin/streptomycin and L-glutamine. Control and ED5364 HDFs were maintained as 
before (see sections 2.2 and 3.2).  
 
5.2.2 DNA Extraction 
 
To extract DNA, approximately 1 x 106 cells were incubated in Digest Mastermix, a 
solution of 400 µl of tail digestion buffer (100 mM Tris (pH 8.0), 5 mM EDTA, 200 mM 
NaCl, 0.2% (w/v) sodium dodecyl sulphate (SDS)) and 10 µl of Proteinase K (50mg/ml), 
for at least 2 hours at 55°C. Following this, the samples were briefly vortexed and spun 
at 500g for 5 minutes. Next, 1 ml of 100% (v/v) ethanol was added and the eppendorf 
inverted; this resulted in the formation of a precipitate. The solution was incubated at - 
80°C for 10 minutes and then, centrifuged (13,700 g) for 30 minutes at 4°C. Following 
the removal of the supernatant, the pellet was washed using 1 ml 70% (v/v) ethanol 
and centrifuged (13,700 g) for 20 minutes at 4°C. Finally, the remaining ethanol was 
discarded and the pellet re-suspended in 100 µl of 1 x Tris-EDTA buffer; this was stored 
at 4°C. 
 
5.2.3 Polymerase Chain Reaction (PCR) 
 
Before being added to a 0.2 ml thin-walled tube, all the PCR components were mixed 
and centrifuged. For the amplification of EMD components were: molecular grade 
double distilled water, 10 x PCR Amplification buffer (Invitrogen), PCR Enhancer Buffer 
(Invitrogen), de-oxynucleotides (dNTPs; 10 mM) (Eppendorf), forward and reverse 
primers (100 µM) (Sigma) (see tables 5.2.1 and 5.2.2), MgSO4 (Invitrogen), Platinum 
Taq polymerase (5U/ µl) (Invitrogen) and genomic DNA. For LAP2, the KAPAHiFiTM DNA 
Polymerase kit (KAPA BIOSYSTEMS) was used.  
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A number of different primers were employed to amplify EMD (table 5.2.1) and LAP2 
(exon 4; table 5.2.2). The reaction solutions were mixed and centrifuged, before being 
placed in the PCR cycler (GenePCR System 2400; Perkin Elmer). The PCR cycles 
required for EMD amplification are shown in tables 5.2.3 and 5.2.4. 
 
 
Table 5.2.1: Primer sequences used to amplify the six exons of EMD 
Primers were designed as per Wulff et al., 1997. 
 
Designated 
name 
Forward 
Primer 
(5’–3’) 
Nucleotide 
position 
Reverse Primer 
(5’–3’) 
Nucleotide 
position 
Expected 
length (bp) 
LAP2αintron
/exon4 
GCTTTGTCTACC
AGGGCAAA 
22726 > 
22707* 
CCAGTGGGGGC
ATAGAGTTA 
21929 > 
21948* 
798 
LAP2α4.1 TCTTGTTGCCAC
AAACTTGC 
969 >  
988$ 
GGCAGCCATCT
TCACTTCAT 
2124 >  
2105$ 
1156 
LAP2α4.2 CCAGGGTGGG
GTAGGTAGTT 
1362 > 
1381$ 
AAATGCCAC 
AAAGGAACCTG 
1548 >  
1529$ 
187 
LAP2α4.3 ACCTGGATCCG
AACTGATGT 
1557 > 
1576$ 
CAGGCTTCCTA
TCTACGCAAA 
2490 >  
2470$ 
934 
 
Table 5.2.2: Primer sequences used to amplify LAP2 (exon 4).  
$Position in mRNA sequence derived from cDNA clones (NM_003276.1/U09086.1: Human 
thymopoietin alpha mRNA, complete cds; Harris et al., 1994). *Position in sequence 
Exon 
Designated 
name 
Forward Primer 
(5’–3’) 
Nucleotide 
position 
Reverse Primer 
(5’–3’) 
Nucleotide 
position 
Expected 
length 
(bp) 
1 
GEMD1F/R 
 
AGCGGCCGTGA
CGCGACAACG 
−67 > −47 
GAGGTCGCGAG
GCGGAGC 
253 > 236 320 
2 GEMD2F/R 
CGCGACCTCCCC
GCTGCC 
245 > 262 
TGCCGCTCTCGA
CCGGCC 
507 > 490 262 
3 GEMD3F/R 
GTCGAGAGCGG
CACTGGA 
495 > 512 
GTCTCAGGTCCT
CCCTGTGAGC 
1034 > 
1014 
232 
4 GEMD4F/R 
CCATCAGGCCA
GGCGGGG 
801 > 818 
TAGGTTGTACCC
AAGTACAGG 
1034 > 
1014 
234 
5 GEMD5F/R 
GTGGGTTCCTG
GCCTCTAACC 
1257 > 
1277 
GGAGCCTGGAC
C CAGAACC 
1477 > 
1459 
221 
6 GEMD6F/R 
GCTCCTGGCCC
ACTTGCTCC 
1473 > 
1492 
CTAAGGCAGTC
AGCCAGGAC 
1888 > 
1869 
416 
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AC013418.32 (Homo sapiens 12 BAC RP11-181C3 (Roswell Park Cancer Institute Human BAC 
Library) complete sequence). 
 
Phase Temperature (°C) Duration Number of cycles 
Initial denaturation 95  2 minutes 1 
Denaturation 
Annealing 
Extension 
95 
60  
68  
45 seconds 
30 seconds* 
1 minute 
 
35 
 
Table 5.2.3: PCR cycle used to amplify EMD’s six exons. 
* varies for each primer pair (see table 3.2.4) 
 
Exon Designated name Optimised PCR 
Enhancer Buffer 
Volume (µl) 
Optimised 
Annealing 
Temperature (°C) 
1 GEMD1F/R 0 61 
2 GEMD2F/R 5 62 
3 GEMD3F/R 0 60 
4 GEMD4F/R 0 59 
5 GEMD5F/R 5 60 
6 GEMD6F/R 5 62 
 
Table 5.2.4: Optimised PCR conditions for the 6 EMD primer pairs 
 
Phase Temperature (°C) Duration Number of cycles 
Initial denaturation 95 2 minutes 1 
Denaturation 
Annealing 
Extension 
98 
60 
68 
20 seconds 
15 seconds 
30 seconds 
 
35 
Final extension 68 3 minutes 1 
 
Table 5.2.5: PCR cycle used to amplify LAP2 exon 4 
 
5.2.4 Agarose Gel Electrophoresis 
 
Correctly sized bands were excised with a sterile scalpel and stored at −20°C until 
further use. 
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5.2.5 Gel Extraction and DNA Quantification 
 
Following the excision of bands from the agarose gel, DNA contained within the gel 
was extracted and purified using a MinElute Gel Extraction Kit (Qiagen).  The 
concentration of the extracted DNA was measured using a Qubit DNA/RNA 
quantification machine. 
 
5.2.6 DNA Sequencing 
 
The DNA sequencing was performed by the DNA Sequencing Service, MSI/WTB 
Complex at the University of Dundee (DNA Sequencing and Services, 2010) using an 
Applied Biosystems 3730 DNA Analyzer. In order for this to be done correctly, DNA 
samples and their respective primer pairs were provided at given concentrations (see 
table 5.2.6).   
 
Size of PCR Product (bp) DNA concentration required 
per reaction 
Primer concentration 
required per reaction 
100–200 1–3 ng 3.2 picomoles 
200–500 3–10 ng 
500–1000 5–20 ng 
 
Table 5.2.6: The DNA concentrations required for efficient sequencing.  
As specified by the DNA sequencing service in Dundee. 
 
5.2.7 Western Blotting 
 
After cells were grown in 10 cm2 dishes to a known density, the medium was removed 
and the cells were washed 3 times with 1 x PBS. Following one wash with double 
distilled water, cells were scraped into 3 x sample buffer (186 mM Tris-HCl, 15% (v/v) 
glycerol, 6% (w/v) SDS, 0.01% (w/v) Bromophenol blue, 0.2% (v/v) β-mercaptoethanol). 
The samples were then boiled for 3 minutes and the required volume adjustments 
were made; at this point, the cells were stored at −20°C.  
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Samples were loaded on a gel (4–15% (w/v) Tris-HCl gradient ready gel (BioRad 
Laboratories)), at a density of 2 x 105 cells, per lane, alongside 10 µl of rainbow marker. 
The gels were run in tank buffer (25 mM Tris, 192 mM Glycine, 0.1% (w/v) SDS) using 
the Mini-PROTEAN II  (BioRad Laboratories) electrophoresis equipment at 50V. 
 
Following this, proteins from the gel were electrophoretically transferred onto a 
nitrocellulose membrane in transfer buffer (50 mM Tris, 380 mM Glycine, 0.1% (w/v) 
SDS, 20% (v/v) Methanol; pH 9.0–9.4) at 250 mA for an hour; this was performed at 
4°C. Subsequently, the membranes were placed in block rinse buffer (10 mM Tris (pH 
7.4), 150 mM NaCl, 1 mM EDTA, 0.1% Tween-20 (v/v)) and then, incubated in blocking 
buffer (4% (w/v) dried milk powder (Marvel)) at 4°C overnight or at room temperature 
for an hour. Once sufficient blocking has taken place, the buffer was removed and the 
blots were rinsed three times, with each rinse lasting 5 minutes, in block rinse buffer. 
Next, 10 ml primary antibody was added to each blot; the incubation time for this was 
1 hour at room temperature. Primary antibodies used were: Novocastra anti-emerin 
(1:250), Novocastra anti-lamin A/C (1:100) and anti-LAP2α (1:200; a kind gift from R. 
Foisner).  In order to eliminate excess antibody, the rinse steps were repeated. A 
second incubation, using 10 ml Alkaline Phosphatase-conjugated secondary antibodies 
(rabbit anti-mouse IgG, rabbit anti-goat IgG and swine anti-rabbit IgG (Sigma)) took 
place for 1 hour at room temperature. Following this, the blots were rinsed once again 
in blot rinse buffer three times. The membranes were then placed in colour 
development buffer (100 mM Tris; pH 9.4) for up to 5 minutes. Finally, the blots were 
incubated in colour reagent (5-bromo-4-chloro-3-indolyl-phosphate (BCIP) and 
nitroblue tetrazolium (NBT) until the bands had sufficiently developed. To stop the 
reaction, the membranes were washed in double distilled water. The molecular 
weights of the bands were determined using the rainbow marker (Sigma) as a 
reference. 
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5.3 RESULTS 
5.3.1 The Amplification of EMD and LAP2 (exon 4) 
5.3.1.1 EMD 
 
In order to successfully sequence EMD, several PCR conditions required optimisation. 
Since the genomic DNA in question is only 2 kb in length, it would be expected that 
amplification using a single primer pair would be straightforward; indeed, several 
other groups have done so (Bione et al., 1995). Here, attempts at this were 
unsuccessful and as a result, it was decided that the gene would be amplified using 
numerous primer pairs as per Wulff et al. (1997; see figure 5.3.1).  
 
Since six different primer pairs were used to amplify the six individual exons, each pair 
had to be optimised in terms of the annealing temperature and the volume of 
enhancer buffer used. This turned out to be a lengthy process; however, the result of 
this optimisation process can be seen in the table below (table 5.3.1). 
 
Exon Designated name Optimised PCR 
Enhancer Buffer 
Volume (µl) 
Optimised 
Annealing 
Temperature (°C) 
1 GEMD1F/R 0 61 
2 GEMD2F/R 5 62 
3 GEMD3F/R 0 60 
4 GEMD4F/R 0 59 
5 GEMD5F/R 5 60 
6 GEMD6F/R 5 62 
 
Table 5.3.1: The conditions required for successful amplification of the six EMD exons 
 
5.3.1.2 LAP2 (exon 4) 
 
In contrast, exon 4 of LAP2 was relatively simple to amplify. 4 different pairs of primers 
were employed to amplify LAP2 exon 4 (see figure 5.3.2 and 5.3.3).  
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    1  GCGCGCAGGCCCCGCCCCTCTCACCCCGCCGCACGCCACAGGGTGACGTCTGGGCTCCCA 
   61  GCCGCATCGCCCTGACTCCCGCGCGGGCCCCGCCCCCTGCCGCTAGCCAATCTGTGCGTT 
  121  TGTGACTTTTGGGCCCGCAGCCCCGCCTGCTCCCACAGCGATACCGGTTTGCATTGCCCT 
  181  GACTCCCGCGCGGGCCCCGCCCCCTACGCCGCTAGCCAATCCATGCATTAGTGGCGTCCG 
  241  GGCTCGCAGTACCGCTCGCTCCCACCGCGAGACCTTCTGCTCCGCGCCCGCGCGGGCCCC 
  301  TCCCCCTCCATCGCTAGCCAATCCCCGTTTTGTGACGTATGGGCTCGCGGCCCCGCTCGC 
  361  TCCCACCGCGAGACCTTTTGCTCCGCGCCCGCGCGGGCCCCGCCCCCTCCATCACTAGCC 
  421  AATCCCCGTGCTTGTGACATATGGGCTTGCGGCCCCGCCCGCTCCCATCGCGAGACCGGT 
  481  TCCCACCGCCCTGACTCCCGGGCGGGCCCCGCCCTCTCCGCCGCTAGCCAATCCTCGCGT 
  541  TGATGACGTTTGGGCTCGCGGCCCCAGCCTCCCAGCTCTCAGGGCACGGCCGGTCTGTGC 
  601  CGGCTGCTCCCGCGGTTAGGTCCCGCCCCGCGCAGCGCGCGCAGCCTGCGGAGCCAGCGG 
  661  CCGTGACGCGACAACGATTCGGCTGTGACGCGACAACGATTCGGCTGTGACGCGAGCGCG 
  721  GCCGCTCCCGATGCGCTCGTGCCGCCCCCGCCGTGCTCCTCGGCAGCCGTTGCTCGGCCG 
  781  GTTTTGGTAGGCCCGGGCCGCCGCCAGGCCTCCGCCTGAGCCCGCACCCGCCATGGACAA 
  841  CTACGCAGATCTTTCGGATACCGAGCTGACCACCTTGCTGCGCCGGTACAACATCCCGCA 
  901  CGGGCCTGTAGTAGGTACGCGGCGGCGGGCGGGACCCCTTCCGGGCCCCCTCCTCGTGCT 
  961  CCGCCTCGCGACCTCCCCGCTGCCCTCCCCGCGCGCCTTCCCCGGCCCGCGGCCCTGACC 
  1021 GCCCCGTGTCCGGCCAGGATCAACTCGTAGGCTTTACGAGAAGAAGATCTTCGAGTACGA 
  1081 GACCCAGAGGCGGCGGCTCTCGCCCCCCAGCTCGTCCGCCGCCTCCTCTTATAGCTTCTC 
  1141 TGGTGAGAGCCTCGCCTGTGGGGACAGCCTGGGACGCGGGGAGGATGGGGTCGCGAGGGT 
  1201 GTGGCAGGGGGGCCGGTCGAGAGCGGCACTGGAGAAAGGGGAGGGAAGTCTGGGGGGGCA 
  1261 AACAGTTCTGTCTCCTCCTTTCAATCCAGACTTGAATTCGACTAGAGGGGATGCAGATAT 
  1321 GTATGATCTTCCCAAGAAAGAGGACGCTTTACTCTACCAGAGCAAGGGTAAGGCAGGGGT 
  1381 TGGGTGGGCACGCTGGCACCTTCACCCGACTTCGTCAGGGACCCCGCTCACAGGGAGGAC 
  1441 CTGAGACCTCAGTCCCAACCACTCCAGCAGCCTTAGGAGGGAGAAACTGTTACAGGTCCC 
  1501 GAAATGGGATTCAGATTAGGGCCATCAGGCCAGGCGGGGCACACCGATGCCCCCTCTGCT 
  1561 ACCGCTGCCCCCCTTCCCAAGGCTACAATGACGACTACTATGAAGAGAGCTACTTCACCA 
  1621 CCAGGACTTATGGGGAGCCCGAGTCTGCCGGCCCGTCCAGGGCTGTCCGCCAGTCAGTGA 
  1681 CTTCATTCCCAGATGCTGACGCTTTCCATCACCAGGTGAGCTGGCTGGCAGGCGTCCTGT 
  1741 ACTTGGGTACAACCTAGGGGATCGCGGCTGTGTTTGGATAAATCCAGGGGGGCACTGGGT 
  1801 ACAAATGGTGGCTCTTGGGCCTCCGGGGAGACTCTGTGTGACTAGAGCACCCTGGTCTGG 
  1861 GATCTAGGCTCAGACTCTTCCTGAGAGTCCTGGGGGCAAAAGGGGATGCTGGGGCATGAG 
  1921 CACAAGTGGCAAGGCCCCATGGATAAAGGGCTGAACACCCAGAGCCATTCAGGAGGGTGT 
  1981 GGGTTCCTGGCCTCTAACCAAAGGTCAGAGGGGACTGGCTGGGGAAGTTTGGACTGAGGG 
  2041 ACATGACAGGGCCATGGTGGCCCTGCCAGCCAGTCCCCTCGCCCTGACTCTCTTCTGCAG 
  2101 GTGCATGATGACGATCTTTTGTCTTCTTCTGAAGAGGAGTGCAAGGATAGGTGCGTAGTG 
  2161 GGGGAGCCCAGGGACGGGCTGGTTCTGGGTCCAGGCTCCTGGCCCACTTGCTCCCCTCTT 
  2221 TTGCCTCAGGGAACGCCCCATGTACGGCCGGGACAGTGCCTACCAGAGCATCACGCACTA 
  2281 CCGCCCTGTTTCAGCCTCCAGGAGCTCCCTGGACCTGTCCTATTATCCTACTTCCTCCTC 
  2341 CACCTCTTTTATGTCCTCCTCATCATCTTCCTCTTCATGGCTCACCCGCCGTGCCATCCG 
  2401 GCCTGAAAACCGTGCTCCTGGGGCTGGGCTGGGCCAGGATCGCCAGGTCCCGCTCTGGGG 
  2461 CCAGCTGCTGCTTTTCCTGGTCTTTGTGATCGTCCTCTTCTTCATTTACCACTTCATGCA 
  2521 GGCTGAAGAAGGCAACCCCTTCTAGAGGGAGCCATGAGGGTCTGGGCTTCAGAGCTAGGT 
  2581 CTTTGGGGAAGTCCTGGCTGACTGCCTTAGCAGTGGGGGTGGGGGTGGGGGCAGGGGCAG 
  2641 GGGCTTTATGTGTTTTTGCTTGGGGGGCGCTGGGCCTAGCCCAGAGTAGTGCTTGCTCCC 
  2701 CCTGCCTTGTCCCACCAGGGAGGCAGCAGACTCAGGCCCTCCATGGTCCTCTTTGTCATT 
  2761 TTGTTGACATGCATTCCTCCTTTTGTCATCTTGTTGGGGGGAGGGGATTAACCAAAGGCC 
  2821 ACCCTGACTTTGTTTTTGTGGACACACAATAAAAGCCCCGTTTATTTGTAATGCGTTGGC 
  2881 TCTTCCTGGAGGAGAGGGTTGGGCTCCCATGGCAAGGGCCTCTGCGTCTTGGGGCTCCAG 
  2941 GATTGCAATCCGGCTTTGTTGGGTCCGCATTTTTGCTTTAGTCTGGGGATAGGAATCAAA 
  3001 TGTTACCCAGAGATGTTTGTGTTTTGTTTGGGAGTTTTATTCCCTAACTCATTCCCCAAA 
  3061 GCACGTGTAACTGCTTATACATATAATCGTGGTACAACAAGGTATATACAGAGAACCCAC 
  3121 TTGGAAATTCAGGCAAAGCTGCATGCACGCTACCAGCAGTCTGCGGGTGTTTTAACTGGA 
  3181 AAAAGCTGAAGTCCACCTCGGTGTCCAATGGCATGGGGATGGAAAGAAAATGAGGCGTCT 
  3241 CTGGCACATCATTCTCAGCTCCTGGAACTGCTGCTTGTTTAACATGGGAGAAAAGCTCCA 
  3301 AAGGCTGAAATGCCCCATCATCCCTGGGTGATTGAATTC 
 
Figure 5.3.1 EMD genomic DNA sequence 
 
E1 
E2 
E3 
E4 
E5 
E6 
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Figure 5.3.1 EMD genomic DNA sequence 
Sequence derived from PubMed (X86810.1). Gene information sourced from Bione et al., 
(1994; 1995). Start (ATG) and stop (TAG) codons are underlined. Protein coding cDNA 
sequence is highlighted in dark grey (as per Bione et al., 1994). Non-protein coding cDNA 
sequence is highlighted in light grey (as per Bione et al., 1995). Forward primers for each exon 
are highlighted in green, while reverse primers are highlighted in red. Overlapping primer 
sequences are highlighted in dark green. Primers as per Wulff et al. (1997). E = exon. 
1    GTTCGTAGTTCGGCTCTGGGGTCTTTTGTGTCCGGGTCTGGCTTGGCTTTGTGTCCGCGA 
61   GTTTTTGTTCCGCTCCGCAGCGCTCTTCCCGGGCAGGAGCCGTGAGGCTCGGAGGCGGCA 
121  GCGCGGTCCCCGGCCAGGAGCAAGCGCGCCGGCGTGAGCGGCGGCGGCAAAGGCTGTGGG 
181  GAGGGGGCTTCGCAGATCCCCGAGATGCCGGAGTTCCTGGAAGACCCCTCGGTCCTGACA 
241  AAAGACAAGTTGAAGAGTGAGTTGGTCGCCAACAATGTGACGCTGCCGGCCGGGGAGCAG 
301  CGCAAAGACGTGTACGTCCAGCTCTACCTGCAGCACCTCACGGCTCGCAACCGGCCGCCG 
361  CTCCCCGCCGGCACCAACAGCAAGGGGCCCCCGGACTTCTCCAGTGACGAAGAGCGCGAG 
421  CCCACCCCGGTCCTCGGCTCTGGGGCCGCCGCCGCGGGCCGGAGCCGAGCAGCCGTCGGC 
481  AGGAAAGCCACAAAAAAAACTGATAAACCCAGACAAGAAGATAAAGATGATCTAGATGTA 
541  ACAGAGCTCACTAATGAAGATCTTTTGGATCAGCTTGTGAAATACGGAGTGAATCCTGGT 
601  CCTATTGTGGGAACAACCAGGAAGCTATATGAGAAAAAGCTTTTGAAACTGAGGGAACAA 
661  GGAACAGAATCAAGATCTTCTACTCCTCTGCCAACAATTTCTTCTTCAGCAGAAAATACA 
721  AGGCAGAATGGAAGTAATGATTCTGACAGATACAGTGACAATGAAGAAGGAAAGAAGAAA 
781  GAACACAAGAAAGTGAAGTCCACTAGGGATATTGTTCCTTTTTCTGAACTTGGAACTACT 
841  CCCTCTGGTGGTGGATTTTTTCAGGGTATTTCTTTTCCTGAAATCTCCACCCGTCCTCCT 
901  TTGGGCAGTACCGAACTACAGGCAGCTAAGAAAGTACATACTTCTAAGGGAGACCTACCT 
961  AGGGAGCCTCTTGTTGCCACAAACTTGCCTGGCAGGGGACAGTTGCAGAAGTTAGCCTCT 
1021 GAAAGGAATTTGTTTATTTCATGCAAGTCTAGCCATGATAGGTGTTTAGAGAAAAGTTCT 
1081 TCGTCATCTTCTCAGCCTGAACACAGTGCCATGTTGGTCTCTACTGCAGCTTCTCCTTCA 
1141 CTGATTAAAGAAACCACCACTGGTTACTATAAAGACATAGTAGAAAATATTTGCGGTAGA 
1201 GAGAAAAGTGGAATTCAACCATTATGTCCTGAGAGGTCCCATATTTCAGATCAATCGCCT 
1261 CTCTCCAGTAAAAGGAAAGCACTAGAAGAGTCTGAGAGCTCACAACTAATTTCTCCGCCA 
1321 CTTGCCCAGGCAATCAGAGATTATGTCAATTCTCTGTTGGTCCAGGGTGGGGTAGGTAGT 
1381 TTGCCTGGAACTTCTAACTCTATGCCCCCACTGGATGTAGAAAACATACAGAAGAGAATT 
1441 GATCAGTCTAAGTTTCAAGAAACTGAATTCCTGTCTCCTCCAAGAAAAGTCCCTAGACTG 
1501 AGTGAGAAGTCAGTGGAGGAAAGGGATTCAGGTTCCTTTGTGGCATTTCAGAACATACCT 
1561 GGATCCGAACTGATGTCTTCTTTTGCCAAAACTGTTGTCTCTCATTCACTCACTACCTTA 
1621 GGTCTAGAAGTGGCTAAGCAATCACAGCATGATAAAATAGATGCCTCAGAACTATCTTTT 
1681 CCCTTCCATGAATCTATTTTAAAAGTAATTGAAGAAGAATGGCAGCAAGTTGACAGGCAG 
1741 CTGCCTTCACTGGCATGCAAATATCCAGTTTCTTCCAGGGAGGCAACACAGATATTATCA 
1801 GTTCCAAAAGTAGATGATGAAATCCTAGGGTTTATTTCTGAAGCCACTCCACTAGGAGGT 
1861 ATTCAAGCAGCCTCCACTGAGTCTTGCAATCAGCAGTTGGACTTAGCACTCTGTAGAGCA 
1921 TATGAAGCTGCAGCATCAGCATTGCAGATTGCAACTCACACTGCCTTTGTAGCTAAGGCT 
1981 ATGCAGGCAGACATTAGTCAAGCTGCACAGATTCTTAGCTCAGATCCTAGTCGTACCCAC 
2041 CAAGCGCTTGGGATTCTGAGCAAAACATATGATGCAGCCTCATATATTTGTGAAGCTGCA 
2101 TTTGATGAAGTGAAGATGGCTGCCCATACCATGGGAAATGCCACTGTAGGTCGTCGATAC 
2161 CTCTGGCTGAAGGATTGCAAAATTAATTTAGCTTCTAAGAATAAGCTGGCTTCCACTCCC 
2221 TTTAAAGGTGGAACATTATTTGGAGGAGAAGTATGCAAAGTAATTAAAAAGCGTGGAAAT 
2281 AAACACTAGTAAAATTAAGGACAAAAAGACATCTATCTTATCTTTCAGGTACTTTATGCC 
2341 AACATTTTCTTTTCTGTTAAGGTTGTTTTAGTTTCCAGATAGGGCTAATTACAAAATGTT 
2401 AAGCTTCTACCCATCAAATTACAGTATAAAAGTAATTGCCTGTGTAGAACTACTTGTCTT 
2461 TTCTAAAGATTTGCGTAGATAGGAAGCCTG 
 
Figure 5.3.2: LAP2 exon 4 cDNA sequence 
 
LAP2 sequence derived from PubMed (NM_003276; Homo sapiens thymopoietin (TMPO), 
transcript variant 1, mRNA). Nucleotides highlighted in teal code for exons 1–3, while those 
highlighted in dark grey code for exon 4. ATG: start of exon 1; GGA: start of exon 4; TAG: end 
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of exon 4. Additional information regarding gene sequence and structure was sourced from 
Harris et al. (1994). 3 different sets of primers used to amplify the exon 4 of LAP2 have been 
colour coded:   
LAP2α4.1F/R:TCTTGTTGCCACAAACTTGC/GGCAGCCATCTTCACTTCAT 
LAP2α4.2F/RCCAGGGTGGGGTAGGTAGTT/AAATGCCACAAAGGAACCTG 
LAP2α4.3F/R:ACCTGGATCCGAACTGATGT/CAGGCTTCCTATCTACGCAAA  
 
20761 TTTTGGAGAATTGTAAAAACATAAGTAAAGCAGGAAACAGAAAACAACTTAGAGACTAAT 
20821 ATGTGATCTAGAAAGCGTTAAATTGTTTGTACCAGGCTTCCTATCTACGCAAATCTTTAG 
20881 AAAAGACAAGTAGTTCTACACAGGCAATTACTTTTATACTGTAATTTGATGGGTAGAAGC 
20941 TTAACATTTTGTAATTAGCCCTATCTGGAAACTAAAACAACCTTAACAGAAAAGAAAATG 
21001 TTGGCATAAAGTACCTGAAAGATAAGATAGATGTCTTTTTGTCCTTAATTTTACTAGTGT 
21061 TTATTTCCACGCTTTTTAATTACTTTGCATACTTCTCCTCCAAATAATGTTCCACCTTTA 
21121 AAGGGAGTGGAAGCCAGCTTATTCTTAGAAGCTAAATTAATTTTGCAATCCTTCAGCCAG 
21181 AGGTATCGACGACCTACAGTGGCATTTCCCATGGTATGGGCAGCCATCTTCACTTCATCA 
21241 AATGCAGCTTCACAAATATATGAGGCTGCATCATATGTTTTGCTCAGAATCCCAAGCGCT 
21301 TGGTGGGTACGACTAGGATCTGAGCTAAGAATCTGTGCAGCTTGACTAATGTCTGCCTGC 
21361 ATAGCCTTAGCTACAAAGGCAGTGTGAGTTGCAATCTGCAATGCTGATGCTGCAGCTTCA 
21421 TATGCTCTACAGAGTGCTAAGTCCAACTGCTGATTGCAAGACTCAGTGGAGGCTGCTTGA 
21481 ATACCTCCTAGTGGAGTGGCTTCAGAAATAAACCCTAGGATTTCATCATCTACTTTTGGA 
21541 ACTGATAATATCTGTGTTGCCTCCCTGGAAGAAACTGGATATTTGCATGCCAGTGAAGGC 
21601 AGCTGCCTGTCAACTTGCTGCCATTCTTCTTCAATTACTTTTAAAATAGATTCATGGAAG 
21661 GGAAAAGATAGTTCTGAGGCATCTATTTTATCATGCTGTGATTGCTTAGCCACTTCTAGA 
21721 CCTAAGGTAGTGAGTGAATGAGAGACAACAGTTTTGGCAAAAGAAGACATCAGTTCGGAT 
21781 CCAGGTATGTTCTGAAATGCCACAAAGGAACCTGAATCCCTTTCCTCCACTGACTTCTCA 
21841 CTCAGTCTAGGGACTTTTCTTGGAGGAGACAGGAATTCAGTTTCTTGAAACTTAGACTGA 
21901 TCAATTCTCTTCTGTATGTTTTCTACATCCAGTGGGGGCATAGAGTTAGAAGTTCCAGGC 
21961 AAACTACCTACCCCACCCTGGACCAACAGAGAATTGACATAATCTCTGATTGCCTGGGCA 
22021 AGTGGCGGAGAAATTAGTTGTGAGCTCTCAGACTCTTCTAGTGCTTTCCTTTTACTGGAG 
22081 AGAGGCGATTGATCTGAAATATGGGACCTCTCAGGACATAATGGTTGAATTCCACTTTTC 
22141 TCTCTACCGCAAATATTTTCTACTATGTCTTTATAGTAACCAGTGGTGGTTTCTTTAATC 
22201 AGTGAAGGAGAAGCTGCAGTAGAGACCAACATGGCACTGTGTTCAGGCTGAGAAGATGAC 
22261 GAAGAACTTTTCTCTAAACACCTATCATGGCTAGACTTGCATGAAATAAACAAATTCCTT 
22321 TCAGAGGCTAACTTCTGCAACTGTCCCCTGCCAGGCAAGTTTGTGGCAACAAGAGGCTCC 
22381 CTAGGTAGGTCTCCCTTAGAAGTATGTACTTTCTTAGCTGCCTGTAGTTCGGTACTGCCC 
22441 AAAGGAGGACGGGTGGAGATTTCAGGAAAAGAAATACCCTGAAAAAATCCACCACCAGAG 
22501 GGAGTAGTTCCAAGTTCAGAAAAAGGAACAATATCCCTAGTGGACTTCACTTTCTTGTGT 
22561 TCTTTCTTCTTTCCTGTAGAGGCAAAAGAGGCAGGAAGTTTAAGCATTACCTGTGTTTGA 
22621 GCTGATTTTATTCTTTGCCTCTTTGCTAAAAATAGTGCTGTCAAAGGAAAAGACTATAAT 
22681 TTCATATTCTGAACTAATCTGCCAGATTTGCCCTGGTAGACAAAGCTTATTGAGATATAA 
22741 ACAATCTGGATCAAAATAAATAATCACAAGTCATATTAATTAAAAGTTTACAAAAATCAA 
 
Figure 5.3.3: LAP2 exon 4 genomic DNA sequence 
 
Sequence derived from PubMed (selected region of AC013418; Homo sapiens 12 BAC RP11-
181C3 (Roswell Park Cancer Institute Human BAC Library) complete sequence). Note that the 
sequence is in reverse orientation to the LAP2 exon 4 cDNA (i.e. exons are coded in descending 
order). Gene information sourced from Harris et al., (1994; 1995). Protein coding nucleotide 
sequence is highlighted in dark grey (as per Harris et al., 1994). 5’ exon/ intron boundary is 
denoted by the black arrow. Primer pairs used to amplify exon 4 plus the 5’exon/ intron 
boundary have been colour coded:                                                                        
LAP2αintron/exon4F/R; GCTTTGTCTACCAGGGCAAA/ CCAGTGGGGGCATAGAGTTA 
LAP2α4.1F/R:TCTTGTTGCCACAAACTTGC/GGCAGCCATCTTCACTTCAT 
LAP2α4.2F/RCCAGGGTGGGGTAGGTAGTT/AAATGCCACAAAGGAACCTG 
LAP2α4.3F/R:ACCTGGATCCGAACTGATGT/CAGGCTTCCTATCTACGCAAA 
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5.3.2 Sequencing  
 
Once exon amplification was successful, the bands were extracted from the agarose 
gel; from this gel, DNA was isolated and sent away for sequencing as per the 
description in the methods and materials section, 5.2. For each DNA sample, the 
sequencing was performed twice, using both forward and reverse primers. Thus, any 
discrepancies present in both forward and reverse sequences were unlikely to be as a 
consequence of inaccurate sequencing. On receiving the results, a BLAST search was 
performed; this system compares the sequence against those in the database and 
highlights those identical or most similar to the sequence in the human genome.  
 
Unfortunately, sequencing did not always produce a positive result. This was not due 
to contamination but to lack of DNA; this is likely to be as a result of using an 
inaccurate DNA quantification system. As a result, at times, far higher concentrations 
than required have been sent away for sequencing.  
 
5.3.3 Determining the EMD mutation present in X-EDMD carrier, ED5364 
 
In order to determine the location and nature of the EMD mutation present in ED5364, 
genomic DNA from this cell line was extracted and then employed to sequence EMD. A 
summary of sequencing results for ED5364 exon 4 can be seen in figure 5.3.4; full 
details can be found in Appendix (ED5364: EMD). 
 
This mutation search was successful; a heterozygous point mutation (c.315T>G) was 
discovered in exon 4 of EMD. This can be seen by the presence of half-peaks in both 
forward and reverse readings at position 315 (see figure 5.3.5). At the amino acid level, 
this mutation is predicted to lead to tyrosine (TAT) being replaced by a stop codon 
(TAG) at residue 105 (p.Tyr105X). The presence of the mutation was confirmed twice.  
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    1  GCGCGCAGGCCCCGCCCCTCTCACCCCGCCGCACGCCACAGGGTGACGTCTGGGCTCCCA 
   61  GCCGCATCGCCCTGACTCCCGCGCGGGCCCCGCCCCCTGCCGCTAGCCAATCTGTGCGTT 
  121  TGTGACTTTTGGGCCCGCAGCCCCGCCTGCTCCCACAGCGATACCGGTTTGCATTGCCCT 
  181  GACTCCCGCGCGGGCCCCGCCCCCTACGCCGCTAGCCAATCCATGCATTAGTGGCGTCCG 
  241  GGCTCGCAGTACCGCTCGCTCCCACCGCGAGACCTTCTGCTCCGCGCCCGCGCGGGCCCC 
  301  TCCCCCTCCATCGCTAGCCAATCCCCGTTTTGTGACGTATGGGCTCGCGGCCCCGCTCGC 
  361  TCCCACCGCGAGACCTTTTGCTCCGCGCCCGCGCGGGCCCCGCCCCCTCCATCACTAGCC 
  421  AATCCCCGTGCTTGTGACATATGGGCTTGCGGCCCCGCCCGCTCCCATCGCGAGACCGGT 
  481  TCCCACCGCCCTGACTCCCGGGCGGGCCCCGCCCTCTCCGCCGCTAGCCAATCCTCGCGT 
  541  TGATGACGTTTGGGCTCGCGGCCCCAGCCTCCCAGCTCTCAGGGCACGGCCGGTCTGTGC 
  601  CGGCTGCTCCCGCGGTTAGGTCCCGCCCCGCGCAGCGCGCGCAGCCTGCGGAGCCAGCGG 
  661  CCGTGACGCGACAACGATTCGGCTGTGACGCGACAACGATTCGGCTGTGACGCGAGCGCG 
  721  GCCGCTCCCGATGCGCTCGTGCCGCCCCCGCCGTGCTCCTCGGCAGCCGTTGCTCGGCCG 
  781  GTTTTGGTAGGCCCGGGCCGCCGCCAGGCCTCCGCCTGAGCCCGCACCCGCCATGGACAA 
  841  CTACGCAGATCTTTCGGATACCGAGCTGACCACCTTGCTGCGCCGGTACAACATCCCGCA 
  901  CGGGCCTGTAGTAGGTACGCGGCGGCGGGCGGGACCCCTTCCGGGCCCCCTCCTCGTGCT 
  961  CCGCCTCGCGACCTCCCCGCTGCCCTCCCCGCGCGCCTTCCCCGGCCCGCGGCCCTGACC 
  1021 GCCCCGTGTCCGGCCAGGATCAACTCGTAGGCTTTACGAGAAGAAGATCTTCGAGTACGA 
  1081 GACCCAGAGGCGGCGGCTCTCGCCCCCCAGCTCGTCCGCCGCCTCCTCTTATAGCTTCTC 
  1141 TGGTGAGAGCCTCGCCTGTGGGGACAGCCTGGGACGCGGGGAGGATGGGGTCGCGAGGGT 
  1201 GTGGCAGGGGGGCCGGTCGAGAGCGGCACTGGAGAAAGGGGAGGGAAGTCTGGGGGGGCA 
  1261 AACAGTTCTGTCTCCTCCTTTCAATCCAGACTTGAATTCGACTAGAGGGGATGCAGATAT 
  1321 GTATGATCTTCCCAAGAAAGAGGACGCTTTACTCTACCAGAGCAAGGGTAAGGCAGGGGT 
  1381 TGGGTGGGCACGCTGGCACCTTCACCCGACTTCGTCAGGGACCCCGCTCACAGGGAGGAC 
  1441 CTGAGACCTCAGTCCCAACCACTCCAGCAGCCTTAGGAGGGAGAAACTGTTACAGGTCCC 
  1501 GAAATGGGATTCAGATTAGGGCCATCAGGCCAGGCGGGGCACACCGATGCCCCCTCTGCT 
  1561 ACCGCTGCCCCCCTTCCCAAGGCTACAATGACGACTACTATGAAGAGAGCTACTTCACCA 
  1621 CCAGGACTTATGGGGAGCCCGAGTCTGCCGGCCCGTCCAGGGCTGTCCGCCAGTCAGTGA 
  1681 CTTCATTCCCAGATGCTGACGCTTTCCATCACCAGGTGAGCTGGCTGGCAGGCGTCCTGT 
  1741 ACTTGGGTACAACCTAGGGGATCGCGGCTGTGTTTGGATAAATCCAGGGGGGCACTGGGT 
  1801 ACAAATGGTGGCTCTTGGGCCTCCGGGGAGACTCTGTGTGACTAGAGCACCCTGGTCTGG 
  1861 GATCTAGGCTCAGACTCTTCCTGAGAGTCCTGGGGGCAAAAGGGGATGCTGGGGCATGAG 
  1921 CACAAGTGGCAAGGCCCCATGGATAAAGGGCTGAACACCCAGAGCCATTCAGGAGGGTGT 
  1981 GGGTTCCTGGCCTCTAACCAAAGGTCAGAGGGGACTGGCTGGGGAAGTTTGGACTGAGGG 
  2041 ACATGACAGGGCCATGGTGGCCCTGCCAGCCAGTCCCCTCGCCCTGACTCTCTTCTGCAG 
  2101 GTGCATGATGACGATCTTTTGTCTTCTTCTGAAGAGGAGTGCAAGGATAGGTGCGTAGTG 
  2161 GGGGAGCCCAGGGACGGGCTGGTTCTGGGTCCAGGCTCCTGGCCCACTTGCTCCCCTCTT 
  2221 TTGCCTCAGGGAACGCCCCATGTACGGCCGGGACAGTGCCTACCAGAGCATCACGCACTA 
  2281 CCGCCCTGTTTCAGCCTCCAGGAGCTCCCTGGACCTGTCCTATTATCCTACTTCCTCCTC 
  2341 CACCTCTTTTATGTCCTCCTCATCATCTTCCTCTTCATGGCTCACCCGCCGTGCCATCCG 
  2401 GCCTGAAAACCGTGCTCCTGGGGCTGGGCTGGGCCAGGATCGCCAGGTCCCGCTCTGGGG 
  2461 CCAGCTGCTGCTTTTCCTGGTCTTTGTGATCGTCCTCTTCTTCATTTACCACTTCATGCA 
  2521 GGCTGAAGAAGGCAACCCCTTCTAGAGGGAGCCATGAGGGTCTGGGCTTCAGAGCTAGGT 
  2581 CTTTGGGGAAGTCCTGGCTGACTGCCTTAGCAGTGGGGGTGGGGGTGGGGGCAGGGGCAG 
  2641 GGGCTTTATGTGTTTTTGCTTGGGGGGCGCTGGGCCTAGCCCAGAGTAGTGCTTGCTCCC 
  2701 CCTGCCTTGTCCCACCAGGGAGGCAGCAGACTCAGGCCCTCCATGGTCCTCTTTGTCATT 
  2761 TTGTTGACATGCATTCCTCCTTTTGTCATCTTGTTGGGGGGAGGGGATTAACCAAAGGCC 
  2821 ACCCTGACTTTGTTTTTGTGGACACACAATAAAAGCCCCGTTTATTTGTAATGCGTTGGC 
  2881 TCTTCCTGGAGGAGAGGGTTGGGCTCCCATGGCAAGGGCCTCTGCGTCTTGGGGCTCCAG 
  2941 GATTGCAATCCGGCTTTGTTGGGTCCGCATTTTTGCTTTAGTCTGGGGATAGGAATCAAA 
  3001 TGTTACCCAGAGATGTTTGTGTTTTGTTTGGGAGTTTTATTCCCTAACTCATTCCCCAAA 
  3061 GCACGTGTAACTGCTTATACATATAATCGTGGTACAACAAGGTATATACAGAGAACCCAC 
  3121 TTGGAAATTCAGGCAAAGCTGCATGCACGCTACCAGCAGTCTGCGGGTGTTTTAACTGGA 
  3181 AAAAGCTGAAGTCCACCTCGGTGTCCAATGGCATGGGGATGGAAAGAAAATGAGGCGTCT 
  3241 CTGGCACATCATTCTCAGCTCCTGGAACTGCTGCTTGTTTAACATGGGAGAAAAGCTCCA 
  3301 AAGGCTGAAATGCCCCATCATCCCTGGGTGATTGAATTC 
 
Figure 5.3.4: Sequencing of EMD in ED5364 
 
Sequence derived from PubMed (X86810.1). Gene information sourced from Bione et al., 
(1994; 1995). Forward primers for each exon are highlighted in green, while reverse primers 
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are highlighted in red. Overlapping primer sequences are highlighted in dark green. Sequenced 
regions are highlighted in turquoise. A database discrepancy is highlighted in yellow. A 
confirmed heterozygous mutation is highlighted in black. Nucleotides highlighted in dark grey 
are protein coding bases which have not been successfully sequenced. Non-protein coding 
cDNA sequence is highlighted in light grey. E = exon. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3.5: The identification of an EMD mutation in the X-EDMD carrier. 
The arrow highlights the presence of a heterozygous point mutation at nucleotide 315 
(c.315T>G) of EMD; this affects residue 105 (p.Tyr105X) of the protein and results in the 
production of a premature stop codon. 
 
5.3.4 Attempting to determine the disease-causing mutation present in atypical 
HGPS cell lines, AG08466 and AG11572  
5.3.4.1 Overview 
 
Since neither of the atypical HGPS cell lines, AG08466 or AG11572, harbour a LMNA 
mutation, both EMD and LAP2 (exon 4) were selected for sequencing. Both proteins 
are binding partners of lamin A and indeed, are documented to cause laminopathy-
based disease when defective.  Thus, the aim of this section was to determine whether 
either cell line exhibits an EMD or LAP2 (exon 4) mutation. 
 
5.3.4.2 EMD 
 
The majority of the 6 EMD exons have been successfully sequenced in both AG08466 
and AG11572; however, so far no mutations have been detected. A database 
discrepancy has been observed; at positions 1581–1583, the mRNA sequence 
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(X86810.1) predicts GGG; however, in all cell lines examined (i.e. AG08466, AG11572 
and ED5364), there appears to be only 2 (nucleotide highlighted in yellow; see figures 
5.3.4, 5.3.6 and 5.3.7).   A summary of sequencing results for AG08466 and AG11572 
can be seen in figures 5.3.6 and 5.3.7, respectively; full details can be found in 
Appendix (AG08466: EMD and AG11572: EMD). 
 
    1  GCGCGCAGGCCCCGCCCCTCTCACCCCGCCGCACGCCACAGGGTGACGTCTGGGCTCCCA 
   61  GCCGCATCGCCCTGACTCCCGCGCGGGCCCCGCCCCCTGCCGCTAGCCAATCTGTGCGTT 
  121  TGTGACTTTTGGGCCCGCAGCCCCGCCTGCTCCCACAGCGATACCGGTTTGCATTGCCCT 
  181  GACTCCCGCGCGGGCCCCGCCCCCTACGCCGCTAGCCAATCCATGCATTAGTGGCGTCCG 
  241  GGCTCGCAGTACCGCTCGCTCCCACCGCGAGACCTTCTGCTCCGCGCCCGCGCGGGCCCC 
  301  TCCCCCTCCATCGCTAGCCAATCCCCGTTTTGTGACGTATGGGCTCGCGGCCCCGCTCGC 
  361  TCCCACCGCGAGACCTTTTGCTCCGCGCCCGCGCGGGCCCCGCCCCCTCCATCACTAGCC 
  421  AATCCCCGTGCTTGTGACATATGGGCTTGCGGCCCCGCCCGCTCCCATCGCGAGACCGGT 
  481  TCCCACCGCCCTGACTCCCGGGCGGGCCCCGCCCTCTCCGCCGCTAGCCAATCCTCGCGT 
  541  TGATGACGTTTGGGCTCGCGGCCCCAGCCTCCCAGCTCTCAGGGCACGGCCGGTCTGTGC 
  601  CGGCTGCTCCCGCGGTTAGGTCCCGCCCCGCGCAGCGCGCGCAGCCTGCGGAGCCAGCGG 
  661  CCGTGACGCGACAACGATTCGGCTGTGACGCGACAACGATTCGGCTGTGACGCGAGCGCG 
  721  GCCGCTCCCGATGCGCTCGTGCCGCCCCCGCCGTGCTCCTCGGCAGCCGTTGCTCGGCCG 
  781  GTTTTGGTAGGCCCGGGCCGCCGCCAGGCCTCCGCCTGAGCCCGCACCCGCCATGGACAA 
  841  CTACGCAGATCTTTCGGATACCGAGCTGACCACCTTGCTGCGCCGGTACAACATCCCGCA 
  901  CGGGCCTGTAGTAGGTACGCGGCGGCGGGCGGGACCCCTTCCGGGCCCCCTCCTCGTGCT 
  961  CCGCCTCGCGACCTCCCCGCTGCCCTCCCCGCGCGCCTTCCCCGGCCCGCGGCCCTGACC 
  1021 GCCCCGTGTCCGGCCAGGATCAACTCGTAGGCTTTACGAGAAGAAGATCTTCGAGTACGA 
  1081 GACCCAGAGGCGGCGGCTCTCGCCCCCCAGCTCGTCCGCCGCCTCCTCTTATAGCTTCTC 
  1141 TGGTGAGAGCCTCGCCTGTGGGGACAGCCTGGGACGCGGGGAGGATGGGGTCGCGAGGGT 
  1201 GTGGCAGGGGGGCCGGTCGAGAGCGGCACTGGAGAAAGGGGAGGGAAGTCTGGGGGGGCA 
  1261 AACAGTTCTGTCTCCTCCTTTCAATCCAGACTTGAATTCGACTAGAGGGGATGCAGATAT 
  1321 GTATGATCTTCCCAAGAAAGAGGACGCTTTACTCTACCAGAGCAAGGGTAAGGCAGGGGT 
  1381 TGGGTGGGCACGCTGGCACCTTCACCCGACTTCGTCAGGGACCCCGCTCACAGGGAGGAC 
  1441 CTGAGACCTCAGTCCCAACCACTCCAGCAGCCTTAGGAGGGAGAAACTGTTACAGGTCCC 
  1501 GAAATGGGATTCAGATTAGGGCCATCAGGCCAGGCGGGGCACACCGATGCCCCCTCTGCT 
  1561 ACCGCTGCCCCCCTTCCCAAGGCTACAATGACGACTACTATGAAGAGAGCTACTTCACCA 
  1621 CCAGGACTTATGGGGAGCCCGAGTCTGCCGGCCCGTCCAGGGCTGTCCGCCAGTCAGTGA 
  1681 CTTCATTCCCAGATGCTGACGCTTTCCATCACCAGGTGAGCTGGCTGGCAGGCGTCCTGT 
  1741 ACTTGGGTACAACCTAGGGGATCGCGGCTGTGTTTGGATAAATCCAGGGGGGCACTGGGT 
  1801 ACAAATGGTGGCTCTTGGGCCTCCGGGGAGACTCTGTGTGACTAGAGCACCCTGGTCTGG 
  1861 GATCTAGGCTCAGACTCTTCCTGAGAGTCCTGGGGGCAAAAGGGGATGCTGGGGCATGAG 
  1921 CACAAGTGGCAAGGCCCCATGGATAAAGGGCTGAACACCCAGAGCCATTCAGGAGGGTGT 
  1981 GGGTTCCTGGCCTCTAACCAAAGGTCAGAGGGGACTGGCTGGGGAAGTTTGGACTGAGGG 
  2041 ACATGACAGGGCCATGGTGGCCCTGCCAGCCAGTCCCCTCGCCCTGACTCTCTTCTGCAG 
  2101 GTGCATGATGACGATCTTTTGTCTTCTTCTGAAGAGGAGTGCAAGGATAGGTGCGTAGTG 
  2161 GGGGAGCCCAGGGACGGGCTGGTTCTGGGTCCAGGCTCCTGGCCCACTTGCTCCCCTCTT 
  2221 TTGCCTCAGGGAACGCCCCATGTACGGCCGGGACAGTGCCTACCAGAGCATCACGCACTA 
  2281 CCGCCCTGTTTCAGCCTCCAGGAGCTCCCTGGACCTGTCCTATTATCCTACTTCCTCCTC 
  2341 CACCTCTTTTATGTCCTCCTCATCATCTTCCTCTTCATGGCTCACCCGCCGTGCCATCCG 
  2401 GCCTGAAAACCGTGCTCCTGGGGCTGGGCTGGGCCAGGATCGCCAGGTCCCGCTCTGGGG 
  2461 CCAGCTGCTGCTTTTCCTGGTCTTTGTGATCGTCCTCTTCTTCATTTACCACTTCATGCA 
  2521 GGCTGAAGAAGGCAACCCCTTCTAGAGGGAGCCATGAGGGTCTGGGCTTCAGAGCTAGGT 
  2581 CTTTGGGGAAGTCCTGGCTGACTGCCTTAGCAGTGGGGGTGGGGGTGGGGGCAGGGGCAG 
  2641 GGGCTTTATGTGTTTTTGCTTGGGGGGCGCTGGGCCTAGCCCAGAGTAGTGCTTGCTCCC 
  2701 CCTGCCTTGTCCCACCAGGGAGGCAGCAGACTCAGGCCCTCCATGGTCCTCTTTGTCATT 
  2761 TTGTTGACATGCATTCCTCCTTTTGTCATCTTGTTGGGGGGAGGGGATTAACCAAAGGCC 
  2821 ACCCTGACTTTGTTTTTGTGGACACACAATAAAAGCCCCGTTTATTTGTAATGCGTTGGC 
  2881 TCTTCCTGGAGGAGAGGGTTGGGCTCCCATGGCAAGGGCCTCTGCGTCTTGGGGCTCCAG 
  2941 GATTGCAATCCGGCTTTGTTGGGTCCGCATTTTTGCTTTAGTCTGGGGATAGGAATCAAA 
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  3001 TGTTACCCAGAGATGTTTGTGTTTTGTTTGGGAGTTTTATTCCCTAACTCATTCCCCAAA 
  3061 GCACGTGTAACTGCTTATACATATAATCGTGGTACAACAAGGTATATACAGAGAACCCAC 
  3121 TTGGAAATTCAGGCAAAGCTGCATGCACGCTACCAGCAGTCTGCGGGTGTTTTAACTGGA 
  3181 AAAAGCTGAAGTCCACCTCGGTGTCCAATGGCATGGGGATGGAAAGAAAATGAGGCGTCT 
  3241 CTGGCACATCATTCTCAGCTCCTGGAACTGCTGCTTGTTTAACATGGGAGAAAAGCTCCA 
  3301 AAGGCTGAAATGCCCCATCATCCCTGGGTGATTGAATTC 
 
Figure 5.3.6: Sequencing of EMD in AG08466 
Sequence derived from PubMed (X86810.1). Gene information sourced from Bione et al., 
(1994; 1995). Forward primers for each exon are highlighted in green, while reverse primers 
are highlighted in red. Overlapping primer sequences are highlighted in dark green. Sequenced 
regions are highlighted in turquoise. A database discrepancy is highlighted in yellow. 
Nucleotides highlighted in dark grey are protein coding bases which have not been successfully 
sequenced. Non-protein coding cDNA sequence is highlighted in light grey. E = exon. 
    1  GCGCGCAGGCCCCGCCCCTCTCACCCCGCCGCACGCCACAGGGTGACGTCTGGGCTCCCA 
   61  GCCGCATCGCCCTGACTCCCGCGCGGGCCCCGCCCCCTGCCGCTAGCCAATCTGTGCGTT 
  121  TGTGACTTTTGGGCCCGCAGCCCCGCCTGCTCCCACAGCGATACCGGTTTGCATTGCCCT 
  181  GACTCCCGCGCGGGCCCCGCCCCCTACGCCGCTAGCCAATCCATGCATTAGTGGCGTCCG 
  241  GGCTCGCAGTACCGCTCGCTCCCACCGCGAGACCTTCTGCTCCGCGCCCGCGCGGGCCCC 
  301  TCCCCCTCCATCGCTAGCCAATCCCCGTTTTGTGACGTATGGGCTCGCGGCCCCGCTCGC 
  361  TCCCACCGCGAGACCTTTTGCTCCGCGCCCGCGCGGGCCCCGCCCCCTCCATCACTAGCC 
  421  AATCCCCGTGCTTGTGACATATGGGCTTGCGGCCCCGCCCGCTCCCATCGCGAGACCGGT 
  481  TCCCACCGCCCTGACTCCCGGGCGGGCCCCGCCCTCTCCGCCGCTAGCCAATCCTCGCGT 
  541  TGATGACGTTTGGGCTCGCGGCCCCAGCCTCCCAGCTCTCAGGGCACGGCCGGTCTGTGC 
  601  CGGCTGCTCCCGCGGTTAGGTCCCGCCCCGCGCAGCGCGCGCAGCCTGCGGAGCCAGCGG 
  661  CCGTGACGCGACAACGATTCGGCTGTGACGCGACAACGATTCGGCTGTGACGCGAGCGCG 
  721  GCCGCTCCCGATGCGCTCGTGCCGCCCCCGCCGTGCTCCTCGGCAGCCGTTGCTCGGCCG 
  781  GTTTTGGTAGGCCCGGGCCGCCGCCAGGCCTCCGCCTGAGCCCGCACCCGCCATGGACAA 
  841  CTACGCAGATCTTTCGGATACCGAGCTGACCACCTTGCTGCGCCGGTACAACATCCCGCA 
  901  CGGGCCTGTAGTAGGTACGCGGCGGCGGGCGGGACCCCTTCCGGGCCCCCTCCTCGTGCT 
  961  CCGCCTCGCGACCTCCCCGCTGCCCTCCCCGCGCGCCTTCCCCGGCCCGCGGCCCTGACC 
  1021 GCCCCGTGTCCGGCCAGGATCAACTCGTAGGCTTTACGAGAAGAAGATCTTCGAGTACGA 
  1081 GACCCAGAGGCGGCGGCTCTCGCCCCCCAGCTCGTCCGCCGCCTCCTCTTATAGCTTCTC 
  1141 TGGTGAGAGCCTCGCCTGTGGGGACAGCCTGGGACGCGGGGAGGATGGGGTCGCGAGGGT 
  1201 GTGGCAGGGGGGCCGGTCGAGAGCGGCACTGGAGAAAGGGGAGGGAAGTCTGGGGGGGCA 
  1261 AACAGTTCTGTCTCCTCCTTTCAATCCAGACTTGAATTCGACTAGAGGGGATGCAGATAT 
  1321 GTATGATCTTCCCAAGAAAGAGGACGCTTTACTCTACCAGAGCAAGGGTAAGGCAGGGGT 
  1381 TGGGTGGGCACGCTGGCACCTTCACCCGACTTCGTCAGGGACCCCGCTCACAGGGAGGAC 
  1441 CTGAGACCTCAGTCCCAACCACTCCAGCAGCCTTAGGAGGGAGAAACTGTTACAGGTCCC 
  1501 GAAATGGGATTCAGATTAGGGCCATCAGGCCAGGCGGGGCACACCGATGCCCCCTCTGCT 
  1561 ACCGCTGCCCCCCTTCCCAAGGCTACAATGACGACTACTATGAAGAGAGCTACTTCACCA 
  1621 CCAGGACTTATGGGGAGCCCGAGTCTGCCGGCCCGTCCAGGGCTGTCCGCCAGTCAGTGA 
  1681 CTTCATTCCCAGATGCTGACGCTTTCCATCACCAGGTGAGCTGGCTGGCAGGCGTCCTGT 
  1741 ACTTGGGTACAACCTAGGGGATCGCGGCTGTGTTTGGATAAATCCAGGGGGGCACTGGGT 
  1801 ACAAATGGTGGCTCTTGGGCCTCCGGGGAGACTCTGTGTGACTAGAGCACCCTGGTCTGG 
  1861 GATCTAGGCTCAGACTCTTCCTGAGAGTCCTGGGGGCAAAAGGGGATGCTGGGGCATGAG 
  1921 CACAAGTGGCAAGGCCCCATGGATAAAGGGCTGAACACCCAGAGCCATTCAGGAGGGTGT 
  1981 GGGTTCCTGGCCTCTAACCAAAGGTCAGAGGGGACTGGCTGGGGAAGTTTGGACTGAGGG 
  2041 ACATGACAGGGCCATGGTGGCCCTGCCAGCCAGTCCCCTCGCCCTGACTCTCTTCTGCAG 
  2101 GTGCATGATGACGATCTTTTGTCTTCTTCTGAAGAGGAGTGCAAGGATAGGTGCGTAGTG 
  2161 GGGGAGCCCAGGGACGGGCTGGTTCTGGGTCCAGGCTCCTGGCCCACTTGCTCCCCTCTT 
  2221 TTGCCTCAGGGAACGCCCCATGTACGGCCGGGACAGTGCCTACCAGAGCATCACGCACTA 
  2281 CCGCCCTGTTTCAGCCTCCAGGAGCTCCCTGGACCTGTCCTATTATCCTACTTCCTCCTC 
  2341 CACCTCTTTTATGTCCTCCTCATCATCTTCCTCTTCATGGCTCACCCGCCGTGCCATCCG 
  2401 GCCTGAAAACCGTGCTCCTGGGGCTGGGCTGGGCCAGGATCGCCAGGTCCCGCTCTGGGG 
  2461 CCAGCTGCTGCTTTTCCTGGTCTTTGTGATCGTCCTCTTCTTCATTTACCACTTCATGCA 
  2521 GGCTGAAGAAGGCAACCCCTTCTAGAGGGAGCCATGAGGGTCTGGGCTTCAGAGCTAGGT 
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  2581 CTTTGGGGAAGTCCTGGCTGACTGCCTTAGCAGTGGGGGTGGGGGTGGGGGCAGGGGCAG 
  2641 GGGCTTTATGTGTTTTTGCTTGGGGGGCGCTGGGCCTAGCCCAGAGTAGTGCTTGCTCCC 
  2701 CCTGCCTTGTCCCACCAGGGAGGCAGCAGACTCAGGCCCTCCATGGTCCTCTTTGTCATT 
  2761 TTGTTGACATGCATTCCTCCTTTTGTCATCTTGTTGGGGGGAGGGGATTAACCAAAGGCC 
  2821 ACCCTGACTTTGTTTTTGTGGACACACAATAAAAGCCCCGTTTATTTGTAATGCGTTGGC 
  2881 TCTTCCTGGAGGAGAGGGTTGGGCTCCCATGGCAAGGGCCTCTGCGTCTTGGGGCTCCAG 
  2941 GATTGCAATCCGGCTTTGTTGGGTCCGCATTTTTGCTTTAGTCTGGGGATAGGAATCAAA 
  3001 TGTTACCCAGAGATGTTTGTGTTTTGTTTGGGAGTTTTATTCCCTAACTCATTCCCCAAA 
  3061 GCACGTGTAACTGCTTATACATATAATCGTGGTACAACAAGGTATATACAGAGAACCCAC 
  3121 TTGGAAATTCAGGCAAAGCTGCATGCACGCTACCAGCAGTCTGCGGGTGTTTTAACTGGA 
  3181 AAAAGCTGAAGTCCACCTCGGTGTCCAATGGCATGGGGATGGAAAGAAAATGAGGCGTCT 
  3241 CTGGCACATCATTCTCAGCTCCTGGAACTGCTGCTTGTTTAACATGGGAGAAAAGCTCCA 
  3301 AAGGCTGAAATGCCCCATCATCCCTGGGTGATTGAATTC 
 
Figure 5.3.7: Sequencing of EMD in AG11572 
Sequence derived from PubMed (X86810.1). Gene information sourced from Bione et al., 
(1994; 1995). Forward primers for each exon are highlighted in green, while reverse primers 
are highlighted in red. Overlapping primer sequences are highlighted in dark green. Sequenced 
regions are highlighted in turquoise. A database discrepancy is highlighted in yellow. 
Nucleotides highlighted in dark grey are protein coding bases which have not been successfully 
sequenced. Non-protein coding cDNA sequence is highlighted in light grey. E = exon. 
5.3.4.3 LAP2 
 
Part of exon 4 LAP2 has been successfully sequenced in AG08466 (see figure 5.3.8); so 
far, no mutations have been observed. The whole of exon 4 LAP2 (including the 5’ 
intron and exon boundary) has been sequenced in AG11572 (see figures 5.3.9 and 
5.3.10); again, no mutations have been identified.  Full details of sequencing results 
can be found in Appendix (AG08466: LAP2 exon 4 and AG11572: LAP2 exon 4). 
 
1    GTTCGTAGTTCGGCTCTGGGGTCTTTTGTGTCCGGGTCTGGCTTGGCTTTGTGTCCGCGA 
61   GTTTTTGTTCCGCTCCGCAGCGCTCTTCCCGGGCAGGAGCCGTGAGGCTCGGAGGCGGCA 
121  GCGCGGTCCCCGGCCAGGAGCAAGCGCGCCGGCGTGAGCGGCGGCGGCAAAGGCTGTGGG 
181  GAGGGGGCTTCGCAGATCCCCGAGATGCCGGAGTTCCTGGAAGACCCCTCGGTCCTGACA 
241  AAAGACAAGTTGAAGAGTGAGTTGGTCGCCAACAATGTGACGCTGCCGGCCGGGGAGCAG 
301  CGCAAAGACGTGTACGTCCAGCTCTACCTGCAGCACCTCACGGCTCGCAACCGGCCGCCG 
361  CTCCCCGCCGGCACCAACAGCAAGGGGCCCCCGGACTTCTCCAGTGACGAAGAGCGCGAG 
421  CCCACCCCGGTCCTCGGCTCTGGGGCCGCCGCCGCGGGCCGGAGCCGAGCAGCCGTCGGC 
481  AGGAAAGCCACAAAAAAAACTGATAAACCCAGACAAGAAGATAAAGATGATCTAGATGTA 
541  ACAGAGCTCACTAATGAAGATCTTTTGGATCAGCTTGTGAAATACGGAGTGAATCCTGGT 
601  CCTATTGTGGGAACAACCAGGAAGCTATATGAGAAAAAGCTTTTGAAACTGAGGGAACAA 
661  GGAACAGAATCAAGATCTTCTACTCCTCTGCCAACAATTTCTTCTTCAGCAGAAAATACA 
721  AGGCAGAATGGAAGTAATGATTCTGACAGATACAGTGACAATGAAGAAGGAAAGAAGAAA 
781  GAACACAAGAAAGTGAAGTCCACTAGGGATATTGTTCCTTTTTCTGAACTTGGAACTACT 
841  CCCTCTGGTGGTGGATTTTTTCAGGGTATTTCTTTTCCTGAAATCTCCACCCGTCCTCCT 
901  TTGGGCAGTACCGAACTACAGGCAGCTAAGAAAGTACATACTTCTAAGGGAGACCTACCT 
961  AGGGAGCCTCTTGTTGCCACAAACTTGCCTGGCAGGGGACAGTTGCAGAAGTTAGCCTCT 
1021 GAAAGGAATTTGTTTATTTCATGCAAGTCTAGCCATGATAGGTGTTTAGAGAAAAGTTCT 
1081 TCGTCATCTTCTCAGCCTGAACACAGTGCCATGTTGGTCTCTACTGCAGCTTCTCCTTCA 
1141 CTGATTAAAGAAACCACCACTGGTTACTATAAAGACATAGTAGAAAATATTTGCGGTAGA 
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1201 GAGAAAAGTGGAATTCAACCATTATGTCCTGAGAGGTCCCATATTTCAGATCAATCGCCT 
1261 CTCTCCAGTAAAAGGAAAGCACTAGAAGAGTCTGAGAGCTCACAACTAATTTCTCCGCCA 
1321 CTTGCCCAGGCAATCAGAGATTATGTCAATTCTCTGTTGGTCCAGGGTGGGGTAGGTAGT 
1381 TTGCCTGGAACTTCTAACTCTATGCCCCCACTGGATGTAGAAAACATACAGAAGAGAATT 
1441 GATCAGTCTAAGTTTCAAGAAACTGAATTCCTGTCTCCTCCAAGAAAAGTCCCTAGACTG 
1501 AGTGAGAAGTCAGTGGAGGAAAGGGATTCAGGTTCCTTTGTGGCATTTCAGAACATACCT 
1561 GGATCCGAACTGATGTCTTCTTTTGCCAAAACTGTTGTCTCTCATTCACTCACTACCTTA 
1621 GGTCTAGAAGTGGCTAAGCAATCACAGCATGATAAAATAGATGCCTCAGAACTATCTTTT 
1681 CCCTTCCATGAATCTATTTTAAAAGTAATTGAAGAAGAATGGCAGCAAGTTGACAGGCAG 
1741 CTGCCTTCACTGGCATGCAAATATCCAGTTTCTTCCAGGGAGGCAACACAGATATTATCA 
1801 GTTCCAAAAGTAGATGATGAAATCCTAGGGTTTATTTCTGAAGCCACTCCACTAGGAGGT 
1861 ATTCAAGCAGCCTCCACTGAGTCTTGCAATCAGCAGTTGGACTTAGCACTCTGTAGAGCA 
1921 TATGAAGCTGCAGCATCAGCATTGCAGATTGCAACTCACACTGCCTTTGTAGCTAAGGCT 
1981 ATGCAGGCAGACATTAGTCAAGCTGCACAGATTCTTAGCTCAGATCCTAGTCGTACCCAC 
2041 CAAGCGCTTGGGATTCTGAGCAAAACATATGATGCAGCCTCATATATTTGTGAAGCTGCA 
2101 TTTGATGAAGTGAAGATGGCTGCCCATACCATGGGAAATGCCACTGTAGGTCGTCGATAC 
2161 CTCTGGCTGAAGGATTGCAAAATTAATTTAGCTTCTAAGAATAAGCTGGCTTCCACTCCC 
2221 TTTAAAGGTGGAACATTATTTGGAGGAGAAGTATGCAAAGTAATTAAAAAGCGTGGAAAT 
2281 AAACACTAGTAAAATTAAGGACAAAAAGACATCTATCTTATCTTTCAGGTACTTTATGCC 
2341 AACATTTTCTTTTCTGTTAAGGTTGTTTTAGTTTCCAGATAGGGCTAATTACAAAATGTT 
2401 AAGCTTCTACCCATCAAATTACAGTATAAAAGTAATTGCCTGTGTAGAACTACTTGTCTT 
2461 TTCTAAAGATTTGCGTAGATAGGAAGCCTG 
 
Figure 5.3.8: Sequencing of LAP2 exon 4 in AG08466 
 
LAP2 sequence derived from PubMed (NM_003276; Homo sapiens thymopoietin (TMPO), 
transcript variant 1, mRNA). Nucleotides highlighted in black code for exons 1–3. Successfully 
sequenced nucleotides are highlighted in turquoise. Nucleotides highlighted in dark grey are 
protein coding bases which have not been successfully sequenced. ATG: start of exon 1; GGA: 
start of exon 4; TAG: end of exon 4. 3 different sets of primers used to amplify the exon 4 of 
LAP2 have been colour coded:   
 
LAP2α4.1F/R:TCTTGTTGCCACAAACTTGC/GGCAGCCATCTTCACTTCAT 
LAP2α4.2F/RCCAGGGTGGGGTAGGTAGTT/AAATGCCACAAAGGAACCTG 
LAP2α4.3F/R:ACCTGGATCCGAACTGATGT/CAGGCTTCCTATCTACGCAAA  
 
1    GTTCGTAGTTCGGCTCTGGGGTCTTTTGTGTCCGGGTCTGGCTTGGCTTTGTGTCCGCGA 
61   GTTTTTGTTCCGCTCCGCAGCGCTCTTCCCGGGCAGGAGCCGTGAGGCTCGGAGGCGGCA 
121  GCGCGGTCCCCGGCCAGGAGCAAGCGCGCCGGCGTGAGCGGCGGCGGCAAAGGCTGTGGG 
181  GAGGGGGCTTCGCAGATCCCCGAGATGCCGGAGTTCCTGGAAGACCCCTCGGTCCTGACA 
241  AAAGACAAGTTGAAGAGTGAGTTGGTCGCCAACAATGTGACGCTGCCGGCCGGGGAGCAG 
301  CGCAAAGACGTGTACGTCCAGCTCTACCTGCAGCACCTCACGGCTCGCAACCGGCCGCCG 
361  CTCCCCGCCGGCACCAACAGCAAGGGGCCCCCGGACTTCTCCAGTGACGAAGAGCGCGAG 
421  CCCACCCCGGTCCTCGGCTCTGGGGCCGCCGCCGCGGGCCGGAGCCGAGCAGCCGTCGGC 
481  AGGAAAGCCACAAAAAAAACTGATAAACCCAGACAAGAAGATAAAGATGATCTAGATGTA 
541  ACAGAGCTCACTAATGAAGATCTTTTGGATCAGCTTGTGAAATACGGAGTGAATCCTGGT 
601  CCTATTGTGGGAACAACCAGGAAGCTATATGAGAAAAAGCTTTTGAAACTGAGGGAACAA 
661  GGAACAGAATCAAGATCTTCTACTCCTCTGCCAACAATTTCTTCTTCAGCAGAAAATACA 
721  AGGCAGAATGGAAGTAATGATTCTGACAGATACAGTGACAATGAAGAAGGAAAGAAGAAA 
781  GAACACAAGAAAGTGAAGTCCACTAGGGATATTGTTCCTTTTTCTGAACTTGGAACTACT 
841  CCCTCTGGTGGTGGATTTTTTCAGGGTATTTCTTTTCCTGAAATCTCCACCCGTCCTCCT 
901  TTGGGCAGTACCGAACTACAGGCAGCTAAGAAAGTACATACTTCTAAGGGAGACCTACCT 
961  AGGGAGCCTCTTGTTGCCACAAACTTGCCTGGCAGGGGACAGTTGCAGAAGTTAGCCTCT 
1021 GAAAGGAATTTGTTTATTTCATGCAAGTCTAGCCATGATAGGTGTTTAGAGAAAAGTTCT 
1081 TCGTCATCTTCTCAGCCTGAACACAGTGCCATGTTGGTCTCTACTGCAGCTTCTCCTTCA 
1141 CTGATTAAAGAAACCACCACTGGTTACTATAAAGACATAGTAGAAAATATTTGCGGTAGA 
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1201 GAGAAAAGTGGAATTCAACCATTATGTCCTGAGAGGTCCCATATTTCAGATCAATCGCCT 
1261 CTCTCCAGTAAAAGGAAAGCACTAGAAGAGTCTGAGAGCTCACAACTAATTTCTCCGCCA 
1321 CTTGCCCAGGCAATCAGAGATTATGTCAATTCTCTGTTGGTCCAGGGTGGGGTAGGTAGT 
1381 TTGCCTGGAACTTCTAACTCTATGCCCCCACTGGATGTAGAAAACATACAGAAGAGAATT 
1441 GATCAGTCTAAGTTTCAAGAAACTGAATTCCTGTCTCCTCCAAGAAAAGTCCCTAGACTG 
1501 AGTGAGAAGTCAGTGGAGGAAAGGGATTCAGGTTCCTTTGTGGCATTTCAGAACATACCT 
1561 GGATCCGAACTGATGTCTTCTTTTGCCAAAACTGTTGTCTCTCATTCACTCACTACCTTA 
1621 GGTCTAGAAGTGGCTAAGCAATCACAGCATGATAAAATAGATGCCTCAGAACTATCTTTT 
1681 CCCTTCCATGAATCTATTTTAAAAGTAATTGAAGAAGAATGGCAGCAAGTTGACAGGCAG 
1741 CTGCCTTCACTGGCATGCAAATATCCAGTTTCTTCCAGGGAGGCAACACAGATATTATCA 
1801 GTTCCAAAAGTAGATGATGAAATCCTAGGGTTTATTTCTGAAGCCACTCCACTAGGAGGT 
1861 ATTCAAGCAGCCTCCACTGAGTCTTGCAATCAGCAGTTGGACTTAGCACTCTGTAGAGCA 
1921 TATGAAGCTGCAGCATCAGCATTGCAGATTGCAACTCACACTGCCTTTGTAGCTAAGGCT 
1981 ATGCAGGCAGACATTAGTCAAGCTGCACAGATTCTTAGCTCAGATCCTAGTCGTACCCAC 
2041 CAAGCGCTTGGGATTCTGAGCAAAACATATGATGCAGCCTCATATATTTGTGAAGCTGCA 
2101 TTTGATGAAGTGAAGATGGCTGCCCATACCATGGGAAATGCCACTGTAGGTCGTCGATAC 
2161 CTCTGGCTGAAGGATTGCAAAATTAATTTAGCTTCTAAGAATAAGCTGGCTTCCACTCCC 
2221 TTTAAAGGTGGAACATTATTTGGAGGAGAAGTATGCAAAGTAATTAAAAAGCGTGGAAAT 
2281 AAACACTAGTAAAATTAAGGACAAAAAGACATCTATCTTATCTTTCAGGTACTTTATGCC 
2341 AACATTTTCTTTTCTGTTAAGGTTGTTTTAGTTTCCAGATAGGGCTAATTACAAAATGTT 
2401 AAGCTTCTACCCATCAAATTACAGTATAAAAGTAATTGCCTGTGTAGAACTACTTGTCTT 
2461 TTCTAAAGATTTGCGTAGATAGGAAGCCTG 
 
Figure 5.3.9: Sequencing of LAP2 exon 4 in AG11572 
 
LAP2 sequence derived from PubMed (NM_003276; Homo sapiens thymopoietin (TMPO), 
transcript variant 1, mRNA). Nucleotides highlighted in black code for exons 1-3. Successfully 
sequenced nucleotides are highlighted in turquoise; primers used to amplify and sequence the 
5’ intron/exon boundary can be seen in figure 5.3.10.  ATG: start of exon 1; GGA: start of exon 
4; TAG: end of exon 4. 3 different sets of primers used to amplify the exon 4 of LAP2 have been 
colour coded:   
LAP2α4.1F/R:TCTTGTTGCCACAAACTTGC/GGCAGCCATCTTCACTTCAT 
LAP2α4.2F/RCCAGGGTGGGGTAGGTAGTT/AAATGCCACAAAGGAACCTG 
LAP2α4.3F/R:ACCTGGATCCGAACTGATGT/CAGGCTTCCTATCTACGCAAA  
 
20761 TTTTGGAGAATTGTAAAAACATAAGTAAAGCAGGAAACAGAAAACAACTTAGAGACTAAT 
20821 ATGTGATCTAGAAAGCGTTAAATTGTTTGTACCAGGCTTCCTATCTACGCAAATCTTTAG 
20881 AAAAGACAAGTAGTTCTACACAGGCAATTACTTTTATACTGTAATTTGATGGGTAGAAGC 
20941 TTAACATTTTGTAATTAGCCCTATCTGGAAACTAAAACAACCTTAACAGAAAAGAAAATG 
21001 TTGGCATAAAGTACCTGAAAGATAAGATAGATGTCTTTTTGTCCTTAATTTTACTAGTGT 
21061 TTATTTCCACGCTTTTTAATTACTTTGCATACTTCTCCTCCAAATAATGTTCCACCTTTA 
21121 AAGGGAGTGGAAGCCAGCTTATTCTTAGAAGCTAAATTAATTTTGCAATCCTTCAGCCAG 
21181 AGGTATCGACGACCTACAGTGGCATTTCCCATGGTATGGGCAGCCATCTTCACTTCATCA 
21241 AATGCAGCTTCACAAATATATGAGGCTGCATCATATGTTTTGCTCAGAATCCCAAGCGCT 
21301 TGGTGGGTACGACTAGGATCTGAGCTAAGAATCTGTGCAGCTTGACTAATGTCTGCCTGC 
21361 ATAGCCTTAGCTACAAAGGCAGTGTGAGTTGCAATCTGCAATGCTGATGCTGCAGCTTCA 
21421 TATGCTCTACAGAGTGCTAAGTCCAACTGCTGATTGCAAGACTCAGTGGAGGCTGCTTGA 
21481 ATACCTCCTAGTGGAGTGGCTTCAGAAATAAACCCTAGGATTTCATCATCTACTTTTGGA 
21541 ACTGATAATATCTGTGTTGCCTCCCTGGAAGAAACTGGATATTTGCATGCCAGTGAAGGC 
21601 AGCTGCCTGTCAACTTGCTGCCATTCTTCTTCAATTACTTTTAAAATAGATTCATGGAAG 
21661 GGAAAAGATAGTTCTGAGGCATCTATTTTATCATGCTGTGATTGCTTAGCCACTTCTAGA 
21721 CCTAAGGTAGTGAGTGAATGAGAGACAACAGTTTTGGCAAAAGAAGACATCAGTTCGGAT 
21781 CCAGGTATGTTCTGAAATGCCACAAAGGAACCTGAATCCCTTTCCTCCACTGACTTCTCA 
21841 CTCAGTCTAGGGACTTTTCTTGGAGGAGACAGGAATTCAGTTTCTTGAAACTTAGACTGA 
21901 TCAATTCTCTTCTGTATGTTTTCTACATCCAGTGGGGGCATAGAGTTAGAAGTTCCAGGC 
21961 AAACTACCTACCCCACCCTGGACCAACAGAGAATTGACATAATCTCTGATTGCCTGGGCA 
22021 AGTGGCGGAGAAATTAGTTGTGAGCTCTCAGACTCTTCTAGTGCTTTCCTTTTACTGGAG 
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22081 AGAGGCGATTGATCTGAAATATGGGACCTCTCAGGACATAATGGTTGAATTCCACTTTTC 
22141 TCTCTACCGCAAATATTTTCTACTATGTCTTTATAGTAACCAGTGGTGGTTTCTTTAATC 
22201 AGTGAAGGAGAAGCTGCAGTAGAGACCAACATGGCACTGTGTTCAGGCTGAGAAGATGAC 
22261 GAAGAACTTTTCTCTAAACACCTATCATGGCTAGACTTGCATGAAATAAACAAATTCCTT 
22321 TCAGAGGCTAACTTCTGCAACTGTCCCCTGCCAGGCAAGTTTGTGGCAACAAGAGGCTCC 
22381 CTAGGTAGGTCTCCCTTAGAAGTATGTACTTTCTTAGCTGCCTGTAGTTCGGTACTGCCC 
22441 AAAGGAGGACGGGTGGAGATTTCAGGAAAAGAAATACCCTGAAAAAATCCACCACCAGAG 
22501 GGAGTAGTTCCAAGTTCAGAAAAAGGAACAATATCCCTAGTGGACTTCACTTTCTTGTGT 
22561 TCTTTCTTCTTTCCTGTAGAGGCAAAAGAGGCAGGAAGTTTAAGCATTACCTGTGTTTGA 
22621 GCTGATTTTATTCTTTGCCTCTTTGCTAAAAATAGTGCTGTCAAAGGAAAAGACTATAAT 
22681 TTCATATTCTGAACTAATCTGCCAGATTTGCCCTGGTAGACAAAGCTTATTGAGATATAA 
22741 ACAATCTGGATCAAAATAAATAATCACAAGTCATATTAATTAAAAGTTTACAAAAATCAA 
 
Figure 5.3.10 Sequencing of LAP2 in AG11572 
Sequence derived from PubMed (selected region of AC013418; Homo sapiens 12 BAC RP11-
181C3 (Roswell Park Cancer Institute Human BAC Library) complete sequence). Note that the 
sequence is in reverse orientation to the LAP2 exon 4 cDNA (i.e. exons are coded in descending 
order). Successfully sequenced nucleotides are highlighted in turquoise. Gene information 
sourced from Harris et al., (1994; 1995). 5’ exon/ intron boundary is denoted by the black 
arrow. Primer pairs used to amplify exon 4 plus the 5’intron/ exon boundary have been colour 
coded:                                                                           
LAP2αintron/exon4F/R; GCTTTGTCTACCAGGGCAAA/ CCAGTGGGGGCATAGAGTTA 
LAP2α4.1F/R:TCTTGTTGCCACAAACTTGC/GGCAGCCATCTTCACTTCAT 
LAP2α4.2F/RCCAGGGTGGGGTAGGTAGTT/AAATGCCACAAAGGAACCTG 
LAP2α4.3F/R:ACCTGGATCCGAACTGATGT/CAGGCTTCCTATCTACGCAAA 
 
5.3.4.4 Western Blotting 
 
In order to determine the presence and load of emerin and LAP2α proteins in the two 
atypical HGPS cell lines, Western blotting was performed. The size and level of lamin 
A/C were also examined, with the aim of confirming that lamin A/C production was 
normal.  Whole cell lysates were sampled from a control HDF cell line (2DD) plus, the 
two aforementioned HGPS cultures. The loading volumes of each lysate were adjusted 
according to the approximate cell numbers. The Western blots results can be seen in 
figure 5.3.11. For all three proteins, respective bands of the correct size were observed 
with minimal or undetectable nonspecific staining. The protein loads for each protein 
were similar for all cell lines, with the exception of LAP2α in AG11572; in this case, the 
band was very faint, albeit, visible (figure 5.3.11). The results of these Western blot 
experiments appear to further reduce the possibility that EMD is mutated in either or 
both atypical HGPS cell lines. The normal size and protein levels of lamin A/C also 
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confirm the previous observation that LMNA is wild-type in such cells. Lastly, these 
blots indicate that LAP2α is the correct size in both AG08466 and AG11572, suggesting 
that if mutations were present in exon of LAP2, they do not result in the production of 
a truncated protein.  The normal level of LAP2α in AG08466 indicates that any 
mutation present would affect protein interactions. The implications of the decreased 
LAP2α protein load observed are possibly suggestive of a mutation. However, this is 
less likely in view of the sequencing results presented in this chapter.  These findings 
are duly considered and discussed in the next section of this chapter (5.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3.11 Western Blot Analysis of proteins extracted from normal and HGPS fibroblasts 
 
Anti-lamin A/C, anti-emerin and anti-LAP2α antibodies were used to identify lamin A/C, emerin 
and LAP2α in control (2DD) and atypical HGPS (AG08466 and AG11572) HDF cell lines. 
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5.3.4.5 Accumulated population doublings (APD) 
 
The rates of cell growth (at the time of protein preparation), were analyzed by 
determining the accumulated population doublings; this was calculated using the 
formula: (log H−log S)/log2.0 where log H is the logarithm of the number of cells 
harvested and log S is the logarithm of the number of cells seeded). APD values were 
plotted for all 3 cell lines (figure 5.3.12). As the graph depicts, the rates of population 
doubling were similar for 2DD, AG08466 and AG11572.    
 
 
 
 
Figure 5.3.12 Comparing APD values for control and atypical HGPS cells at the time of protein 
preparation 
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5.4 DISCUSSION 
5.4.1 ED5364 
 
DNA sequencing of EMD in the X-EDMD carrier revealed the presence of a 
heterozygous point mutation (c.315T>G) in exon 4. At the amino acid level, this 
mutation exchanges tyrosine for a premature stop codon at residue 105 (p.Tyr105X). 
This mutation has previously been reported in 4 individuals and results in the loss of 
the Ddel restriction site (Muntoni et al., 1998). The EMD mutation database (last 
updated 2007), which can be found at www.umd.be/EMD/ (The EMD mutations 
database, 2007), is a great source of information regarding reported EMD mutations. It 
is possible to determine mutation frequency for all exons. As of 2007, the details of 
203 X-EDMD cases (splice mutations excluded) had been reported. Of these, 37 
mutations (excluding intronic mutations) were detected in exon 4. 32.5% of all 
mutations in exon 4 were nonsense mutations. Exon 4 encodes 45 codons and out of 
these, 13 potential stop codons exist; one of which is tyrosine 105. Of the 20 reported 
mutations affecting residue 105 of exon 4, the majority (16/20; 80%) are deletions 
(314_315delAT); nonsense mutations at this amino acid account for only 20% (4/20). 
Mutations affecting residue 105 account for approximately 54% of all exon 4 
mutations. 
 
Importantly, the EMD mutation presented in this study leads to the absence of emerin 
in affected cells. Indeed, the majority of X-EDMD mutations lead to the total absence 
of emerin (Yates et al., 1999). Since the individual is an X-EDMD carrier, the remaining 
population produce functional emerin; this is due to the random nature of X-
inactivation. Why does the presence of this stop codon inhibit the detection of emerin 
in affected cells? Muntoni et al. (1998) hypothesised that it produces an unstable 
mutant protein. Post-translationally, emerin is found to enter the ER before diffusing 
to the nuclear envelope; importantly, the protein’s C-terminal transmembrane domain 
is required for such events (Soullam and Worman, 1995; Cartegni et al., 1997; Ellis et 
al., 1998). It is suggested that the loss of this domain prevents the correct targeting of 
the protein to the ER and as a result, the protein is degraded rapidly (Yates et al., 
1999).  
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While X-EDMD is largely characterised by lack of emerin expression, the disease can 
also be caused by missense mutations and in-frame shifts. Yates et al. (1999) reported 
2 in-frame EMD deletions, both of which resulted in reduced emerin levels (as 
compared to wildtype). It is suggested that these mutations lead to impaired NE 
targeting. This paper also documented a novel missense mutation; cells harbouring 
this mutation produced emerin at normal amounts. Interestingly, genotype-phenotype 
analysis revealed that the in-frame deletions produced a similar phenotype to emerin 
null X-EDMD cells, while the missense mutation produced a milder phenotype.   
 
5.4.2 Atypical HGPS 
5.4.2.1 EMD 
 
So far, the sequencing of both EMD and LAP2 (exon 4) in the atypical HGPS patients 
has failed to reveal any mutations. The Western blotting experiments performed 
demonstrate that if the aforementioned atypical HGPS cell lines do harbour mutations 
in EMD, they do not lead to the loss of emerin expression. The results also indicate 
that a splicing mutation is unlikely since the size of the protein is very similar to that 
seen in the control. Therefore, if an emerin mutation were present in either of the cell 
lines, it is most probable that it would interfere with the protein’s structure or capacity 
to bind to protein partners. However, the phenotypes displayed by AG08466 and 
AG11572 patients at the point of diagnosis are not suggestive of EMD mutations. 
While patients with disease-causing EMD mutations generally present with early 
contractures and muscle wasting and weakness (Emery, 2000), neither AG08466 nor 
AG11572 exhibited evidence of muscular problems (ccr.coriell.org). 
 
Since both cell lines were derived from female patients, it is unlikely that mutations in 
EMD are the sole cause of disease in these two patients. Why?  Due to X-inactivation, a 
heterozygous EMD mutation in a female would lead to a mosaic pattern of expression; 
one population of cells would produce functional emerin while the other would 
produce a mutant variant of the protein. Thus, the female would be a carrier of the 
disease rather than a sufferer of the disease. The other scenario is that both copies of 
chromosome X harbour mutations in EMD. This is highly improbable since it would 
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require that the mother be a carrier of the disease and the father a sufferer. However, 
it is possible that 2 independent mutations, one within EMD and the other in another 
gene, exist in the patient cells. Indeed, double mutations in LMNA and EMD have been 
reported in patients (Ben Yaou et al., 2007). 
 
5.4.2.2 LAP2 
 
Sequencing of LAP2 exon 4 (specific to the LAP2α isoform) in AG08466 and AG11572 
has not yet revealed any mutations. Western blot analysis demonstrated that LAP2α 
protein levels were barely detectable in AG11572, while in AG08466, expression was 
on a par with control. There are two possible explanations for this; either (1) the gene 
encoding LAP2α is mutated, causing low-level expression or (2) the culture, from which 
the AG11572 sample was derived, was senescent. Indeed, a mutation in exon 4 of LAP2 
has been demonstrated to reduce LAP2α levels in human DCM (Taylor et al., 2005). 
While the symptoms displayed by these 2 DCM patients primarily affected the heart, it 
is unknown whether the patient from whom AG11572 was derived displayed cardiac 
involvement. Since reports of disease causing LAP2 mutations are rare, it is difficult to 
hypothesise whether a spectrum of clinical phenotypes can be caused by different 
LAP2 exon 4 mutations.      
 
The other possible cause for reduced LAP2α expression in AG11572 is if the 
proliferative status of the culture was different to that of AG08466 and control. 
Indeed, there is a correlation between LAP2α expression and cell cycle status 
(Markiewicz et al., 2002; Pekovic et al., 2007). On entry into serum-starvation induced 
quiescence, LAP2α is down-regulated; expression levels begin to increase after re-
stimulation (Markiewicz et al., 2002; Pekovic et al., 2007). Conversely, lamin A is up-
regulated in quiescence (Pugh et al., 1997). Indeed, siRNA knock-down of LAP2α in 
HDFs leads cell cycle arrest (Pekovic et al., 2007). Thus, Pekovic et al. (2007) 
hypothesize that the loss of LAP2α may play a role in driving cellular senescence. Taken 
together, these findings suggest that LAP2α expression may be down-regulated in 
senescence and as a result, cultures which are composed of mainly senescent cells are 
likely to contain lower levels of LAP2α protein than largely proliferating cultures. 
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Unfortunately pKi67 counts were not taken at the time of protein preparation. 
However, APD graphs demonstrated that AG11572 was growing at a rate similar to 
control and AG08466 cell lines in culture. This suggests that the proliferative capacity 
of the cultures at the time of protein preparation were comparable and thus, none of 
cultures were quiescent or senescent.  
 
The observation that AG11572 fibroblasts display a period of hyper-proliferation 
(Bridger and Kill, 2004) questions the likelihood that mutant LAP2α, at low-levels, is a 
direct cause of disease in these cells. The DCM causing mutation in LAP2 disrupts the 
formation of LAP2α-lamin A complexes (Taylor et al., 2005); such complexes are 
reported to maintain a cell’s proliferative state (Pekovic et al., 2007). Therefore, the 
loss of LAP2α function is likely to induce cell cycle arrest (Pekovic et al., 2007) rather 
than drive the high rates of proliferation observed in AG11572 (Bridger and Kill, 2004).  
 
Although this study has failed to reveal a mutation in exon 4 of LAP2 in AG11572, the 
fact that LAP2α protein levels are reduced suggests that the sequencing results 
presented require further verification. Another possibility is that the disease-causing 
mutation resides in one of the other exons which encode LAP2α, exons 1–3. While 
there are no documented cases of human disease resulting from mutations affecting 
these exons, the possibility cannot be ruled out. If this were the case, the other LAP2 
isoforms, LAP2β and LAP2γ, would be affected since they are also encoded by these 
exons (Harris et al., 1995). Since I have not investigated either LAP2β or LAP2γ, I 
cannot state whether levels of these proteins are normal. In light of this, it may be 
pertinent to investigate these proteins before further sequencing of other genes.   
 
5.4.2.3 Additional candidate genes 
 
If neither EMD nor LAP2 mutations are responsible for the HGPS symptoms in 
AG08466 and AG11572 patients, what are the other candidate genes? Interestingly, 
when analyzing the karyotypic profile of four HGPS cell lines, Corso et al. (2005) 
repeatedly observed the amplification of 11q13 ~ q23 in the culture, AG08466. This is 
potentially interesting since it is home to farnesylated protein-converting enzyme 2 
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(FACE-2), a gene which encodes an enzyme involved in the proteolytic maturation of 
farnesylated proteins (Otto et al., 1999; Freije et al., 1999). This is important because a 
similar protein, FACE-1 (otherwise known as ZMPSTE24), is shown to be mutated in 
laminopathy-based disease (Navarro et al., 2004; Moulson et al., 2005; Navarro et al., 
2005). Although, FACE-2 has not yet been demonstrated to be involved in the 
processing of lamin proteins, it is certainly worthy of investigation.  
 
Both AG08466 and AG11572 were sourced from the Coriell Cell Repository; it was from 
here that any details regarding clinical presentation were derived.  Since the start of 
this project, the clinical features of patient AG08466 have been updated to include 
that ‘Marfan features have also developed’. This is intriguing since Marfan syndrome is 
a connective tissue disease caused by mutations in the FBN1 gene (Dietz et al., 1991). 
FBN1 encodes profibrillin-1, which is then processed to form fibrillin, an extracellular 
glycoprotein (Frydman, 2008). There are a range of symptoms displayed by Marfan 
syndrome patients (Frydman, 2008); interestingly, some of which overlap with the 
clinical features reported for both AG08466 and AG11572. Although it is likely that 
symptoms observed in Marfan syndrome overlap with a number of other disorders, it 
would be pertinent to investigate fibrillin in both these atypical HGPS cell lines.  
 
Lastly, it must be considered that the protein or proteins affected in these atypical 
HGPS patients have yet to be characterized. Indeed, Schirmer et al. (2003) report that 
in addition to the 13 known NE proteins, 67 uncharacterised others exist. This is an 
exciting but daunting prospect for a mutation search such as this present one; a 
number of these 67 proteins could potentially be the cause of disease in AG08466 and 
AG11572. In fact, there are hundreds of instances where the genetic cause of a 
dystrophy has not yet been identified in patients. Of the 67 proteins discovered, the 
corresponding genes of 23 have been mapped to chromosome regions previously 
linked to 14 human dystrophies (Schirmer et al., 2003).    
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5.4.3 Adopting another approach to identify disease-causing mutations 
 
The attempt to determine the specific EMD mutation in ED5364 has been successful. 
However, the search for the disease-causing mutations in the atypical HGPS cell lines 
proved much more difficult and high-risk. The ED5364 search was considerably easier 
since previous work demonstrated that the mutation affected the EMD gene; while, 
with the atypical HGPS patients, only a small number of genes could be eliminated 
with certainty. In hindsight, perhaps it would have been more efficient to perform 
heteroduplex analysis of the PCR products before sequencing the exons. In 
heteroduplex analysis, the region of interest is subjected to denaturation and 
annealing steps, post-PCR; if a mutation is present in one of the alleles, heteroduplexes 
will be formed in solution. Heteroduplexes consist of a wild-type DNA strand and a 
mutated strand; homoduplexes are composed wholly of normal DNA. Since the 
electrophoretic mobility of these heteroduplexes is retarded, they can be 
differentiated from homoduplexes using specialized gels (for review, see Nataraj et al., 
1999). The use of heteroduplex analysis in this present study would have indicated to 
the presence or absence of a mutation without the need for complete sequencing.  
 
Rather than continuing to sequence candidate genes, selected primarily on the basis of 
their reported functions and interactions, which can be an expensive and time-
consuming process, it would be perhaps sensible to use a different approach in order 
to identify the mutated genes. One approach could be functional complementation, 
whereby microcell-mediated chromosome transfer (MMCT) would be used to 
introduce single copies of chromosomes into disease cell lines. A panel of 
human:rodent somatic cell hybrids such as that developed by Cuthbert et al. (1995) 
would be employed. By monitoring each clone, the chromosome which rescues or 
improves the disease phenotype is then investigated in terms of candidate genes. Only 
then would such genes be amplified and then subjected to heteroduplex analysis and 
sequencing.     
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5.4.4 Conclusion 
 
In conclusion, the findings of this study suggest that EMD is unlikely to be the site of 
the disease-causing mutation in AG08466 and AG11572. While sequencing has failed 
to reveal any mutations in exon 4 of LAP2 in either cell line, Western blotting indicates 
that LAP2α levels are normal in AG08466 and reduced in AG11572. As a result, the 
sequencing of LAP2 exon 4 in AG11572 requires further verification to confirm that no 
mutations exist in this specific exon. It is also plausible that other LAP2 exons are the 
source of the disease-causing mutation. 
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6.1   INTRODUCTION 
6.1.1 Overview of the NE and NPCs 
Within eukaryotic organisms, nuclear and cytoplasmic activities are separated by the 
NE. While the outer nuclear membrane is continuous with the ER, the inner face of the 
nuclear membrane is lined by the NL (Gerace and Burke, 1988). The NE is perforated 
with NPCs which mediate nucleocytoplasmic transport (Allen et al., 2000). While small 
molecules can diffuse freely through the NPCs, larger molecules (>40 kDa) require the 
assistance of receptor proteins such as importins (for review, see Lim et al., 2008). 
NPCs are large, multi-protein complexes; proteomic analysis reveals that both yeast 
and mammalian NPCs are composed of 29 different nucleoporins (Rout et al., 2000; 
Cronshaw et al., 2002). The vertebrate NPC exhibits a tripartite architecture, with an 
hour-glass shaped, central framework at the core. This component, also known as the 
spoke complex, spans the membrane and exhibits an octagonal symmetry. The 
cytoplasmic face of this central framework is known as the cytoplasmic ring moiety 
and is connected to protruding cytoplasmic filaments. On the inner face of the NE, the 
corresponding nuclear ring moiety anchors a nuclear basket, which is composed of 
eight filaments and a distal ring (Stoffler et al., 2003; for reviews see Fahrenhrog and 
Aebi, 2003; Lim et al., 2008). Human NPCs are reported to have an outer diameter of 
120 nm and an inner diameter of 50 nm (Elad et al., 2009). While the outer diameter of 
NPCs in Xenopus oocytes are of comparable size to humans (110–120 nm; Goldberg 
and Allen, 1996), this diameter is slightly reduced in tobacco BY-2 plant cells (~ 105 
nm; Fiserova et al., 2009) and smaller still in yeast (~95 nm; Kiseleva et al., 2004). 
 
6.1.2 Lamin organisation 
 
Since the NL is largely inaccessible due to its tight association with chromatin, the in 
vivo organisation of the NL in vertebrates is poorly understood (Goldberg et al., 
2008a). Our comprehension of lamin organisation is largely based on work performed 
using Xenopus oocytes, whose NL is primarily composed of LIII/lamin B3 (Krohne et al., 
1981; Stick., 1988). Goldberg et al. (2008b) used Xenopus oocytes to examine the 
organisation of somatic lamins. This is a useful system since exogenously expressed 
lamins are not incorporated into the endogenous lamina; instead, they form structures 
on top of the existing lamina (Ralle et al., 2004). While the expression of A-type lamins 
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produced thick lamin filaments and increased the rigidity of the NE, the expression of 
B-type lamins resulted in the formation of single filament layers (Goldberg et al., 
2008b).  
 
6.1.3 A link between the NL and NPCs 
 
Evidence demonstrates that there is a link between NPCs and the NL (Goldberg and 
Allen, 1996; Liu et al., 2000; Daigle et al., 2001). Indeed, nucleoporins are found to 
interact directly and indirectly with lamin proteins (Smythe et al., 2000; Hubner et al., 
2006; Pan et al., 2007). It has been suggested that lamin proteins anchor NPCs via 
binding to NUP153 (Smythe et al., 2000). Significantly, lamins are found to regulate 
NPC formation and distribution (Lenz-Bohme et al., 1997; Maeshima et al., 2006). In 
line with this, NPC clustering has been reported in late-passage HGPS cells (Goldman et 
al., 2004). Furthermore, nuclear import appears reduced in cells expressing lamin A 
mutants (Busch et al., 2009). These studies strengthen the link between mutant lamin 
A and an ageing phenotype since there is a reported reduction in NPC integrity 
(D’Angelo et al., 2009) and nuclear protein import (Pujol et al., 2002) with age. 
 
6.1.4 Inner NM structure 
6.1.4.1 Preparations employed to visualise inner NM/NS structure 
 
The methodologies employed to isolate and visualise the structure of the NM/NS vary. 
Traditionally, they involve a combination of non-ionic detergents and hypertonic salt 
concentrations to extract soluble proteins and digested or non-NM associated DNA 
(Berezney and Coffey, 1974; He et al., 1990; Nickerson et al., 1997; for review, see 
Nickerson, 2001). Critics of such preparations suggest that these harsh preparations 
induce the formation of artefacts within the nucleus, which are misinterpreted as 
evidence for a NM/NS (Pederson, 2000).  However, a number of modified preparations 
have been developed which produce structures similar to those revealed by traditional 
methodologies (Jackson and Cook, 1988; Nickerson et al., 1997; Wan et al., 1999). The 
DNA halo preparation as described in previous chapters (2 and 3) involves the 
extraction of histones and other soluble proteins using Triton X-100, digitonin, and 
high salt molarities (as per Bridger and Lichter, 1999). Since this protocol is useful for 
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studying DNA interactions with the residual nuclear structure, the use of DNase I is 
omitted (e.g. Gerdes et al., 1994).   In contrast, variations of another methodology, the 
NM extraction, have been primarily used to study the structural basis of the inner NM 
(e.g. He et al., 1990; Nickerson et al., 1992; Nickerson et al., 1997; Wan et al., 1999).  
Since, unlike the DNA halo preparation, it uses nuclease treatment followed by 
ammonium sulphate elution to remove the bulk of attached DNA, an examination of 
underlying NM filaments can be performed.  
 
6.1.4.2  EM studies analysing NM/NS structure 
Using resinless sections of HeLa cells for EM, He et al. (1990) described the presence of 
thick polymorphic fibres which overlay core filaments with diameters of 9–13nm. It is 
these filaments that are suggested to link the internal NM with the peripheral NL 
(Nickerson et al., 2001). A similar structure has been reported by other labs (Hozak et 
al,. 1995; Nickerson et al., 1997). Furthermore, Hozak et al. (1995) confirmed using EM, 
earlier observations which suggested that lamin proteins were components of the 
internal NM (Goldman et al., 1992; Bridger et al., 1993).  
 
One of the major gaps in NM research is knowledge of the NMPs which form the NM 
filaments observed by EM. While it is known that hundreds of NM associated proteins 
exist (Mika and Rost, 2005), a full molecular characterisation of the NM/NS has yet to 
be performed. In 2001, Nickerson and colleagues discussed the need for a 
characterisation of this nature and suggested the structural composition rather than 
the functional relevance of the NM should be the focus of future NM research. Nearly 
ten years later, it is still not understood how and which proteins form these NM 
filaments.       
 
6.1.5 Examining nuclear structure in control and disease HDFs  
6.1.5.1 Examining nuclear structure during and following two NM extraction 
protocols using Field Emission Scanning Electron Microscopy (feSEM) 
 
The DNA halo preparation has been used extensively in previous chapters in order to 
examine interactions between different genomic elements and the NM. It thus seemed 
pertinent to follow the progress of this extraction using feSEM. Indeed, feSEM is a 
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useful tool for studying nuclear structure (Goldberg et al., 2008b) since it provides 
clear images at extremely high resolutions, with minimal sample damage; it is thus, 
superior to conventional SEM (Hitachi High Technologies America, 2010). In order to 
attempt to visualise the structure of the underlying residual nucleus produced by this 
preparation, which is usually obscured by dense chromatin, it was, at times, also 
combined with nuclease digestion. Cells were subjected to another NM extraction, 
known as the NM preparation (as per Dyer et al., 1997), allowing resulting nuclear 
morphologies to be compared.  Normal HDFs were grown on silicon chips, taken 
through either preparation and then prepared for feSEM. At different stages of each 
methodology, silicon chips were removed and treated accordingly; this allowed the 
progress of the extraction to be observed.   
 
Analysis of specimens fixed following Triton X-100 extraction in both protocols 
revealed the NL perforated with structures resembling NPCs. However, the interior of 
residual nuclei was only observed in cells extracted using the DNA halo preparation.  In 
DNA halo prepared nuclei treated with DNase I, filaments, which were assumed to be 
of the inner NM, were exposed in places. Such filaments exhibited a mean diameter 
very similar to those measurements presented previously (He et al., 1990; Nickerson et 
al., 1997; Nickerson et al., 1999). The morphology of these filaments was also 
analogous to those presented by Hozak et al. (1995).  
 
6.1.5.2 The absence of both lamin A and emerin disrupt the structural integrity of the 
NE  
 
In order to examine nuclear ultrastructure in cells lacking functional NE proteins such 
as lamin A, emerin and LBR, disease fibroblasts were subjected to either one or both of 
the aforementioned NM extraction protocols. Unlike the lamin A mutant cells studied 
in previous chapters, the cell line used in this section was derived from a patient with a 
homozygous Y259X LMNA nonsense mutation (van Engelen et al., 2005; Pekovic et al., 
2007). The phenotype was lethal and hence, the sample was obtained during an 
autopsy. In the heterozygous form, this mutation, which was present in a family 
member, produces classical LGMD1B (van Engelen et al., 2005). The cells used to study 
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the impact of emerin loss were sourced from previously described X-EDMD patients 
(KK and AP; chapter 4).  
 
The importance of LBR in maintaining nuclear structure was also examined. LBR is an 
evolutionarily conserved, inner nuclear membrane protein, which binds chromatin and 
B-type lamins via its N-terminus (Worman et al., 1988; Meier and Georgatos, 1994; 
Pyrpasopoulou et al., 1996; Kawahire et al., 1997; Duband-Goulet and Courvalin, 2000; 
Makatsori et al., 2004; Wagner et al., 2004). Significantly, mutations in LBR are found 
to produce two human diseases; Greenberg Dysplasia (Waterham et al., 2003) and 
PHA (Hoffmann et al., 2002). While the former is an autosomal recessive, fatal disorder 
(Waterham et al., 2003), the latter, autosomal dominant disease generates a far milder 
phenotype (Hoffmann et al., 2002). In this study, cells were derived from two PHA 
patients; one of which harboured a heterozygous mutation, while the other was 
homozygous.  
 
Examination of the nucleus following the permeabilisation of the cellular and nuclear 
membranes revealed that in cells lacking lamin A and emerin, the NL was irregular and 
disordered. While EMD-/Y cells exhibited slight disruptions, LMNA-/- nuclei were highly 
compromised and displayed evidence of NPC clustering. Neither NL disruption nor NPC 
clustering were detected in LBR mutant nuclei. The dimensions of residual NPCs were 
similar in all control and disease cell lines; however, the largest dimensions were 
recorded in those cells extracted in the presence of RNase inhibitors. 
 
While the findings documented in this section are more suggestive than conclusive due 
to the absence of immunolabelling, the use of these NM extraction protocols have 
revealed some interesting structures which without doubt require further 
investigation.     
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6.2 METHODS AND MATERIALS 
6.2.1 Cell Culture 
 
All primary HDF cell lines (table 6.2.1) were maintained in 10% NCS in conditions 
described in previous chapters (2.2.1 and 4.2.1). 
 
Table 6.2.1: The primary HDF cell lines used and their corresponding phenotypes 
All primary HDFs cell lines were provided by Professor CJ Hutchison. 
 
Cells were grown on ethanol-sterilised 5 mm x 5 mm silicon chips (Agar Scientific Ltd) 
in 6-well plates; each well contained 2 silicon chips and was seeded with ~0.5–1 x 105 
cells. Since the Y259X cells did not grow well on plain silicon chips, the chips used for 
this cell line were coated with 0.01 mg/ml Poly-D-lysine (Sigma) overnight and then 
were left to dry for two hours before use.    
 
6.2.2 Preparation of Nuclear Matrices 
 
This procedure, originally sourced from Nickerson et al. (1992), was modified by Dyer 
et al. (1997). All of the following buffers included 1% (v/v) of a protease inhibitor 
cocktail (Sigma).  In some cases, RNase inhibitors (40 U/µl) (Sigma) were also added to 
all buffers. Cells grown on silicon chips were washed with PBS and then washed 3 
times in ice-cold CSK buffer (10 mM Pipes (pH 6.8), 100 mM NaCl, 300 mM sucrose, 3 
mM MgCl2, 1 mM EGTA). Next, cells were incubated in CSK buffer plus 0.5% (v/v) 
Triton X-100 for 10 minutes at 4°C. Following this, they were rinsed three times in ice-
cold RSB buffer (42.5 mM Tris-HCl (pH 8.7), 8.5 mM NaCl, 2.6 mM MgCl2) and 
incubated in RSB Magik (RSB containing 1% (v/v) Tween 20 and 0.5% (v/v) sodium 
Phenotype Cell line Genotype 
Normal HDF Normal 
X-EDMD 
KK 
EMD-/Y (hemizygous) 
AP 
LGMD1B (fatal) Y259X LMNA-/- (homozygous) 
LBR 
99P0598 LBR-/+ (heterozygous) 
99P0599 LBR-/- (homozygous) 
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deoxycholate) for 10 minutes at 4°C. The cells were then rinsed twice in ice-cold 
digestion buffer (10 mM Pipes pH 8.3, 50 mM NaCl, 300 mM sucrose, 3 mM MgCl2, 1 
mM EGTA). In order to remove DNA, the cells were incubated in digestion buffer 
containing DNase I (500 U/ml) (Sigma) for 30 minutes at room temperature. To this 
solution, 1 M (NH4)2 SO4 was slowly added to give a final concentration of 0.25 M; this 
was incubated for 5 minutes at 4°C and removed the digested material.  
 
6.2.3 DNA halo extraction 
 
Chips were taken through the DNA halo preparation as per chapter 2.2. For selected 
cell lines, cells were incubated in DNase I (500 U/ml) (Sigma) for 30 minutes at room 
temperature after PBS and ethanol rows.  
 
6.2.4 Sample preparation 
 
The chips were removed at different stages throughout both extraction procedures 
and then placed and stored in fixative (3% (v/v) glutaraldehyde, 1% (w/v) PFA in 0.1M 
sodium cacodylate buffer). The chips were next washed in 0.2 M sodium cacodylate 
buffer and incubated in 1% (w/v) osmium tetroxide (OsO4) for 15 minutes at room 
temperature. Following this, the chips were placed in distilled water and taken 
straight-through an ethanol row of 50%, 70%, 95% and 100% (v/v). Specimens were 
critical point dried with CO2 using a Bal-Tec CPD 030 (BAL-TEC) machine. A Cressington 
Coating System 308R (Ted Pella, Inc) was then used to sputter coat the chips with 
either platinum or chromium (1–3 nm). The specimens were viewed using a Hitachi 
Model S-5200 feSEM (Hitachi High-Technologies) at various accelerating voltages. 
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6.3 RESULTS 
6.3.1 Examining nuclear structure during and following NM extraction in normal 
fibroblasts  
6.3.1.1 Using feSEM to visualise nuclear structure during NM extraction  
 
Normal HDFs were subjected to either the DNA halo preparation (as per Bridger and 
Lichter, 1999; see figure 6.3.1) or the NM preparation (as per Dyer et al., 1997; see 
figure 6.3.2). At different stages of the preparations, chips were removed, fixed and 
prepared for feSEM. Both methodologies employed the early use of Triton X-100 which 
functions to permeabilise cellular and nuclear membranes (Jackson and Cook, 1988).  
Importantly, such detergent treatment extracts both inner and outer nuclear 
membranes (Aaronson and Blobel, 1974). Indeed, Triton X-100 is documented to 
solubilise approximately 95% of nuclear phospholipids and 10% of nuclear proteins 
(Aaronson and Blobel, 1974). After normal HDFs were subjected to Triton X-100 
permeabilisation, a membrane-like structure remained (figure 6.3.3). Since the 
phospholipid element of the inner and outer nuclear membranes is largely removed 
following Triton X-100 incubation (Aaronson and Blobel, 1974) and the NL resists such 
extraction (Gerace et al., 1984; He et al., 1990; Hozak et al., 1995; Ma et al., 1999; 
Markiewicz et al., 2002), the remnant structure is likely to be composed of the outer 
face of the NL and any insoluble nuclear proteins. In DNA halo prepared nuclei; this 
surface was composed of a mesh-like structure, which exhibited no apparent 
symmetry or order (figure 6.3.3d).  A similar structure was exposed in nuclei extracted 
using the NM preparation, however, the mesh-like composition was not as evident. 
The surface of the NL was also covered by structures which appeared to be ribosomal- 
like; indeed, they exhibited a diameter of 20–25 nm, a value similar to that 
documented for ribosomes in unextracted cells (Brakmann et al., 2010). Of further 
note were the filaments which overlaid the NL surface; evidence of these was 
observed with both extraction methodologies (figure 6.3.1). Since cytoskeletal IFs are 
anchored by the NL and remain after 2M NaCl extraction (He et al., 1990), it is likely 
that these filaments were IFs of cytoskeletal origin and are composed of vimentin 
(Franke et al., 1978). In order to identify the exact identity of these IFs, feSEM would 
need to be coupled with immunolabelling.    
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Figure 6.3.1: An overview of the DNA halo preparation 
 
Whole cells grown on silicon chips are subjected to 3 rinses in 1 x PBS; following this, they are 
incubated in CSK buffer for 15 minutes at 4°C. The detergent activity of Triton X-100 extracts 
the majority of phosopholipids present in the plasma and nuclear membranes (Aaronson and 
Blobel, 1974; Fey et al., 1974). Furthermore, 65% of total cellular proteins are released (Fey et 
al., 1974) and of these 10% are nuclear proteins (Aaronson and Blobel, 1974). The residual 
structure is rinsed in 1 x PBS and then placed in EXT buffer, which contains digitonin and 2M 
NaCl, for 4 minutes. Following this incubation, cells are taken through 10x, 5x, 2x and 1x PBS 
for 1 minute/concentration. This process (mainly 2M NaCl) results in the release of histones 
and other soluble proteins, including outer NM proteins. Furthermore, non-NM associated 
DNA is extracted into the area surrounding the residual nucleus, while being tethered to the 
NM via MARs (at the base of the loops). After such treatment, these residual nuclei consist 
primarily of the peripheral NL and the core filaments of the inner NM, although both 
structures are obscured by DNA (He et al., 1990; Gerdes et al. 1994; Ma et al., 1999). A 
variation of this methodology has also been used in this chapter; using DNase I, DNA is 
digested before incubation in EXT buffer. As a result, the majority of DNA, histones and other 
soluble proteins are eluted during the following extraction steps and consequently, the core 
filaments of the inner NM can be visualised.   
 
Figure 6.3.2: An overview of the NM preparation 
  
Whole cells were washed 3 times in ice-cold CSK buffer and then incubated in CSK buffer (plus 
0.5% Triton X-100) for 10 minutes at 4°C. As for the DNA halo preparation, Triton X-100 
removes soluble proteins and the majority of phospholipids; thus, extracting the majority of 
plasma and nuclear membranes. The residual structures were rinsed 3 times in ice-cold RSB 
buffer and incubated in RSB-Magik (which contains 1% Tween 20 and 0.5% sodium 
deoxycholate) for 10 minutes at 4°C. This removes the majority of cytoskeletal proteins which 
leaves a residual nucleus with attached IFs (Nickerson et al., 1992). Following 2 rinses with ice-
cold digestion buffer, the residual structures are placed in DNase I (in digestion buffer) for 30 
minutes at room temperature. This digests the DNA. To this solution, 1M (NH4)2 SO4 is slowly 
added to obtain a final concentration of 0.25M and is incubated for 5 minutes at 4°C. This 
elutes the cleaved DNA and also extracts histones and other soluble proteins. As a result, the 
polymorphic fibres of the inner NM are revealed. Although not performed in this study, 2M 
NaCl can then be employed to visualise the core filaments of the inner NM (as per He et al., 
1990).   
 
Figure 6.3.3: Nuclear morphology in control HDFs revealed by feSEM following cytoskeleton 
extraction 
 
The morphology of the outer NE following the removal of the cytoskeleton using (a–c) the NM 
preparation (chips were removed after the ice-cold RSB buffer rinse) and (d) the DNA halo 
preparation (chips removed after the CSK buffer). Magnification = 100k; scale bar = 150 nm 
(images 25% of actual size). White arrowheads indicate residual NPCs, while structures 
assumed to be ribosomes are marked using yellow arrowheads. Green arrowheads indicate 
filaments most likely to be the intermediate filament, vimentin. (e–f) The morphology of 
residual NPCs following the NM preparation; in (e) the eight constituent elements of the 
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octagonal spoke complex have been numbered and the white arrowhead indicates to a 
structure which resembles a nuclear basket. Magnification = 100k; scale bar = 50 nm. 
 
 
The surface of NL appeared to be perforated with complexes resembling NPCs. These 
complexes exhibited an octagonal morphology and in selected NPCs, an attached 
basket-type structure was observed, which is probably representative of a nuclear 
basket (figure 6.3.3e). Indeed, since NPCs interact with and are anchored by the NL 
(Goldberg and Allen, 1996; Lenz-Bohme et al., 1997; Liu et al., 2000; Smythe et al., 
2000; Daigle et al., 2001; Maeshima et al., 2006; Hubner et al., 2006; Pan et al., 2007) 
and thus, remain following 2M NaCl extraction (Gerdes et al., 1994), their presence 
after Triton X-100 treatment is unsurprising.  There was variation in the preservation of 
NPC morphology in a sample and also when comparing these complexes in cells 
extracted using either the NM or the DNA halo preparation.  NPC structure 
preservation was superior in those cells subjected to the NM preparation; a possible 
explanation for this is that protease inhibitors were used throughout this extraction 
procedure while they were not employed in the DNA halo methodology. Significantly, 
in places, a network of filaments was observed to be radiating from NPCs which can be 
most clearly seen in figure 6.3.3e. Once again, without immunolabelling, it is difficult to 
determine the composition of such filaments; however, it is probable that they are 
lamin filaments since they appear to be embedded in the NL. In order to determine the 
dimensions of these NPCs, the mean inner and outer diameters of the residual NPCs 
were recorded. For the NM preparation, the mean inner and outer diameters of the 
NPCs were 39.1 nm (± 5.4 (± standard deviation); n (NPCs) = 17) and 81.7 nm (± 3.6; n = 
17), while for the DNA halo preparation, these diameters were 34.5 nm (± 7.0; n = 2) 
and 74.6 nm (± 8.0; n = 2). NPCs in cells extracted using the primary stages of the DNA 
halo preparation were on average smaller than those NPCs in NM preparations (table 
6.3.1).  
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Table 6.3.1 Dimensions of residual NPCs in control and disease HDFs 
The mean inner and outer diameters of residual NPCs were determined for control and 
disease HDFs. SD = standard deviation. 
 
6.3.1.2 Using feSEM to visualise residual nuclei following the DNA halo preparation 
  
The genome is proposed to be organised into repeating loops of DNA through its 
interaction with the NM; such loops are predicted to be 50–200 kb in length. Those 
sequences which anchor DNA to the NM are known as MARs or SARs (Laemmli et al., 
1992; Heng et al., 2004). Following the DNA halo preparation, only inextractable 
elements of the nucleus are demonstrated to remain. Indeed, this includes a residual 
nucleus, which contains the inner NM and the peripheral NL; attached to this 
structure, via MARs, are loops of DNA which radiate from the residual nucleus and 
form a DNA halo (Gerdes et al., 1994). In order to visualise the residual nucleus 
following a NM extraction using feSEM, normal HDFs were subjected to the entire DNA 
halo preparation. As expected, a mass of DNA appeared to be attached to the 
underlying residual nucleus; surrounding which, was a halo of extracted DNA (figure 
Cell line Genotype Extraction 
method 
Number 
of NPCs 
analysed 
Mean inner 
diameter in 
nm (SD) 
Mean outer 
diameter in 
nm (SD) 
HDF Normal NM 17 39.1 (5.4)  81.7 (3.6) 
DNA halo 2 34.5 (7.0)  74.6 (8.0) 
Y259X LMNA -/- DNA halo 13 35.6 (5.9) 89.9 (5.9) 
KK EMD -/Y 
 
NM 21 42.9 (4.6) 90.7 (5.6) 
DNA halo 24 41.0 (4.2) 89.2 (4.2) 
AP EMD -/Y NM 18 37.5 (4.2) 79.3 (3.6) 
99P0598 LBR-/+ 
NM 10 43.1 (5.7) 87.3 (3.0) 
NM (plus 
RNase 
inhibitors) 
11 46.1 (5.6) 91.1 (8.5) 
99P0599 LBR-/- NM 5 37.8 (6.2) 87.7 (4.0) 
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6.3.4). Thus, this concurred with observations of DNA halos using UV microscopy (see 
chapters 2 and 3). Significantly, the DNA fibres composing this halo exhibited a mean 
diameter of 10.3 nm (± 2.3; n (fibres) = 30); since DNA has a helical diameter of 2.2-2.6 
nm (Mandelkern et al., 1981), this suggested that the DNA was not fully extended and 
instead, was partially supercoiled.    
 
6.3.1.3 Visualisation of residual filaments following extraction by the DNA halo 
preparation  
 
In an attempt to observe the structure of the internal NM, cells were taken through a 
modified version of the DNA halo preparation, which included the additional step of 
DNase I digestion. By following such DNase I digestion with 2M NaCl extraction, the 
digested DNA, associated histones and other soluble proteins were eluted. The 
removal of chromatin allowed the visualisation of the underlying structure, in places 
(figure 6.3.5). Indeed, NM extraction methodologies involving 2M NaCl are reported to 
extract the outer NM proteins and reveal a highly branched and heterogeneous 
network of core filaments (He et al., 1990). The morphology of the filaments remaining 
after extraction in this study was not unlike this description. These residual filaments 
exhibited a mean diameter of 9.0 nm (± 2.3; n (filaments) = 74) which is in line with the 
published diameter of core filaments (He et al., 1990).  However, in the study by He et 
al. (1990), the ionic strength employed to reveal such filaments was increased 
gradually (i.e. 0.25 M ammonium sulphate followed by 2M NaCl); while in this present 
study, the ionic strength was rapidly increased (i.e. 2M NaCl) following DNase I 
digestion.  He et al. (1990) demonstrate that such a rapid increase in ionic strength 
preserves the morphology of the core filaments less efficiently than a gradual rise and 
results in their aggregation (He et al., 1990). In fact, the residual structure seen in 
figure 6.3.5a is not dissimilar to that presented on page 573 of the paper by He et al. 
(1990), which was revealed following DNase I–2M NaCl treatment.  Thus, it is likely 
that the filaments observed in 6.3.5 represent a partial aggregation of core filaments. 
Without immunolabelling or the use of mass spectrometry, it is impossible to conclude 
the composition of the residual filaments presented in this study. However, it is likely 
that they are RNA-rich since 67% of nuclear RNA is said to be retained in core filaments 
of the NM and also, RNase A treatment is demonstrated to destroy filament integrity 
Chapter 6: Exploring nuclear structure in LMNA, EMD and LBR mutant fibroblasts 
 
219 
 
(He et al., 1990). Furthermore, it is probable that these filaments are composed of 
actin and NuMA since both are demonstrated to be are proteins of core filaments (He 
et al., 1990; Zeng et al., 1994). 
 
 
Figure 6.3.4: Residual nuclei surrounded by a halo of DNA visualised by feSEM  
(a–b) The morphology of the residual nucleus (RN) and surrounding DNA halo (DH) in control 
HDFs following extraction by the DNA halo preparation. Magnification = 6k (a) and 7k (b); scale 
bar = 2.5 µm. (c–d) Extracted, supercoiled DNA (white arrowheads); scale bar 300 nm. 
 
Figure 6.3.5: Residual NM filaments following extraction by the DNA halo preparation and 
DNase I digestion  
(a–b) The morphology of residual NM filaments in control HDFs following extraction by the 
DNA halo preparation and DNase I digestion. White arrowheads indicate filaments which are 
assumed to be constituents of the inner NM. Magnification = 100k; scale bar = 200 nm.  
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6.3.2 Examining nuclear structure during NM extraction in diseased fibroblasts 
 
Nuclear structure is perturbed in human and murine cells harbouring LMNA/Lmna 
(Fidzianska and Hausmanowa-Petrusewicz, 2003; Goldman et al., 2004; Columbaro et 
al., 2005; Scaffidi and Misteli, 2005; Filesi et al., 2005; Capell et al., 2005; Yang et al., 
2005; Meaburn et al., 2007; Verstraeten et al., 2008; Park et al., 2009), EMD/Emd 
(Lammerding et al., 2005; Ozawa et al., 2006) and LBR (Hoffmann et al., 2002) 
mutations. In light of this, nuclear morphology was examined and compared in cells 
derived from patients that were either LMNA-/-, EMD-/Y, LBR-/+ or LBR-/-. Due to time 
restrictions as a visiting scientist, only selected cell lines were subjected to both NM 
extraction procedures; the remaining cell lines were extracted with one or the other. 
Since evidence demonstrates that the NM is RNA-rich and that RNase degradation 
destroys filament integrity (He et al., 1990), certain extractions were performed in the 
presence of RNase inhibitors. 
 
In view of the fact that LMNA-/- and EMD-/Y cells were extracted using the DNA halo 
preparation, while the LBR mutants were subjected to the NM preparation, respective 
nuclear structures cannot be directly compared. However, such morphology for each 
disease cell line can be assessed according to control images produced using the same 
extraction technique. In cells harbouring LMNA (Y259X) or EMD (KK and AP) mutations, 
the outer face of the NL was disrupted (figure 6.3.6c and d, respectively); this was 
particularly true in Y259X, where the structural integrity of the NL appeared to be 
extremely compromised. In these LMNA-/- HDFs, the NL exhibited a ruffled morphology 
and appeared highly disordered (figure 6.3.6c). In cells with heterozygous or 
homozygous LBR mutations, the morphology of the NL was similar to controls. 
Significantly, there was evidence of NPC clustering in Y259X (figure 6.3.6c), which 
appears to be as a consequence of NL disorder; however, this was not detected in the 
EMD or LBR mutants. In order to determine whether the use of RNase inhibitors made 
a visible difference to nuclear morphology, cells extracted in the presence and absence 
of RNase inhibitors were compared. The most obvious difference between the two 
populations was an expected one; in those cells that were extracted in the presence of 
RNase inhibitors, an increase in the number of ribosomal-like structures on the surface 
of the outer face of the NL, was reported (figure 6.3.7).   
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The inner and outer diameters of NPC structures were recorded for control and 
disease cell lines (table 6.3.1). Mean inner pore diameters ranged from 34.5 (HDF; DNA 
halo) to 46.1 nm (99PO598; nuclear extraction (plus RNase inhibitors)), while mean 
outer pore diameters ranged from 74.6 (HDF; DNA halo) to 91.1 nm (99PO598; nuclear 
extraction (plus RNase inhibitors)). The largest mean inner and outer pore diameters 
were recorded in 99PO598 fibroblasts extracted in the presence of RNase inhibitors; 
thus, this suggests that inhibiting RNase activity preserves NPCs more effectively. 
Significantly, there were no consistent differences between control and disease cells 
with respect to NPC dimensions (table 6.3.1). 
 
 
 
Figure 6.3.6: Nuclear morphology in control and disease HDFs following cytoskeleton 
extraction  
In order to visualise the NL, HDFs were subjected to the primary stages of the NM preparation 
(a, e, g, f, k, l) or the DNA halo preparation (b, c, d, h, i, j). The morphology of the outer NL in 
(a, b) control, (c) LMNA-/-, (d) EMD-/-, (e) LBR+/- and (f) LBR-/- HDFs. White arrowheads indicate 
residual NPCs, while structures assumed to be ribosomes are marked using yellow arrowheads. 
Green arrowheads indicate filaments most likely to be the intermediate filament, vimentin. 
Magnification = 100k; scale bar = 150 nm (images 25% of actual size). The morphology of 
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residual NPCs in (g, h) control, (i) LMNA-/-, (j) EMD-/-, (k) LBR+/- and (l) LBR-/- HDFs.  Magnification 
= 100k; scale bar = 50 nm. White arrowheads highlight filamentous structures that appear to 
radiate from the NPCs in LBR mutants.  
 
Figure 6.3.7: A comparison of nuclear morphology in LBR+/- HDFs following cytoskeleton 
extraction in the presence and absence of RNase inhibitors  
NM preparations performed in the absence (a, c, d) and presence (b, e, f) of RNase inhibitors. 
The morphology of (a, b) the outer NL; magnification = 100k; scale bar = 200 nm and (c–f) 
residual NPCs; magnification = 100k; scale bar = 50 nm. White arrowheads indicate residual 
NPCs, while structures assumed to be ribosomes are marked using yellow arrowheads. Green 
arrowheads indicate filaments most likely to be the intermediate filament, vimentin. 
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6.4 DISCUSSION 
6.4.1 Delineating the ultrastructure of the DNA halo prepared residual nuclei  
 
The DNA observed following in situ NM preparations is highly supercoiled (Cook and 
Brazell, 1975; Berezney and Buchholtz, 1981). The methodologies employed to 
produce DNA halos act to relax such supercoiling by using ethanol dehydration and/or 
airdrying steps (Ma et al., 1999). However, although the degree of supercoiling is less 
extensive in DNA halos, the DNA still exhibits partial supercoiling (Comings and Okada, 
1976; Vogelstein et al., 1980). Indeed, in this study, the mean diameter of the DNA 
extracted into the halo was approximately 10 nm; since DNA has a helical diameter of 
2.2–2.6 nm (Mandelkern et al., 1981), this suggested that the DNA was not fully 
extended and instead, exhibited supercoiling.  
 
The removal of DNA using DNase I allowed the observation of the underlying residual 
nucleus. In places, an array of filaments, approximately 9 nm in diameter, were 
recorded. This is intriguing since it is purported that the internal NM is composed of 
core filaments with a diameter of 10 nm, which underlie thick polymorphic fibres of 
varying sizes (He et al., 1990). Furthermore, the filaments presented in this chapter 
look similar to those presented previously (He et al., 1990). The obvious criticism of 
this present study is that these underlying filaments could be remnants of a collapsed 
NL. In order to interpret these structures correctly, EM would need to be coupled with 
the immunolabelling of A- and B-type lamins. Since evidence demonstrates that the 
core filaments of the internal NM are not enriched with lamin proteins (Hozak et al., 
1995), this would aid in determining whether or not the filaments originated from the 
NL. Antibodies raised against cellular proteins such as vimentin would also help to 
delineate the structure.  
 
6.4.2 The integrity of the NL is disrupted in cells harbouring LMNA and EMD 
mutations  
 
By permeabilising the cellular and nuclear membranes of control and disease 
fibroblasts, a membrane-like structure was revealed. Since Triton X-100 is documented 
to disrupt and remove the inner and outer nuclear membranes (Aaronson and Blobel, 
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1974), it is likely that this remnant structure was the NL. Indeed, the NL is found to be 
insoluble and resistant to such extraction (Gerace et al., 1984; He et al., 1990; Hozak et 
al., 1995; Ma et al., 1999; Markiewicz et al., 2002). The observation that this structure 
was perforated with NPCs concurs with the notion that the nuclear membrane is not 
necessarily required for the anchorage of these complexes within the nucleus 
(Aaronson and Blobel, 1974). It also reinforces the previously documented link 
between lamin proteins, the NL and NPCs (Goldberg and Allen, 1996; Smythe et al., 
2000; Liu et al., 2000; Daigle et al., 2001; Hubner et al., 2006; Pan et al., 2007).     
 
The structural integrity of the NL appeared to be compromised to varying extents in 
disease fibroblasts. The severest disruption was observed in LMNA-/- cells; in these, the 
NL was highly irregular and disordered.  This is to be expected since the NL, of which 
lamin A is a constituent, is assumed to be weakened is such cells.  Indeed, there have 
been numerous reports of abnormal nuclear morphology in cells with LMNA mutations 
(Sullivan et al., 1999; Novelli et al., 2002; Bechert et al., 2003; Glynn and Glover, 2003, 
Bridger and Kill, 2004; Muchir et al., 2004; Goldman et al., 2004; Paradisi et al., 2005; 
Wang et al., 2006). Thus, it has been hypothesised that in cells harbouring LMNA 
mutations, the NL is weakened which in turn compromises the structural mechanics of 
the nucleus (Lammerding et al., 2004; Broers et al., 2004). A recent study suggests that 
lamin A is required to maintain the ‘internal inertia’ of the nucleus (De Vos et al., 
2010).  Therefore, it is logical to suggest that when lamin A is missing or mutant, the 
rigidity of the NL is partially lost and as a result, the NL becomes more flaccid and 
disorganised.  This is probably a contributing factor to the abnormal clustering of NPCs 
evident in LMNA-/- cells. Such clustering of NPCs has been described previously in 
Drosophila and human lamin mutants (Lenz-Bohme et al., 1997; Goldman et al., 2004). 
Indeed, lamins and nucleoporins interact (Smythe et al., 2000; Hubner et al., 2006; Pan 
et al., 2007) and as a result, it has been hypothesised that lamin proteins have a role in 
anchoring NPCs (Smythe et al., 2000). Thus, it appears that in LMNA-/- nuclei, NPC 
organisation is disrupted in two ways: firstly, due to the irregularity of the NL and 
secondly, as a result of the perturbed or lost interaction with lamin proteins.  
 
The electron micrographs revealed that the NL was also perturbed in X-EDMD nuclei, 
concurring with previous observations of abnormal nuclear morphology in EMD 
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mutant cells (Lammerding et al., 2005; Ozawa et al., 2006). However, the extent of this 
disorganisation was not as extreme as in LMNA-/- nuclei.   Furthermore, the clustering 
of NPCs was not detected in these emerin null fibroblasts. This agrees with previous 
work which shows that while lamin A/C is important for NPC formation and 
localisation, emerin is not (Maeshima et al., 2006). This disparity in the disturbance of 
NL integrity is reflective of the difference in disease severity seen in mice that are 
either lamin A or emerin null. In humans, heterozygous EMD mutations are not 
sufficient to cause X-EDMD; thus, heterozygous females (EMD+/-) are carriers while the 
disease pathology is observed in hemizygous males (EMD-/Y; Bione et al., 1994; Yates et 
al., 1999). Disease-causing LMNA mutations are most common in the heterozygous 
state (Bonne et al., 1999; Eriksson et al., 2003; De Sandre-Giovannoli et al., 2003); 
while homozygous LMNA mutations do exist, they are rare, cause more severe 
phenotypes and can be fatal (Raffaele di Barletta et al., 2000; De Sandre - Giovannoli et 
al., 2002; van Engelen et al., 2005).  
 
Although EMD mutant mouse models do not fully reflect the X-EDMD disease 
phenotype, it does reinforce the notion that LMNA and EMD mutations exhibit 
differing disease causing capacities. Emerin deficient mice display a mild clinical 
phenotype which does not affect growth rate or fertility (Ozawa et al., 2006), whereas 
mice null for lamin A are growth retarded and die prematurely (Sullivan et al., 1999). In 
addition, Lmna -/- mice exhibit skeletal and cardiac dysfunction (Sullivan et al., 1999) 
while Emd -/Y mice are largely unaffected by such disorders (Ozawa et al., 2006).  
   
The outer surface of the NL appeared to be normal in both heterozygous and 
homozygous LBR mutants. LBR is found at the nuclear periphery; this is likely due to 
the protein’s interaction with lamin B (Worman et al., 1988; Ye and Worman, 1994; 
Reichart et al., 2004). Importantly, LBR appears to have at least two distinct functions. 
Firstly, it is implicated in chromatin organisation through its association with DNA and 
HP1 (Ye and Worman, 1994; 1996; Ye et al., 1997). Furthermore, the protein also 
exhibits cholesterol biosynthetic enzymatic activity (Waterham et al., 2003). In 
humans, heterozygous LBR mutations lead to PHA which is a benign disease 
characterised primarily by the hypolobulated nuclei of blood granulocytes; chromatin 
organisation is also perturbed (Hoffmann et al., 2002). The aberrant shape in 
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granulocytes is caused by the failure of nuclear lobes to develop correctly.  In the 
homozygous form, LBR mutations can cause a spectrum of disease severity; with AR-
PHA at the mild end and Greenberg skeletal dysplasia, at the other (Hoffmann et al., 
2002; Waterham et al., 2003). In granulocytes derived from AR-PHA, nuclei are round 
and non-segmented (Hoffmann et al., 2002).  While NL disruption was not observed in 
cells harbouring LBR mutants, it is possible that such perturbations were so subtle that 
they could not be detected visually. It could be suggested that LBR is more actively 
involved in the formation or maintenance of nuclear shape in granulocytes than in 
fibroblasts; however, the overexpression of LBR has been demonstrated to result in NE 
invaginations in non-leukocytes (Ma et al., 2007).  
 
Significantly, the inner and outer pore diameters were similar in all cell lines (control 
and disease) using both extraction techniques. This is important since it indicates that 
there is consistency in the nuclear structure and morphology revealed by extraction 
procedures performed on different days.  The measurements for inner and outer pore 
diameters (34.5–46.1 nm and 74.6–91.1 nm, respectively) were significantly smaller 
than those reported for the human NPC (outer diameter 120 nm, inner diameter 50 
nm; Elad et al., 2009). However, this is perhaps expected since the extraction 
procedures used in this chapter most probably resulted in the collapse and shrinkage 
of the cell/nucleus. Indeed, differences in dimensions and observed structure have 
been reported in native versus detergent-extracted NPCs (Fahrenkrog and Aebi, 2003).   
  
6.4.3 Concluding remarks  
 
Interpreting the results produced by such harsh, non-physiological extraction 
procedures is fraught with difficulty, mainly because the remnant nucleus does not 
represent any in vivo structure. However, as long as investigations using these 
methodologies are comparative, they can aid in our understanding of nuclear structure 
in normal cells and the disruption of such structure in diseased cells. Without coupling 
EM with immunolabelling, it would be incorrect to derive any firm conclusions from 
this study; nonetheless, the findings do confirm the observations of previous studies 
regarding the fragility of the NL in the absence of functional lamin A and emerin. These 
findings also reinforce the notion that the NL and NPC network is highly integrated.         
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7.1 Examining the nature of NM-genome interactions using the DNA halo assay 
 
The NM or NS is a permanent network of core filaments, underlying thicker fibres, 
present regardless of transcriptional activity (Jackson and Cook, 1988; He et al., 1990; 
Hozak et al., 1995; Philimonenko et al., 2001; Nickerson et al., 2001). It is found to be 
both RNA and protein rich; indeed, treatment with RNase A destroys filament integrity 
(He et al., 1990). Significantly, the NM is proposed to organise the genome; indeed, 
chromosomes (Ma et al., 1999; Croft et al., 2001), genes (Tocharoentanaphol et al., 
1994; Repping et al., 2003; Iarovaia et al., 2004) and telomeres (de Lange, 1992; 
Luderus et al., 1996) are demonstrated to be anchored to this structure. Therefore, it 
was logical to hypothesize that if the NM is dysfunctional its capacity to perform such 
function is restricted. In order to test this, it was necessary to develop an assay which 
allowed NM-genome interactions to be examined. As a result, the DNA halo 
preparation was selected. The residual nuclei remaining following such an extraction 
procedure represents a salt-resistant structure termed the NM. Since the use of DNA 
digestion is omitted, NM-associated DNA is anchored to the NM, while DNA which 
does not interact with the NM is extracted into the surrounding space to form a halo of 
DNA. By coupling the DNA halo preparation with different variants of FISH, it was 
possible to visualise interactions between the NM and specific parts of the genome. 
Significantly, chapter 2 demonstrated that the majority of chromosomes, telomeres 
and genes are anchored to this salt-resistant structure. Furthermore, these studies 
revealed that there was no significant difference in such NM-associations between 
proliferating and senescent HDFs; however, this anchorage did differ in quiescence. 
Importantly, these studies show that the DNA halo assay employed to examine such 
interactions, generates consistent and reproducible results. 
 
7.2 Perturbed genome organisation in disease 
7.2.1 NM-genome interactions 
 
In light of this, it seemed pertinent to examine whether mutations in certain NM-
associated proteins affect the capacity of the NM to tether chromatin within the 
interphase nucleus. Since both lamin A (Hozak et al., 1995; Barboro et al., 2002) and 
emerin (Squarzoni et al., 1998; Ellis et al., 1998; Takata et al., 2009) are NM proteins, 
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cells harbouring mutations in the genes encoding these proteins, presented an 
excellent opportunity to examine this hypothesis.  In chapter 3, NM-genome 
interactions were investigated, using the DNA halo assay, in a variety of HGPS and X-
EDMD cell lines, which exhibit mutations in LMNA and EMD, respectively. 
Chromosome anchorage by the NM was analysed in HGPS and significantly, half of the 
chromosomes examined displayed disrupted NM interactions. Subsequently, NM-
telomere associations were investigated in HGPS and X-EDMD fibroblasts; indeed, 
these studies revealed a reduction in telomere anchorage for all disease cell lines. 
Since HGPS telomeres exhibit considerably shorter telomeres than those found in 
controls (Allsopp et al., 1992; Decker et al., 2009), it seemed necessary to question 
whether the activation of telomerase in these cells would affect telomere binding to 
the NM. To do this, classical HGPS cells, previously immortalised by the stable 
transfection of hTERT, were subjected to the DNA halo assay and telomere-PNA FISH. 
Surprisingly, this appeared to increase the number of NM-telomere interactions to a 
level statistically similar to control cells, which indicates that by immortalising HGPS 
HDFs, some telomere-related phenotypes can be rescued in lamin A mutant cells. 
These findings posed another question: what is the nature of NM-telomere 
interactions in cancer cell lines, which are consistently immortalised? To tackle this 
question, telomere anchorage by the NM was assessed in two melanoma cell lines 
(one highly tumourigenic, the other non-tumourigenic) using the DNA halo assay. 
Significantly, although the DNA halos generated from the melanoma cells were the 
most extensive of all the cell lines studied, telomere anchorage was similar to control 
HDFs. Taken together, these experiments using immortalised HGPS and melanoma cell 
lines suggest that telomerase activation most probably affects telomere binding to the 
NM.  
 
7.2.2 Interphase gene positioning in non-extracted fibroblasts 
 
While evidence linking LMNA mutations and disorganised genome organisation is quite 
extensive (Sewry et al., 2001; Fidzianska and Hausmanowa, 2003; Goldman et al., 
2004; Filesi et al., 2005; Maraldi et al., 2006; Meaburn et al., 2007; Lattanzi et al., 2007; 
Hakelien et al., 2008; Park et al., 2009), the same cannot be said for EMD (Fidzianska et 
al., 1998; Ognibene et al., 1999; Meaburn et al., 2007). Therefore, to test whether EMD 
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mutations disrupt gene positioning, the locations of 4 genes were examined in control 
and 3 X-EDMD patient cell lines using 2D and 3D FISH. To determine if such positioning 
changes in senescent cells, both proliferating (pKi67+) and non-proliferating (pKi67−) 
populations were studied. Since previous research has reported that one of these 
genes (C-MYC) is up-regulated in X-EDMD (Markiewicz et al., 2006), this gave the study 
a dual aim. Firstly, to test whether the locations of these four genes were disrupted in 
X-EDMD and secondly, to examine whether any modifications in such positioning 
correlated with any changes in the expression of these genes by RT-PCR.  Importantly, 
while there were subtle changes in gene positioning, there was no evidence of 
dysregulated transcription.   
 
7.2.3 The role of lamin A and emerin in mediating genome organisation and 
structural integrity  
 
By using the DNA halo assay, it has been demonstrated that telomere binding to the 
NM is weakened in LMNA and EMD mutant HDFs.  Importantly, while cells lacking 
emerin exhibited perturbed telomere anchorage, such interactions were more severely 
affected in dominant-negative lamin A mutants. This fits with the previously observed 
trend regarding differences in disease severity; emerin’s absence is less disruptive than 
the presence of lamin A mutants. Indeed, the loss of emerin did not appear to 
significantly affect the positioning of 4 selected genes in X-EDMD. What does this 
suggest? Firstly, it indicates that lamin A is more important for tethering chromatin 
within the nucleus than emerin. Indeed, lamin A is demonstrated to interact with DNA 
directly (Shoeman and Traub, 1990; Taniura et al., 1995; Stierle et al., 2003), while 
emerin’s association with chromatin is likely to be indirectly mediated by BAF (Lin et 
al., 2000; Lee et al., 2001; Segura-Totten and Wilson, 2004). It is interesting that 
telomere anchorage is perturbed in extracted X-EDMD cells, while gene positioning in 
non-extracted cells lacks signs of significant disruption. Perhaps this indicates that 
while emerin is involved in the NM-complexes which tether telomeres to the NM, the 
protein is less implicated in those complexes which tether genome-wide MARs. This 
would thus suggest a differentiation between telomeric MARs and other MARs 
throughout the genome.      
Chapter 7: General Discussion 
 
231 
 
In addition to demonstrating that NM-genome associations are disrupted in LMNA and 
EMD mutants, the results presented in this thesis also indicate that in such cells, 
nuclear integrity is compromised. In chapter 6, control and disease HDFs were 
gradually extracted using either the DNA halo preparation or another procedure. This 
study revealed that the absence of functional lamin A more severely disrupted the 
integrity of the NL than emerin. This was not a surprising finding since lamin A is a 
major component of the NL, while emerin is tethered to the NP via its interaction with 
lamin A. However, the observation that emerin’s absence weakened the NL is an 
important observation.  
 
Taken together, these chapters demonstrate that while both lamin A and emerin are 
important for organising the genome and maintaining nuclear structural integrity, 
lamin A is less dispensable to the cell than emerin.    
 
7.3 Delineating the effects of a dysfunctional NM 
7.3.1 Transcription 
 
Since LMNA and EMD mutations perturb the NM’s ability to anchor chromatin within 
the interphase nucleus, it is necessary to consider the possible implications of such 
dysfunction on the nucleus. One possible consequence could be the deregulation of 
transcription. Indeed, the NM provides the foundation upon which transcription 
factories operate (Iborra et al., 1996). Thus, the effect of mutant lamin A or emerin on 
transcription could be multifaceted. Firstly, the presence of dominant-negative lamin A 
mutants or the absence of emerin contributes to NM dysfunction by failing to anchor 
MARs correctly. If genes are incorrectly positioned, their normal local environment 
may change significantly and therefore, altering the type of transcription factories 
available in the vicinity. As a result of this, gene expression could be mis-regulated, 
with genes either not participating in transcription or being forced to use sub-optimal 
factories. In line with this, transcription deregulation has been reported in both HGPS 
(Ly et al., 2000; Csoka et al., 2004) and X-EDMD (Tsukahara et al., 2002) cell lines. 
Mutant forms of lamin A and emerin may affect transcription in additional ways; 
indeed, if lamin proteins are missing or mutant, this nuclear process is perturbed. 
Spann et al. (2001) reported that the presence of mutant lamin A inhibits the activity 
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of RNA polymerase. Furthermore, depleting lamin B1 levels by interference technology 
significantly disrupts RNA synthesis (Tang et al., 2008).  
 
7.3.2 DNA repair 
 
In addition to the NM’s role in transcription, the nuclear structure is implicated in co-
ordinating DNA damage signalling (McCready and Cook, 1984; Harless and Hewitt, 
1987; Koehler and Hanawalt, 1996; Jiang et al., 2001; Kamiuchi et al., 2002; Mladenov 
et al., 2009). Significantly, p53 binding to the NM increases in response to DNA damage 
(Jiang et al., 2001); it is thus plausible that if p53 cannot interact correctly due to a 
dysfunctional NM, such signalling becomes disordered.  In line with this, p53 signalling 
is up-regulated in cells harbouring mutant lamin A (Varela et al., 2005). Furthermore, 
Rad51, a key homologous recombination protein, forms NM-associated foci in 
response to DNA damage (Mladenov et al., 2006, 2007, and 2009); in HGPS, there is 
evidence that the recruitment of this protein is perturbed (Liu et al., 2005). Therefore, 
it is likely that mutant lamin A hampers the NM’s capacity to recruit such proteins, 
thus, impairing the DNA damage response. 
 
What accounts for the shorter telomeres reported in HGPS patients (Allsopp et al., 
1992; Decker et al., 2009)? It is suggested that compromised DNA damage pathways 
are possibly the cause of this phenomenon in HGPS. It is thus likely that in HGPS, 
damaged telomeres are not efficiently repaired and as a result, they are eroded at 
varying speeds; this could account for the wide variation seen in HGPS telomeric length 
(Decker et al., 2009). Consequently, HGPS telomeres reach a critical length far quicker 
than normal and as a result, these chromosome ends are recognised as DNA damage, 
leading to senescence or apoptosis (Decker et al., 2009). This increased proportion of 
senescent cells due to telomere dysfunction could illicit a compensatory response in 
the remaining pool of cells, in the form of enhanced proliferation (Decker et al., 2009). 
Indeed, hyper-proliferation and increased rates of apoptosis have been observed 
previously in HGPS (Bridger and Kill, 2004).  
 
Does the incorrect telomere anchorage seen in HGPS and X-EDMD merely reflect the 
effect of LMNA and EMD mutations on NM function or does it contribute to the 
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disease phenotype seen in these patients? If the latter is the case, how does perturbed 
NM-telomere binding affect telomere biology on a larger scale? Since telomeres are 
vitally important for chromosome stability (Blackburn et al., 2001), it is likely that their 
anchorage to the NM contributes to this function. In light of the fact that the NM 
mediates DNA replication and repair processes, this seems especially logical. The 
binding of telomeres to this nuclear structure may also aid in the prevention of 
telomere fusions. Therefore, in HGPS and X-EDMD, it is possible that the reduction in 
telomere anchorage by the NM impairs the replication and repair of telomeres and as 
a result, increases genome instability through telomere erosion.  
 
This discussion suggests that a sub-optimal NM contributes to the dysfunctional 
telomere biology observed in HGPS in different ways. Firstly, by the inefficient 
recruitment of proteins involved in DNA repair to the NM and secondly, by failing to 
anchor telomeres correctly. Furthermore, perhaps the inability of the lamin A mutant-
NM to mediate telomere binding is also a contributing factor to the accelerated 
telomere erosion documented in HGPS. The study of telomeres in HGPS appears to be 
central to elucidating the mechanisms involved in premature ageing, particularly since 
signs of telomere dysfunction and DNA damage are found to increase with age (Jiang 
et al., 2008).  
 
7.4 Summary 
 
Taken together, the results presented in this thesis demonstrate the importance of 
lamin A, emerin and the NM in mediating correct genome organisation. Indeed, in cells 
harbouring mutant forms of these NM proteins, the structure’s ability to tether 
chromosomes and telomeres, is perturbed. These findings further strengthen the view 
that the NM is a significant nuclear structure which participates and regulates 
numerous nuclear processes.   
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ED5364: EMD 
 
1. Exon 1 
a. Forward sequence (BLAST) 
> ref|NM_000117.2|  Homo sapiens emerin (EMD), mRNA 
Length=1370 
 
 GENE ID: 2010 EMD | emerin [Homo sapiens] (Over 10 PubMed links) 
 
 
 Score =  398 bits (215),  Expect = 2e-108 
 Identities = 222/225 (98%), Gaps = 2/225 (0%) 
 Strand=Plus/Plus 
 
Query  6    CGAC-ACGATTCGGCTGTGA-GCGAGCGCGGCCGCTCCCGATGCGCTCGTGCCGCCCCCG  63 
            |||| ||||||||||||||| ||||||||||||||||||||||||||||||||||||||| 
Sbjct  107  CGACAACGATTCGGCTGTGACGCGAGCGCGGCCGCTCCCGATGCGCTCGTGCCGCCCCCG  166 
 
Query  64   CCGTGCTCCTCGGCAGCCGTTGCTCGGCCGGTTTTGGTAGGCCCGGGCCGCCGCCAGGCC  123 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  167  CCGTGCTCCTCGGCAGCCGTTGCTCGGCCGGTTTTGGTAGGCCCGGGCCGCCGCCAGGCC  226 
 
Query  124  CCCGCCTGAGCCCGCACCCGCCATGGACAACTACGCAGATCTTTCGGATACCGAGCTGAC  183 
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  227  TCCGCCTGAGCCCGCACCCGCCATGGACAACTACGCAGATCTTTCGGATACCGAGCTGAC  286 
 
Query  184  CACCTTGCTGCGCCGGTACAACATCCCGCACGGGCCTGTAGTAGG  228 
            ||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  287  CACCTTGCTGCGCCGGTACAACATCCCGCACGGGCCTGTAGTAGG  331 
 
b. Forward sequence (vs. X86810.1) 
 
  601 CGGCTGCTCCCGCGGTTAGGTCCCGCCCCGCGCAGCGCGCGCAGCCTGCGGAGCCAGCGG 
                                                                   
 
  661 CCGTGACGCGACAACGATTCGGCTGTGACGCGACAACGATTCGGCTGTGACGCGAGCGCG 
                          
 
  721 GCCGCTCCCGATGCGCTCGTGCCGCCCCCGCCGTGCTCCTCGGCAGCCGTTGCTCGGCCG 
       >…………………………………………………………………………………………………………………………………………………………                                                           
 
  781 GTTTTGGTAGGCCCGGGCCGCCGCCAGGCCTCCGCCTGAGCCCGCACCCGCCATGGACAA 
      ………………………………………………………………………………………………………………………………………………………………                                                             
 
  841 CTACGCAGATCTTTCGGATACCGAGCTGACCACCTTGCTGCGCCGGTACAACATCCCGCA 
      ………………………………………………………………………………………………………………………………………………………………                                                             
 
  901 CGGGCCTGTAGTAGGTACGCGGCGGCGGGCGGGACCCCTTCCGGGCCCCCTCCTCGTGCT 
      …………………………………<                                                             
 
961 CCGCCTCGCGACCTCCCCGCTGCCCTCCCCGCGCGCCTTCCCCGGCCCGCGGCCCTGACC 
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c. Reverse sequence (BLAST) 
> ref|NM_000117.2|  Homo sapiens emerin (EMD), mRNA 
Length=1370 
 
 GENE ID: 2010 EMD | emerin [Homo sapiens] (Over 10 PubMed links) 
 
 
 Score =  462 bits (250),  Expect = 6e-128 
 Identities = 254/256 (99%), Gaps = 0/256 (0%) 
 Strand=Plus/Minus 
 
Query  33   CCTACTACAGGCCCGTGCGGGATGTTGTACCGGCGCAGCAAGGTGGTCAGCTCGGTATCC  92 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  331  CCTACTACAGGCCCGTGCGGGATGTTGTACCGGCGCAGCAAGGTGGTCAGCTCGGTATCC  272 
 
Query  93   GAAAGATCTGCGTAGTTGTCCATGGCGGGTGCGGGCTCAGGCGGAGGCCTGGCGGCGGCC  152 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  271  GAAAGATCTGCGTAGTTGTCCATGGCGGGTGCGGGCTCAGGCGGAGGCCTGGCGGCGGCC  212 
 
Query  153  CGGGCCTACCAAAACCGGCCGAGCAACGGCTGCCGAGGAGCACGGCGGGGGCGGCACGAG  212 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  211  CGGGCCTACCAAAACCGGCCGAGCAACGGCTGCCGAGGAGCACGGCGGGGGCGGCACGAG  152 
 
Query  213  CGCATCGGGAGCGGCCGCGCTCGCGTCACAGCCGAATCGTTGTCGCGTCACAGCCGAAAC  272 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||| | 
Sbjct  151  CGCATCGGGAGCGGCCGCGCTCGCGTCACAGCCGAATCGTTGTCGCGTCACAGCCGAATC  92 
 
Query  273  GTTGTCGCGTCCCGGC  288 
            ||||||||||| |||| 
Sbjct  91   GTTGTCGCGTCACGGC  76 
 
d. Reverse sequence (vs. X86810.1)  
                                  
  601 CGGCTGCTCCCGCGGTTAGGTCCCGCCCCGCGCAGCGCGCGCAGCCTGCGGAGCCAGCGG 
                                                                   
 
  661 CCGTGACGCGACAACGATTCGGCTGTGACGCGACAACGATTCGGCTGTGACGCGAGCGCG 
                                                                   
 
  721 GCCGCTCCCGATGCGCTCGTGCCGCCCCCGCCGTGCTCCTCGGCAGCCGTTGCTCGGCCG 
      >………….………………………………………………………………………………………………………………………………………………                                                            
 
  781 GTTTTGGTAGGCCCGGGCCGCCGCCAGGCCTCCGCCTGAGCCCGCACCCGCCATGGACAA 
      ………………………………………………………………………………………………………………………………………………………………                                                             
 
  841 CTACGCAGATCTTTCGGATACCGAGCTGACCACCTTGCTGCGCCGGTACAACATCCCGCA 
      ………………………………………………………………………………………………………………………………………………………………                                                             
 
  901 CGGGCCTGTAGTAGGTACGCGGCGGCGGGCGGGACCCCTTCCGGGCCCCCTCCTCGTGCT 
      …………………………………<                                                             
 
  961 CCGCCTCGCGACCTCCCCGCTGCCCTCCCCGCGCGCCTTCCCCGGCCCGCGGCCCTGACC 
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e. Combined sequencing (forward and reverse sequences) 
   
 
  601 CGGCTGCTCCCGCGGTTAGGTCCCGCCCCGCGCAGCGCGCGCAGCCTGCGGAGCCAGCGG 
                                                                   
 
  661 CCGTGACGCGACAACGATTCGGCTGTGACGCGACAACGATTCGGCTGTGACGCGAGCGCG 
                                                                   
 
  721 GCCGCTCCCGATGCGCTCGTGCCGCCCCCGCCGTGCTCCTCGGCAGCCGTTGCTCGGCCG 
      >……………………………………………………………………………………………………………………………………………………………                                                              
 
  781 GTTTTGGTAGGCCCGGGCCGCCGCCAGGCCTCCGCCTGAGCCCGCACCCGCCATGGACAA 
      ………………………………………………………………………………………………………………………………………………………………                                                             
 
  841 CTACGCAGATCTTTCGGATACCGAGCTGACCACCTTGCTGCGCCGGTACAACATCCCGCA 
      ………………………………………………………………………………………………………………………………………………………………                                                             
 
  901 CGGGCCTGTAGTAGGTACGCGGCGGCGGGCGGGACCCCTTCCGGGCCCCCTCCTCGTGCT 
      …………………………………<                                               
 
961 CCGCCTCGCGACCTCCCCGCTGCCCTCCCCGCGCGCCTTCCCCGGCCCGCGGCCCTGACC 
 
2. Exon 2 
a. Forward sequence (BLAST) 
 
> ref|NM_000117.2|  Homo sapiens emerin (EMD), mRNA 
Length=1370 
 
 GENE ID: 2010 EMD | emerin [Homo sapiens] (Over 10 PubMed links) 
 
 
 Score =  198 bits (107),  Expect = 1e-48 
 Identities = 107/107 (100%), Gaps = 0/107 (0%) 
 Strand=Plus/Plus 
 
Query  35   AGGATCAACTCGTAGGCTTTACGAGAAGAAGATCTTCGAGTACGAGACCCAGAGGCGGCG  94 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  329  AGGATCAACTCGTAGGCTTTACGAGAAGAAGATCTTCGAGTACGAGACCCAGAGGCGGCG  388 
 
Query  95   GCTCTCGCCCCCCAGCTCGTCCGCCGCCTCCTCTTATAGCTTCTCTG  141 
            ||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  389  GCTCTCGCCCCCCAGCTCGTCCGCCGCCTCCTCTTATAGCTTCTCTG  435 
 
b. Forward sequence (vs. X86810.1) 
 
  961 CCGCCTCGCGACCTCCCCGCTGCCCTCCCCGCGCGCCTTCCCCGGCCCGCGGCCCTGACC 
 
  
 1021 GCCCCGTGTCCGGCCAGGATCAACTCGTAGGCTTTACGAGAAGAAGATCTTCGAGTACGA       
                       >……………………………………………………………………………………………………………… 
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 1081 GACCCAGAGGCGGCGGCTCTCGCCCCCCAGCTCGTCCGCCGCCTCCTCTTATAGCTTCTC       
      ………………………………………………………………………………………………………………………………………………………………    
 
 1141 TGGTGAGAGCCTCGCCTGTGGGGACAGCCTGGGACGCGGGGAGGATGGGGTCGCGAGGGT       
      …< 
 
 1201  GTGGCAGGGGGGCCGGTCGAGAGCGGCACTGGAGAAAGGGGAGGGAAGTCTGGGGGGGCA       
 
c. Reverse sequence (BLAST) 
> ref|NM_000117.2|  Homo sapiens emerin (EMD), mRNA 
Length=1370 
 
 GENE ID: 2010 EMD | emerin [Homo sapiens] (Over 10 PubMed links) 
 
 
 Score =  198 bits (107),  Expect = 1e-48 
 Identities = 107/107 (100%), Gaps = 0/107 (0%) 
 Strand=Plus/Minus 
 
Query  48   CAGAGAAGCTATAAGAGGAGGCGGCGGACGAGCTGGGGGGCGAGAGCCGCCGCCTCTGGG  107 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  435  CAGAGAAGCTATAAGAGGAGGCGGCGGACGAGCTGGGGGGCGAGAGCCGCCGCCTCTGGG  376 
 
Query  108  TCTCGTACTCGAAGATCTTCTTCTCGTAAAGCCTACGAGTTGATCCT  154 
            ||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  375  TCTCGTACTCGAAGATCTTCTTCTCGTAAAGCCTACGAGTTGATCCT  329 
 
d. Reverse sequence (vs. X86810.1) 
 
  961 CCGCCTCGCGACCTCCCCGCTGCCCTCCCCGCGCGCCTTCCCCGGCCCGCGGCCCTGACC       
 
 
 1021 GCCCCGTGTCCGGCCAGGATCAACTCGTAGGCTTTACGAGAAGAAGATCTTCGAGTACGA       
                       >………………………………………………………………………………………………………………     
 
 1081 GACCCAGAGGCGGCGGCTCTCGCCCCCCAGCTCGTCCGCCGCCTCCTCTTATAGCTTCTC       
      ………………………………………………………………………………………………………………………………………………………………    
 
 1141 TGGTGAGAGCCTCGCCTGTGGGGACAGCCTGGGACGCGGGGAGGATGGGGTCGCGAGGGT       
      …< 
 
1201 GTGGCAGGGGGGCCGGTCGAGAGCGGCACTGGAGAAAGGGGAGGGAAGTCTGGGGGGGCA       
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e. Combined sequencing (forward and reverse sequences) 
 
 961 CCGCCTCGCGACCTCCCCGCTGCCCTCCCCGCGCGCCTTCCCCGGCCCGCGGCCCTGACC 
                                                                            
  
1021 GCCCCGTGTCCGGCCAGGATCAACTCGTAGGCTTTACGAGAAGAAGATCTTCGAGTACGA       
                      >………………………………………………………………………………………………………………              
  
1081 GACCCAGAGGCGGCGGCTCTCGCCCCCCAGCTCGTCCGCCGCCTCCTCTTATAGCTTCTC       
     ……………………………………………………………………………………………………………………………………………………………… 
 
1141 TGGTGAGAGCCTCGCCTGTGGGGACAGCCTGGGACGCGGGGAGGATGGGGTCGCGAGGGT       
     …< 
 
1201  GTGGCAGGGGGGCCGGTCGAGAGCGGCACTGGAGAAAGGGGAGGGAAGTCTGGGGGGGCA       
 
 
3. Exon 3 
a. Forward sequence (BLAST) 
 
> ref|NM_000117.2|  Homo sapiens emerin (EMD), mRNA 
Length=1370 
 
 GENE ID: 2010 EMD | emerin [Homo sapiens] (Over 10 PubMed links) 
 
 
 Score =  148 bits (80),  Expect = 2e-33 
 Identities = 80/80 (100%), Gaps = 0/80 (0%) 
 Strand=Plus/Plus 
 
 
Query  49   GACTTGAATTCGACTAGAGGGGATGCAGATATGTATGATCTTCCCAAGAAAGAGGACGCT  108 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  435  GACTTGAATTCGACTAGAGGGGATGCAGATATGTATGATCTTCCCAAGAAAGAGGACGCT  494 
 
Query  109  TTACTCTACCAGAGCAAGGG  128 
            |||||||||||||||||||| 
Sbjct  495  TTACTCTACCAGAGCAAGGG  514 
 
 
b. Forward sequence (vs. X86810.1)  
 
1201 GTGGCAGGGGGGCCGGTCGAGAGCGGCACTGGAGAAAGGGGAGGGAAGTCTGGGGGGGCA  
      
 
1261 AACAGTTCTGTCTCCTCCTTTCAATCCAGACTTGAATTCGACTAGAGGGGATGCAGATAT       
                                 >………………………………………………………………………………… 
 
1321 GTATGATCTTCCCAAGAAAGAGGACGCTTTACTCTACCAGAGCAAGGGTAAGGCAGGGGT       
     ……………………………………………………………………………………………………………………………< 
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1381 TGGGTGGGCACGCTGGCACCTTCACCCGACTTCGTCAGGGACCCCGCTCACAGGGAGGAC      
 
 
1441 CTGAGACCTCAGTCCCAACCACTCCAGCAGCCTTAGGAGGGAGAAACTGTTACAGGTCCC  
 
 
c. Reverse sequence (BLAST) 
 
> ref|NM_000117.2|  Homo sapiens emerin (EMD), mRNA 
Length=1370 
 
 GENE ID: 2010 EMD | emerin [Homo sapiens] (Over 10 PubMed links) 
 
 
 Score =  148 bits (80),  Expect = 4e-35 
 Identities = 80/80 (100%), Gaps = 0/80 (0%) 
 Strand=Plus/Minus 
 
Query  55   CCCTTGCTCTGGTAGAGTAAAGCGTCCTCTTTCTTGGGAAGATCATACATATCTGCATCC  114 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  514  CCCTTGCTCTGGTAGAGTAAAGCGTCCTCTTTCTTGGGAAGATCATACATATCTGCATCC  455 
 
Query  115  CCTCTAGTCGAATTCAAGTC  134 
            |||||||||||||||||||| 
Sbjct  454  CCTCTAGTCGAATTCAAGTC  435 
 
 
d. Reverse sequence (vs. X86810.1)  
  
1201 GTGGCAGGGGGGCCGGTCGAGAGCGGCACTGGAGAAAGGGGAGGGAAGTCTGGGGGGGCA  
      
 
1261 AACAGTTCTGTCTCCTCCTTTCAATCCAGACTTGAATTCGACTAGAGGGGATGCAGATAT       
                                 >…………………………………………………………………………………                  
 
1321 GTATGATCTTCCCAAGAAAGAGGACGCTTTACTCTACCAGAGCAAGGGTAAGGCAGGGGT       
     ………………………………………………………………………………………………………………………………< 
 
1381 TGGGTGGGCACGCTGGCACCTTCACCCGACTTCGTCAGGGACCCCGCTCACAGGGAGGAC      
 
 
1441 CTGAGACCTCAGTCCCAACCACTCCAGCAGCCTTAGGAGGGAGAAACTGTTACAGGTCCC       
 
 
e. Combined sequencing (forward and reverse sequences) 
 
1201 GTGGCAGGGGGGCCGGTCGAGAGCGGCACTGGAGAAAGGGGAGGGAAGTCTGGGGGGGCA  
      
 
1261 AACAGTTCTGTCTCCTCCTTTCAATCCAGACTTGAATTCGACTAGAGGGGATGCAGATAT       
                                 >………………………………………………………………………………… 
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1321 GTATGATCTTCCCAAGAAAGAGGACGCTTTACTCTACCAGAGCAAGGGTAAGGCAGGGGT       
     ………………………………………………………………………………………………………………………………< 
 
1381 TGGGTGGGCACGCTGGCACCTTCACCCGACTTCGTCAGGGACCCCGCTCACAGGGAGGAC      
 
 
1441  CTGAGACCTCAGTCCCAACCACTCCAGCAGCCTTAGGAGGGAGAAACTGTTACAGGTCCC       
 
 
4. Exon 4 
a. Forward sequence 1 (BLAST) 
> ref|NM_000117.2|  Homo sapiens emerin (EMD), mRNA 
Length=1370 
 
 GENE ID: 2010 EMD | emerin [Homo sapiens] (Over 10 PubMed links) 
 
 
 Score =  255 bits (138),  Expect = 7e-66 
 Identities = 141/142 (99%), Gaps = 1/142 (0%) 
 Strand=Plus/Plus 
 
Query  22   CAA-GGCTACAATGACGACTACTATGAAGAGAGCTACTTCACCACCAGGACTTATGGGGA  80 
            ||| |||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  509  CAAGGGCTACAATGACGACTACTATGAAGAGAGCTACTTCACCACCAGGACTTATGGGGA  568 
 
Query  81   GCCCGAGTCTGCCGGCCCGTCCAGGGCTGTCCGCCAGTCAGTGACTTCATTCCCAGATGC  140 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  569  GCCCGAGTCTGCCGGCCCGTCCAGGGCTGTCCGCCAGTCAGTGACTTCATTCCCAGATGC  628 
 
Query  141  TGACGCTTTCCATCACCAGGTG  162 
            |||||||||||||||||||||| 
Sbjct  629  TGACGCTTTCCATCACCAGGTG  650 
 
 
b. Forward sequence 1 (vs. X86810.1)  
 
1501 GAAATGGGATTCAGATTAGGGCCATCAGGCCAGGCGGGGCACACCGATGCCCCCTCTGCT       
 
 
1561 ACCGCTGCCCCCCTTCCCAAGGCTACAATGACGACTACTATGAAGAGAGCTACTTCACCA       
                          >…………………………………………………………………………………………………… 
         
1621 CCAGGACTTATGGGGAGCCCGAGTCTGCCGGCCCGTCCAGGGCTGTCCGCCAGTCAGTGA    
     ……………………………………………………………………………………………………………………………………………………………… 
     
1681 CTTCATTCCCAGATGCTGACGCTTTCCATCACCAGGTGAGCTGGCTGGCAGGCGTCCTGT       
     …………………………………………………………………………………………< 
      
1741 ACTTGGGTACAACCTAGGGGATCGCGGCTGTGTTTGGATAAATCCAGGGGGGCACTGGGT     
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c. Forward sequence 2 (BLAST)  
> ref|NM_000117.2|  Homo sapiens emerin (EMD), mRNA 
Length=1370 
 
 GENE ID: 2010 EMD | emerin [Homo sapiens] (Over 10 PubMed links) 
 
 
 Score =  255 bits (138),  Expect = 5e-66 
 Identities = 141/142 (99%), Gaps = 1/142 (0%) 
 Strand=Plus/Plus 
 
Query  32   CAA-GGCTACAATGACGACTACTATGAAGAGAGCTACTTCACCACCAGGACTTATGGGGA  90 
            ||| |||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  509  CAAGGGCTACAATGACGACTACTATGAAGAGAGCTACTTCACCACCAGGACTTATGGGGA  568 
 
Query  91   GCCCGAGTCTGCCGGCCCGTCCAGGGCTGTCCGCCAGTCAGTGACTTCATTCCCAGATGC  150 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  569  GCCCGAGTCTGCCGGCCCGTCCAGGGCTGTCCGCCAGTCAGTGACTTCATTCCCAGATGC  628 
 
Query  151  TGACGCTTTCCATCACCAGGTG  172 
            |||||||||||||||||||||| 
Sbjct  629  TGACGCTTTCCATCACCAGGTG  650 
 
 
d. Forward sequence 2 (vs. X86810.1) 
 
1501 GAAATGGGATTCAGATTAGGGCCATCAGGCCAGGCGGGGCACACCGATGCCCCCTCTGCT      
 
 
1561 ACCGCTGCCCCCCTTCCCAAGGCTACAATGACGACTACTATGAAGAGAGCTACTTCACCA       
                          >……………………………………………………………………………………………………  
 
1621 CCAGGACTTATGGGGAGCCCGAGTCTGCCGGCCCGTCCAGGGCTGTCCGCCAGTCAGTGA 
     ……………………………………………………………………………………………………………………………………………………………… 
           
1681 CTTCATTCCCAGATGCTGACGCTTTCCATCACCAGGTGAGCTGGCTGGCAGGCGTCCTGT       
     …………………………………………………………………………………………< 
 
1741 ACTTGGGTACAACCTAGGGGATCGCGGCTGTGTTTGGATAAATCCAGGGGGGCACTGGGT 
 
 
e. Reverse sequence 2 (BLAST)  
 
> ref|NM_000117.2|  Homo sapiens emerin (EMD), mRNA 
Length=1370 
 
 GENE ID: 2010 EMD | emerin [Homo sapiens] (Over 10 PubMed links) 
 
 Score =  239 bits (129),  Expect = 8e-61 
 Identities = 136/139 (97%), Gaps = 2/139 (1%) 
 Strand=Plus/Minus 
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Query  27   CTGGTGATGG-AAGCGTCAGCATCTGGGAATGAAGTCACTGACTGGCGGACAGCCCTGGA  85 
            |||||||||| ||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  647  CTGGTGATGGAAAGCGTCAGCATCTGGGAATGAAGTCACTGACTGGCGGACAGCCCTGGA  588 
 
Query  86   CGGGCCGGCAGACTCGGGCTCCCCCTAAGTCCTGGTGGTGAAGTAGCTCTCTTCATAGTA  145 
            |||||||||||||||||||||||| ||||||||||||||||||||||||||||||||||| 
Sbjct  587  CGGGCCGGCAGACTCGGGCTCCCCATAAGTCCTGGTGGTGAAGTAGCTCTCTTCATAGTA  528 
 
Query  146  GTCGTCATTGTAGCC-TTG  163 
            ||||||||||||||| ||| 
Sbjct  527  GTCGTCATTGTAGCCCTTG  509 
 
f. Reverse sequence 2 (vs. X86810.1) 
        
1501 GAAATGGGATTCAGATTAGGGCCATCAGGCCAGGCGGGGCACACCGATGCCCCCTCTGCT   
 
          
1561 ACCGCTGCCCCCCTTCCCAAGGCTACAATGACGACTACTATGAAGAGAGCTACTTCACCA 
                          >……………………………………………………………………………………………………    
           
1621 CCAGGACTTATGGGGAGCCCGAGTCTGCCGGCCCGTCCAGGGCTGTCCGCCAGTCAGTGA   
     ……………………………………………………………………………………………………………………………………………………………… 
          
1681 CTTCATTCCCAGATGCTGACGCTTTCCATCACCAGGTGAGCTGGCTGGCAGGCGTCCTGT   
     …………………………………………………………………………………………< 
          
1741 ACTTGGGTACAACCTAGGGGATCGCGGCTGTGTTTGGATAAATCCAGGGGGGCACTGGGT     
 
 
g. Combined sequencing (forward and reverse sequences) 
     
1501 GAAATGGGATTCAGATTAGGGCCATCAGGCCAGGCGGGGCACACCGATGCCCCCTCTGCT   
 
          
1561 ACCGCTGCCCCCCTTCCCAAGGCTACAATGACGACTACTATGAAGAGAGCTACTTCACCA 
                          >……………………………………………………………………………………………………    
           
1621 CCAGGACTTATGGGGAGCCCGAGTCTGCCGGCCCGTCCAGGGCTGTCCGCCAGTCAGTGA   
     ……………………………………………………………………………………………………………………………………………………………… 
          
1681 CTTCATTCCCAGATGCTGACGCTTTCCATCACCAGGTGAGCTGGCTGGCAGGCGTCCTGT   
     …………………………………………………………………………………………< 
          
1741 ACTTGGGTACAACCTAGGGGATCGCGGCTGTGTTTGGATAAATCCAGGGGGGCACTGGGT     
 
 
 
 
 
Appendix I 
 
299 
 
5. Exon 5 
a. Forward sequence (BLAST) 
> ref|NM_000117.2|  Homo sapiens emerin (EMD), mRNA 
Length=1370 
 
 GENE ID: 2010 EMD | emerin [Homo sapiens] (Over 10 PubMed links) 
 
 
 Score =  100 bits (54),  Expect = 4e-19 
 Identities = 54/54 (100%), Gaps = 0/54 (0%) 
 Strand=Plus/Plus 
 
Query  85   CAGGTGCATGATGACGATCTTTTGTCTTCTTCTGAAGAGGAGTGCAAGGATAGG  138 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  645  CAGGTGCATGATGACGATCTTTTGTCTTCTTCTGAAGAGGAGTGCAAGGATAGG  698 
 
b. Forward sequence (vs. X86810.1)  
 
1921 CACAAGTGGCAAGGCCCCATGGATAAAGGGCTGAACACCCAGAGCCATTCAGGAGGGTGT 
                                                                   
 
1981 GGGTTCCTGGCCTCTAACCAAAGGTCAGAGGGGACTGGCTGGGGAAGTTTGGACTGAGGG 
                                                                   
 
2041 ACATGACAGGGCCATGGTGGCCCTGCCAGCCAGTCCCCTCGCCCTGACTCTCTTCTGCAG 
                                                                   
 
2101 GTGCATGATGACGATCTTTTGTCTTCTTCTGAAGAGGAGTGCAAGGATAGGTGCGTAGTG 
     >………………………………………………………………………………………………………………………………<                                                              
 
2161 GGGGAGCCCAGGGACGGGCTGGTTCTGGGTCCAGGCTCCTGGCCCACTTGCTCCCCTCTT 
 
c. Reverse sequence (BLAST) 
 
> ref|NM_000117.2|  Homo sapiens emerin (EMD), mRNA 
Length=1370 
 
 GENE ID: 2010 EMD | emerin [Homo sapiens] (Over 10 PubMed links) 
 
 
 Score =  100 bits (54),  Expect = 3e-19 
 Identities = 54/54 (100%), Gaps = 0/54 (0%) 
 Strand=Plus/Minus 
 
Query  16   CCTATCCTTGCACTCCTCTTCAGAAGAAGACAAAAGATCGTCATCATGCACCTG  69 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  698  CCTATCCTTGCACTCCTCTTCAGAAGAAGACAAAAGATCGTCATCATGCACCTG  645 
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d. Reverse sequence (vs. X86810.1) 
                                                                    
1921 CACAAGTGGCAAGGCCCCATGGATAAAGGGCTGAACACCCAGAGCCATTCAGGAGGGTGT 
                                                                   
 
1981 GGGTTCCTGGCCTCTAACCAAAGGTCAGAGGGGACTGGCTGGGGAAGTTTGGACTGAGGG 
                                                                   
 
2041 ACATGACAGGGCCATGGTGGCCCTGCCAGCCAGTCCCCTCGCCCTGACTCTCTTCTGCAG 
                                                                   
 
2101 GTGCATGATGACGATCTTTTGTCTTCTTCTGAAGAGGAGTGCAAGGATAGGTGCGTAGTG 
     >………………………………………………………………………………………………………………………………<                                                              
 
2161 GGGGAGCCCAGGGACGGGCTGGTTCTGGGTCCAGGCTCCTGGCCCACTTGCTCCCCTCTT 
 
e. Combined sequencing (forward and reverse sequences) 
                                                            
1921 CACAAGTGGCAAGGCCCCATGGATAAAGGGCTGAACACCCAGAGCCATTCAGGAGGGTGT 
                                                                   
 
1981 GGGTTCCTGGCCTCTAACCAAAGGTCAGAGGGGACTGGCTGGGGAAGTTTGGACTGAGGG 
                                                                   
 
2041 ACATGACAGGGCCATGGTGGCCCTGCCAGCCAGTCCCCTCGCCCTGACTCTCTTCTGCAG 
 
 
2101 GTGCATGATGACGATCTTTTGTCTTCTTCTGAAGAGGAGTGCAAGGATAGGTGCGTAGTG 
     >………………………………………………………………………………………………………………………………<                                                               
 
2161 GGGGAGCCCAGGGACGGGCTGGTTCTGGGTCCAGGCTCCTGGCCCACTTGCTCCCCTCTT 
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AG08466: EMD 
 
1. Exon 1 
a. Forward sequence (BLAST) 
ref|NM_000117.2|  Homo sapiens emerin (EMD), mRNA 
Length=1370 
 
 GENE ID: 2010 EMD | emerin [Homo sapiens] (Over 10 PubMed links) 
 
 
 Score =  401 bits (217),  Expect = 9e-110 
 Identities = 233/240 (97%), Gaps = 3/240 (1%) 
 Strand=Plus/Plus 
 
Query  1    ATTTGGCGGTGA-GCG-CCACGATTTCGGCTGTGACGCGAGCGCGGCCGCTCCCGATGCG  58 
            ||| ||| |||| ||| | |||| |||||||||||||||||||||||||||||||||||| 
Sbjct  93   ATTCGGCTGTGACGCGACAACGA-TTCGGCTGTGACGCGAGCGCGGCCGCTCCCGATGCG  151 
 
Query  59   CTCGTGCCGCCCCCGCCGTGCTCCTCGGCAGCCGTTGCTCGGCCGGTTTTGGTAGGCCCG  118 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  152  CTCGTGCCGCCCCCGCCGTGCTCCTCGGCAGCCGTTGCTCGGCCGGTTTTGGTAGGCCCG  211 
 
Query  119  GGCCGCCGCCAGGCCTCCGCCTGAGCCCGCACCCGCCATGGACAACTACGCAAATCTTTC  178 
            |||||||||||||||||||||||||||||||||||||||||||||||||||| ||||||| 
Sbjct  212  GGCCGCCGCCAGGCCTCCGCCTGAGCCCGCACCCGCCATGGACAACTACGCAGATCTTTC  271 
 
Query  179  GGATACCGAGCTGACCACCTTGCTGCGCCGGTACAACATCCCGCACGGGCCTGTAGTAGG  238 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  272  GGATACCGAGCTGACCACCTTGCTGCGCCGGTACAACATCCCGCACGGGCCTGTAGTAGG  331 
 
 
b. Forward sequence (vs. X86810.1)  
 
  601 CGGCTGCTCCCGCGGTTAGGTCCCGCCCCGCGCAGCGCGCGCAGCCTGCGGAGCCAGCGG 
                                                                   
 
  661 CCGTGACGCGACAACGATTCGGCTGTGACGCGACAACGATTCGGCTGTGACGCGAGCGCG 
                          
 
  721 GCCGCTCCCGATGCGCTCGTGCCGCCCCCGCCGTGCTCCTCGGCAGCCGTTGCTCGGCCG 
        >…………………………………………………………………………………………………………………………………………………………                                                           
 
  781 GTTTTGGTAGGCCCGGGCCGCCGCCAGGCCTCCGCCTGAGCCCGCACCCGCCATGGACAA 
      ………………………………………………………………………………………………………………………………………………………………                                                             
 
  841 CTACGCAGATCTTTCGGATACCGAGCTGACCACCTTGCTGCGCCGGTACAACATCCCGCA 
      ………………………………………………………………………………………………………………………………………………………………                                                             
 
  901 CGGGCCTGTAGTAGGTACGCGGCGGCGGGCGGGACCCCTTCCGGGCCCCCTCCTCGTGCT 
      …………………………………<                                                             
 
  961 CCGCCTCGCGACCTCCCCGCTGCCCTCCCCGCGCGCCTTCCCCGGCCCGCGGCCCTGACC 
 
 
 
c. Reverse sequence (BLAST) 
> ref|NM_000117.2|  Homo sapiens emerin (EMD), mRNA 
Length=1370 
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 GENE ID: 2010 EMD | emerin [Homo sapiens] (Over 10 PubMed links) 
 
 
 Score =  300 bits (162),  Expect = 3e-79 
 Identities = 186/198 (93%), Gaps = 0/198 (0%) 
 Strand=Plus/Minus 
 
Query  44   CCTACTACAGGCCCGTGCGGGATGTTGTACCGGCGCAGCATGGTGGTCAGCTCGGTATCC  103 
            |||||||||||||||||||||||||||||||||||||||| ||||||||||||||||||| 
Sbjct  331  CCTACTACAGGCCCGTGCGGGATGTTGTACCGGCGCAGCAAGGTGGTCAGCTCGGTATCC  272 
 
Query  104  GAAAGATCTGCGTAGTTGTCCTTGGCGGGTGCGGGCTCAGGCGGAGGCCTGGCGGCGGCC  163 
            ||||||||||||||||||||| |||||||||||||||||||||||||||||||||||||| 
Sbjct  271  GAAAGATCTGCGTAGTTGTCCATGGCGGGTGCGGGCTCAGGCGGAGGCCTGGCGGCGGCC  212 
 
Query  164  CGGGCCTACCAAAACCGGCCGAGCAACGGCTGTTGTGGAGCACGGGGGGGGCTGTACGAG  223 
            ||||||||||||||||||||||||||||||||  | ||||||||| |||||| | ||||| 
Sbjct  211  CGGGCCTACCAAAACCGGCCGAGCAACGGCTGCCGAGGAGCACGGCGGGGGCGGCACGAG  152 
 
Query  224  TTCATCGGTAGCGGTCGC  241 
              |||||| ||||| ||| 
Sbjct  151  CGCATCGGGAGCGGCCGC  134 
 
 
d. Reverse sequence (vs. X86810.1)  
 
  601 CGGCTGCTCCCGCGGTTAGGTCCCGCCCCGCGCAGCGCGCGCAGCCTGCGGAGCCAGCGG 
                                                                   
 
  661 CCGTGACGCGACAACGATTCGGCTGTGACGCGACAACGATTCGGCTGTGACGCGAGCGCG 
                                                                   
 
  721 GCCGCTCCCGATGCGCTCGTGCCGCCCCCGCCGTGCTCCTCGGCAGCCGTTGCTCGGCCG 
        >…………………………………………………………………………………………………………………………………………………………                                                            
 
  781 GTTTTGGTAGGCCCGGGCCGCCGCCAGGCCTCCGCCTGAGCCCGCACCCGCCATGGACAA 
      ………………………………………………………………………………………………………………………………………………………………                                                             
 
  841 CTACGCAGATCTTTCGGATACCGAGCTGACCACCTTGCTGCGCCGGTACAACATCCCGCA 
      ………………………………………………………………………………………………………………………………………………………………                                                             
 
  901 CGGGCCTGTAGTAGGTACGCGGCGGCGGGCGGGACCCCTTCCGGGCCCCCTCCTCGTGCT 
      …………………………………<                                                             
 
  961 CCGCCTCGCGACCTCCCCGCTGCCCTCCCCGCGCGCCTTCCCCGGCCCGCGGCCCTGACC 
 
   
e. Combined sequencing (forward and reverse sequences) 
 
  601 CGGCTGCTCCCGCGGTTAGGTCCCGCCCCGCGCAGCGCGCGCAGCCTGCGGAGCCAGCGG 
                                                                   
 
  661 CCGTGACGCGACAACGATTCGGCTGTGACGCGACAACGATTCGGCTGTGACGCGAGCGCG 
                                                                   
 
  721 GCCGCTCCCGATGCGCTCGTGCCGCCCCCGCCGTGCTCCTCGGCAGCCGTTGCTCGGCCG 
        >……………………………………………………………………………………………………………………………………………………………                                                              
 
  781 GTTTTGGTAGGCCCGGGCCGCCGCCAGGCCTCCGCCTGAGCCCGCACCCGCCATGGACAA 
      ………………………………………………………………………………………………………………………………………………………………                                                             
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  841 CTACGCAGATCTTTCGGATACCGAGCTGACCACCTTGCTGCGCCGGTACAACATCCCGCA 
      ………………………………………………………………………………………………………………………………………………………………                                                             
 
  901 CGGGCCTGTAGTAGGTACGCGGCGGCGGGCGGGACCCCTTCCGGGCCCCCTCCTCGTGCT 
      …………………………………<                                               
 
  961 CCGCCTCGCGACCTCCCCGCTGCCCTCCCCGCGCGCCTTCCCCGGCCCGCGGCCCTGACC 
 
 
2. Exon 2 
a. Forward sequence (BLAST) 
> ref|NM_000117.2|  Homo sapiens emerin (EMD), mRNA 
Length=1370 
 
 GENE ID: 2010 EMD | emerin [Homo sapiens] (Over 10 PubMed links) 
 
 
 Score =  169 bits (91),  Expect = 9e-40 
 Identities = 102/107 (95%), Gaps = 1/107 (0%) 
 Strand=Plus/Plus 
 
Query  47   AGGATCAACTCGTAGGCTTTACGAGAAGAAGA-CTTCGAGTACGAGACCCAGAGGCGGCG  105 
            |||||||||||||||||||||||||||||||| ||||||||||||||||||||||||||| 
Sbjct  329  AGGATCAACTCGTAGGCTTTACGAGAAGAAGATCTTCGAGTACGAGACCCAGAGGCGGCG  388 
 
Query  106  GCTCTCGCCCCCTTGCTCGTCCGCCGCCTCCTCTTATTGTTTCTCTG  152 
            ||||||||||||  ||||||||||||||||||||||| | ||||||| 
Sbjct  389  GCTCTCGCCCCCCAGCTCGTCCGCCGCCTCCTCTTATAGCTTCTCTG  435 
 
 
b. Forward sequence (vs. X86810.1)  
 
961 CCGCCTCGCGACCTCCCCGCTGCCCTCCCCGCGCGCCTTCCCCGGCCCGCGGCCCTGACC 
 
  
 1021 GCCCCGTGTCCGGCCAGGATCAACTCGTAGGCTTTACGAGAAGAAGATCTTCGAGTACGA       
                       >……………………………………………………………………………………………………………… 
 
 1081 GACCCAGAGGCGGCGGCTCTCGCCCCCCAGCTCGTCCGCCGCCTCCTCTTATAGCTTCTC       
      ………………………………………………………………………………………………………………………………………………………………    
 
 1141 TGGTGAGAGCCTCGCCTGTGGGGACAGCCTGGGACGCGGGGAGGATGGGGTCGCGAGGGT       
      …< 
 
 1201  GTGGCAGGGGGGCCGGTCGAGAGCGGCACTGGAGAAAGGGGAGGGAAGTCTGGGGGGGCA       
 
 
c. Reverse sequence (BLAST) 
> ref|NM_000117.2|  Homo sapiens emerin (EMD), mRNA 
Length=1370 
 
 GENE ID: 2010 EMD | emerin [Homo sapiens] (Over 10 PubMed links) 
 
 
 Score =  198 bits (107),  Expect = 9e-49 
 Identities = 107/107 (100%), Gaps = 0/107 (0%) 
 Strand=Plus/Minus 
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Query  60   CAGAGAAGCTATAAGAGGAGGCGGCGGACGAGCTGGGGGGCGAGAGCCGCCGCCTCTGGG  119 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  435  CAGAGAAGCTATAAGAGGAGGCGGCGGACGAGCTGGGGGGCGAGAGCCGCCGCCTCTGGG  376 
 
Query  120  TCTCGTACTCGAAGATCTTCTTCTCGTAAAGCCTACGAGTTGATCCT  166 
            ||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  375  TCTCGTACTCGAAGATCTTCTTCTCGTAAAGCCTACGAGTTGATCCT  329 
 
 
d. Reverse sequence (vs. X86810.1) 
 
 
  961 CCGCCTCGCGACCTCCCCGCTGCCCTCCCCGCGCGCCTTCCCCGGCCCGCGGCCCTGACC       
 
 
 1021 GCCCCGTGTCCGGCCAGGATCAACTCGTAGGCTTTACGAGAAGAAGATCTTCGAGTACGA       
                       >………………………………………………………………………………………………………………     
 
 1081 GACCCAGAGGCGGCGGCTCTCGCCCCCCAGCTCGTCCGCCGCCTCCTCTTATAGCTTCTC       
      ………………………………………………………………………………………………………………………………………………………………    
 
 1141 TGGTGAGAGCCTCGCCTGTGGGGACAGCCTGGGACGCGGGGAGGATGGGGTCGCGAGGGT       
      …< 
 
 1201  GTGGCAGGGGGGCCGGTCGAGAGCGGCACTGGAGAAAGGGGAGGGAAGTCTGGGGGGGCA       
 
 
e. Combined sequencing (forward and reverse sequences) 
 
 961 CCGCCTCGCGACCTCCCCGCTGCCCTCCCCGCGCGCCTTCCCCGGCCCGCGGCCCTGACC 
                                                                            
  
1021 GCCCCGTGTCCGGCCAGGATCAACTCGTAGGCTTTACGAGAAGAAGATCTTCGAGTACGA       
                      >………………………………………………………………………………………………………………              
  
1081 GACCCAGAGGCGGCGGCTCTCGCCCCCCAGCTCGTCCGCCGCCTCCTCTTATAGCTTCTC       
     ……………………………………………………………………………………………………………………………………………………………… 
 
1141 TGGTGAGAGCCTCGCCTGTGGGGACAGCCTGGGACGCGGGGAGGATGGGGTCGCGAGGGT       
     …< 
 
1201  GTGGCAGGGGGGCCGGTCGAGAGCGGCACTGGAGAAAGGGGAGGGAAGTCTGGGGGGGCA    
    
 
3. Exon 3 
4. Exon 4 
a. Forward sequence (BLAST) 
ref|NM_000117.2|  Homo sapiens emerin (EMD), mRNA 
Length=1370 
 
 GENE ID: 2010 EMD | emerin [Homo sapiens] (Over 10 PubMed links) 
 
 
 Score =  255 bits (138),  Expect = 5e-66 
 Identities = 141/142 (99%), Gaps = 1/142 (0%) 
 Strand=Plus/Plus 
 
Query  32   CAA-GGCTACAATGACGACTACTATGAAGAGAGCTACTTCACCACCAGGACTTATGGGGA  90 
            ||| |||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  509  CAAGGGCTACAATGACGACTACTATGAAGAGAGCTACTTCACCACCAGGACTTATGGGGA  568 
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Query  91   GCCCGAGTCTGCCGGCCCGTCCAGGGCTGTCCGCCAGTCAGTGACTTCATTCCCAGATGC  150 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  569  GCCCGAGTCTGCCGGCCCGTCCAGGGCTGTCCGCCAGTCAGTGACTTCATTCCCAGATGC  628 
 
Query  151  TGACGCTTTCCATCACCAGGTG  172 
            |||||||||||||||||||||| 
Sbjct  629  TGACGCTTTCCATCACCAGGTG  650 
 
b. Forward sequence (vs. X86810.1)  
 
1501 GAAATGGGATTCAGATTAGGGCCATCAGGCCAGGCGGGGCACACCGATGCCCCCTCTGCT       
 
 
1561 ACCGCTGCCCCCCTTCCCAAGGCTACAATGACGACTACTATGAAGAGAGCTACTTCACCA       
                          >…………………………………………………………………………………………………… 
         
1621 CCAGGACTTATGGGGAGCCCGAGTCTGCCGGCCCGTCCAGGGCTGTCCGCCAGTCAGTGA    
     ……………………………………………………………………………………………………………………………………………………………… 
     
1681 CTTCATTCCCAGATGCTGACGCTTTCCATCACCAGGTGAGCTGGCTGGCAGGCGTCCTGT       
     …………………………………………………………………………………………< 
      
1741 ACTTGGGTACAACCTAGGGGATCGCGGCTGTGTTTGGATAAATCCAGGGGGGCACTGGGT     
 
c. Reverse sequence (BLAST) 
> ref|NM_000117.2|  Homo sapiens emerin (EMD), mRNA 
Length=1370 
 
 GENE ID: 2010 EMD | emerin [Homo sapiens] (Over 10 PubMed links) 
 
 
 Score =  244 bits (132),  Expect = 1e-62 
 Identities = 137/139 (98%), Gaps = 2/139 (1%) 
 Strand=Plus/Minus 
 
Query  17   CTGGTGATGG-AAGCGTCAGCATCTGGGAATGAAGTCACTGACTGGCGGACAGCCCTGGA  75 
            |||||||||| ||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  647  CTGGTGATGGAAAGCGTCAGCATCTGGGAATGAAGTCACTGACTGGCGGACAGCCCTGGA  588 
 
Query  76   CGGGCCGGCAGACTCGGGCTCCCCATAAGTCCTGGTGGTGAAGTAGCTCTCTTCATAGTA  135 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  587  CGGGCCGGCAGACTCGGGCTCCCCATAAGTCCTGGTGGTGAAGTAGCTCTCTTCATAGTA  528 
 
Query  136  GTCGTCATTGTAGCC-TTG  153 
            ||||||||||||||| ||| 
Sbjct  527  GTCGTCATTGTAGCCCTTG  509 
 
 
d. Reverse sequence (vs. X86810.1)  
 
1501 GAAATGGGATTCAGATTAGGGCCATCAGGCCAGGCGGGGCACACCGATGCCCCCTCTGCT      
 
 
1561 ACCGCTGCCCCCCTTCCCAAGGCTACAATGACGACTACTATGAAGAGAGCTACTTCACCA       
                          >……………………………………………………………………………………………………  
 
1621 CCAGGACTTATGGGGAGCCCGAGTCTGCCGGCCCGTCCAGGGCTGTCCGCCAGTCAGTGA 
     ……………………………………………………………………………………………………………………………………………………………… 
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1681 CTTCATTCCCAGATGCTGACGCTTTCCATCACCAGGTGAGCTGGCTGGCAGGCGTCCTGT       
     …………………………………………………………………………………………< 
 
1741 ACTTGGGTACAACCTAGGGGATCGCGGCTGTGTTTGGATAAATCCAGGGGGGCACTGGGT 
 
 
e. Combined sequencing (forward and reverse sequences) 
 
1501 GAAATGGGATTCAGATTAGGGCCATCAGGCCAGGCGGGGCACACCGATGCCCCCTCTGCT   
 
          
1561 ACCGCTGCCCCCCTTCCCAAGGCTACAATGACGACTACTATGAAGAGAGCTACTTCACCA 
                          >……………………………………………………………………………………………………    
           
1621 CCAGGACTTATGGGGAGCCCGAGTCTGCCGGCCCGTCCAGGGCTGTCCGCCAGTCAGTGA   
     ……………………………………………………………………………………………………………………………………………………………… 
          
1681 CTTCATTCCCAGATGCTGACGCTTTCCATCACCAGGTGAGCTGGCTGGCAGGCGTCCTGT   
     …………………………………………………………………………………………< 
          
1741 ACTTGGGTACAACCTAGGGGATCGCGGCTGTGTTTGGATAAATCCAGGGGGGCACTGGGT     
 
 
5. Exon 5 
a. Forward sequence (BLAST) 
> ref|NM_000117.2|  Homo sapiens emerin (EMD), mRNA 
Length=1370 
 
 GENE ID: 2010 EMD | emerin [Homo sapiens] (Over 10 PubMed links) 
 
 
 Score =  100 bits (54),  Expect = 2e-19 
 Identities = 54/54 (100%), Gaps = 0/54 (0%) 
 Strand=Plus/Plus 
 
Query  93   CAGGTGCATGATGACGATCTTTTGTCTTCTTCTGAAGAGGAGTGCAAGGATAGG  146 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  645  CAGGTGCATGATGACGATCTTTTGTCTTCTTCTGAAGAGGAGTGCAAGGATAGG  698 
 
 
b. Forward sequence (vs. X86810.1)  
 
1921 CACAAGTGGCAAGGCCCCATGGATAAAGGGCTGAACACCCAGAGCCATTCAGGAGGGTGT 
                                                                   
 
1981 GGGTTCCTGGCCTCTAACCAAAGGTCAGAGGGGACTGGCTGGGGAAGTTTGGACTGAGGG 
                                                                   
 
2041 ACATGACAGGGCCATGGTGGCCCTGCCAGCCAGTCCCCTCGCCCTGACTCTCTTCTGCAG 
                                                                   
 
2101 GTGCATGATGACGATCTTTTGTCTTCTTCTGAAGAGGAGTGCAAGGATAGGTGCGTAGTG 
     >………………………………………………………………………………………………………………………………<                                                              
 
2161 GGGGAGCCCAGGGACGGGCTGGTTCTGGGTCCAGGCTCCTGGCCCACTTGCTCCCCTCTT 
 
 
c. Reverse sequence (BLAST) 
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> ref|NM_000117.2|  Homo sapiens emerin (EMD), mRNA 
Length=1370 
 
 GENE ID: 2010 EMD | emerin [Homo sapiens] (Over 10 PubMed links) 
 
 
 Score =  100 bits (54),  Expect = 8e-21 
 Identities = 54/54 (100%), Gaps = 0/54 (0%) 
 Strand=Plus/Minus 
 
Query  25   CCTATCCTTGCACTCCTCTTCAGAAGAAGACAAAAGATCGTCATCATGCACCTG  78 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  698  CCTATCCTTGCACTCCTCTTCAGAAGAAGACAAAAGATCGTCATCATGCACCTG  645 
 
 
d. Reverse sequence (vs. X86810.1)  
                                                                   
1921 CACAAGTGGCAAGGCCCCATGGATAAAGGGCTGAACACCCAGAGCCATTCAGGAGGGTGT 
                                                                   
 
1981 GGGTTCCTGGCCTCTAACCAAAGGTCAGAGGGGACTGGCTGGGGAAGTTTGGACTGAGGG 
                                                                   
 
2041 ACATGACAGGGCCATGGTGGCCCTGCCAGCCAGTCCCCTCGCCCTGACTCTCTTCTGCAG 
                                                                   
 
2101 GTGCATGATGACGATCTTTTGTCTTCTTCTGAAGAGGAGTGCAAGGATAGGTGCGTAGTG 
     >………………………………………………………………………………………………………………………………<                                                              
 
2161 GGGGAGCCCAGGGACGGGCTGGTTCTGGGTCCAGGCTCCTGGCCCACTTGCTCCCCTCTT 
                                                               
     
e. Combined sequencing (forward and reverse sequences) 
 
1921 CACAAGTGGCAAGGCCCCATGGATAAAGGGCTGAACACCCAGAGCCATTCAGGAGGGTGT 
                                                                   
 
1981 GGGTTCCTGGCCTCTAACCAAAGGTCAGAGGGGACTGGCTGGGGAAGTTTGGACTGAGGG 
                                                                   
 
2041 ACATGACAGGGCCATGGTGGCCCTGCCAGCCAGTCCCCTCGCCCTGACTCTCTTCTGCAG 
 
 
2101 GTGCATGATGACGATCTTTTGTCTTCTTCTGAAGAGGAGTGCAAGGATAGGTGCGTAGTG 
     >………………………………………………………………………………………………………………………………<                                                               
 
2161 GGGGAGCCCAGGGACGGGCTGGTTCTGGGTCCAGGCTCCTGGCCCACTTGCTCCCCTCTT 
 
 
6. Exon 6 
a. Forward sequence 1 (BLAST) 
> ref|NM_000117.2|  Homo sapiens emerin (EMD), mRNA 
Length=1370 
 
 GENE ID: 2010 EMD | emerin [Homo sapiens] (Over 10 PubMed links) 
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 Score =  446 bits (241),  Expect = 2e-124 
 Identities = 330/373 (88%), Gaps = 5/373 (1%) 
 Strand=Plus/Plus 
 
Query  21    ATGTACGGCCTGGA-AGTGCCTACCAGAGCAACACGCACTACCGCCCTG-TTCAATTTTA  78 
             |||||||||| ||| |||||||||||||||| ||||||||||||||||| ||||   |   
Sbjct  708   ATGTACGGCCGGGACAGTGCCTACCAGAGCATCACGCACTACCGCCCTGTTTCAGCCTCC  767 
 
Query  79    AGAAGAGCTCCCAGGACCTGTCCTATTATCCTACTTCCTCCTCCACCTCTCTAATGTCCT  138 
             ||  |||||||| ||||||||||||||||||||||||||||||||||||| | ||||||| 
Sbjct  768   AG--GAGCTCCCTGGACCTGTCCTATTATCCTACTTCCTCCTCCACCTCTTTTATGTCCT  825 
 
Query  139   ACTCATCATCTTCCTCTTCATGGCTCACCCGCCGTGCCATCCGGCATGAAAACCGTGCTC  198 
              |||||||||||||||||||||||||||||||||||||||||||| |||||||||||||| 
Sbjct  826   CCTCATCATCTTCCTCTTCATGGCTCACCCGCCGTGCCATCCGGCCTGAAAACCGTGCTC  885 
 
Query  199   CTGGGGCTGGGCTGGGCCAGGATCGCCAGGCCCCTCTCTGGGTCCACCTGCTGCTTTTCC  258 
             |||||||||||||||||||||||||||||| ||| ||||||| ||| ||||||||||||| 
Sbjct  886   CTGGGGCTGGGCTGGGCCAGGATCGCCAGGTCCCGCTCTGGGGCCAGCTGCTGCTTTTCC  945 
 
Query  259   TGGTCTTTGTGATCGTCCTTTTCTTCATTTACCACTTCCTGCAAGCTGAACAAAGCAAAA  318 
             ||||||||||||||||||| |||||||||||||||||| |||| |||||| || ||||   
Sbjct  946   TGGTCTTTGTGATCGTCCTCTTCTTCATTTACCACTTCATGCAGGCTGAAGAAGGCAACC  1005 
 
Query  319   CCTTCCAGATGTAGCTATGAGGGTATGAGCTTCACATCAACGTTTTTGGAAAAAATCCTG  378 
             ||||| ||| | ||| |||||||| || |||||| | | | || |||||  ||  ||||| 
Sbjct  1006  CCTTCTAGAGGGAGCCATGAGGGTCTGGGCTTCAGAGCTAGGTCTTTGGGGAAG-TCCTG  1064 
 
Query  379   GCTAACTGCCTTA  391 
             ||| ||||||||| 
Sbjct  1065  GCTGACTGCCTTA  1077 
 
 
b. Forward sequence 1 (vs. X86810.1) 
 
2161 GGGGAGCCCAGGGACGGGCTGGTTCTGGGTCCAGGCTCCTGGCCCACTTGCTCCCCTCTT       
 
 
2221 TTGCCTCAGGGAACGCCCCATGTACGGCCGGGACAGTGCCTACCAGAGCATCACGCACTA       
               
 
2281 CCGCCCTGTTTCAGCCTCCAGGAGCTCCCTGGACCTGTCCTATTATCCTACTTCCTCCTC       
 
 
2341 CACCTCTTTTATGTCCTCCTCATCATCTTCCTCTTCATGGCTCACCCGCCGTGCCATCCG       
 
 
2401 GCCTGAAAACCGTGCTCCTGGGGCTGGGCTGGGCCAGGATCGCCAGGTCCCGCTCTGGGG       
 
 
2461 CCAGCTGCTGCTTTTCCTGGTCTTTGTGATCGTCCTCTTCTTCATTTACCACTTCATGCA       
                     
      
2521 GGCTGAAGAAGGCAACCCCTTCTAGAGGGAGCCATGAGGGTCTGGGCTTCAGAGCTAGGT       
                           
 
2581 CTTTGGGGAAGTCCTGGCTGACTGCCTTAGCAGTGGGGGTGGGGGTGGGGGCAGGGGCAG       
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c. Forward sequence 2 (BLAST) 
> ref|NM_000117.2|  Homo sapiens emerin (EMD), mRNA 
Length=1370 
 
 GENE ID: 2010 EMD | emerin [Homo sapiens] (Over 10 PubMed links) 
 
 
 Score =  678 bits (367),  Expect = 0.0 
 Identities = 372/374 (99%), Gaps = 2/374 (0%) 
 Strand=Plus/Plus 
 
Query  4     CCCATGTACGGCCGGGA-AGTGCCTACCAGAGCATCACGCACTACCGCCCTGTTTCAGCC  62 
             ||||||||||||||||| |||||||||||||||||||||||||||||||||||||||||| 
Sbjct  705   CCCATGTACGGCCGGGACAGTGCCTACCAGAGCATCACGCACTACCGCCCTGTTTCAGCC  764 
 
Query  63    TCCAGGAGCTCCCTGGACCTGTCCTATTATCCTACTTCCTCCTCCACCTCTTTTATGTCC  122 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  765   TCCAGGAGCTCCCTGGACCTGTCCTATTATCCTACTTCCTCCTCCACCTCTTTTATGTCC  824 
 
Query  123   TCCTCATCATCTTCCTCTTCATGGCTCACCCGCCGTGCCATCCGGCCTGAAAACCGTGCT  182 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  825   TCCTCATCATCTTCCTCTTCATGGCTCACCCGCCGTGCCATCCGGCCTGAAAACCGTGCT  884 
 
Query  183   CCTGGGGCTGGGCTGGGCCAGGATCGCCAGGTCCCGCTCTGGGGCCAGCTGCTGCTTTTC  242 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  885   CCTGGGGCTGGGCTGGGCCAGGATCGCCAGGTCCCGCTCTGGGGCCAGCTGCTGCTTTTC  944 
 
Query  243   CTGGTCTTTGTGATCGTCCTCTTCTTCATTTACCACTTCATGCAGGCTGAAGAAGGCAAC  302 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  945   CTGGTCTTTGTGATCGTCCTCTTCTTCATTTACCACTTCATGCAGGCTGAAGAAGGCAAC  1004 
 
Query  303   CCCTTCTAGAGGGAGCCATGAGGGTCTGGGCTTCAGAGCTAGGTCTTTGGGGAAGTCCTG  362 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1005  CCCTTCTAGAGGGAGCCATGAGGGTCTGGGCTTCAGAGCTAGGTCTTTGGGGAAGTCCTG  1064 
 
Query  363   GCTGA-TGCCTTAG  375 
             ||||| |||||||| 
Sbjct  1065  GCTGACTGCCTTAG  1078 
 
 
d. Forward sequence 2 (vs. X86810.1) 
 
2161 GGGGAGCCCAGGGACGGGCTGGTTCTGGGTCCAGGCTCCTGGCCCACTTGCTCCCCTCTT       
 
 
2221 TTGCCTCAGGGAACGCCCCATGTACGGCCGGGACAGTGCCTACCAGAGCATCACGCACTA 
               
 
2281 CCGCCCTGTTTCAGCCTCCAG>GAGCTCCCTGGACCTGTCCTATTATCCTACTTCCTCCTC       
    
 
2341 CACCTCTTTTATGTCCTCCTCATCATCTTCCTCTTCATGGCTCACCCGCCGTGCCATCCG    
 
 
2401 GCCTGAAAACCGTGCTCCTGGGGCTGGGCTGGGCCAGGATCGCCAGGTCCCGCTCTGGGG 
  
 
2461 CCAGCTGCTGCTTTTCCTGGTCTTTGTGATCGTCCTCTTCTTCATTTACCACTTCATGCA 
 
 
2521 GGCTGAAGAAGGCAACCCCTTCTAGAGGGAGCCATGAGGGTCTGGGCTTCAGAGCTAGGT   
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2581 CTTTGGGGAAGTCCTGGCTGACTGCCTTAGCAGTGGGGGTGGGGGTGGGGGCAGGGGCAG 
 
e. Reverse sequence 1 (BLAST) 
> ref|NM_000117.2|  Homo sapiens emerin (EMD), mRNA 
Length=1370 
 
 GENE ID: 2010 EMD | emerin [Homo sapiens] (Over 10 PubMed links) 
 
 
 Score =  377 bits (204),  Expect = 1e-102 
 Identities = 241/259 (93%), Gaps = 2/259 (0%) 
 Strand=Plus/Minus 
 
Query  21    CCAGACCCTCTTGGCTCCCTCTAGAAGGGGTTGCCTTCTTCAGCCTGCATGAAGTGGTAA  80 
             |||||||||| ||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1033  CCAGACCCTCATGGCTCCCTCTAGAAGGGGTTGCCTTCTTCAGCCTGCATGAAGTGGTAA  974 
 
Query  81    ATGAAGACGAGGACGATCATTT-GACCAGGAAAAGCTGCAGCTGGCCCCACAGCGGGACC  139 
             ||||||| |||||||||||    ||||||||||||| ||||||||||||| ||||||||| 
Sbjct  973   ATGAAGAAGAGGACGATCACAAAGACCAGGAAAAGCAGCAGCTGGCCCCAGAGCGGGACC  914 
 
Query  140   TGGCGATCCTGGCCCAGCCCATCCCCATGAGCACGGTTTTCAGGCCTGATGGCACGGCGG  199 
             ||||||||||||||||||||| ||||| |||||||||||||||||| ||||||||||||| 
Sbjct  913   TGGCGATCCTGGCCCAGCCCAGCCCCAGGAGCACGGTTTTCAGGCCGGATGGCACGGCGG  854 
 
Query  200   GTGAGCCTTGAAGAGGAATATGATGAGGAGGACATATA-GAGGTGGATGAGGAAGTAGGA  258 
             ||||||| |||||||||| ||||||||||||||||| | |||||||| |||||||||||| 
Sbjct  853   GTGAGCCATGAAGAGGAAGATGATGAGGAGGACATAAAAGAGGTGGAGGAGGAAGTAGGA  794 
 
Query  259   TAATATGACAGGTCCTGGG  277 
             ||||| ||||||||| ||| 
Sbjct  793   TAATAGGACAGGTCCAGGG  775 
 
 
f. Reverse sequence 1 (vs. X86810.1) 
 
2161 GGGGAGCCCAGGGACGGGCTGGTTCTGGGTCCAGGCTCCTGGCCCACTTGCTCCCCTCTT       
 
 
2221 TTGCCTCAGGGAACGCCCCATGTACGGCCGGGACAGTGCCTACCAGAGCATCACGCACTA 
               
 
2281 CCGCCCTGTTTCAGCCTCCAG>GAGCTCCCTGGACCTGTCCTATTATCCTACTTCCTCCTC       
    
 
2341 CACCTCTTTTATGTCCTCCTCATCATCTTCCTCTTCATGGCTCACCCGCCGTGCCATCCG    
 
 
2401 GCCTGAAAACCGTGCTCCTGGGGCTGGGCTGGGCCAGGATCGCCAGGTCCCGCTCTGGGG 
  
 
2461 CCAGCTGCTGCTTTTCCTGGTCTTTGTGATCGTCCTCTTCTTCATTTACCACTTCATGCA 
 
 
2521 GGCTGAAGAAGGCAACCCCTTCTAGAGGGAGCCATGAGGGTCTGGGCTTCAGAGCTAGGT   
                           
 
2581 CTTTGGGGAAGTCCTGGCTGACTGCCTTAGCAGTGGGGGTGGGGGTGGGGGCAGGGGCAG 
 
 
g. Reverse sequence 2 (BLAST) 
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ref|NM_000117.2|  Homo sapiens emerin (EMD), mRNA 
Length=1370 
 
 GENE ID: 2010 EMD | emerin [Homo sapiens] (Over 10 PubMed links) 
 
 
 Score =  623 bits (337),  Expect = 4e-176 
 Identities = 337/337 (100%), Gaps = 0/337 (0%) 
 Strand=Plus/Minus 
 
Query  8     CAGACCCTCATGGCTCCCTCTAGAAGGGGTTGCCTTCTTCAGCCTGCATGAAGTGGTAAA  67 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1032  CAGACCCTCATGGCTCCCTCTAGAAGGGGTTGCCTTCTTCAGCCTGCATGAAGTGGTAAA  973 
 
Query  68    TGAAGAAGAGGACGATCACAAAGACCAGGAAAAGCAGCAGCTGGCCCCAGAGCGGGACCT  127 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  972   TGAAGAAGAGGACGATCACAAAGACCAGGAAAAGCAGCAGCTGGCCCCAGAGCGGGACCT  913 
 
Query  128   GGCGATCCTGGCCCAGCCCAGCCCCAGGAGCACGGTTTTCAGGCCGGATGGCACGGCGGG  187 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  912   GGCGATCCTGGCCCAGCCCAGCCCCAGGAGCACGGTTTTCAGGCCGGATGGCACGGCGGG  853 
 
Query  188   TGAGCCATGAAGAGGAAGATGATGAGGAGGACATAAAAGAGGTGGAGGAGGAAGTAGGAT  247 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  852   TGAGCCATGAAGAGGAAGATGATGAGGAGGACATAAAAGAGGTGGAGGAGGAAGTAGGAT  793 
 
Query  248   AATAGGACAGGTCCAGGGAGCTCCTGGAGGCTGAAACAGGGCGGTAGTGCGTGATGCTCT  307 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  792   AATAGGACAGGTCCAGGGAGCTCCTGGAGGCTGAAACAGGGCGGTAGTGCGTGATGCTCT  733 
 
Query  308   GGTAGGCACTGTCCCGGCCGTACATGGGGCGTTCCCT  344 
             ||||||||||||||||||||||||||||||||||||| 
Sbjct  732   GGTAGGCACTGTCCCGGCCGTACATGGGGCGTTCCCT  696 
 
 
h. Reverse sequence 2 (vs. X86810.1) 
    
2161 GGGGAGCCCAGGGACGGGCTGGTTCTGGGTCCAGGCTCCTGGCCCACTTGCTCCCCTCTT       
 
 
2221 TTGCCTCAGGGAACGCCCCATGTACGGCCGGGACAGTGCCTACCAGAGCATCACGCACTA 
               
 
2281 CCGCCCTGTTTCAGCCTCCAG>GAGCTCCCTGGACCTGTCCTATTATCCTACTTCCTCCTC       
    
 
2341 CACCTCTTTTATGTCCTCCTCATCATCTTCCTCTTCATGGCTCACCCGCCGTGCCATCCG    
 
 
2401 GCCTGAAAACCGTGCTCCTGGGGCTGGGCTGGGCCAGGATCGCCAGGTCCCGCTCTGGGG 
  
 
2461 CCAGCTGCTGCTTTTCCTGGTCTTTGTGATCGTCCTCTTCTTCATTTACCACTTCATGCA 
 
 
2521 GGCTGAAGAAGGCAACCCCTTCTAGAGGGAGCCATGAGGGTCTGGGCTTCAGAGCTAGGT   
                           
 
2581 CTTTGGGGAAGTCCTGGCTGACTGCCTTAGCAGTGGGGGTGGGGGTGGGGGCAGGGGCAG 
      
 
i. Combined sequencing (forward and reverse sequences) 
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2161 GGGGAGCCCAGGGACGGGCTGGTTCTGGGTCCAGGCTCCTGGCCCACTTGCTCCCCTCTT 
       
 
2221 TTGCCTCAGGGAACGCCCCATGTACGGCCGGGACAGTGCCTACCAGAGCATCACGCACTA  
               
 
2281 CCGCCCTGTTTCAGCCTCCAGGAGCTCCCTGGACCTGTCCTATTATCCTACTTCCTCCTC       
      
 
2341 CACCTCTTTTATGTCCTCCTCATCATCTTCCTCTTCATGGCTCACCCGCCGTGCCATCCG       
      
 
2401 GCCTGAAAACCGTGCTCCTGGGGCTGGGCTGGGCCAGGATCGCCAGGTCCCGCTCTGGGG       
 
 
2461 CCAGCTGCTGCTTTTCCTGGTCTTTGTGATCGTCCTCTTCTTCATTTACCACTTCATGCA       
                     
 
2521 GGCTGAAGAAGGCAACCCCTTCTAGAGGGAGCCATGAGGGTCTGGGCTTCAGAGCTAGGT       
                           
 
2581 CTTTGGGGAAGTCCTGGCTGACTGCCTTAGCAGTGGGGGTGGGGGTGGGGGCAGGGGCAG       
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AG11572: EMD 
 
1. Exon 1 
a. Forward sequence (BLAST) 
> ref|NM_000117.2|  Homo sapiens emerin (EMD), mRNA 
Length=1370 
 
 GENE ID: 2010 EMD | emerin [Homo sapiens] (Over 10 PubMed links) 
 
 
 Score =  161 bits (87),  Expect = 1e-37 
 Identities = 147/176 (83%), Gaps = 4/176 (2%) 
 Strand=Plus/Plus 
 
Query  8    TGCGGCTCGTTGCCGCCCCCGCTGGGAAACAGGGGGAGCCGTTGCTCGGCCGGTTTTGGT  67 
            ||| ||||| |||||||||||| | |   |   || |||||||||||||||||||||||| 
Sbjct  148  TGC-GCTCG-TGCCGCCCCCGCCGTG-CTCCTCGGCAGCCGTTGCTCGGCCGGTTTTGGT  204 
 
Query  68   AGGCCCGGATCATAAAACAGGCCTCCGACTGAGCCCGCACTCGCCATGGATAACTACTCA  127 
            ||||||||  |      |||||||||| |||||||||||| ||||||||| |||||| || 
Sbjct  205  AGGCCCGGGCCGCCGC-CAGGCCTCCGCCTGAGCCCGCACCCGCCATGGACAACTACGCA  263 
 
Query  128  CATCTTTCGGATACCGATCTTTCTACCTTGCTGCGCCGGTACAACATCCCCCACGG  183 
             |||||||||||||||| ||  | |||||||||||||||||||||||||| ||||| 
Sbjct  264  GATCTTTCGGATACCGAGCTGACCACCTTGCTGCGCCGGTACAACATCCCGCACGG  319 
 
 
b. Forward sequence (vs. X86810.1)  
 
  601 CGGCTGCTCCCGCGGTTAGGTCCCGCCCCGCGCAGCGCGCGCAGCCTGCGGAGCCAGCGG 
                                                                   
 
  661 CCGTGACGCGACAACGATTCGGCTGTGACGCGACAACGATTCGGCTGTGACGCGAGCGCG 
                                                                   
 
  721 GCCGCTCCCGATGCGCTCGTGCCGCCCCCGCCGTGCTCCTCGGCAGCCGTTGCTCGGCCG 
        >………………………………………………………………………………………………………………………………………………………                                                            
 
  781 GTTTTGGTAGGCCCGGGCCGCCGCCAGGCCTCCGCCTGAGCCCGCACCCGCCATGGACAA 
      ………………………………………………………………………………………………………………………………………………………………                                                             
 
  841 CTACGCAGATCTTTCGGATACCGAGCTGACCACCTTGCTGCGCCGGTACAACATCCCGCA 
      ………………………………………………………………………………………………………………………………………………………………                                                             
 
  901 CGGGCCTGTAGTAGGTACGCGGCGGCGGGCGGGACCCCTTCCGGGCCCCCTCCTCGTGCT 
      …………………………………<                                                             
 
  961 CCGCCTCGCGACCTCCCCGCTGCCCTCCCCGCGCGCCTTCCCCGGCCCGCGGCCCTGACC 
 
 
c. Reverse sequence (BLAST) 
> ref|NM_000117.2|  Homo sapiens emerin (EMD), mRNA 
Length=1370 
 
 GENE ID: 2010 EMD | emerin [Homo sapiens] (Over 10 PubMed links) 
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 Score =  329 bits (178),  Expect = 4e-88 
 Identities = 208/223 (93%), Gaps = 0/223 (0%) 
 Strand=Plus/Minus 
 
Query  43   CTACTACAGGCCCGTGCGGGATGTTGTACCGGCGCAAAAAGGTGGGCAGCTCGGTATCCG  102 
            ||||||||||||||||||||||||||||||||||||  ||||||| |||||||||||||| 
Sbjct  330  CTACTACAGGCCCGTGCGGGATGTTGTACCGGCGCAGCAAGGTGGTCAGCTCGGTATCCG  271 
 
Query  103  AAAGATCTGCGTAGTTGTCCATGGCGGGTGCGGGCTCAGGCGGAGGCCTGGCGGCGGCCC  162 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  270  AAAGATCTGCGTAGTTGTCCATGGCGGGTGCGGGCTCAGGCGGAGGCCTGGCGGCGGCCC  211 
 
Query  163  GGGCCTACCAAAACCGGTCGAGCAACGGCTGCCGAGGAACACGGCGGGGGCGGCACAAGC  222 
            ||||||||||||||||| |||||||||||||||||||| ||||||||||||||||| ||| 
Sbjct  210  GGGCCTACCAAAACCGGCCGAGCAACGGCTGCCGAGGAGCACGGCGGGGGCGGCACGAGC  151 
 
Query  223  GCATCGGTATCGGTCGCTCTCCCTTCACAACCGAATAATTGTC  265 
            ||||||| | ||| ||| ||| | ||||| ||||||  ||||| 
Sbjct  150  GCATCGGGAGCGGCCGCGCTCGCGTCACAGCCGAATCGTTGTC  108 
 
d. Reverse sequence (vs. X86810.1)  
 
  601 CGGCTGCTCCCGCGGTTAGGTCCCGCCCCGCGCAGCGCGCGCAGCCTGCGGAGCCAGCGG 
                                                                   
 
  661 CCGTGACGCGACAACGATTCGGCTGTGACGCGACAACGATTCGGCTGTGACGCGAGCGCG 
                                                                   
 
  721 GCCGCTCCCGATGCGCTCGTGCCGCCCCCGCCGTGCTCCTCGGCAGCCGTTGCTCGGCCG 
        >………………………………………………………………………………………………………………………………………………………                                                            
 
  781 GTTTTGGTAGGCCCGGGCCGCCGCCAGGCCTCCGCCTGAGCCCGCACCCGCCATGGACAA 
      ………………………………………………………………………………………………………………………………………………………………                                                             
 
  841 CTACGCAGATCTTTCGGATACCGAGCTGACCACCTTGCTGCGCCGGTACAACATCCCGCA 
      ………………………………………………………………………………………………………………………………………………………………                                                             
 
  901 CGGGCCTGTAGTAGGTACGCGGCGGCGGGCGGGACCCCTTCCGGGCCCCCTCCTCGTGCT 
      …………………………………<                                                             
 
  961 CCGCCTCGCGACCTCCCCGCTGCCCTCCCCGCGCGCCTTCCCCGGCCCGCGGCCCTGACC 
 
             
e. Combined sequencing (forward and reverse sequences) 
 
  601 CGGCTGCTCCCGCGGTTAGGTCCCGCCCCGCGCAGCGCGCGCAGCCTGCGGAGCCAGCGG 
                                                                   
 
  661 CCGTGACGCGACAACGATTCGGCTGTGACGCGACAACGATTCGGCTGTGACGCGAGCGCG 
                                                                  
 
  721 GCCGCTCCCGATGCGCTCGTGCCGCCCCCGCCGTGCTCCTCGGCAGCCGTTGCTCGGCCG 
        >………………………………………………………………………………………………………………………………………………………                                                            
 
  781 GTTTTGGTAGGCCCGGGCCGCCGCCAGGCCTCCGCCTGAGCCCGCACCCGCCATGGACAA 
      ………………………………………………………………………………………………………………………………………………………………                                                              
 
  841 CTACGCAGATCTTTCGGATACCGAGCTGACCACCTTGCTGCGCCGGTACAACATCCCGCA 
      ………………………………………………………………………………………………………………………………………………………………                                                             
 
  901 CGGGCCTGTAGTAGGTACGCGGCGGCGGGCGGGACCCCTTCCGGGCCCCCTCCTCGTGCT 
      …………………………………<                                                             
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  961 CCGCCTCGCGACCTCCCCGCTGCCCTCCCCGCGCGCCTTCCCCGGCCCGCGGCCCTGACC 
 
2. Exon 2 
a. Forward sequence (BLAST) 
 
> ref|NM_000117.2|  Homo sapiens emerin (EMD), mRNA 
Length=1370 
 
 GENE ID: 2010 EMD | emerin [Homo sapiens] (Over 10 PubMed links) 
 
 
 Score =  106 bits (57),  Expect = 8e-21 
 Identities = 68/73 (93%), Gaps = 2/73 (2%) 
 Strand=Plus/Plus 
 
Query  43   AGGATCAACTCGTAGGCTTTACGAGAAGAAGATCTTCGAGTACGAGACCCATGAGGCGTT  102 
            ||||||||||||||||||||||||||||||||||||||||||||||||||| ||||||   
Sbjct  329  AGGATCAACTCGTAGGCTTTACGAGAAGAAGATCTTCGAGTACGAGACCCA-GAGGCGGC  387 
 
Query  103  GGCTCT-GACCCC  114 
            |||||| | |||| 
Sbjct  388  GGCTCTCGCCCCC  400 
 
b. Forward sequence (vs. X86810.1)  
 
  961 CCGCCTCGCGACCTCCCCGCTGCCCTCCCCGCGCGCCTTCCCCGGCCCGCGGCCCTGACC 
 
  
 1021 GCCCCGTGTCCGGCCAGGATCAACTCGTAGGCTTTACGAGAAGAAGATCTTCGAGTACGA       
                       >……………………………………………………………………………………………………………… 
 
 1081 GACCCAGAGGCGGCGGCTCTCGCCCCCCAGCTCGTCCGCCGCCTCCTCTTATAGCTTCTC       
      ………………………………………………………………………………………………………………………………………………………………    
 
 1141 TGGTGAGAGCCTCGCCTGTGGGGACAGCCTGGGACGCGGGGAGGATGGGGTCGCGAGGGT       
      …< 
 
 1201  GTGGCAGGGGGGCCGGTCGAGAGCGGCACTGGAGAAAGGGGAGGGAAGTCTGGGGGGGCA       
 
c. Reverse sequence (BLAST) 
 
> ref|NM_000117.2|  Homo sapiens emerin (EMD), mRNA 
Length=1370 
 
 GENE ID: 2010 EMD | emerin [Homo sapiens] (Over 10 PubMed links) 
 
 
 Score =  198 bits (107),  Expect = 2e-48 
 Identities = 107/107 (100%), Gaps = 0/107 (0%) 
 Strand=Plus/Minus 
 
Query  59   CAGAGAAGCTATAAGAGGAGGCGGCGGACGAGCTGGGGGGCGAGAGCCGCCGCCTCTGGG  118 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  435  CAGAGAAGCTATAAGAGGAGGCGGCGGACGAGCTGGGGGGCGAGAGCCGCCGCCTCTGGG  376 
 
Query  119  TCTCGTACTCGAAGATCTTCTTCTCGTAAAGCCTACGAGTTGATCCT  165 
            ||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  375  TCTCGTACTCGAAGATCTTCTTCTCGTAAAGCCTACGAGTTGATCCT  329 
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d. Reverse sequence (vs. X86810.1) 
 
 
  961 CCGCCTCGCGACCTCCCCGCTGCCCTCCCCGCGCGCCTTCCCCGGCCCGCGGCCCTGACC       
 
 
 1021 GCCCCGTGTCCGGCCAGGATCAACTCGTAGGCTTTACGAGAAGAAGATCTTCGAGTACGA       
                       >………………………………………………………………………………………………………………     
 
 1081 GACCCAGAGGCGGCGGCTCTCGCCCCCCAGCTCGTCCGCCGCCTCCTCTTATAGCTTCTC       
      ………………………………………………………………………………………………………………………………………………………………    
 
 1141 TGGTGAGAGCCTCGCCTGTGGGGACAGCCTGGGACGCGGGGAGGATGGGGTCGCGAGGGT       
      …< 
 
 1201  GTGGCAGGGGGGCCGGTCGAGAGCGGCACTGGAGAAAGGGGAGGGAAGTCTGGGGGGGCA       
 
 
e. Combined sequencing (forward and reverse sequences) 
 
 961 CCGCCTCGCGACCTCCCCGCTGCCCTCCCCGCGCGCCTTCCCCGGCCCGCGGCCCTGACC 
                                                                            
  
1021 GCCCCGTGTCCGGCCAGGATCAACTCGTAGGCTTTACGAGAAGAAGATCTTCGAGTACGA       
                      >………………………………………………………………………………………………………………              
  
1081 GACCCAGAGGCGGCGGCTCTCGCCCCCCAGCTCGTCCGCCGCCTCCTCTTATAGCTTCTC       
     ……………………………………………………………………………………………………………………………………………………………… 
 
1141 TGGTGAGAGCCTCGCCTGTGGGGACAGCCTGGGACGCGGGGAGGATGGGGTCGCGAGGGT       
     …< 
 
1201  GTGGCAGGGGGGCCGGTCGAGAGCGGCACTGGAGAAAGGGGAGGGAAGTCTGGGGGGGCA       
 
 
3. Exon 3 
a. Forward sequence (BLAST) 
 
> ref|NM_000117.2|  Homo sapiens emerin (EMD), mRNA 
Length=1370 
 
 GENE ID: 2010 EMD | emerin [Homo sapiens] (Over 10 PubMed links) 
 
 
 Score =  143 bits (77),  Expect = 4e-32 
 Identities = 79/80 (98%), Gaps = 0/80 (0%) 
 Strand=Plus/Plus 
 
Query  47   GACTTGAATTCGACTAGAGGGGATGCAGATTTGTATGATCTTCCCAAGAAAGAGGACGCT  106 
            |||||||||||||||||||||||||||||| ||||||||||||||||||||||||||||| 
Sbjct  435  GACTTGAATTCGACTAGAGGGGATGCAGATATGTATGATCTTCCCAAGAAAGAGGACGCT  494 
 
Query  107  TTACTCTACCAGAGCAAGGG  126 
            |||||||||||||||||||| 
Sbjct  495  TTACTCTACCAGAGCAAGGG  514 
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b. Forward sequence (vs. X86810.1)  
 
1201 GTGGCAGGGGGGCCGGTCGAGAGCGGCACTGGAGAAAGGGGAGGGAAGTCTGGGGGGGCA  
      
 
1261 AACAGTTCTGTCTCCTCCTTTCAATCCAGACTTGAATTCGACTAGAGGGGATGCAGATAT       
                                 >………………………………………………………………………………… 
 
1321 GTATGATCTTCCCAAGAAAGAGGACGCTTTACTCTACCAGAGCAAGGGTAAGGCAGGGGT       
     ……………………………………………………………………………………………………………………………< 
 
1381 TGGGTGGGCACGCTGGCACCTTCACCCGACTTCGTCAGGGACCCCGCTCACAGGGAGGAC      
 
 
1441 CTGAGACCTCAGTCCCAACCACTCCAGCAGCCTTAGGAGGGAGAAACTGTTACAGGTCCC  
 
 
c. Reverse sequence (BLAST) 
ref|NM_000117.2|  Homo sapiens emerin (EMD), mRNA 
Length=1370 
 
 GENE ID: 2010 EMD | emerin [Homo sapiens] (Over 10 PubMed links) 
 
 
 Score =  148 bits (80),  Expect = 8e-34 
 Identities = 80/80 (100%), Gaps = 0/80 (0%) 
 Strand=Plus/Minus 
 
Query  57   CCCTTGCTCTGGTAGAGTAAAGCGTCCTCTTTCTTGGGAAGATCATACATATCTGCATCC  116 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  514  CCCTTGCTCTGGTAGAGTAAAGCGTCCTCTTTCTTGGGAAGATCATACATATCTGCATCC  455 
 
Query  117  CCTCTAGTCGAATTCAAGTC  136 
            |||||||||||||||||||| 
Sbjct  454  CCTCTAGTCGAATTCAAGTC  435 
 
 
d. Reverse sequence (vs. X86810.1)  
 
1201 GTGGCAGGGGGGCCGGTCGAGAGCGGCACTGGAGAAAGGGGAGGGAAGTCTGGGGGGGCA  
      
 
1261 AACAGTTCTGTCTCCTCCTTTCAATCCAGACTTGAATTCGACTAGAGGGGATGCAGATAT       
                                 >…………………………………………………………………………………                  
 
1321 GTATGATCTTCCCAAGAAAGAGGACGCTTTACTCTACCAGAGCAAGGGTAAGGCAGGGGT       
     ………………………………………………………………………………………………………………………………< 
 
1381 TGGGTGGGCACGCTGGCACCTTCACCCGACTTCGTCAGGGACCCCGCTCACAGGGAGGAC      
 
 
1441 CTGAGACCTCAGTCCCAACCACTCCAGCAGCCTTAGGAGGGAGAAACTGTTACAGGTCCC       
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e. Combined sequencing (forward and reverse sequences) 
 
1201 GTGGCAGGGGGGCCGGTCGAGAGCGGCACTGGAGAAAGGGGAGGGAAGTCTGGGGGGGCA  
      
 
1261 AACAGTTCTGTCTCCTCCTTTCAATCCAGACTTGAATTCGACTAGAGGGGATGCAGATAT       
                                 >………………………………………………………………………………… 
 
1321 GTATGATCTTCCCAAGAAAGAGGACGCTTTACTCTACCAGAGCAAGGGTAAGGCAGGGGT       
     ………………………………………………………………………………………………………………………………< 
 
1381 TGGGTGGGCACGCTGGCACCTTCACCCGACTTCGTCAGGGACCCCGCTCACAGGGAGGAC      
1441 CTGAGACCTCAGTCCCAACCACTCCAGCAGCCTTAGGAGGGAGAAACTGTTACAGGTCCC       
 
 
4. Exon 4 
a. Forward sequence (BLAST) 
 
> ref|NM_000117.2|  Homo sapiens emerin (EMD), mRNA 
Length=1370 
 
 GENE ID: 2010 EMD | emerin [Homo sapiens] (Over 10 PubMed links) 
 
 
 Score =  141 bits (76),  Expect = 1e-31 
 Identities = 122/143 (85%), Gaps = 7/143 (4%) 
 Strand=Plus/Plus 
 
 
Query  36   CAA-GGCTACAATGACGACTACTATGAAGAGAGCTACTTCAAAAAAAAGAAGGGATGGGG  94 
            ||| |||||||||||||||||||||||||||||||||||||  |  | ||    |||||| 
Sbjct  509  CAAGGGCTACAATGACGACTACTATGAAGAGAGCTACTTCACCACCAGGACTT-ATGGGG  567 
 
Query  95   AGCCCGAGTCTGCCGGCCCGTCCAGC-CTTTTGTCCGCCACCCCCCCGACTTCATTCCCA  153 
            |||||||||||||||||||||||||  ||   ||||||||  |    ||||||||||||| 
Sbjct  568  AGCCCGAGTCTGCCGGCCCGTCCAGGGCT---GTCCGCCAGTCAGT-GACTTCATTCCCA  623 
 
Query  154  GATGCTGACGCTTTCCATCACCA  176 
            ||||||||||||||||||||||| 
Sbjct  624  GATGCTGACGCTTTCCATCACCA  646 
 
 
b. Forward sequence (vs. X86810.1)  
 
1501 GAAATGGGATTCAGATTAGGGCCATCAGGCCAGGCGGGGCACACCGATGCCCCCTCTGCT 
 
           
1561 ACCGCTGCCCCCCTTCCCAAGGCTACAATGACGACTACTATGAAGAGAGCTACTTCACCA 
                         >………………………………………………………………………………………………………  
           
1621 CCAGGACTTATGGGGAGCCCGAGTCTGCCGGCCCGTCCAGGGCTGTCCGCCAGTCAGTGA       
     ……………………………………………………………………………………………………………………………………………………………… 
 
1681 CTTCATTCCCAGATGCTGACGCTTTCCATCACCAGGTGAGCTGGCTGGCAGGCGTCCTGT 
     ……………………………………………………………………………………………< 
           
1741 ACTTGGGTACAACCTAGGGGATCGCGGCTGTGTTTGGATAAATCCAGGGGGGCACTGGGT 
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c. Reverse sequence (BLAST) 
> ref|NM_000117.2|  Homo sapiens emerin (EMD), mRNA 
Length=1370 
 
 GENE ID: 2010 EMD | emerin [Homo sapiens] (Over 10 PubMed links) 
 
 
 Score =  241 bits (130),  Expect = 1e-61 
 Identities = 138/141 (97%), Gaps = 3/141 (2%) 
 Strand=Plus/Minus 
 
Query  17   ACCTGGTG-TGG-AAGCGTCAGCATCTGGGAATGAAGTCACTGACTGGCGGACAGCCCTG  74 
            |||||||| ||| ||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  649  ACCTGGTGATGGAAAGCGTCAGCATCTGGGAATGAAGTCACTGACTGGCGGACAGCCCTG  590 
 
Query  75   GACGGGCCGGCAGACTCGGGCTCCCCATAAGTCCTGGTGGTGAAGTAGCTCTCTTCATAG  134 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  589  GACGGGCCGGCAGACTCGGGCTCCCCATAAGTCCTGGTGGTGAAGTAGCTCTCTTCATAG  530 
 
Query  135  TAGTCGTCATTGTAGCC-TTG  154 
            ||||||||||||||||| ||| 
Sbjct  529  TAGTCGTCATTGTAGCCCTTG  509 
 
 
d.  Reverse sequence (vs. X86810.1)  
          
1501 GAAATGGGATTCAGATTAGGGCCATCAGGCCAGGCGGGGCACACCGATGCCCCCTCTGCT 
 
           
1561 ACCGCTGCCCCCCTTCCCAAGGCTACAATGACGACTACTATGAAGAGAGCTACTTCACCA       
                         >………………………………………………………………………………………………………   
 
1621 CCAGGACTTATGGGGAGCCCGAGTCTGCCGGCCCGTCCAGGGCTGTCCGCCAGTCAGTGA    
     ……………………………………………………………………………………………………………………………………………………………… 
         
1681 CTTCATTCCCAGATGCTGACGCTTTCCATCACCAGGTGAGCTGGCTGGCAGGCGTCCTGT       
     ……………………………………………………………………………………………< 
      
1741  ACTTGGGTACAACCTAGGGGATCGCGGCTGTGTTTGGATAAATCCAGGGGGGCACTGGGT 
 
 
e. Combined sequencing (forward and reverse sequences) 
 
1501 GAAATGGGATTCAGATTAGGGCCATCAGGCCAGGCGGGGCACACCGATGCCCCCTCTGCT 
 
             
1561 ACCGCTGCCCCCCTTCCCAAGGCTACAATGACGACTACTATGAAGAGAGCTACTTCACCA 
                         >……………………………………………………………………………………………………… 
           
1621 CCAGGACTTATGGGGAGCCCGAGTCTGCCGGCCCGTCCAGGGCTGTCCGCCAGTCAGTGA 
     ……………………………………………………………………………………………………………………………………………………………… 
            
1681 CTTCATTCCCAGATGCTGACGCTTTCCATCACCAGGTGAGCTGGCTGGCAGGCGTCCTGT   
     ……………………………………………………………………………………………< 
          
1740 ACTTGGGTACAACCTAGGGGATCGCGGCTGTGTTTGGATAAATCCAGGGGGGCACTGGGT     
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5. Exon 5 
a. Forward sequence (BLAST) 
> ref|NM_000117.2|  Homo sapiens emerin (EMD), mRNA 
Length=1370 
 
 GENE ID: 2010 EMD | emerin [Homo sapiens] (Over 10 PubMed links) 
 
 
 Score =  100 bits (54),  Expect = 5e-19 
 Identities = 54/54 (100%), Gaps = 0/54 (0%) 
 Strand=Plus/Plus 
 
Query  92   CAGGTGCATGATGACGATCTTTTGTCTTCTTCTGAAGAGGAGTGCAAGGATAGG  145 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  645  CAGGTGCATGATGACGATCTTTTGTCTTCTTCTGAAGAGGAGTGCAAGGATAGG  698 
 
 
b. Forward sequence (vs. X86810.1)  
 
1921 CACAAGTGGCAAGGCCCCATGGATAAAGGGCTGAACACCCAGAGCCATTCAGGAGGGTGT 
                                                                   
 
1981 GGGTTCCTGGCCTCTAACCAAAGGTCAGAGGGGACTGGCTGGGGAAGTTTGGACTGAGGG 
                                                                   
 
2041 ACATGACAGGGCCATGGTGGCCCTGCCAGCCAGTCCCCTCGCCCTGACTCTCTTCTGCAG 
                                                                   
 
2101 GTGCATGATGACGATCTTTTGTCTTCTTCTGAAGAGGAGTGCAAGGATAGGTGCGTAGTG 
     >………………………………………………………………………………………………………………………………<                                                              
 
2161 GGGGAGCCCAGGGACGGGCTGGTTCTGGGTCCAGGCTCCTGGCCCACTTGCTCCCCTCTT 
 
c. Reverse sequence (BLAST) 
ref|NT_167198.1|  Homo sapiens chromosome X genomic contig, GRCh37 
reference primary  
assembly 
Length=6178498 
 
 Features in this part of subject sequence: 
   emerin 
 
 
 Score =  292 bits (158),  Expect = 8e-77 
 Identities = 177/186 (95%), Gaps = 2/186 (1%) 
 Strand=Plus/Minus 
 
Query  14       CACTACGCA-CTATCCTTGCACTCCTCTTCAGAAG-AGACAAAAGATCGTCATCATGCAC  71 
                ||||||||| ||||||||||||||||||||||||| |||||||||||||||||||||||| 
Sbjct  4527110  CACTACGCACCTATCCTTGCACTCCTCTTCAGAAGAAGACAAAAGATCGTCATCATGCAC  
4527051 
 
Query  72       CTGCAGAAGAGAGTCAGGGCGAGGGGACTGGCTGGCAGGGCCACCATGGCCCTGTCATGT  131 
                |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  4527050  CTGCAGAAGAGAGTCAGGGCGAGGGGACTGGCTGGCAGGGCCACCATGGCCCTGTCATGT  
4526991 
 
Query  132      CCCTCAGTCCAAACTTCCCCAGCCAGTCCCCTCGGACCTTTGGTTGGAGCCCCCGACCCC  191 
                ||||||||||||||||||||||||||||||||| ||||||||||| ||| ||  || ||| 
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Sbjct  4526990  CCCTCAGTCCAAACTTCCCCAGCCAGTCCCCTCTGACCTTTGGTTAGAGGCCAGGAACCC  
4526931 
 
Query  192      ACTCCC  197 
                || ||| 
Sbjct  4526930  ACACCC  4526925 
 
 
d. Reverse sequence (vs. X86810.1)  
                                                         
1921 CACAAGTGGCAAGGCCCCATGGATAAAGGGCTGAACACCCAGAGCCATTCAGGAGGGTGT 
                                                                   
 
1981 GGGTTCCTGGCCTCTAACCAAAGGTCAGAGGGGACTGGCTGGGGAAGTTTGGACTGAGGG 
                                                                   
 
2041 ACATGACAGGGCCATGGTGGCCCTGCCAGCCAGTCCCCTCGCCCTGACTCTCTTCTGCAG 
                                                                   
 
2101 GTGCATGATGACGATCTTTTGTCTTCTTCTGAAGAGGAGTGCAAGGATAGGTGCGTAGTG 
     >………………………………………………………………………………………………………………………………<                                                              
 
2161 GGGGAGCCCAGGGACGGGCTGGTTCTGGGTCCAGGCTCCTGGCCCACTTGCTCCCCTCTT 
 
                                                                   
e. Combined sequencing (forward and reverse sequences) 
 
1921 CACAAGTGGCAAGGCCCCATGGATAAAGGGCTGAACACCCAGAGCCATTCAGGAGGGTGT 
                                                                   
 
1981 GGGTTCCTGGCCTCTAACCAAAGGTCAGAGGGGACTGGCTGGGGAAGTTTGGACTGAGGG 
                                                                   
 
2041 ACATGACAGGGCCATGGTGGCCCTGCCAGCCAGTCCCCTCGCCCTGACTCTCTTCTGCAG 
 
 
2101 GTGCATGATGACGATCTTTTGTCTTCTTCTGAAGAGGAGTGCAAGGATAGGTGCGTAGTG 
     >………………………………………………………………………………………………………………………………<                                                               
 
2161 GGGGAGCCCAGGGACGGGCTGGTTCTGGGTCCAGGCTCCTGGCCCACTTGCTCCCCTCTT 
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AG08466: LAP2 exon 4 
 
1. Primer pair: LAP2α4.2 
a. Forward sequence (BLAST) 
ef|NM_003276.1|  Homo sapiens thymopoietin (TMPO), transcript 
variant 1, mRNA 
Length=2490 
 
 
 Score =  252 bits (127),  Expect = 8e-65 
 Identities = 127/127 (100%), Gaps = 0/127 (0%) 
 Strand=Plus/Plus 
 
Query  5     AAACATACAGAAGAGAATTGATCAGTCTAAGTTTCAAGAAACTGAATTCCTGTCTCCTCC  64 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1422  AAACATACAGAAGAGAATTGATCAGTCTAAGTTTCAAGAAACTGAATTCCTGTCTCCTCC  1481 
 
Query  65    AAGAAAAGTCCCTAGACTGAGTGAGAAGTCAGTGGAGGAAAGGGATTCAGGTTCCTTTGT  124 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1482  AAGAAAAGTCCCTAGACTGAGTGAGAAGTCAGTGGAGGAAAGGGATTCAGGTTCCTTTGT  1541 
 
Query  125   GGCATTT  131 
             ||||||| 
Sbjct  1542  GGCATTT  1548 
 
 
b. Forward sequence (vs. NM_003276.1) 
 
1321 CTTGCCCAGGCAATCAGAGATTATGTCAATTCTCTGTTGGTCCAGGGTGGGGTAGGTAGT 
1381 TTGCCTGGAACTTCTAACTCTATGCCCCCACTGGATGTAGAAAACATACAGAAGAGAATT 
1441 GATCAGTCTAAGTTTCAAGAAACTGAATTCCTGTCTCCTCCAAGAAAAGTCCCTAGACTG 
1501 AGTGAGAAGTCAGTGGAGGAAAGGGATTCAGGTTCCTTTGTGGCATTTCAGAACATACCT 
 
 
2. Primer pair: LAP2α4.3 
a. Forward sequence (BLAST) 
> ref|NM_003276.1|  Homo sapiens thymopoietin (TMPO), transcript 
variant 1, mRNA 
Length=2490 
 
 GENE ID: 7112 TMPO | thymopoietin [Homo sapiens] (Over 10 PubMed links) 
 
 
 Score = 1620 bits (877),  Expect = 0.0 
 Identities = 891/897 (99%), Gaps = 4/897 (0%) 
 Strand=Plus/Plus 
 
Query  5     AAACCTGTTTGTCTCTC-TTC-CTCACTACCTTAGGTCTAGAAGTGGCTAAGCAATCACA  62 
             ||| ||| ||||||||| ||| |||||||||||||||||||||||||||||||||||||| 
Sbjct  1588  AAAACTG-TTGTCTCTCATTCACTCACTACCTTAGGTCTAGAAGTGGCTAAGCAATCACA  1646 
 
Query  63    GCATGATAAAATAGATGCCTCAGAACTATCTTTTCCCTTCCATGAATCTATTTTAAAAGT  122 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1647  GCATGATAAAATAGATGCCTCAGAACTATCTTTTCCCTTCCATGAATCTATTTTAAAAGT  1706 
 
Query  123   AATTGAAGAAGAATGGCAGCAAGTTGACAGGCAGCTGCCTTCACTGGCATGCAAATATCC  182 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1707  AATTGAAGAAGAATGGCAGCAAGTTGACAGGCAGCTGCCTTCACTGGCATGCAAATATCC  1766 
 
Appendix I 
 
323 
 
Query  183   AGTTTCTTCCAGGGAGGCAACACAGATATTATCAGTTCCAAAAGTAGATGATGAAATCCT  242 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1767  AGTTTCTTCCAGGGAGGCAACACAGATATTATCAGTTCCAAAAGTAGATGATGAAATCCT  1826 
 
Query  243   AGGGTTTATTTCTGAAGCCACTCCACTAGGAGGTATTCAAGCAGCCTCCACTGAGTCTTG  302 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1827  AGGGTTTATTTCTGAAGCCACTCCACTAGGAGGTATTCAAGCAGCCTCCACTGAGTCTTG  1886 
 
Query  303   CAATCAGCAGTTGGACTTAGCACTCTGTAGAGCATATGAAGCTGCAGCATCAGCATTGCA  362 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1887  CAATCAGCAGTTGGACTTAGCACTCTGTAGAGCATATGAAGCTGCAGCATCAGCATTGCA  1946 
 
Query  363   GATTGCAACTCACACTGCCTTTGTAGCTAAGGCTATGCAGGCAGACATTAGTCAAGCTGC  422 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1947  GATTGCAACTCACACTGCCTTTGTAGCTAAGGCTATGCAGGCAGACATTAGTCAAGCTGC  2006 
 
Query  423   ACAGATTCTTAGCTCAGATCCTAGTCGTACCCACCAAGCGCTTGGGATTCTGAGCAAAAC  482 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2007  ACAGATTCTTAGCTCAGATCCTAGTCGTACCCACCAAGCGCTTGGGATTCTGAGCAAAAC  2066 
 
Query  483   ATATGATGCAGCCTCATATATTTGTGAAGCTGCATTTGATGAAGTGAAGATGGCTGCCCA  542 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2067  ATATGATGCAGCCTCATATATTTGTGAAGCTGCATTTGATGAAGTGAAGATGGCTGCCCA  2126 
 
Query  543   TACCATGGGAAATGCCACTGTAGGTCGTCGATACCTCTGGCTGAAGGATTGCAAAATTAA  602 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2127  TACCATGGGAAATGCCACTGTAGGTCGTCGATACCTCTGGCTGAAGGATTGCAAAATTAA  2186 
 
Query  603   TTTAGCTTCTAAGAATAAGCTGGCTTCCACTCCCTTTAAAGGTGGAACATTATTTGGAGG  662 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2187  TTTAGCTTCTAAGAATAAGCTGGCTTCCACTCCCTTTAAAGGTGGAACATTATTTGGAGG  2246 
 
Query  663   AGAAGTATGCAAAGTAATTAAAAAGCGTGGAAATAAACACTAGTAAAATTAAGGACAACA  722 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||| | 
Sbjct  2247  AGAAGTATGCAAAGTAATTAAAAAGCGTGGAAATAAACACTAGTAAAATTAAGGACAAAA  2306 
 
Query  723   AGACATCTATCTTATCTTTCAGGTACTTTATGCCAACATTTTCTTTTCTGTTAAGGTTGT  782 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2307  AGACATCTATCTTATCTTTCAGGTACTTTATGCCAACATTTTCTTTTCTGTTAAGGTTGT  2366 
 
Query  783   TTTAGTTTCCAGATAGGGCTAATTACAAAATGTTAAGCTTCTACCCATCAAATTACAGTA  842 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2367  TTTAGTTTCCAGATAGGGCTAATTACAAAATGTTAAGCTTCTACCCATCAAATTACAGTA  2426 
 
Query  843   TAAAAGTAATTGCCTGTGTAGAACTACTTGTCTTTTCTAAAGATTTGCGTAG-TAGG  898 
             |||||||||||||||||||||||||||||||||||||||||||||||||||| |||| 
Sbjct  2427  TAAAAGTAATTGCCTGTGTAGAACTACTTGTCTTTTCTAAAGATTTGCGTAGATAGG  2483 
 
 
b. Forward sequence (vs. NM_003276.1) 
1501 AGTGAGAAGTCAGTGGAGGAAAGGGATTCAGGTTCCTTTGTGGCATTTCAGAACATACCT 
1561 GGATCCGAACTGATGTCTTCTTTTGCCAAAACTGTTGTCTCTCATTCACTCACTACCTTA 
1621 GGTCTAGAAGTGGCTAAGCAATCACAGCATGATAAAATAGATGCCTCAGAACTATCTTTT 
1681 CCCTTCCATGAATCTATTTTAAAAGTAATTGAAGAAGAATGGCAGCAAGTTGACAGGCAG 
1741 CTGCCTTCACTGGCATGCAAATATCCAGTTTCTTCCAGGGAGGCAACACAGATATTATCA 
1801 GTTCCAAAAGTAGATGATGAAATCCTAGGGTTTATTTCTGAAGCCACTCCACTAGGAGGT 
1861 ATTCAAGCAGCCTCCACTGAGTCTTGCAATCAGCAGTTGGACTTAGCACTCTGTAGAGCA 
1921 TATGAAGCTGCAGCATCAGCATTGCAGATTGCAACTCACACTGCCTTTGTAGCTAAGGCT 
1981 ATGCAGGCAGACATTAGTCAAGCTGCACAGATTCTTAGCTCAGATCCTAGTCGTACCCAC 
2041 CAAGCGCTTGGGATTCTGAGCAAAACATATGATGCAGCCTCATATATTTGTGAAGCTGCA 
2101 TTTGATGAAGTGAAGATGGCTGCCCATACCATGGGAAATGCCACTGTAGGTCGTCGATAC 
2161 CTCTGGCTGAAGGATTGCAAAATTAATTTAGCTTCTAAGAATAAGCTGGCTTCCACTCCC 
2221 TTTAAAGGTGGAACATTATTTGGAGGAGAAGTATGCAAAGTAATTAAAAAGCGTGGAAAT 
2281 AAACACTAGTAAAATTAAGGACAAAAAGACATCTATCTTATCTTTCAGGTACTTTATGCC 
2341 AACATTTTCTTTTCTGTTAAGGTTGTTTTAGTTTCCAGATAGGGCTAATTACAAAATGTT 
2401 AAGCTTCTACCCATCAAATTACAGTATAAAAGTAATTGCCTGTGTAGAACTACTTGTCTT 
2461 TTCTAAAGATTTGCGTAGATAGGAAGCCTG 
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c. Reverse sequence (BLAST) 
ref|NM_003276.1|  Homo sapiens thymopoietin (TMPO), transcript 
variant 1, mRNA 
Length=2490 
 
 GENE ID: 7112 TMPO | thymopoietin [Homo sapiens] (Over 10 PubMed links) 
 
 
 Score = 1629 bits (882),  Expect = 0.0 
 Identities = 891/895 (99%), Gaps = 1/895 (0%) 
 Strand=Plus/Minus 
 
Query  6     AAGTAGTGGCTACACAGGCAATTACTTTTATACTGTAATTTGATGGGTAGAAGCTTAACA  65 
             |||||||  ||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2455  AAGTAGT-TCTACACAGGCAATTACTTTTATACTGTAATTTGATGGGTAGAAGCTTAACA  2397 
 
Query  66    TTTTGTAATTAGCCCTATCTGGAAACTAAAACAACCTTAACAGAAAAGAAAATGTTGGCA  125 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2396  TTTTGTAATTAGCCCTATCTGGAAACTAAAACAACCTTAACAGAAAAGAAAATGTTGGCA  2337 
 
Query  126   TAAAGTACCTGAAAGATAAGATAGATGTCTTTTTGTCCTTAATTTTACTAGTGTTTATTT  185 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2336  TAAAGTACCTGAAAGATAAGATAGATGTCTTTTTGTCCTTAATTTTACTAGTGTTTATTT  2277 
 
Query  186   CCACGCTTTTTAATTACTTTGCATACTTCTCCTCCAAATAATGTTCCACCTTTAAAGGGA  245 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2276  CCACGCTTTTTAATTACTTTGCATACTTCTCCTCCAAATAATGTTCCACCTTTAAAGGGA  2217 
 
Query  246   GTGGAAGCCAGCTTATTCTTAGAAGCTAAATTAATTTTGCAATCCTTCAGCCAGAGGTAT  305 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2216  GTGGAAGCCAGCTTATTCTTAGAAGCTAAATTAATTTTGCAATCCTTCAGCCAGAGGTAT  2157 
 
Query  306   CGACGACCTACAGTGGCATTTCCCATGGTATGGGCAGCCATCTTCACTTCATCAAATGCA  365 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2156  CGACGACCTACAGTGGCATTTCCCATGGTATGGGCAGCCATCTTCACTTCATCAAATGCA  2097 
 
Query  366   GCTTCACAAATATATGAGGCTGCATCATATGTTTTGCTCAGAATCCCAAGCGCTTGGTGG  425 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2096  GCTTCACAAATATATGAGGCTGCATCATATGTTTTGCTCAGAATCCCAAGCGCTTGGTGG  2037 
 
Query  426   GTACGACTAGGATCTGAGCTAAGAATCTGTGCAGCTTGACTAATGTCTGCCTGCATAGCC  485 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2036  GTACGACTAGGATCTGAGCTAAGAATCTGTGCAGCTTGACTAATGTCTGCCTGCATAGCC  1977 
 
Query  486   TTAGCTACAAAGGCAGTGTGAGTTGCAATCTGCAATGCTGATGCTGCAGCTTCATATGCT  545 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1976  TTAGCTACAAAGGCAGTGTGAGTTGCAATCTGCAATGCTGATGCTGCAGCTTCATATGCT  1917 
 
Query  546   CTACAGAGTGCTAAGTCCAACTGCTGATTGCAAGACTCAGTGGAGGCTGCTTGAATACCT  605 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1916  CTACAGAGTGCTAAGTCCAACTGCTGATTGCAAGACTCAGTGGAGGCTGCTTGAATACCT  1857 
 
Query  606   CCTAGTGGAGTGGCTTCAGAAATAAACCCTAGGATTTCATCATCTACTTTTGGAACTGAT  665 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1856  CCTAGTGGAGTGGCTTCAGAAATAAACCCTAGGATTTCATCATCTACTTTTGGAACTGAT  1797 
 
Query  666   AATATCTGTGTTGCCTCCCTGGAAGAAACTGGATATTTGCATGCCAGTGAAGGCAGCTGC  725 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1796  AATATCTGTGTTGCCTCCCTGGAAGAAACTGGATATTTGCATGCCAGTGAAGGCAGCTGC  1737 
 
Query  726   CTGTCAACTTGCTGCCATTCTTCTTCAATTACTTTTAAAATAGATTCATGGAAGGGAAAA  785 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1736  CTGTCAACTTGCTGCCATTCTTCTTCAATTACTTTTAAAATAGATTCATGGAAGGGAAAA  1677 
 
Query  786   GATAGTTCTGAGGCATCTATTTTATCATGCTGTGATTGCTTAGCCACTTCTAGACCTAAG  845 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1676  GATAGTTCTGAGGCATCTATTTTATCATGCTGTGATTGCTTAGCCACTTCTAGACCTAAG  1617 
 
Appendix I 
 
325 
 
Query  846   GTAGTGAGTGAATGAGAGACAACAGTTTTGGCAAAAGAAGACATCAGATCAGATC  900 
             ||||||||||||||||||||||||||||||||||||||||||||||| || |||| 
Sbjct  1616  GTAGTGAGTGAATGAGAGACAACAGTTTTGGCAAAAGAAGACATCAGTTCGGATC  1562 
 
 
d. Reverse sequence (vs. NM_003276.1) 
 
1501 AGTGAGAAGTCAGTGGAGGAAAGGGATTCAGGTTCCTTTGTGGCATTTCAGAACATACCT 
1561 GGATCCGAACTGATGTCTTCTTTTGCCAAAACTGTTGTCTCTCATTCACTCACTACCTTA 
1621 GGTCTAGAAGTGGCTAAGCAATCACAGCATGATAAAATAGATGCCTCAGAACTATCTTTT 
1681 CCCTTCCATGAATCTATTTTAAAAGTAATTGAAGAAGAATGGCAGCAAGTTGACAGGCAG 
1741 CTGCCTTCACTGGCATGCAAATATCCAGTTTCTTCCAGGGAGGCAACACAGATATTATCA 
1801 GTTCCAAAAGTAGATGATGAAATCCTAGGGTTTATTTCTGAAGCCACTCCACTAGGAGGT 
1861 ATTCAAGCAGCCTCCACTGAGTCTTGCAATCAGCAGTTGGACTTAGCACTCTGTAGAGCA 
1921 TATGAAGCTGCAGCATCAGCATTGCAGATTGCAACTCACACTGCCTTTGTAGCTAAGGCT 
1981 ATGCAGGCAGACATTAGTCAAGCTGCACAGATTCTTAGCTCAGATCCTAGTCGTACCCAC 
2041 CAAGCGCTTGGGATTCTGAGCAAAACATATGATGCAGCCTCATATATTTGTGAAGCTGCA 
2101 TTTGATGAAGTGAAGATGGCTGCCCATACCATGGGAAATGCCACTGTAGGTCGTCGATAC 
2161 CTCTGGCTGAAGGATTGCAAAATTAATTTAGCTTCTAAGAATAAGCTGGCTTCCACTCCC 
2221 TTTAAAGGTGGAACATTATTTGGAGGAGAAGTATGCAAAGTAATTAAAAAGCGTGGAAAT 
2281 AAACACTAGTAAAATTAAGGACAAAAAGACATCTATCTTATCTTTCAGGTACTTTATGCC 
2341 AACATTTTCTTTTCTGTTAAGGTTGTTTTAGTTTCCAGATAGGGCTAATTACAAAATGTT 
2401 AAGCTTCTACCCATCAAATTACAGTATAAAAGTAATTGCCTGTGTAGAACTACTTGTCTT 
2461 TTCTAAAGATTTGCGTAGATAGGAAGCCTG 
 
e. Combined sequencing (forward and reverse sequences) 
 
1501 AGTGAGAAGTCAGTGGAGGAAAGGGATTCAGGTTCCTTTGTGGCATTTCAGAACATACCT 
1561 GGATCCGAACTGATGTCTTCTTTTGCCAAAACTGTTGTCTCTCATTCACTCACTACCTTA 
1621 GGTCTAGAAGTGGCTAAGCAATCACAGCATGATAAAATAGATGCCTCAGAACTATCTTTT 
1681 CCCTTCCATGAATCTATTTTAAAAGTAATTGAAGAAGAATGGCAGCAAGTTGACAGGCAG 
1741 CTGCCTTCACTGGCATGCAAATATCCAGTTTCTTCCAGGGAGGCAACACAGATATTATCA 
1801 GTTCCAAAAGTAGATGATGAAATCCTAGGGTTTATTTCTGAAGCCACTCCACTAGGAGGT 
1861 ATTCAAGCAGCCTCCACTGAGTCTTGCAATCAGCAGTTGGACTTAGCACTCTGTAGAGCA 
1921 TATGAAGCTGCAGCATCAGCATTGCAGATTGCAACTCACACTGCCTTTGTAGCTAAGGCT 
1981 ATGCAGGCAGACATTAGTCAAGCTGCACAGATTCTTAGCTCAGATCCTAGTCGTACCCAC 
2041 CAAGCGCTTGGGATTCTGAGCAAAACATATGATGCAGCCTCATATATTTGTGAAGCTGCA 
2101 TTTGATGAAGTGAAGATGGCTGCCCATACCATGGGAAATGCCACTGTAGGTCGTCGATAC 
2161 CTCTGGCTGAAGGATTGCAAAATTAATTTAGCTTCTAAGAATAAGCTGGCTTCCACTCCC 
2221 TTTAAAGGTGGAACATTATTTGGAGGAGAAGTATGCAAAGTAATTAAAAAGCGTGGAAAT 
2281 AAACACTAGTAAAATTAAGGACAAAAAGACATCTATCTTATCTTTCAGGTACTTTATGCC 
2341 AACATTTTCTTTTCTGTTAAGGTTGTTTTAGTTTCCAGATAGGGCTAATTACAAAATGTT 
2401 AAGCTTCTACCCATCAAATTACAGTATAAAAGTAATTGCCTGTGTAGAACTACTTGTCTT 
2461 TTCTAAAGATTTGCGTAGATAGGAAGCCTG 
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AG11572: LAP2 exon 4 
 
1. Primer pair: LAP2αintron/exon4 
a. Forward sequence (BLAST) 
> ref|NT_029419.12|  Homo sapiens chromosome 12 genomic contig, 
GRCh37 reference primary  
assembly 
Length=71516776 
 
 Features in this part of subject sequence: 
   thymopoietin isoform beta 
   thymopoietin isoform gamma 
 
 
 Score = 1362 bits (737),  Expect = 0.0 
 Identities = 744/747 (99%), Gaps = 2/747 (0%) 
 Strand=Plus/Plus 
 
Query  13        ATATGGAATTATAGTCTTTTCCTTTGACAGCACTATTTTTAGCAAAGAGGCAAAGAATAA  72 
                 ||||| |||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61069793  ATATGAAATTATAGTCTTTTCCTTTGACAGCACTATTTTTAGCAAAGAGGCAAAGAATAA  
61069852 
 
Query  73        AATCAGCTCAAACACAGGTAATGCTTAAACTTCCTGCCTCTTTTGCCTCTACAGGAAAGA  
132 
                 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61069853  AATCAGCTCAAACACAGGTAATGCTTAAACTTCCTGCCTCTTTTGCCTCTACAGGAAAGA  
61069912 
 
Query  133       AGAAAGAACACAAGAAAGTGAAGTCCACTAGGGATATTGTTCCTTTTTCTGAACTTGGAA  
192 
                 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61069913  AGAAAGAACACAAGAAAGTGAAGTCCACTAGGGATATTGTTCCTTTTTCTGAACTTGGAA  
61069972 
 
Query  193       CTACTCCCTCTGGTGGTGGATTTTTTCAGGGTATTTCTTTTCCTGAAATCTCCACCCGTC  
252 
                 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61069973  CTACTCCCTCTGGTGGTGGATTTTTTCAGGGTATTTCTTTTCCTGAAATCTCCACCCGTC  
61070032 
 
Query  253       CTCCTTTGGGCAGTACCGAACTACAGGCAGCTAAGAAAGTACATACTTCTAAGGGAGACC  
312 
                 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61070033  CTCCTTTGGGCAGTACCGAACTACAGGCAGCTAAGAAAGTACATACTTCTAAGGGAGACC  
61070092 
 
Query  313       TACCTAGGGAGCCTCTTGTTGCCACAAACTTGCCTGGCAGGGGACAGTTGCAGAAGTTAG  
372 
                 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61070093  TACCTAGGGAGCCTCTTGTTGCCACAAACTTGCCTGGCAGGGGACAGTTGCAGAAGTTAG  
61070152 
 
Query  373       CCTCTGAAAGGAATTTGTTTATTTCATGCAAGTCTAGCCATGATAGGTGTTTAGAGAAAA  
432 
                 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61070153  CCTCTGAAAGGAATTTGTTTATTTCATGCAAGTCTAGCCATGATAGGTGTTTAGAGAAAA  
61070212 
 
Query  433       GTTCTTCGTCATCTTCTCAGCCTGAACACAGTGCCATGTTGGTCTCTACTGCAGCTTCTC  
492 
                 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61070213  GTTCTTCGTCATCTTCTCAGCCTGAACACAGTGCCATGTTGGTCTCTACTGCAGCTTCTC  
61070272 
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Query  493       CTTCACTGATTAAAGAAACCACCACTGGTTACTATAAAGACATAGTAGAAAATATTTGCG  
552 
                 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61070273  CTTCACTGATTAAAGAAACCACCACTGGTTACTATAAAGACATAGTAGAAAATATTTGCG  
61070332 
 
Query  553       GTAGAGAGAAAAGTGGAATTCAACCATTATGTCCTGAGAGGTCCCATATTTCAGATCAAT  
612 
                 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61070333  GTAGAGAGAAAAGTGGAATTCAACCATTATGTCCTGAGAGGTCCCATATTTCAGATCAAT  
61070392 
 
Query  613       CGCCTCTCTCCAGTAAAAGGAAAGCACTAGAAGAGTCTGAGAGCTCACAACTAATTTCTC  
672 
                 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61070393  CGCCTCTCTCCAGTAAAAGGAAAGCACTAGAAGAGTCTGAGAGCTCACAACTAATTTCTC  
61070452 
 
Query  673       CGCCACTTGCCCAGGCAATCAGAGATTATGTCAATTCTCTGTTGGTCCAGGGTGGG-TAG  
731 
                 |||||||||||||||||||||||||||||||||||||||||||||||||||||||| ||| 
Sbjct  61070453  CGCCACTTGCCCAGGCAATCAGAGATTATGTCAATTCTCTGTTGGTCCAGGGTGGGGTAG  
61070512 
 
Query  732       GGTAGTTTGCCTGGAACTTCTAACTCT  758 
                 | ||||||||||||||||||||||||| 
Sbjct  61070513  G-TAGTTTGCCTGGAACTTCTAACTCT  61070538 
 
 
b. Forward sequence (vs. AC013418.32)  
 
    21901 TCAATTCTCT TCTGTATGTT TTCTACATCC AGTGGGGGCA TAGAGTTAGA AGTTCCAGGC 
    21961 AAACTACCTA CCCCACCCTG GACCAACAGA GAATTGACAT AATCTCTGAT TGCCTGGGCA 
    22021 AGTGGCGGAG AAATTAGTTG TGAGCTCTCA GACTCTTCTA GTGCTTTCCT TTTACTGGAG 
    22081 AGAGGCGATT GATCTGAAAT ATGGGACCTC TCAGGACATA ATGGTTGAAT TCCACTTTTC 
    22141 TCTCTACCGC AAATATTTTC TACTATGTCT TTATAGTAAC CAGTGGTGGT TTCTTTAATC 
    22201 AGTGAAGGAG AAGCTGCAGT AGAGACCAAC ATGGCACTGT GTTCAGGCTG AGAAGATGAC 
    22261 GAAGAACTTT TCTCTAAACA CCTATCATGG CTAGACTTGC ATGAAATAAA CAAATTCCTT 
    22321 TCAGAGGCTA ACTTCTGCAA CTGTCCCCTG CCAGGCAAGT TTGTGGCAAC AAGAGGCTCC 
    22381 CTAGGTAGGT CTCCCTTAGA AGTATGTACT TTCTTAGCTG CCTGTAGTTC GGTACTGCCC 
    22441 AAAGGAGGAC GGGTGGAGAT TTCAGGAAAA GAAATACCCT GAAAAAATCC ACCACCAGAG 
    22501 GGAGTAGTTC CAAGTTCAGA AAAAGGAACA ATATCCCTAG TGGACTTCAC TTTCTTGTGT 
    22561 TCTTTCTTCT TTCCTGTAGA GGCAAAAGAG GCAGGAAGTT TAAGCATTAC CTGTGTTTGA 
    22621 GCTGATTTTA TTCTTTGCCT CTTTGCTAAA AATAGTGCTG TCAAAGGAAA AGACTATAAT 
    22681 TTCATATTCT GAACTAATCT GCCAGATTTG CCCTGGTAGA CAAAGCTTAT TGAGATATAA 
 
c. Reverse sequence (BLAST) 
> ref|NT_029419.12|  Homo sapiens chromosome 12 genomic contig, 
GRCh37 reference primary  
assembly 
Length=71516776 
 
 
 Features in this part of subject sequence: 
   thymopoietin isoform beta 
   thymopoietin isoform gamma 
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 Score = 1406 bits (761),  Expect = 0.0 
 Identities = 764/765 (99%), Gaps = 1/765 (0%) 
 Strand=Plus/Minus 
 
Query  8         ACTACCTACCCCACCCTGGACCAACAGAGAATTGACATAATCTCTGATTGCCTGGGCAAG  
67 
                 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61070517  ACTACCTACCCCACCCTGGACCAACAGAGAATTGACATAATCTCTGATTGCCTGGGCAAG  
61070458 
 
Query  68        TGGCGGAGAAATTAGTTGTGAGCTCTCAGACTCTTCTAGTGCTTTCCTTTTACTGGAGAG  
127 
                 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61070457  TGGCGGAGAAATTAGTTGTGAGCTCTCAGACTCTTCTAGTGCTTTCCTTTTACTGGAGAG  
61070398 
 
Query  128       AGGCGATTGATCTGAAATATGGGACCTCTCAGGACATAATGGTTGAATTCCACTTTTCTC  
187 
                 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61070397  AGGCGATTGATCTGAAATATGGGACCTCTCAGGACATAATGGTTGAATTCCACTTTTCTC  
61070338 
 
Query  188       TCTACCGCAAATATTTTCTACTATGTCTTTATAGTAACCAGTGGTGGTTTCTTTAATCAG  
247 
                 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61070337  TCTACCGCAAATATTTTCTACTATGTCTTTATAGTAACCAGTGGTGGTTTCTTTAATCAG  
61070278 
 
Query  248       TGAAGGAGAAGCTGCAGTAGAGACCAACATGGCACTGTGTTCAGGCTGAGAAGATGACGA  
307 
                 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61070277  TGAAGGAGAAGCTGCAGTAGAGACCAACATGGCACTGTGTTCAGGCTGAGAAGATGACGA  
61070218 
 
Query  308       AGAACTTTTCTCTAAACACCTATCATGGCTAGACTTGCATGAAATAAACAAATTCCTTTC  
367 
                 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61070217  AGAACTTTTCTCTAAACACCTATCATGGCTAGACTTGCATGAAATAAACAAATTCCTTTC  
61070158 
 
Query  368       AGAGGCTAACTTCTGCAACTGTCCCCTGCCAGGCAAGTTTGTGGCAACAAGAGGCTCCCT  
427 
                 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61070157  AGAGGCTAACTTCTGCAACTGTCCCCTGCCAGGCAAGTTTGTGGCAACAAGAGGCTCCCT  
61070098 
 
Query  428       AGGTAGGTCTCCCTTAGAAGTATGTACTTTCTTAGCTGCCTGTAGTTCGGTACTGCCCAA  
487 
                 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61070097  AGGTAGGTCTCCCTTAGAAGTATGTACTTTCTTAGCTGCCTGTAGTTCGGTACTGCCCAA  
61070038 
 
Query  488       AGGAGGACGGGTGGAGATTTCAGGAAAAGAAATACCCTGAAAAAATCCACCACCAGAGGG  
547 
                 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61070037  AGGAGGACGGGTGGAGATTTCAGGAAAAGAAATACCCTGAAAAAATCCACCACCAGAGGG  
61069978 
 
Query  548       AGTAGTTCCAAGTTCAGAAAAAGGAACAATATCCCTAGTGGACTTCACTTTCTTGTGTTC  
607 
                 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61069977  AGTAGTTCCAAGTTCAGAAAAAGGAACAATATCCCTAGTGGACTTCACTTTCTTGTGTTC  
61069918 
 
Query  608       TTTCTTCTTTCCTGTAGAGGCAAAAGAGGCAGGAAGTTTAAGCATTACCTGTGTTTGAGC  
667 
                 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61069917  TTTCTTCTTTCCTGTAGAGGCAAAAGAGGCAGGAAGTTTAAGCATTACCTGTGTTTGAGC  
61069858 
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Query  668       TGATTTTATTCTTTGCCTCTTTGCTAAAAATAGTGCTGTCAAAGGAAAAGACTATAATTT  
727 
                 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61069857  TGATTTTATTCTTTGCCTCTTTGCTAAAAATAGTGCTGTCAAAGGAAAAGACTATAATTT  
61069798 
 
Query  728       CATATTCTGAACTAATCTGCCAGATTTGCCCTGGTAAGACAAAGC  772 
                 |||||||||||||||||||||||||||||||||||| |||||||| 
Sbjct  61069797  CATATTCTGAACTAATCTGCCAGATTTGCCCTGGTA-GACAAAGC  61069754 
 
 
d. Reverse sequence (vs. AC013418.32)  
 
    21901 TCAATTCTCT TCTGTATGTT TTCTACATCC AGTGGGGGCA TAGAGTTAGA AGTTCCAGGC 
    21961 AAACTACCTA CCCCACCCTG GACCAACAGA GAATTGACAT AATCTCTGAT TGCCTGGGCA 
    22021 AGTGGCGGAG AAATTAGTTG TGAGCTCTCA GACTCTTCTA GTGCTTTCCT TTTACTGGAG 
    22081 AGAGGCGATT GATCTGAAAT ATGGGACCTC TCAGGACATA ATGGTTGAAT TCCACTTTTC 
    22141 TCTCTACCGC AAATATTTTC TACTATGTCT TTATAGTAAC CAGTGGTGGT TTCTTTAATC 
    22201 AGTGAAGGAG AAGCTGCAGT AGAGACCAAC ATGGCACTGT GTTCAGGCTG AGAAGATGAC 
    22261 GAAGAACTTT TCTCTAAACA CCTATCATGG CTAGACTTGC ATGAAATAAA CAAATTCCTT 
    22321 TCAGAGGCTA ACTTCTGCAA CTGTCCCCTG CCAGGCAAGT TTGTGGCAAC AAGAGGCTCC 
    22381 CTAGGTAGGT CTCCCTTAGA AGTATGTACT TTCTTAGCTG CCTGTAGTTC GGTACTGCCC 
    22441 AAAGGAGGAC GGGTGGAGAT TTCAGGAAAA GAAATACCCT GAAAAAATCC ACCACCAGAG 
    22501 GGAGTAGTTC CAAGTTCAGA AAAAGGAACA ATATCCCTAG TGGACTTCAC TTTCTTGTGT 
    22561 TCTTTCTTCT TTCCTGTAGA GGCAAAAGAG GCAGGAAGTT TAAGCATTAC CTGTGTTTGA 
    22621 GCTGATTTTA TTCTTTGCCT CTTTGCTAAA AATAGTGCTG TCAAAGGAAA AGACTATAAT 
    22681 TTCATATTCT GAACTAATCT GCCAGATTTG CCCTGGTAGA CAAAGCTTAT TGAGATATAA 
 
e. Combined sequencing (forward and reverse sequences) 
 
    21901 TCAATTCTCT TCTGTATGTT TTCTACATCC AGTGGGGGCA TAGAGTTAGA AGTTCCAGGC 
    21961 AAACTACCTA CCCCACCCTG GACCAACAGA GAATTGACAT AATCTCTGAT TGCCTGGGCA 
    22021 AGTGGCGGAG AAATTAGTTG TGAGCTCTCA GACTCTTCTA GTGCTTTCCT TTTACTGGAG 
    22081 AGAGGCGATT GATCTGAAAT ATGGGACCTC TCAGGACATA ATGGTTGAAT TCCACTTTTC 
    22141 TCTCTACCGC AAATATTTTC TACTATGTCT TTATAGTAAC CAGTGGTGGT TTCTTTAATC 
    22201 AGTGAAGGAG AAGCTGCAGT AGAGACCAAC ATGGCACTGT GTTCAGGCTG AGAAGATGAC 
    22261 GAAGAACTTT TCTCTAAACA CCTATCATGG CTAGACTTGC ATGAAATAAA CAAATTCCTT 
    22321 TCAGAGGCTA ACTTCTGCAA CTGTCCCCTG CCAGGCAAGT TTGTGGCAAC AAGAGGCTCC 
    22381 CTAGGTAGGT CTCCCTTAGA AGTATGTACT TTCTTAGCTG CCTGTAGTTC GGTACTGCCC 
    22441 AAAGGAGGAC GGGTGGAGAT TTCAGGAAAA GAAATACCCT GAAAAAATCC ACCACCAGAG 
    22501 GGAGTAGTTC CAAGTTCAGA AAAAGGAACA ATATCCCTAG TGGACTTCAC TTTCTTGTGT 
    22561 TCTTTCTTCT TTCCTGTAGA GGCAAAAGAG GCAGGAAGTT TAAGCATTAC CTGTGTTTGA 
    22621 GCTGATTTTA TTCTTTGCCT CTTTGCTAAA AATAGTGCTG TCAAAGGAAA AGACTATAAT 
    22681 TTCATATTCT GAACTAATCT GCCAGATTTG CCCTGGTAGA CAAAGCTTAT TGAGATATAA 
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2. Primer pair: LAP2α4.1 
a. Forward sequence (BLAST) 
> ref|NM_003276.1|  Homo sapiens thymopoietin (TMPO), 
transcript variant 1, mRNA 
Length=2490 
 
 GENE ID: 7112 TMPO | thymopoietin [Homo sapiens] (Over 10 
PubMed links) 
 
 
 Score = 1868 bits (1011),  Expect = 0.0 
 Identities = 1050/1067 (98%), Gaps = 9/1067 (0%) 
 Strand=Plus/Plus 
 
Query  3      
GGGGGC-GTTGC-G-AGTTAGCCTCTG-AAGG-ATTTGTTTATTTCATGCAAGTCTAGCC  57 
|||| | ||||| | |||||||||||| |||| ||||||||||||||||||||||||||| 
Sbjct  995   GGGGACAGTTGCAGAAGTTAGCCTCTGAAAGGAATTTGTTTATTTCATGCAAGTCTAGCC  1054 
 
Query  58    ATGATAGGTGTTTAGAGAAAAGTTCTTCGTCATCTTCTCAGCCTGAACACAGTGCCATGT  117 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1055  ATGATAGGTGTTTAGAGAAAAGTTCTTCGTCATCTTCTCAGCCTGAACACAGTGCCATGT  1114 
 
Query  118   TGGTCTCTACTGCAGCTTCTCCTTCACTGATTAAAGAAACCACCACTGGTTACTATAAAG  177 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1115  TGGTCTCTACTGCAGCTTCTCCTTCACTGATTAAAGAAACCACCACTGGTTACTATAAAG  1174 
 
Query  178   ACATAGTAGAAAATATTTGCGGTAGAGAGAAAAGTGGAATTCAACCATTATGTCCTGAGA  237 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1175  ACATAGTAGAAAATATTTGCGGTAGAGAGAAAAGTGGAATTCAACCATTATGTCCTGAGA  1234 
 
Query  238   GGTCCCATATTTCAGATCAATCGCCTCTCTCCAGTAAAAGGAAAGCACTAGAAGAGTCTG  297 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1235  GGTCCCATATTTCAGATCAATCGCCTCTCTCCAGTAAAAGGAAAGCACTAGAAGAGTCTG  1294 
 
Query  298   AGAGCTCACAACTAATTTCTCCGCCACTTGCCCAGGCAATCAGAGATTATGTCAATTCTC  357 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1295  AGAGCTCACAACTAATTTCTCCGCCACTTGCCCAGGCAATCAGAGATTATGTCAATTCTC  1354 
 
Query  358   TGTTGGTCCAGGGTGGGGTAGGTAGTTTGCCTGGAACTTCTAACTCTATGCCCCCACTGG  417 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1355  TGTTGGTCCAGGGTGGGGTAGGTAGTTTGCCTGGAACTTCTAACTCTATGCCCCCACTGG  1414 
 
Query  418   ATGTAGAAAACATACAGAAGAGAATTGATCAGTCTAAGTTTCAAGAAACTGAATTCCTGT  477 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1415  ATGTAGAAAACATACAGAAGAGAATTGATCAGTCTAAGTTTCAAGAAACTGAATTCCTGT  1474 
 
Query  478   CTCCTCCAAGAAAAGTCCCTAGACTGAGTGAGAAGTCAGTGGAGGAAAGGGATTCAGGTT  537 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1475  CTCCTCCAAGAAAAGTCCCTAGACTGAGTGAGAAGTCAGTGGAGGAAAGGGATTCAGGTT  1534 
 
Query  538   CCTTTGTGGCATTTCAGAACATACCTGGATCCGAACTGATGTCTTCTTTTGCCAAAACTG  597 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1535  CCTTTGTGGCATTTCAGAACATACCTGGATCCGAACTGATGTCTTCTTTTGCCAAAACTG  1594 
 
Query  598   TTGTCTCTCATTCACTCACTACCTTAGGTCTAGAAGTGGCTAAGCAATCACAGCATGATA  657 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1595  TTGTCTCTCATTCACTCACTACCTTAGGTCTAGAAGTGGCTAAGCAATCACAGCATGATA  1654 
 
Query  658   AAATAGATGCCTCAGAACTATCTTTTCCCTTCCATGAATCTATTTTAAAAGTAATTGAAG  717 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1655  AAATAGATGCCTCAGAACTATCTTTTCCCTTCCATGAATCTATTTTAAAAGTAATTGAAG  1714 
 
Query  718   AAGAATGGCAGCAAGTTGACAGGCAGCTGCCTTCACTGGCATGCAAATATCCAGTTTCTT  777 
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             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1715  AAGAATGGCAGCAAGTTGACAGGCAGCTGCCTTCACTGGCATGCAAATATCCAGTTTCTT  1774 
 
Query  778   CCAGGGAGGCAACACAGATATTATCAGTTCCAAAAGTAGATGATGAAATCCTAGGGTTTA  837 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1775  CCAGGGAGGCAACACAGATATTATCAGTTCCAAAAGTAGATGATGAAATCCTAGGGTTTA  1834 
 
Query  838   TTTCTGAAGCCACTCCACTAGGAGGTATTCAAGCAGCCTCCACTGAGTCTTGCAATCAGC  897 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1835  TTTCTGAAGCCACTCCACTAGGAGGTATTCAAGCAGCCTCCACTGAGTCTTGCAATCAGC  1894 
 
Query  898   AGTTGGACTTAGCACTCTGTAGAGCATATGAAGCTGCAGCATCAGCATTGCGGATTGCGA  957 
||||||||||||||||||||||||||||||||||||||||||||||||||| |||||| | 
Sbjct  1895  AGTTGGACTTAGCACTCTGTAGAGCATATGAAGCTGCAGCATCAGCATTGCAGATTGCAA  1954 
 
Query  958    
CTCACACTGCCTTTGTAGCTAAGGCTATGCAGACAGACATAAGTCAAGCTGC-CAGATTC  1016 
|||||||||||||||||||||||||||||||| ||||||| ||||||||||| ||||||| 
Sbjct  1955  CTCACACTGCCTTTGTAGCTAAGGCTATGCAGGCAGACATTAGTCAAGCTGCACAGATTC  2014 
 
Query  1017  TTAACTCAGATCCAAGTCGTACCC-CCAAGCGCCTGG-ATTTCTGAG  1061 
             ||| ||||||||| |||||||||| |||||||| ||| ||| ||||| 
Sbjct  2015  TTAGCTCAGATCCTAGTCGTACCCACCAAGCGCTTGGGATT-CTGAG  2060 
 
b. Forward sequence (vs. NM_003276.1) 
 
961  AGGGAGCCTCTTGTTGCCACAAACTTGCCTGGCAGGGGACAGTTGCAGAAGTTAGCCTCT 
1021 GAAAGGAATTTGTTTATTTCATGCAAGTCTAGCCATGATAGGTGTTTAGAGAAAAGTTCT 
1081 TCGTCATCTTCTCAGCCTGAACACAGTGCCATGTTGGTCTCTACTGCAGCTTCTCCTTCA 
1141 CTGATTAAAGAAACCACCACTGGTTACTATAAAGACATAGTAGAAAATATTTGCGGTAGA 
1201 GAGAAAAGTGGAATTCAACCATTATGTCCTGAGAGGTCCCATATTTCAGATCAATCGCCT 
1261 CTCTCCAGTAAAAGGAAAGCACTAGAAGAGTCTGAGAGCTCACAACTAATTTCTCCGCCA 
1321 CTTGCCCAGGCAATCAGAGATTATGTCAATTCTCTGTTGGTCCAGGGTGGGGTAGGTAGT 
1381 TTGCCTGGAACTTCTAACTCTATGCCCCCACTGGATGTAGAAAACATACAGAAGAGAATT 
1441 GATCAGTCTAAGTTTCAAGAAACTGAATTCCTGTCTCCTCCAAGAAAAGTCCCTAGACTG 
1501 AGTGAGAAGTCAGTGGAGGAAAGGGATTCAGGTTCCTTTGTGGCATTTCAGAACATACCT 
1561 GGATCCGAACTGATGTCTTCTTTTGCCAAAACTGTTGTCTCTCATTCACTCACTACCTTA 
1621 GGTCTAGAAGTGGCTAAGCAATCACAGCATGATAAAATAGATGCCTCAGAACTATCTTTT 
1681 CCCTTCCATGAATCTATTTTAAAAGTAATTGAAGAAGAATGGCAGCAAGTTGACAGGCAG 
1741 CTGCCTTCACTGGCATGCAAATATCCAGTTTCTTCCAGGGAGGCAACACAGATATTATCA 
1801 GTTCCAAAAGTAGATGATGAAATCCTAGGGTTTATTTCTGAAGCCACTCCACTAGGAGGT 
1861 ATTCAAGCAGCCTCCACTGAGTCTTGCAATCAGCAGTTGGACTTAGCACTCTGTAGAGCA 
1921 TATGAAGCTGCAGCATCAGCATTGCAGATTGCAACTCACACTGCCTTTGTAGCTAAGGCT 
1981 ATGCAGGCAGACATTAGTCAAGCTGCACAGATTCTTAGCTCAGATCCTAGTCGTACCCAC 
2041 CAAGCGCTTGGGATTCTGAGCAAAACATATGATGCAGCCTCATATATTTGTGAAGCTGCA 
2101 TTTGATGAAGTGAAGATGGCTGCCCATACCATGGGAAATGCCACTGTAGGTCGTCGATAC 
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c. Reverse sequence (BLAST) 
> ref|NM_003276.1|  Homo sapiens thymopoietin (TMPO), transcript 
variant 1, mRNA 
Length=2490 
 
 GENE ID: 7112 TMPO | thymopoietin [Homo sapiens] (Over 10 PubMed links) 
 
 
 Score = 1930 bits (1045),  Expect = 0.0 
 Identities = 1082/1098 (98%), Gaps = 9/1098 (0%) 
 Strand=Plus/Minus 
 
Query  9     AAATATATGAGGCTGCATCATATGTTTTGCTCAGAATCCCAAGCGCTTGGTGGGTACGAC  68 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2089  AAATATATGAGGCTGCATCATATGTTTTGCTCAGAATCCCAAGCGCTTGGTGGGTACGAC  2030 
 
Query  69    TAGGATCTGAGCTAAGAATCTGTGCAGCTTGACTAATGTCTGCCTGCATAGCCTTAGCTA  128 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2029  TAGGATCTGAGCTAAGAATCTGTGCAGCTTGACTAATGTCTGCCTGCATAGCCTTAGCTA  1970 
 
Query  129   CAAAGGCAGTGTGAGTTGCAATCTGCAATGCTGATGCTGCAGCTTCATATGCTCTACAGA  188 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1969  CAAAGGCAGTGTGAGTTGCAATCTGCAATGCTGATGCTGCAGCTTCATATGCTCTACAGA  1910 
 
Query  189   GTGCTAAGTCCAACTGCTGATTGCAAGACTCAGTGGAGGCTGCTTGAATACCTCCTAGTG  248 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1909  GTGCTAAGTCCAACTGCTGATTGCAAGACTCAGTGGAGGCTGCTTGAATACCTCCTAGTG  1850 
 
Query  249   GAGTGGCTTCAGAAATAAACCCTAGGATTTCATCATCTACTTTTGGAACTGATAATATCT  308 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1849  GAGTGGCTTCAGAAATAAACCCTAGGATTTCATCATCTACTTTTGGAACTGATAATATCT  1790 
 
Query  309   GTGTTGCCTCCCTGGAAGAAACTGGATATTTGCATGCCAGTGAAGGCAGCTGCCTGTCAA  368 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1789  GTGTTGCCTCCCTGGAAGAAACTGGATATTTGCATGCCAGTGAAGGCAGCTGCCTGTCAA  1730 
 
Query  369   CTTGCTGCCATTCTTCTTCAATTACTTTTAAAATAGATTCATGGAAGGGAAAAGATAGTT  428 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1729  CTTGCTGCCATTCTTCTTCAATTACTTTTAAAATAGATTCATGGAAGGGAAAAGATAGTT  1670 
 
Query  429   CTGAGGCATCTATTTTATCATGCTGTGATTGCTTAGCCACTTCTAGACCTAAGGTAGTGA  488 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1669  CTGAGGCATCTATTTTATCATGCTGTGATTGCTTAGCCACTTCTAGACCTAAGGTAGTGA  1610 
 
Query  489   GTGAATGAGAGACAACAGTTTTGGCAAAAGAAGACATCAGTTCGGATCCAGGTATGTTCT  548 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1609  GTGAATGAGAGACAACAGTTTTGGCAAAAGAAGACATCAGTTCGGATCCAGGTATGTTCT  1550 
 
Query  549   GAAATGCCACAAAGGAACCTGAATCCCTTTCCTCCACTGACTTCTCACTCAGTCTAGGGA  608 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1549  GAAATGCCACAAAGGAACCTGAATCCCTTTCCTCCACTGACTTCTCACTCAGTCTAGGGA  1490 
 
Query  609   CTTTTCTTGGAGGAGACAGGAATTCAGTTTCTTGAAACTTAGACTGATCAATTCTCTTCT  668 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1489  CTTTTCTTGGAGGAGACAGGAATTCAGTTTCTTGAAACTTAGACTGATCAATTCTCTTCT  1430 
 
Query  669   GTATGTTTTCTACATCCAGTGGGGGCATAGAGTTAGAAGTTCCAGGCAAACTACCTACCC  728 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1429  GTATGTTTTCTACATCCAGTGGGGGCATAGAGTTAGAAGTTCCAGGCAAACTACCTACCC  1370 
 
Query  729   CACCCTGGACCAACAGAGAATTGACATAATCTCTGATTGCCTGGGCAAGTGGCGGAGAAA  788 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1369  CACCCTGGACCAACAGAGAATTGACATAATCTCTGATTGCCTGGGCAAGTGGCGGAGAAA  1310 
 
Query  789   TTAGTTGTGAGCTCTCAGACTCTTCTAGTGCTTTCCTTTTACTGGAGAGAGGCGATTGAT  848 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1309  TTAGTTGTGAGCTCTCAGACTCTTCTAGTGCTTTCCTTTTACTGGAGAGAGGCGATTGAT  1250 
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Query  849   CTGAAATATGGGACCTCTCAGGACATAATGGTTGAATTCCACTTTTCTCTCTACCGCAAA  908 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1249  CTGAAATATGGGACCTCTCAGGACATAATGGTTGAATTCCACTTTTCTCTCTACCGCAAA  1190 
 
Query  909   TATTTTCTACTATGTCTTTATAGTAACCAGTGGTGGTTTCTTTAATCAGTGAAGGAGAAG  968 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1189  TATTTTCTACTATGTCTTTATAGTAACCAGTGGTGGTTTCTTTAATCAGTGAAGGAGAAG  1130 
 
Query  969   CTGCAGTACAGACCAACATGGCACTGTGTTCAGGCTGAGAAGATGACGAAGAACTTTTCT  1028 
             |||||||| ||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1129  CTGCAGTAGAGACCAACATGGCACTGTGTTCAGGCTGAGAAGATGACGAAGAACTTTTCT  1070 
 
Query  1029  CTAA-CACCTATCATG-CTAGCCTTGCATGAA-TGACCGA-TTCCTT-CAG---CTA-CT  1079 
             |||| ||||||||||| |||| |||||||||| | | | | |||||| |||   ||| || 
Sbjct  1069  CTAAACACCTATCATGGCTAGACTTGCATGAAATAAACAAATTCCTTTCAGAGGCTAACT  1010 
 
Query  1080  TCTGCAACTGTACTCTGC  1097 
             ||||||||||| | |||| 
Sbjct  1009  TCTGCAACTGTCCCCTGC  992 
 
d. Reverse sequence (vs. NM_003276.1)  
 
961  AGGGAGCCTCTTGTTGCCACAAACTTGCCTGGCAGGGGACAGTTGCAGAAGTTAGCCTCT 
1021 GAAAGGAATTTGTTTATTTCATGCAAGTCTAGCCATGATAGGTGTTTAGAGAAAAGTTCT 
1081 TCGTCATCTTCTCAGCCTGAACACAGTGCCATGTTGGTCTCTACTGCAGCTTCTCCTTCA 
1141 CTGATTAAAGAAACCACCACTGGTTACTATAAAGACATAGTAGAAAATATTTGCGGTAGA 
1201 GAGAAAAGTGGAATTCAACCATTATGTCCTGAGAGGTCCCATATTTCAGATCAATCGCCT 
1261 CTCTCCAGTAAAAGGAAAGCACTAGAAGAGTCTGAGAGCTCACAACTAATTTCTCCGCCA 
1321 CTTGCCCAGGCAATCAGAGATTATGTCAATTCTCTGTTGGTCCAGGGTGGGGTAGGTAGT 
1381 TTGCCTGGAACTTCTAACTCTATGCCCCCACTGGATGTAGAAAACATACAGAAGAGAATT 
1441 GATCAGTCTAAGTTTCAAGAAACTGAATTCCTGTCTCCTCCAAGAAAAGTCCCTAGACTG 
1501 AGTGAGAAGTCAGTGGAGGAAAGGGATTCAGGTTCCTTTGTGGCATTTCAGAACATACCT 
1561 GGATCCGAACTGATGTCTTCTTTTGCCAAAACTGTTGTCTCTCATTCACTCACTACCTTA 
1621 GGTCTAGAAGTGGCTAAGCAATCACAGCATGATAAAATAGATGCCTCAGAACTATCTTTT 
1681 CCCTTCCATGAATCTATTTTAAAAGTAATTGAAGAAGAATGGCAGCAAGTTGACAGGCAG 
1741 CTGCCTTCACTGGCATGCAAATATCCAGTTTCTTCCAGGGAGGCAACACAGATATTATCA 
1801 GTTCCAAAAGTAGATGATGAAATCCTAGGGTTTATTTCTGAAGCCACTCCACTAGGAGGT 
1861 ATTCAAGCAGCCTCCACTGAGTCTTGCAATCAGCAGTTGGACTTAGCACTCTGTAGAGCA 
1921 TATGAAGCTGCAGCATCAGCATTGCAGATTGCAACTCACACTGCCTTTGTAGCTAAGGCT 
1981 ATGCAGGCAGACATTAGTCAAGCTGCACAGATTCTTAGCTCAGATCCTAGTCGTACCCAC 
2041 CAAGCGCTTGGGATTCTGAGCAAAACATATGATGCAGCCTCATATATTTGTGAAGCTGCA 
2101 TTTGATGAAGTGAAGATGGCTGCCCATACCATGGGAAATGCCACTGTAGGTCGTCGATAC 
 
e. Combined sequencing (forward and reverse sequences) 
961  AGGGAGCCTCTTGTTGCCACAAACTTGCCTGGCAGGGGACAGTTGCAGAAGTTAGCCTCT 
1021 GAAAGGAATTTGTTTATTTCATGCAAGTCTAGCCATGATAGGTGTTTAGAGAAAAGTTCT 
1081 TCGTCATCTTCTCAGCCTGAACACAGTGCCATGTTGGTCTCTACTGCAGCTTCTCCTTCA 
1141 CTGATTAAAGAAACCACCACTGGTTACTATAAAGACATAGTAGAAAATATTTGCGGTAGA 
1201 GAGAAAAGTGGAATTCAACCATTATGTCCTGAGAGGTCCCATATTTCAGATCAATCGCCT 
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1261 CTCTCCAGTAAAAGGAAAGCACTAGAAGAGTCTGAGAGCTCACAACTAATTTCTCCGCCA 
1321 CTTGCCCAGGCAATCAGAGATTATGTCAATTCTCTGTTGGTCCAGGGTGGGGTAGGTAGT 
1381 TTGCCTGGAACTTCTAACTCTATGCCCCCACTGGATGTAGAAAACATACAGAAGAGAATT 
1441 GATCAGTCTAAGTTTCAAGAAACTGAATTCCTGTCTCCTCCAAGAAAAGTCCCTAGACTG 
1501 AGTGAGAAGTCAGTGGAGGAAAGGGATTCAGGTTCCTTTGTGGCATTTCAGAACATACCT 
1561 GGATCCGAACTGATGTCTTCTTTTGCCAAAACTGTTGTCTCTCATTCACTCACTACCTTA 
1621 GGTCTAGAAGTGGCTAAGCAATCACAGCATGATAAAATAGATGCCTCAGAACTATCTTTT 
1681 CCCTTCCATGAATCTATTTTAAAAGTAATTGAAGAAGAATGGCAGCAAGTTGACAGGCAG 
1741 CTGCCTTCACTGGCATGCAAATATCCAGTTTCTTCCAGGGAGGCAACACAGATATTATCA 
1801 GTTCCAAAAGTAGATGATGAAATCCTAGGGTTTATTTCTGAAGCCACTCCACTAGGAGGT 
1861 ATTCAAGCAGCCTCCACTGAGTCTTGCAATCAGCAGTTGGACTTAGCACTCTGTAGAGCA 
1921 TATGAAGCTGCAGCATCAGCATTGCAGATTGCAACTCACACTGCCTTTGTAGCTAAGGCT 
1981 ATGCAGGCAGACATTAGTCAAGCTGCACAGATTCTTAGCTCAGATCCTAGTCGTACCCAC 
2041 CAAGCGCTTGGGATTCTGAGCAAAACATATGATGCAGCCTCATATATTTGTGAAGCTGCA 
2101 TTTGATGAAGTGAAGATGGCTGCCCATACCATGGGAAATGCCACTGTAGGTCGTCGATAC 
 
3. Primer pair: LAP2α4.2 
a. Forward sequence (BLAST) 
ref|NM_003276.1|  Homo sapiens thymopoietin (TMPO), transcript 
variant 1, mRNA 
Length=2490 
 
 
 Score =  252 bits (127),  Expect = 8e-65 
 Identities = 127/127 (100%), Gaps = 0/127 (0%) 
 Strand=Plus/Plus 
 
Query  5     AAACATACAGAAGAGAATTGATCAGTCTAAGTTTCAAGAAACTGAATTCCTGTCTCCTCC  64 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1422  AAACATACAGAAGAGAATTGATCAGTCTAAGTTTCAAGAAACTGAATTCCTGTCTCCTCC  1481 
 
Query  65    AAGAAAAGTCCCTAGACTGAGTGAGAAGTCAGTGGAGGAAAGGGATTCAGGTTCCTTTGT  124 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1482  AAGAAAAGTCCCTAGACTGAGTGAGAAGTCAGTGGAGGAAAGGGATTCAGGTTCCTTTGT  1541 
 
Query  125   GGCATTT  131 
             ||||||| 
Sbjct  1542  GGCATTT  1548 
 
b. Forward sequence  (vs. NM_003276.1) 
1321 CTTGCCCAGGCAATCAGAGATTATGTCAATTCTCTGTTGGTCCAGGGTGGGGTAGGTAGT 
1381 TTGCCTGGAACTTCTAACTCTATGCCCCCACTGGATGTAGAAAACATACAGAAGAGAATT 
1441 GATCAGTCTAAGTTTCAAGAAACTGAATTCCTGTCTCCTCCAAGAAAAGTCCCTAGACTG 
1501 AGTGAGAAGTCAGTGGAGGAAAGGGATTCAGGTTCCTTTGTGGCATTTCAGAACATACCT 
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4. Primer pair: LAP2α4.3 
a. Forward sequence (BLAST) 
> ref|NM_003276.1|  Homo sapiens thymopoietin (TMPO), transcript 
variant 1, mRNA 
Length=2490 
 
 GENE ID: 7112 TMPO | thymopoietin [Homo sapiens] (Over 10 PubMed links) 
 
 
 Score = 1640 bits (888),  Expect = 0.0 
 Identities = 896/899 (99%), Gaps = 3/899 (0%) 
 Strand=Plus/Plus 
 
Query  5     AACTGTTGTCTCTCATTC-CTCACTACCTTAGGTCTAGAAGTGGCTAAGCAATCACAGCA  63 
             |||||||||||||||||| ||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1590  AACTGTTGTCTCTCATTCACTCACTACCTTAGGTCTAGAAGTGGCTAAGCAATCACAGCA  1649 
 
Query  64    TGATAAAATAGATGCCTCAGAACTATCTTTTCCCTTCCATGAATCTATTTTAAAAGTAAT  123 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1650  TGATAAAATAGATGCCTCAGAACTATCTTTTCCCTTCCATGAATCTATTTTAAAAGTAAT  1709 
 
Query  124   TGAAGAAGAATGGCAGCAAGTTGACAGGCAGCTGCCTTCACTGGCATGCAAATATCCAGT  183 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1710  TGAAGAAGAATGGCAGCAAGTTGACAGGCAGCTGCCTTCACTGGCATGCAAATATCCAGT  1769 
 
Query  184   TTCTTCCAGGGAGGCAACACAGATATTATCAGTTCCAAAAGTAGATGATGAAATCCTAGG  243 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1770  TTCTTCCAGGGAGGCAACACAGATATTATCAGTTCCAAAAGTAGATGATGAAATCCTAGG  1829 
 
Query  244   GTTTATTTCTGAAGCCACTCCACTAGGAGGTATTCAAGCAGCCTCCACTGAGTCTTGCAA  303 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1830  GTTTATTTCTGAAGCCACTCCACTAGGAGGTATTCAAGCAGCCTCCACTGAGTCTTGCAA  1889 
 
Query  304   TCAGCAGTTGGACTTAGCACTCTGTAGAGCATATGAAGCTGCAGCATCAGCATTGCAGAT  363 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1890  TCAGCAGTTGGACTTAGCACTCTGTAGAGCATATGAAGCTGCAGCATCAGCATTGCAGAT  1949 
 
Query  364   TGCAACTCACACTGCCTTTGTAGCTAAGGCTATGCAGGCAGACATTAGTCAAGCTGCACA  423 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1950  TGCAACTCACACTGCCTTTGTAGCTAAGGCTATGCAGGCAGACATTAGTCAAGCTGCACA  2009 
 
Query  424   GATTCTTAGCTCAGATCCTAGTCGTACCCACCAAGCGCTTGGGATTCTGAGCAAAACATA  483 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2010  GATTCTTAGCTCAGATCCTAGTCGTACCCACCAAGCGCTTGGGATTCTGAGCAAAACATA  2069 
 
Query  484   TGATGCAGCCTCATATATTTGTGAAGCTGCATTTGATGAAGTGAAGATGGCTGCCCATAC  543 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2070  TGATGCAGCCTCATATATTTGTGAAGCTGCATTTGATGAAGTGAAGATGGCTGCCCATAC  2129 
 
Query  544   CATGGGAAATGCCACTGTAGGTCGTCGATACCTCTGGCTGAAGGATTGCAAAATTAATTT  603 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2130  CATGGGAAATGCCACTGTAGGTCGTCGATACCTCTGGCTGAAGGATTGCAAAATTAATTT  2189 
 
Query  604   AGCTTCTAAGAATAAGCTGGCTTCCACTCCCTTTAAAGGTGGAACATTATTTGGAGGAGA  663 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2190  AGCTTCTAAGAATAAGCTGGCTTCCACTCCCTTTAAAGGTGGAACATTATTTGGAGGAGA  2249 
 
Query  664   AGTATGCAAAGTAATTAAAAAGCGTGGAAATAAACACTAGTAAAATTAAGGACAAAAAGA  723 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2250  AGTATGCAAAGTAATTAAAAAGCGTGGAAATAAACACTAGTAAAATTAAGGACAAAAAGA  2309 
 
Query  724   CATCTATCTTATCTTTCAGGTACTTTATGCCAACATTTTCTTTTCTGTTAAGGTTGTTTT  783 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2310  CATCTATCTTATCTTTCAGGTACTTTATGCCAACATTTTCTTTTCTGTTAAGGTTGTTTT  2369 
 
Query  784   AGTTTCCAGATAGGGCTAATTACAAAATGTTAAGCTTCTACCCATCAAATTACAGTATAA  843 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
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Sbjct  2370  AGTTTCCAGATAGGGCTAATTACAAAATGTTAAGCTTCTACCCATCAAATTACAGTATAA  2429 
 
Query  844   AAGTAATTGCCTGTGTAGAACTACTTGTCTTTTCTAAAGATTTGCGTAG-TAGGGAAGC  901 
             ||||||||||||||||||||||||||||||||||||||||||||||||| |||| |||| 
Sbjct  2430  AAGTAATTGCCTGTGTAGAACTACTTGTCTTTTCTAAAGATTTGCGTAGATAGG-AAGC  2487  
 
 
b. Forward sequence (vs. NM_003276.1) 
1501 AGTGAGAAGTCAGTGGAGGAAAGGGATTCAGGTTCCTTTGTGGCATTTCAGAACATACCT 
1561 GGATCCGAACTGATGTCTTCTTTTGCCAAAACTGTTGTCTCTCATTCACTCACTACCTTA 
1621 GGTCTAGAAGTGGCTAAGCAATCACAGCATGATAAAATAGATGCCTCAGAACTATCTTTT 
1681 CCCTTCCATGAATCTATTTTAAAAGTAATTGAAGAAGAATGGCAGCAAGTTGACAGGCAG 
1741 CTGCCTTCACTGGCATGCAAATATCCAGTTTCTTCCAGGGAGGCAACACAGATATTATCA 
1801 GTTCCAAAAGTAGATGATGAAATCCTAGGGTTTATTTCTGAAGCCACTCCACTAGGAGGT 
1861 ATTCAAGCAGCCTCCACTGAGTCTTGCAATCAGCAGTTGGACTTAGCACTCTGTAGAGCA 
1921 TATGAAGCTGCAGCATCAGCATTGCAGATTGCAACTCACACTGCCTTTGTAGCTAAGGCT 
1981 ATGCAGGCAGACATTAGTCAAGCTGCACAGATTCTTAGCTCAGATCCTAGTCGTACCCAC 
2041 CAAGCGCTTGGGATTCTGAGCAAAACATATGATGCAGCCTCATATATTTGTGAAGCTGCA 
2101 TTTGATGAAGTGAAGATGGCTGCCCATACCATGGGAAATGCCACTGTAGGTCGTCGATAC 
2161 CTCTGGCTGAAGGATTGCAAAATTAATTTAGCTTCTAAGAATAAGCTGGCTTCCACTCCC 
2221 TTTAAAGGTGGAACATTATTTGGAGGAGAAGTATGCAAAGTAATTAAAAAGCGTGGAAAT 
2281 AAACACTAGTAAAATTAAGGACAAAAAGACATCTATCTTATCTTTCAGGTACTTTATGCC 
2341 AACATTTTCTTTTCTGTTAAGGTTGTTTTAGTTTCCAGATAGGGCTAATTACAAAATGTT 
2401 AAGCTTCTACCCATCAAATTACAGTATAAAAGTAATTGCCTGTGTAGAACTACTTGTCTT 
2461 TTCTAAAGATTTGCGTAGATAGGAAGCCTG 
 
c. Reverse sequence (BLAST) 
> ref|NM_003276.1|  Homo sapiens thymopoietin (TMPO), transcript 
variant 1, mRNA 
Length=2490 
 
 GENE ID: 7112 TMPO | thymopoietin [Homo sapiens] (Over 10 PubMed links) 
 
 
 Score = 1626 bits (880),  Expect = 0.0 
 Identities = 895/901 (99%), Gaps = 5/901 (0%) 
 Strand=Plus/Minus 
 
Query  4     AAGA-AGGTAGTTTCTACACAGGC-ATTACTTTTATACTGTAATTTGATGGGTAGAAGCT  61 
             |||| | |||| |||||||||||| ||||||||||||||||||||||||||||||||||| 
Sbjct  2460  AAGACAAGTAG-TTCTACACAGGCAATTACTTTTATACTGTAATTTGATGGGTAGAAGCT  2402 
 
Query  62    TAACATTTTGTAATTAGCCCTATCTGGAAACTAAAACAACCTTAACAGAAAAGAAAATGT  121 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2401  TAACATTTTGTAATTAGCCCTATCTGGAAACTAAAACAACCTTAACAGAAAAGAAAATGT  2342 
 
Query  122   TGGCATAAAGTACCTGAAAGATAAGATAGATGTCTTTTTGTCCTTAATTTTACTAGTGTT  181 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2341  TGGCATAAAGTACCTGAAAGATAAGATAGATGTCTTTTTGTCCTTAATTTTACTAGTGTT  2282 
 
Query  182   TATTTCCACGCTTTTTAATTACTTTGCATACTTCTCCTCCAAATAATGTTCCACCTTTAA  241 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2281  TATTTCCACGCTTTTTAATTACTTTGCATACTTCTCCTCCAAATAATGTTCCACCTTTAA  2222 
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Query  242   AGGGAGTGGAAGCCAGCTTATTCTTAGAAGCTAAATTAATTTTGCAATCCTTCAGCCAGA  301 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2221  AGGGAGTGGAAGCCAGCTTATTCTTAGAAGCTAAATTAATTTTGCAATCCTTCAGCCAGA  2162 
 
Query  302   GGTATCGACGACCTACAGTGGCATTTCCCATGGTATGGGCAGCCATCTTCACTTCATCAA  361 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2161  GGTATCGACGACCTACAGTGGCATTTCCCATGGTATGGGCAGCCATCTTCACTTCATCAA  2102 
 
Query  362   ATGCAGCTTCACAAATATATGAGGCTGCATCATATGTTTTGCTCAGAATCCCAAGCGCTT  421 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2101  ATGCAGCTTCACAAATATATGAGGCTGCATCATATGTTTTGCTCAGAATCCCAAGCGCTT  2042 
 
Query  422   GGTGGGTACGACTAGGATCTGAGCTAAGAATCTGTGCAGCTTGACTAATGTCTGCCTGCA  481 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  2041  GGTGGGTACGACTAGGATCTGAGCTAAGAATCTGTGCAGCTTGACTAATGTCTGCCTGCA  1982 
 
Query  482   TAGCCTTAGCTACAAAGGCAGTGTGAGTTGCAATCTGCAATGCTGATGCTGCAGCTTCAT  541 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1981  TAGCCTTAGCTACAAAGGCAGTGTGAGTTGCAATCTGCAATGCTGATGCTGCAGCTTCAT  1922 
 
Query  542   ATGCTCTACAGAGTGCTAAGTCCAACTGCTGATTGCAAGACTCAGTGGAGGCTGCTTGAA  601 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1921  ATGCTCTACAGAGTGCTAAGTCCAACTGCTGATTGCAAGACTCAGTGGAGGCTGCTTGAA  1862 
 
Query  602   TACCTCCTAGTGGAGTGGCTTCAGAAATAAACCCTAGGATTTCATCATCTACTTTTGGAA  661 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1861  TACCTCCTAGTGGAGTGGCTTCAGAAATAAACCCTAGGATTTCATCATCTACTTTTGGAA  1802 
 
Query  662   CTGATAATATCTGTGTTGCCTCCCTGGAAGAAACTGGATATTTGCATGCCAGTGAAGGCA  721 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1801  CTGATAATATCTGTGTTGCCTCCCTGGAAGAAACTGGATATTTGCATGCCAGTGAAGGCA  1742 
 
Query  722   GCTGCCTGTCAACTTGCTGCCATTCTTCTTCAATTACTTTTAAAATAGATTCATGGAAGG  781 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1741  GCTGCCTGTCAACTTGCTGCCATTCTTCTTCAATTACTTTTAAAATAGATTCATGGAAGG  1682 
 
Query  782   GAAAAGATAGTTCTGAGGCATCTATTTTATCATGCTGTGATTGCTTAGCCACTTCTAGAC  841 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1681  GAAAAGATAGTTCTGAGGCATCTATTTTATCATGCTGTGATTGCTTAGCCACTTCTAGAC  1622 
 
Query  842   CTAAGGTAGTGAGTGAATGAGAGACAACAGTTTTGGCAAAAGAAGACATCAGT-CGGGAT  900 
             ||||||||||||||||||||||||||||||||||||||||||||||||||||| ||| || 
Sbjct  1621  CTAAGGTAGTGAGTGAATGAGAGACAACAGTTTTGGCAAAAGAAGACATCAGTTCGG-AT  1563 
 
Query  901   C  901 
             | 
Sbjct  1562  C  1562 
 
d. Reverse sequencing (vs. NM_003276.1) 
1501 AGTGAGAAGTCAGTGGAGGAAAGGGATTCAGGTTCCTTTGTGGCATTTCAGAACATACCT 
1561 GGATCCGAACTGATGTCTTCTTTTGCCAAAACTGTTGTCTCTCATTCACTCACTACCTTA 
1621 GGTCTAGAAGTGGCTAAGCAATCACAGCATGATAAAATAGATGCCTCAGAACTATCTTTT 
1681 CCCTTCCATGAATCTATTTTAAAAGTAATTGAAGAAGAATGGCAGCAAGTTGACAGGCAG 
1741 CTGCCTTCACTGGCATGCAAATATCCAGTTTCTTCCAGGGAGGCAACACAGATATTATCA 
1801 GTTCCAAAAGTAGATGATGAAATCCTAGGGTTTATTTCTGAAGCCACTCCACTAGGAGGT 
1861 ATTCAAGCAGCCTCCACTGAGTCTTGCAATCAGCAGTTGGACTTAGCACTCTGTAGAGCA 
1921 TATGAAGCTGCAGCATCAGCATTGCAGATTGCAACTCACACTGCCTTTGTAGCTAAGGCT 
1981 ATGCAGGCAGACATTAGTCAAGCTGCACAGATTCTTAGCTCAGATCCTAGTCGTACCCAC 
2041 CAAGCGCTTGGGATTCTGAGCAAAACATATGATGCAGCCTCATATATTTGTGAAGCTGCA 
2101 TTTGATGAAGTGAAGATGGCTGCCCATACCATGGGAAATGCCACTGTAGGTCGTCGATAC 
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2161 CTCTGGCTGAAGGATTGCAAAATTAATTTAGCTTCTAAGAATAAGCTGGCTTCCACTCCC 
2221 TTTAAAGGTGGAACATTATTTGGAGGAGAAGTATGCAAAGTAATTAAAAAGCGTGGAAAT 
2281 AAACACTAGTAAAATTAAGGACAAAAAGACATCTATCTTATCTTTCAGGTACTTTATGCC 
2341 AACATTTTCTTTTCTGTTAAGGTTGTTTTAGTTTCCAGATAGGGCTAATTACAAAATGTT 
2401 AAGCTTCTACCCATCAAATTACAGTATAAAAGTAATTGCCTGTGTAGAACTACTTGTCTT 
2461 TTCTAAAGATTTGCGTAGATAGGAAGCCTG 
 
e. Combined sequencing (forward and reverse sequences) 
1501 AGTGAGAAGTCAGTGGAGGAAAGGGATTCAGGTTCCTTTGTGGCATTTCAGAACATACCT 
1561 GGATCCGAACTGATGTCTTCTTTTGCCAAAACTGTTGTCTCTCATTCACTCACTACCTTA 
1621 GGTCTAGAAGTGGCTAAGCAATCACAGCATGATAAAATAGATGCCTCAGAACTATCTTTT 
1681 CCCTTCCATGAATCTATTTTAAAAGTAATTGAAGAAGAATGGCAGCAAGTTGACAGGCAG 
1741 CTGCCTTCACTGGCATGCAAATATCCAGTTTCTTCCAGGGAGGCAACACAGATATTATCA 
1801 GTTCCAAAAGTAGATGATGAAATCCTAGGGTTTATTTCTGAAGCCACTCCACTAGGAGGT 
1861 ATTCAAGCAGCCTCCACTGAGTCTTGCAATCAGCAGTTGGACTTAGCACTCTGTAGAGCA 
1921 TATGAAGCTGCAGCATCAGCATTGCAGATTGCAACTCACACTGCCTTTGTAGCTAAGGCT 
1981 ATGCAGGCAGACATTAGTCAAGCTGCACAGATTCTTAGCTCAGATCCTAGTCGTACCCAC 
2041 CAAGCGCTTGGGATTCTGAGCAAAACATATGATGCAGCCTCATATATTTGTGAAGCTGCA 
2101 TTTGATGAAGTGAAGATGGCTGCCCATACCATGGGAAATGCCACTGTAGGTCGTCGATAC 
2161 CTCTGGCTGAAGGATTGCAAAATTAATTTAGCTTCTAAGAATAAGCTGGCTTCCACTCCC 
2221 TTTAAAGGTGGAACATTATTTGGAGGAGAAGTATGCAAAGTAATTAAAAAGCGTGGAAAT 
2281 AAACACTAGTAAAATTAAGGACAAAAAGACATCTATCTTATCTTTCAGGTACTTTATGCC 
2341 AACATTTTCTTTTCTGTTAAGGTTGTTTTAGTTTCCAGATAGGGCTAATTACAAAATGTT 
2401 AAGCTTCTACCCATCAAATTACAGTATAAAAGTAATTGCCTGTGTAGAACTACTTGTCTT 
2461 TTCTAAAGATTTGCGTAGATAGGAAGCCTG 
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